trial_idx,source_vendor,source_model,source_condition,source_repeat_idx,source_label,source_quote,source_quote_sha1,source_quote_valid,ground_truth,judge_vendor,judge_model,raw_output,verdict,format_valid,supports_label
0,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We randomly assigned patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual),fc7bb4a1f2e57bc303295fd86d2ec6c2c8ca0505,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
1,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma with prespecified FGFR alterations,0160b11634f2b30a9d244e76b12d448a9151fb57,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
2,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"In this phase 3 study, we aimed to compare overall survival in patients with advanced or metastatic soft-tissue sarcoma who received eribulin with that in patients who received dacarbazine",cf3614b788fdddf6d88bbe8c5a0531acbefc221b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
4,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,To investigate the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing after second-line or further treatment.,c9e609f99613768550cecda30d5261632a03cdcd,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
5,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.,095a4141eb262225a4f7a27dacfdcec099af798c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
6,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Localised prostate cancer is commonly treated with external beam radiotherapy,0c49d50c3d7e6e3b243439cb9d2a760b787b52c7,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
7,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"In this randomised controlled trial, we recruited postmenopausal women aged 50-74 years from 13 centres in National Health Service Trusts in England, Wales, and Northern Ireland.",c0b3f644539d5fce65e71e6ffad366dbfc3ba94e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
8,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,women had to be at increased risk of breast cancer (judged on the basis of specific criteria),f6e99365f989a7d0a77de7cdc0f7e02d7e48083c,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
9,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma",f7c8ae218aa2a3d30f7332ef5fdf9e777dc7d8dc,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
10,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab.",0591ee004c0def46184a426053dd9738f35bbfe6,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
11,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer.",d1e614fe7b5029804a8fbe3e3a04765c4bffb316,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
12,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1 to 3 prior regimens and performance status of 0 to 2.",f3409732cc7d4683f100ffbb4e6a413730016a80,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
13,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,5102 patients with HER2-positive early breast cancer,42e034cabf2625e843f4f5548b2fb5d4b396f648,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
14,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer,51ec0273befa1e47d1450daed3776964587877f4,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
15,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer were randomly assigned",84ec036d9366cf4a0250f89f04a963cb3b9da6ed,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
16,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.",7e1f10ae979f9c975e6f844c7d8c536f7403d433,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
17,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast",c6bec3db773bc407f94951fa1e0122a502885747,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
18,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,healthy women older than 25 years,7cef698a40287e43633ef9741ddf42790931b86d,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
20,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer,7705de340e41b57febb4d8971de9d1fa7442e04e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
21,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation,8558a85da1ba64adc29d0d287b8124a5c93b74ba,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"we randomly assigned 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations",32924e6cfd4d4f195549c678749a0c82e6d5b7ad,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
23,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,140 patients with early breast cancer were randomly assigned,bff69170118c768e1eb092596381a3c543eed253,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
25,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Barcelona Clinic Liver Cancer stage B or C disease,c7301b6296b7bdbecfa1ac7e161014afb25491ea,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
26,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,Women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing in combination with liquid-based cytology,bbda95a47068f488276798ce98cd978a28681a60,False,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
27,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned,bfee109a10676ba8e9aa75d74715bb869358dc39,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
30,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,1500 women with axillary node-positive or high-risk node-negative breast cancer,bcdd56e17d1a840c3afc168e772f2dc8dca708c5,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
31,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously,324aade2b9dcc7564cab85ec6def80cff9e1bad4,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
32,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Patients with centrally confirmed HER2-positive gastric or gastroesophageal junction adenocarcinoma that had progressed while they were receiving at least two previous therapies, including trastuzumab",83e41a14d9cc5141b01a709074a904e7e85884b7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
33,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"In a multicenter, sham-controlled trial, we randomly assigned 127 patients with dysplastic Barrett's esophagus",32a9eef18cf13b2c780494445c6368dd83b84420,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
34,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Eligible patients were premenopausal women aged 18-59 years who had histologically or cytologically confirmed HR-positive, HER2-negative, advanced breast cancer",376bc86d88c5629dd3f7472a123ac28182d128a6,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
35,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy,5a943ca8e986a9372d87d3a446983858c218bfb1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
36,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned",bef7dc4daef6dba31ca7cb28ef2c7402a9b0617e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
37,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,eligible patients recruited in 138 clinics from 24 countries (aged ≥18 years with histologically or cytologically confirmed advanced non-small-cell lung cancer,dd4a2579bcb6d5baa7eb513d87860f580f708e7d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
38,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma",4dccde99f317d5f36d314601c66701d8accae702,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
39,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma,fcc8b382a999378f1e6c81cc8bc685b7d2fad526,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
40,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We sought to determine the efficacy and safety of sunitinib in patients with locoregional renal-cell carcinoma at high risk for tumor recurrence after nephrectomy.,c082bcd6fe87f693cd29a356941c7d8d288f67e6,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
41,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Standard first-line regimens for patients with metastatic gastroesophageal adenocarcinomas have an approximate 40% objective response rate (ORR).,43c6405e58d7844115495f18c7fbe2aafae3c296,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
42,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b,823afbdce5dc36ee194b7d774c5eaaf9d0366acf,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
43,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer and who had chosen surgery as their treatment approach,6c7bbb749c23a76c07155510f2a35c4213821cd1,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
44,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We assessed the effects of combined docetaxel and estramustine on relapse in patients with high-risk localised prostate cancer.,786ab75603b505994389571e11eaa12e57c099cc,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
45,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated,02d496a2dd8422ce71898eb8c05bed6bc7046068,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
46,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer without neuroendocrine differentiation,d8b422adbc7e21bce8ba462cb2cfd07fe0ae4df0,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
47,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen,e4721392778786e03d84fcd2855ac39157cedcdd,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
48,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we recruited patients aged 18 years or older who had received taxane therapy and undergone two or fewer previous chemotherapy regimens for metastatic breast cancer,c76e796fffd838f7d92822c2d1386d920f8b782c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
49,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer",cfbf220f019f4e538d01b925b7d7555d6a0e6e8a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
50,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we enrolled patients with stage IIIB or IV adenocarcinoma,0825e4d60d1fa4f662bb55c1140ae89e2cce2319,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
51,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer",97d6bfead549bd200270e4c195e1f70f5a675d31,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
53,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,adjuvant chemotherapy for operable node-positive breast cancer,d831e475033b14ff9450885da9a3f45addd83004,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
54,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy.,c02ea06c108110323e6de9212ef4743b789afcb7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
55,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"In the Prostate Cancer Prevention Trial (PCPT), finasteride significantly reduced the risk of prostate cancer",61f3e6a7146bfbb6e0c92599b2e3abca0e51ee7b,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
56,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,men treated with radiotherapy for prostate cancer,3785749ee005f17e910b4e193d9dfe606c193607,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
57,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,patients with radiologically confirmed painful bone metastases,86cb4376c17caed9db019d633d3111c8c42964c5,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
58,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer",98a8176ee5187d630adb8aeaa485ef5593c3909e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
59,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,We assessed the efficacy and safety of pertuzumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic gastric or gastro-oesophageal junction cancer.,c96be6c17272c3b6a08ee06032afbfaf76e684ab,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
60,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer,eb39c499b2390ac2dd1d4534274471899a2f3445,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
62,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease)",4d8a53f9ab4779215bbb08f3398f784bae600b5a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
63,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) who had disease progression after receiving EGFR tyrosine-kinase inhibitor therapy,c6ea67fb9b85a8261880f550b0ffcca8ee4134e5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
64,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,patients with advanced renal cell carcinoma and no previous systemic therapy,27873bec3229f421e7a00bd2e3a69d89aa463abb,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
65,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease, children (≥365 days of age) who had stage 3 tumors with favorable histopathological features, and infants who had stage 4S disease with a diploid DNA index or unfavorable histopathological features.",e2f405aa914f41ce9361dcd11d7d73d45a94569d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
66,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment",92b54c29dfeb350fb3e61b31231bb4b6ae50a08e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
67,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned",0d6ba56beb6830ccb551ce364ac1ff2caf808724,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
68,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,patients aged 18 years or older with unresectable hepatocellular carcinoma,dafec26da4015cf84651f3e0d1d6c58a92a0471e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma,96d38b1bcb1aa5ffc0fdc50e988558ea509561ce,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
70,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Randomization was stratified based on site of metastasis (visceral, bone only, or other)",6ea62c972b956e36c633136528c0a1dd84c8e97a,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
71,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
72,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with resected stage III melanoma with BRAF V600E or V600K mutations,579a7383ae80b1ae9fe530ed163c8b19a1c1d3ec,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
73,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"This international, multicenter, open-label parallel-group phase 2 randomized clinical trial was conducted at 9 tertiary academic cancer centers in Canada and Australia and enrolled patients with T1-T2N0-2 p16-positive OPSCC",5f23cfb9eedad535fea0acd3ed0d3338419d02ae,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
74,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries,bf89fe51434b0d644946853de71f676f18751fd0,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
75,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors",705c0db343db93f7def5ac17051a9587b6be6529,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
76,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,Pragmatic randomized clinical trial from March 2013 to July 2016 among 5999 participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings.,55256a245d0faecee3ad6ecb733169dfa86e371e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
77,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,2f473300ee2ed5d6e679dd22a6fb62b3b64bf27b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
78,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer (cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer)",20f35dbfe1c2d4338016708f34248860a1dba4ce,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
79,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy",0405aa34a2137529c9041abdac3e50222c00c304,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
80,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment, enzalutamide significantly increased overall survival compared with placebo.",c34877d78c6b666cca66be8b0ea0be09064ed5e7,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
81,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
82,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,patients with untreated locally recurrent inoperable or metastatic triple-negative breast cancer,29fb90e05aab5f09411ed2d741d293bd2063769a,False,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
83,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients 18 to 75 years of age with resectable cancer of the middle or lower third of the esophagus,0baebef4cd924b3a4022d771beea312b006e770c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
84,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,previously untreated recurrent and/or metastatic ERBB2-positive breast cancer,710609f4c90c54721c6ff50e3f5906bc48e4cc5f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
85,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C,91cec28e5c907eadc7e24c39b2db70269724b18c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
86,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy",8ca5067dadf24757c361c89491a6f0977f3e888c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
87,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract",feac9e353db3a2317bbb6d8f79e649e29d2c384c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
88,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,840 patients with stage IB-IIIA NSCLC from 101 centres in 14 countries were randomly assigned to observation (n=433) or to 30 mg/m(2) vinorelbine plus 100 mg/m(2) cisplatin (n=407).,b63664706fb59899ae2ce5dda6f04bdf65982d18,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
89,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"histopathologically diagnosed with undifferentiated or differentiated, non-keratinising, locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus",6066226c122c0b9b37ac9622c8c2759dbd45608e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
90,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"To determine if the addition of celecoxib to adjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) improves disease-free survival in patients with stage III colon cancer.",49ff2f8d949d4746f41ca8d1a792d27bbe3dee1c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
91,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Sentinel-lymph-node biopsy is associated with increased melanoma-specific survival (i.e., survival until death from melanoma) among patients with node-positive intermediate-thickness melanomas (1.2 to 3.5 mm).",dd2ce66947ca9e027a74abf5aab423fca1f3744c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
92,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Eligible patients (aged ≥18 years) had histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma with first disease recurrence more than 6 months after first-line platinum-based chemotherapy",efb5c3a90dacb2bf43619b9c28e38d5779aa313f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
93,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence",c37659491a000415239367e1978caf776dc39280,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
94,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,comparing atezolizumab plus bevacizumab versus sunitinib in first-line metastatic renal cell carcinoma,2a9315e96c1d5e7fed9a565a224f05cb302f1a14,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
95,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
96,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment,7ad600db6616635fc16a44ff62e3125d220e6c0e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
97,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC",0b402dc18bfbf2b3abe6d6e47c3cc9b7ada85791,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
98,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy",dcbe702f34b4ba40177de4b6f4df1dd179f0d943,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
99,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs) and enrolled",b7e8d2cdc9533f4eb4de4a221f8b6dc7bd9167f1,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
100,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.",2bb4c508e081004e847881868ce95d43864f22fb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
101,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,locoregionally advanced nasopharyngeal carcinoma,2edcecb4d1b79b8fa4d89eb6411cb292d075cebd,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
102,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage.",9a226940bcf144b135766bfa4bf9bf3e09e0a381,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
103,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.,e17cfaf030de1c203c1c5a45a0f85f9ffc6a7796,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
104,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma,fa08345d653fe100e478be37169783281485351b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
105,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Randomisation was done via the minimisation method with biased-coin balancing for Eastern Cooperative Oncology Group performance status, disease stage at enrolment, and institution.",0cb6744cc662dde9e8f633cc0a52e5bbc16eee32,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
106,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
107,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer,925a41b4143b75a761a76d588e6b8fbc0d961442,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
108,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"patients with advanced cancer, aged at least 18 years, admitted to the palliative and supportive care unit at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), with refractory agitation",c39b3f6f7eb39a439e7f57b846d303f827a00ac0,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
109,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma",6f23b4ecc422bab373dea947e4bb3946b5ac0614,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
110,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease",42edce59222b2d92f7594e370656ad2a9f95330c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
111,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
112,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction,7764aacefa5c6343a21be2968247573405ba770c,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
113,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"we randomly assigned, in a 1:1 ratio, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to receive 500 mg of nicotinamide twice daily or placebo for 12 months",8d9b12c4a7e614356b0e109df4cf4ab5cfd9b92a,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
114,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment,4864296f7ae844ff2919e93269293aa144b83745,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
115,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy,2f7ab902b18cc5cdd9667c868b8ed71e403d9958,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
116,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma",4e9d1b2e87d328e571dc9c7e55c1d887aef3d569,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
117,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.,1e5a0d07bcab51fdb16ae60707f07703b41de616,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
118,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible patients were aged 18-75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)",666abb58c43dc6cbad55d9584c2ff02bb0c5a432,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
119,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with palpable T1-T2 invasive breast cancer were recruited,8e7d379bc116332307e54f6cef9d8d517b082952,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
120,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"patients with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer",a5ce4ad3a274bfe8aa55aadfaa00d7624f32c56d,False,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
122,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors,bcec87f427a1c6e6a336726d281fb67543d3cf78,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
123,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma",d57a0e70cd847b04f4eb56ebbf449fa9bc55841a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
124,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.",f01be5f907ffb3968529022574e3b780796c8912,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
125,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease,fbb28621ca792d0faff6a84d142934f1380805f2,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease,2013657070185ba51f4157a780dc6214d4a149b4,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
127,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC were enrolled,f6ae1a7979a85cbb3361ae4ed55a331be7d7d488,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
128,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",62a9896c1da9a80e07fb82397217a16d1d84584a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
129,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
130,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm,4296d5fb72270e8341ca5ee07edb61cf79b35b50,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
131,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
132,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor,91bd9ce646c85b4c45e39bd471eb05419d1cc62e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
133,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with stage IV melanoma with no evidence of disease after surgery or radiotherapy,f85f0257d1ab124153605d0bbffc6c0db04db633,False,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
134,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,patients with untreated stage IV or recurrent NSCLC,0c85b8487b0acb5a3977724399f64a26805c26c5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
135,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Among patients with high-risk relapsed metastatic neuroblastoma, oral β-glucan adjuvant during GD2/GD3 ganglioside vaccine boost has stimulated IgG antibody response",8deda0b2488b04e6850c168c5df2fc2cd550ea0f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
136,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre.,a6faddd453e53720422bf2bb801ad8dfcd687277,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
138,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,adults aged 18 years or older with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum that was refractory to previous standard therapy,af633a6944eb57692b1eedaba57650900c92a1b9,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"523 patients with curable stage T2b, T3, or T4 gastric cancer were randomly assigned during surgery to D2 lymphadenectomy alone (263 patients) or to D2 lymphadenectomy plus PAND (260 patients)",490954a6e6f8f512ac272d794f2793653b2bb8ac,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
140,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
141,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression,187b46812f1d8adc55b45569e5fa26ef2e61a69a,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
142,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)",22ba5ffce0ae91fc338c92ab90641a6944ad8acb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
143,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"Anal cancer is an increasing issue in HIV-positive men who have sex with men (MSM). Screening for its precursor, anal intraepithelial neoplasia (AIN), is subject of discussion.",353b737861e00823d1b60d2aba28bb14722c5e7e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
144,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,spinal cord compression caused by metastatic cancer,8cb9910a1b04bc12e5d19bac259fcc3e2c21ab9a,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
145,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"patients aged 18 years or older from 129 UK centres who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy",d9579960f4cb2a8af4b3cafdef8256e00fe93b8e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
146,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States,12f69eadbafed10c6733ff923755b0fb906407e0,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
147,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.,69b842dffdbffa24b7350f9d02f2376643d86b1b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
148,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
149,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.",5dd83413e5cf0f338a57224082e25970f5d5aa27,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
150,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Superficial basal-cell carcinoma is most commonly treated with topical non-surgical treatments,a1cbe9d785f284b52fca25573b8f8a6cc81dead9,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
151,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.",12f0f83eee4f297d5b656a2bc3371efacee7671e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
152,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,We included chemotherapy-naive men (aged ≥18 years) with mCRPC who had not been previously treated with androgen biosynthesis signalling inhibitors,234ef7b029d3c6b6fe6e4a16d75c5e4f63861090,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
153,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment",623aaaee2065b1baf7cf0c6d1adae0950ab244e3,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
154,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Women older than 18 years with histologically confirmed HER2-overexpressing breast cancer and CNS recurrence or progression as determined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) during or after treatment with trastuzumab, lapatinib, or both, were eligible.",25d39f9ae00ffa521ebe07ab3bb1d89b5117c54e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
155,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
156,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery,497bfcf94eef00225dfe6be3ee39ac77b8c6b7a2,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
157,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,we enrolled patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less,5c2cf0243d55d96dd4292233768c76e266a6f0e2,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
158,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
159,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,children and young adults (<30 years) with high-risk neuroblastoma were randomly assigned at diagnosis,b41ff7b720bc34fc428c92ded59893dd848cc9bb,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
160,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy",05c2939dada0672749ec4cb4ea3d7457c7858303,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
161,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Outcomes are poor in patients with HER2-negative, advanced gastric or gastro-oesophageal junction adenocarcinomas.",81f3a0d81fc79f36f8808045aceb3a981bf715f2,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
162,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
163,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer from 81 Italian centres",42c2125c9d0d81288538f25dd8b3c047203713de,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
164,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation,583a76088c72262449dac8aacd51fb58b93120b8,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
165,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"adult patients (aged ≥18 years) with advanced, progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal origin were enrolled",1097520aab3d197f4867ce88a13d038e7c72ae07,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"We conducted a phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of trastuzumab deruxtecan (a HER2 antibody-drug conjugate) with those of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.",e50544c83b7956b22ab1ac15fff8159eb88637bb,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
167,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.,5fc989ef5fe2c3d505652b55cb785026b6bb9235,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
168,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"HR-positive, HER2-negative advanced breast cancer",faee86c53010ff6d9154771948e27e86ca8b279f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
169,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,We enrolled female patients with HER2-overexpressing metastatic breast cancer who had progressed on or following adjuvant trastuzumab or first-line treatment of metastatic disease with trastuzumab.,e9c238aef87e34090486f21c9fb8626127670618,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
170,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,We randomly assigned 1838 participants with H. pylori infection to receive either eradication therapy,c3ed5167be671bd93f25be64ff45859e98ded5b5,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
171,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-positive early breast cancer in premenopausal women,e2e40fd85b9bba6397be29b29ac5c6c0bdfeea59,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
173,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,To assess whether stereotactic body radiotherapy on a single tumor site preceding pembrolizumab treatment enhances tumor response in patients with metastatic NSCLC.,374e60a2a29d21ed4816c49171017e2b69b302d3,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
174,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"Men and women, who had indicated on a previous questionnaire that they would probably attend screening if invited, were randomly assigned (1:2) to an intervention group (offered flexible sigmoidoscopy screening) or a control group (not contacted).",00be356bb6b02279d8af11c34900d2702dc5397f,False,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
175,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who had been pretreated with platinum-based chemotherapy.,9e6203ad597e2d1e23acd743cea428eb86362819,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
176,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"From 1993 through 2001, we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects).",529c7a2f02b5029cc173759afd736b6a80629cf1,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
177,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.,70d475696cdc082bcacbd6384e423ff7da28aba6,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
178,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"demonstrate the efficacy of ivosidenib (AG-120)-a first-in-class, oral, small-molecule inhibitor of mutant IDH1-vs placebo for patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation",160d6dd97964e72f3e4ee7ea40f2d3fc4f700252,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
179,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Patients (age 1-20 years) with neuroblastoma were eligible to be randomly assigned if they had completed a multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide with or without topotecan, vincristine, and doxorubicin) and achieved an adequate disease response.",0d65348acebaddbbcf21c23018e019f526dfc462,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,had previously untreated recurrent or metastatic nasopharyngeal carcinoma,bb06d0c31dc58f6a446b63ce25a67cb6e3404c9b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
182,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more,8238f81c269109ba3c048924442cdc35631824df,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
183,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with previously untreated stage II or stage III triple-negative breast cancer,df1fbc5bb5dcbf5062226f899b54c592cad0ffc2,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
184,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer,823f122356f8f86a5e76455b661c9dd507b9fb64,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
185,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,Eligible participants aged 1-18 years with newly diagnosed cancer and normal audiometry were randomly assigned (1:1) to receive sodium thiosulfate or observation (control group) in addition to their planned cisplatin-containing chemotherapy regimen,a8a037c85beae667177bdf82856f613163a24083,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
186,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
187,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"patients with locoregionally advanced, unresectable disease... stage III or stage IV disease and no distant metastases",67e772b38e26fbd01cfb432fd112411f8eea3964,False,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
188,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent",406f22033394df460ac3a4a6de3cf7b661fbcc51,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
189,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"a randomised, placebo-controlled, double-blind trial of exemestane 25 mg a day for the primary prevention of breast cancer",775a173bb31c607563b6c7d1ad882376d7fc252f,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
190,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer,1d5ab5aa44d4b9fe7746b357e8ac868cb49cd851,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
191,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
192,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer",32ca4d3fff954ed57510ab1bee98e9767a91dddc,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
193,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Eligible patients were adults (aged 18 years or older) with progressive, advanced, well differentiated pancreatic NETs",5203160dfb07efc646930d7c8a2ed8f5ea77ac99,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
194,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions,83b241e5412ffc76522b5f4b1eb8c2ba5559c311,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
195,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung who had progressed after at least four cycles of platinum-based-chemotherapy.,7b6c6e36b482f1636c166e4378de25d7832b70ee,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
196,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel",b0d5b8e000da10259a494d9d1d935a8a5098b10d,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
197,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Patients aged 18 years and older with metastatic soft-tissue sarcomas,5aa95ecda2edcb243e6f1061f50ba6de22c5831e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
198,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry.,0dba11ee514688d77c9254edf4807a4baff8b71f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
199,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment,0278ffd332ca1b2e0bf80b280ebe480fb8d41250,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
0,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We randomly assigned patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual),fc7bb4a1f2e57bc303295fd86d2ec6c2c8ca0505,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
0,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We randomly assigned patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual),fc7bb4a1f2e57bc303295fd86d2ec6c2c8ca0505,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
1,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma with prespecified FGFR alterations,0160b11634f2b30a9d244e76b12d448a9151fb57,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
1,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma with prespecified FGFR alterations,0160b11634f2b30a9d244e76b12d448a9151fb57,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
2,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"In this phase 3 study, we aimed to compare overall survival in patients with advanced or metastatic soft-tissue sarcoma who received eribulin with that in patients who received dacarbazine",cf3614b788fdddf6d88bbe8c5a0531acbefc221b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
2,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"In this phase 3 study, we aimed to compare overall survival in patients with advanced or metastatic soft-tissue sarcoma who received eribulin with that in patients who received dacarbazine",cf3614b788fdddf6d88bbe8c5a0531acbefc221b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
4,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,To investigate the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing after second-line or further treatment.,c9e609f99613768550cecda30d5261632a03cdcd,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
4,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,To investigate the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing after second-line or further treatment.,c9e609f99613768550cecda30d5261632a03cdcd,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
5,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.,095a4141eb262225a4f7a27dacfdcec099af798c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
5,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.,095a4141eb262225a4f7a27dacfdcec099af798c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
6,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Localised prostate cancer is commonly treated with external beam radiotherapy,0c49d50c3d7e6e3b243439cb9d2a760b787b52c7,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
6,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Localised prostate cancer is commonly treated with external beam radiotherapy,0c49d50c3d7e6e3b243439cb9d2a760b787b52c7,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
7,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"We recruited postmenopausal women aged 50-74 years from 13 centres in National Health Service Trusts in England, Wales, and Northern Ireland.",507ed5b5e16c7afa7515b71d2a45e6af6b23c385,False,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
7,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"We recruited postmenopausal women aged 50-74 years from 13 centres in National Health Service Trusts in England, Wales, and Northern Ireland.",507ed5b5e16c7afa7515b71d2a45e6af6b23c385,False,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
8,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,postmenopausal women who are at high risk of the disease,a29a8e17895852ca8a39d9cdf67189f8e9161a2e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
8,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"To be eligible, women had to be at increased risk of breast cancer",e23b8207c614a3044014c44d56f786b3d775384d,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
9,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma",f7c8ae218aa2a3d30f7332ef5fdf9e777dc7d8dc,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
9,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma",f7c8ae218aa2a3d30f7332ef5fdf9e777dc7d8dc,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
10,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab.",0591ee004c0def46184a426053dd9738f35bbfe6,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
10,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab.",0591ee004c0def46184a426053dd9738f35bbfe6,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
11,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer.",d1e614fe7b5029804a8fbe3e3a04765c4bffb316,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
11,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer.",d1e614fe7b5029804a8fbe3e3a04765c4bffb316,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
12,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1 to 3 prior regimens and performance status of 0 to 2.",f3409732cc7d4683f100ffbb4e6a413730016a80,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
12,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1 to 3 prior regimens and performance status of 0 to 2.",f3409732cc7d4683f100ffbb4e6a413730016a80,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
13,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,5102 patients with HER2-positive early breast cancer,42e034cabf2625e843f4f5548b2fb5d4b396f648,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
13,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,5102 patients with HER2-positive early breast cancer,42e034cabf2625e843f4f5548b2fb5d4b396f648,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
14,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer,51ec0273befa1e47d1450daed3776964587877f4,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
14,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer,51ec0273befa1e47d1450daed3776964587877f4,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
15,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer were randomly assigned",84ec036d9366cf4a0250f89f04a963cb3b9da6ed,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
15,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer were randomly assigned",84ec036d9366cf4a0250f89f04a963cb3b9da6ed,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
16,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.",7e1f10ae979f9c975e6f844c7d8c536f7403d433,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
16,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.",7e1f10ae979f9c975e6f844c7d8c536f7403d433,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
17,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast",c6bec3db773bc407f94951fa1e0122a502885747,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
17,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast",c6bec3db773bc407f94951fa1e0122a502885747,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
18,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,healthy women older than 25 years,7cef698a40287e43633ef9741ddf42790931b86d,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
18,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,healthy women older than 25 years,7cef698a40287e43633ef9741ddf42790931b86d,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
20,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer,7705de340e41b57febb4d8971de9d1fa7442e04e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
20,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"previously untreated (except for neoadjuvant or adjuvant chemotherapy completed ≥180 days before recurrence), HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer",82f9ae49f05c3afc0efa3efd85ae63994cee48e1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
21,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation,8558a85da1ba64adc29d0d287b8124a5c93b74ba,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
21,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation,8558a85da1ba64adc29d0d287b8124a5c93b74ba,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"we randomly assigned 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations",32924e6cfd4d4f195549c678749a0c82e6d5b7ad,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
22,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"we randomly assigned 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations",32924e6cfd4d4f195549c678749a0c82e6d5b7ad,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
23,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,140 patients with early breast cancer were randomly assigned,bff69170118c768e1eb092596381a3c543eed253,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
23,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,140 patients with early breast cancer,8dbe064277815c984c0fdd220e7ff087d90f2f09,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
25,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Barcelona Clinic Liver Cancer stage B or C disease,c7301b6296b7bdbecfa1ac7e161014afb25491ea,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
25,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Barcelona Clinic Liver Cancer stage B or C disease,c7301b6296b7bdbecfa1ac7e161014afb25491ea,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
26,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,Women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing,d85113a3698d87094482ce17b9c7375fc21bddad,False,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
26,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,Women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing,d85113a3698d87094482ce17b9c7375fc21bddad,False,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
27,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned,bfee109a10676ba8e9aa75d74715bb869358dc39,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
27,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned,bfee109a10676ba8e9aa75d74715bb869358dc39,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
30,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"we randomly assigned (centrally by computer; stratified by node status, HER2 status, and centre) 1500 women with axillary node-positive or high-risk node-negative breast cancer",51d14a3b6c6f874d36fada30f09e46b36132ee73,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
30,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,1500 women with axillary node-positive or high-risk node-negative breast cancer,bcdd56e17d1a840c3afc168e772f2dc8dca708c5,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
31,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously,324aade2b9dcc7564cab85ec6def80cff9e1bad4,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
31,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously,324aade2b9dcc7564cab85ec6def80cff9e1bad4,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
32,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Patients with centrally confirmed HER2-positive gastric or gastroesophageal junction adenocarcinoma that had progressed while they were receiving at least two previous therapies, including trastuzumab",83e41a14d9cc5141b01a709074a904e7e85884b7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
32,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Patients with centrally confirmed HER2-positive gastric or gastroesophageal junction adenocarcinoma that had progressed while they were receiving at least two previous therapies, including trastuzumab",83e41a14d9cc5141b01a709074a904e7e85884b7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
33,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"In a multicenter, sham-controlled trial, we randomly assigned 127 patients with dysplastic Barrett's esophagus",32a9eef18cf13b2c780494445c6368dd83b84420,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
33,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"In a multicenter, sham-controlled trial, we randomly assigned 127 patients with dysplastic Barrett's esophagus",32a9eef18cf13b2c780494445c6368dd83b84420,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
34,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Eligible patients were premenopausal women aged 18-59 years who had histologically or cytologically confirmed HR-positive, HER2-negative, advanced breast cancer",376bc86d88c5629dd3f7472a123ac28182d128a6,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
34,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"premenopausal women with hormone-receptor-positive, advanced breast cancer",b7f7973899cec2a7ea0e17bdc7fb5beca630fe8d,False,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
35,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,No treatments are presently available to increase survival in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy.,db9632759935187a78e1099978d7773d20859809,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
35,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy,5a943ca8e986a9372d87d3a446983858c218bfb1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
36,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned",bef7dc4daef6dba31ca7cb28ef2c7402a9b0617e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
36,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned",bef7dc4daef6dba31ca7cb28ef2c7402a9b0617e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
37,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,eligible patients recruited in 138 clinics from 24 countries (aged ≥18 years with histologically or cytologically confirmed advanced non-small-cell lung cancer,dd4a2579bcb6d5baa7eb513d87860f580f708e7d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
37,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,eligible patients recruited in 138 clinics from 24 countries (aged ≥18 years with histologically or cytologically confirmed advanced non-small-cell lung cancer,dd4a2579bcb6d5baa7eb513d87860f580f708e7d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
38,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma",4dccde99f317d5f36d314601c66701d8accae702,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
38,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma",4dccde99f317d5f36d314601c66701d8accae702,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
39,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma,fcc8b382a999378f1e6c81cc8bc685b7d2fad526,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
39,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma,fcc8b382a999378f1e6c81cc8bc685b7d2fad526,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
40,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with locoregional renal-cell carcinoma at high risk for tumor recurrence after nephrectomy,219ebaf5950154794a2f340f0970c3ee40bbd79a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
40,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We sought to determine the efficacy and safety of sunitinib in patients with locoregional renal-cell carcinoma at high risk for tumor recurrence after nephrectomy.,c082bcd6fe87f693cd29a356941c7d8d288f67e6,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
41,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Standard first-line regimens for patients with metastatic gastroesophageal adenocarcinomas have an approximate 40% objective response rate (ORR).,43c6405e58d7844115495f18c7fbe2aafae3c296,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
41,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Standard first-line regimens for patients with metastatic gastroesophageal adenocarcinomas have an approximate 40% objective response rate (ORR).,43c6405e58d7844115495f18c7fbe2aafae3c296,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
42,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627),b1c09b3e60339f032a3371c9409dd5cba859d47c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
42,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned,35ab9758ff3cbe8aab8a9ca6d7d0aebc9404d81a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
43,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer and who had chosen surgery as their treatment approach,6c7bbb749c23a76c07155510f2a35c4213821cd1,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
43,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer and who had chosen surgery as their treatment approach,6c7bbb749c23a76c07155510f2a35c4213821cd1,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
44,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We assessed the effects of combined docetaxel and estramustine on relapse in patients with high-risk localised prostate cancer.,786ab75603b505994389571e11eaa12e57c099cc,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
44,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We assessed the effects of combined docetaxel and estramustine on relapse in patients with high-risk localised prostate cancer.,786ab75603b505994389571e11eaa12e57c099cc,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
45,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated,02d496a2dd8422ce71898eb8c05bed6bc7046068,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
45,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated,02d496a2dd8422ce71898eb8c05bed6bc7046068,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
46,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer without neuroendocrine differentiation,d8b422adbc7e21bce8ba462cb2cfd07fe0ae4df0,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
46,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer without neuroendocrine differentiation,d8b422adbc7e21bce8ba462cb2cfd07fe0ae4df0,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
47,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen,e4721392778786e03d84fcd2855ac39157cedcdd,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
47,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen,e4721392778786e03d84fcd2855ac39157cedcdd,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
48,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,patients with previously treated metastatic breast cancer,d4d34620582aba440ad57f1a5e1e98bf67366997,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
48,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,two or fewer previous chemotherapy regimens for metastatic breast cancer,8d2244853502618d92c71778dd81ff892a6b294a,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
49,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer",cfbf220f019f4e538d01b925b7d7555d6a0e6e8a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
49,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer",cfbf220f019f4e538d01b925b7d7555d6a0e6e8a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
50,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we enrolled patients with stage IIIB or IV adenocarcinoma,0825e4d60d1fa4f662bb55c1140ae89e2cce2319,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
50,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we enrolled patients with stage IIIB or IV adenocarcinoma,0825e4d60d1fa4f662bb55c1140ae89e2cce2319,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
51,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer",97d6bfead549bd200270e4c195e1f70f5a675d31,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
51,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer",97d6bfead549bd200270e4c195e1f70f5a675d31,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
53,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,adjuvant chemotherapy for operable node-positive breast cancer,d831e475033b14ff9450885da9a3f45addd83004,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
53,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,adjuvant chemotherapy for operable node-positive breast cancer,d831e475033b14ff9450885da9a3f45addd83004,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
54,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy.,c02ea06c108110323e6de9212ef4743b789afcb7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
54,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy.,c02ea06c108110323e6de9212ef4743b789afcb7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
56,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,scheduled to receive radiotherapy for prostate cancer,2aff11e016c46ad17f1370f6028d113cc18b8f28,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
56,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Two hundred forty-two participants with intact erectile function scheduled to receive radiotherapy for prostate cancer were recruited,4dfc3c6bf55043377fadff9f1319f7b1fa5cb037,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
57,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,enrolled 160 patients with radiologically confirmed painful bone metastases,bf827c4b70a3b2c7f466645b23a47ece3ad69f79,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
57,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"This prospective, randomized, single-institution phase 2 noninferiority trial conducted at a tertiary cancer care center enrolled 160 patients with radiologically confirmed painful bone metastases",47914415954e0030186cf36c2cee2a69d12adcbe,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
58,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, who had received one or two previous systemic treatments for metastatic disease",146630f6cb4e92394cc4d3fde32029546edc2f5d,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
58,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer",98a8176ee5187d630adb8aeaa485ef5593c3909e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
59,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,We assessed the efficacy and safety of pertuzumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic gastric or gastro-oesophageal junction cancer.,c96be6c17272c3b6a08ee06032afbfaf76e684ab,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
59,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We assessed the efficacy and safety of pertuzumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic gastric or gastro-oesophageal junction cancer.,c96be6c17272c3b6a08ee06032afbfaf76e684ab,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
60,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer,eb39c499b2390ac2dd1d4534274471899a2f3445,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
60,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer,eb39c499b2390ac2dd1d4534274471899a2f3445,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
61,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,patients with symptoms suggestive of colorectal cancer,7885ebd7581b37dd829f169a8a87475b044c38d1,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
62,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease)",4d8a53f9ab4779215bbb08f3398f784bae600b5a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
62,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease)",4d8a53f9ab4779215bbb08f3398f784bae600b5a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
63,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) who had disease progression after receiving EGFR tyrosine-kinase inhibitor therapy,c5e339c43af4750dbfb418920c5f2588026bbffe,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
63,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) who had disease progression after receiving EGFR tyrosine-kinase inhibitor therapy,c6ea67fb9b85a8261880f550b0ffcca8ee4134e5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
64,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,patients with advanced renal cell carcinoma and no previous systemic therapy,27873bec3229f421e7a00bd2e3a69d89aa463abb,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
64,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,patients with advanced renal cell carcinoma and no previous systemic therapy,27873bec3229f421e7a00bd2e3a69d89aa463abb,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
65,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease, children (≥365 days of age) who had stage 3 tumors with favorable histopathological features, and infants who had stage 4S disease with a diploid DNA index or unfavorable histopathological features.",e2f405aa914f41ce9361dcd11d7d73d45a94569d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
65,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease, children (≥365 days of age) who had stage 3 tumors with favorable histopathological features, and infants who had stage 4S disease with a diploid DNA index or unfavorable histopathological features.",e2f405aa914f41ce9361dcd11d7d73d45a94569d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
66,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment",92b54c29dfeb350fb3e61b31231bb4b6ae50a08e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
66,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment",92b54c29dfeb350fb3e61b31231bb4b6ae50a08e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
67,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned",0d6ba56beb6830ccb551ce364ac1ff2caf808724,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
67,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned",0d6ba56beb6830ccb551ce364ac1ff2caf808724,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
68,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,patients aged 18 years or older with unresectable hepatocellular carcinoma,dafec26da4015cf84651f3e0d1d6c58a92a0471e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
68,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,patients aged 18 years or older with unresectable hepatocellular carcinoma,dafec26da4015cf84651f3e0d1d6c58a92a0471e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma,96d38b1bcb1aa5ffc0fdc50e988558ea509561ce,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma,96d38b1bcb1aa5ffc0fdc50e988558ea509561ce,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
70,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Randomization was stratified based on site of metastasis (visceral, bone only, or other) and resistance to prior ET (primary vs secondary).",e18234726dba6d1cc4bc57a45cb3ece481ff1ab1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
70,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Randomization was stratified based on site of metastasis (visceral, bone only, or other)",6ea62c972b956e36c633136528c0a1dd84c8e97a,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
71,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
71,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
72,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients who had resected stage III melanoma with BRAF V600E or V600K mutations,12ccaf4f82680f37fe37be42eec6ed337dfc63bc,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
72,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with resected stage III melanoma with BRAF V600E or V600K mutations,579a7383ae80b1ae9fe530ed163c8b19a1c1d3ec,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
73,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,T1-T2N0-2 p16-positive OPSCC,e13bde1e6308ed1b899f8f16b6d26c3a5e5a66ca,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
73,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,enrolled patients with T1-T2N0-2 p16-positive OPSCC,64ce7a66da3b9350c6ec61deff324c165f4fd575,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
74,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries,bf89fe51434b0d644946853de71f676f18751fd0,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
74,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited,0298c4ebd14147a2c51e15d5aff9edd861061538,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
75,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors",705c0db343db93f7def5ac17051a9587b6be6529,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
75,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors",705c0db343db93f7def5ac17051a9587b6be6529,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
76,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,among 5999 participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings,a84a329d9800aee76b206256d580ce80ed8d7b5b,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
76,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"Among persons aged 50 to 64 years receiving primary care at a safety-net institution, mailed outreach invitations offering FIT or colonoscopy compared with usual care increased the proportion completing CRC screening process within 3 years.",08f34ef91e10d3fff4c15c6ee368a53718cecf8c,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
77,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,2f473300ee2ed5d6e679dd22a6fb62b3b64bf27b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
77,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,2f473300ee2ed5d6e679dd22a6fb62b3b64bf27b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
78,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer (cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer)",20f35dbfe1c2d4338016708f34248860a1dba4ce,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
78,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer (cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer)",20f35dbfe1c2d4338016708f34248860a1dba4ce,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
79,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy",0405aa34a2137529c9041abdac3e50222c00c304,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
79,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy",0405aa34a2137529c9041abdac3e50222c00c304,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
80,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment, enzalutamide significantly increased overall survival compared with placebo.",c34877d78c6b666cca66be8b0ea0be09064ed5e7,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
80,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment, enzalutamide significantly increased overall survival compared with placebo.",c34877d78c6b666cca66be8b0ea0be09064ed5e7,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
81,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
81,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
82,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,randomly assigned patients 2:1 with untreated locally recurrent inoperable or metastatic triple-negative breast cancer,50a04a731744183c77c6309f4fd72c4f43944b0a,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
82,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,untreated locally recurrent inoperable or metastatic triple-negative breast cancer,4e05d39ea4883688eba77cc5809eb230ee88e5f7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
83,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients 18 to 75 years of age with resectable cancer of the middle or lower third of the esophagus,0baebef4cd924b3a4022d771beea312b006e770c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
83,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients 18 to 75 years of age with resectable cancer of the middle or lower third of the esophagus,0baebef4cd924b3a4022d771beea312b006e770c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
84,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized,2af9700c1ac362442bdb36b45f67e71d24763b0d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
84,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized,2af9700c1ac362442bdb36b45f67e71d24763b0d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
85,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C who had not received previous treatment with a KRAS G12C inhibitor,5f29fd8a3860573fff492e09ca4330436eb220a2,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
85,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C who had not received previous treatment with a KRAS G12C inhibitor,5f29fd8a3860573fff492e09ca4330436eb220a2,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
86,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy",44543fcedf1e506791ac2be2f6c729782b756273,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
86,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"enrolling patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy",a71040b3a8b377cf20ea24365216ca338c38a6ea,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
87,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract",feac9e353db3a2317bbb6d8f79e649e29d2c384c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
87,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract",feac9e353db3a2317bbb6d8f79e649e29d2c384c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
88,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,840 patients with stage IB-IIIA NSCLC from 101 centres in 14 countries were randomly assigned to observation (n=433) or to 30 mg/m(2) vinorelbine plus 100 mg/m(2) cisplatin (n=407).,b63664706fb59899ae2ce5dda6f04bdf65982d18,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
88,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,840 patients with stage IB-IIIA NSCLC from 101 centres in 14 countries were randomly assigned to observation (n=433) or to 30 mg/m(2) vinorelbine plus 100 mg/m(2) cisplatin (n=407).,b63664706fb59899ae2ce5dda6f04bdf65982d18,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
89,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus",72edf0593dcdbaa0c3bea1a320c43bf3f1472076,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
89,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus",72edf0593dcdbaa0c3bea1a320c43bf3f1472076,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
90,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with stage III colon cancer,edf15d4023c95bc0cedb01d9c45ec1dbf2dc2d03,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
90,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with stage III colon cancer,edf15d4023c95bc0cedb01d9c45ec1dbf2dc2d03,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
91,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with sentinel-node metastases detected by means of standard pathological assessment or a multimarker molecular assay,82d72671c923b8736e62499c5d98a618f2432ae2,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
91,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Sentinel-lymph-node biopsy is associated with increased melanoma-specific survival (i.e., survival until death from melanoma) among patients with node-positive intermediate-thickness melanomas (1.2 to 3.5 mm).",dd2ce66947ca9e027a74abf5aab423fca1f3744c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
93,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence",c37659491a000415239367e1978caf776dc39280,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
93,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence",c37659491a000415239367e1978caf776dc39280,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
94,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,a phase 3 trial comparing atezolizumab plus bevacizumab versus sunitinib in first-line metastatic renal cell carcinoma,ff75c2eee75a5b6c52756cac79f7af79ffc683dd,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
94,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,patients with previously untreated metastatic renal cell carcinoma,d39b284e062de97f1ada89226d8b6168e2099764,False,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
95,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
95,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
96,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment,7ad600db6616635fc16a44ff62e3125d220e6c0e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
96,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment,7ad600db6616635fc16a44ff62e3125d220e6c0e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
97,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC",0b402dc18bfbf2b3abe6d6e47c3cc9b7ada85791,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
97,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC",0b402dc18bfbf2b3abe6d6e47c3cc9b7ada85791,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
98,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy",dcbe702f34b4ba40177de4b6f4df1dd179f0d943,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
98,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 2:1 ratio",53a464af8f4765b601194c6ed2b698be42e8d2b2,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
99,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs) and enrolled",b7e8d2cdc9533f4eb4de4a221f8b6dc7bd9167f1,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
99,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs) and enrolled",b7e8d2cdc9533f4eb4de4a221f8b6dc7bd9167f1,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
100,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.",2bb4c508e081004e847881868ce95d43864f22fb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
100,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.",2bb4c508e081004e847881868ce95d43864f22fb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
101,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,locoregionally advanced nasopharyngeal carcinoma,2edcecb4d1b79b8fa4d89eb6411cb292d075cebd,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
101,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,locoregionally advanced nasopharyngeal carcinoma,2edcecb4d1b79b8fa4d89eb6411cb292d075cebd,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
102,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage.",9a226940bcf144b135766bfa4bf9bf3e09e0a381,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
102,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage.",9a226940bcf144b135766bfa4bf9bf3e09e0a381,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
103,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.,e17cfaf030de1c203c1c5a45a0f85f9ffc6a7796,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
103,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.,e17cfaf030de1c203c1c5a45a0f85f9ffc6a7796,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
104,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma,fa08345d653fe100e478be37169783281485351b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
104,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma and adequate cardiac, renal, and hepatic function.",47305802b893796a8363fba1844bb539f1eefa15,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
105,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Randomisation was done via the minimisation method with biased-coin balancing for Eastern Cooperative Oncology Group performance status, disease stage at enrolment, and institution.",0cb6744cc662dde9e8f633cc0a52e5bbc16eee32,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
105,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,Patients with small-cell lung cancer that responded to first-line treatment but showed evidence of disease relapse or progression at least 90 days after completion of the first-line treatment were eligible to participate.,7a675638797d3a81ba42bbb525134d8c2a5eaebf,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
106,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
106,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
107,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer,925a41b4143b75a761a76d588e6b8fbc0d961442,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
107,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer,925a41b4143b75a761a76d588e6b8fbc0d961442,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
108,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"patients with advanced cancer, aged at least 18 years, admitted to the palliative and supportive care unit at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), with refractory agitation",c39b3f6f7eb39a439e7f57b846d303f827a00ac0,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
108,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"patients with advanced cancer, aged at least 18 years, admitted to the palliative and supportive care unit at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), with refractory agitation, despite low-dose haloperidol",0b7f5d5aa0566c9284b0dc46892d61e4b77c7915,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
109,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma",6f23b4ecc422bab373dea947e4bb3946b5ac0614,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
109,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma",6f23b4ecc422bab373dea947e4bb3946b5ac0614,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
110,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease",42edce59222b2d92f7594e370656ad2a9f95330c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
110,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease",42edce59222b2d92f7594e370656ad2a9f95330c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
111,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
111,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
112,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction,7764aacefa5c6343a21be2968247573405ba770c,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
112,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction,7764aacefa5c6343a21be2968247573405ba770c,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
113,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"we randomly assigned, in a 1:1 ratio, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to receive 500 mg of nicotinamide twice daily or placebo for 12 months",8d9b12c4a7e614356b0e109df4cf4ab5cfd9b92a,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
113,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"we randomly assigned, in a 1:1 ratio, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to receive 500 mg of nicotinamide twice daily or placebo for 12 months",8d9b12c4a7e614356b0e109df4cf4ab5cfd9b92a,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
114,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment,4864296f7ae844ff2919e93269293aa144b83745,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
114,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment,4864296f7ae844ff2919e93269293aa144b83745,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
115,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy,2f7ab902b18cc5cdd9667c868b8ed71e403d9958,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
115,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy,2f7ab902b18cc5cdd9667c868b8ed71e403d9958,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
116,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma",4e9d1b2e87d328e571dc9c7e55c1d887aef3d569,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
116,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma",4e9d1b2e87d328e571dc9c7e55c1d887aef3d569,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
117,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.,1e5a0d07bcab51fdb16ae60707f07703b41de616,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
117,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.,1e5a0d07bcab51fdb16ae60707f07703b41de616,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
118,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Eligible patients were aged 18-75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)",666abb58c43dc6cbad55d9584c2ff02bb0c5a432,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
118,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients were aged 18-75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)",666abb58c43dc6cbad55d9584c2ff02bb0c5a432,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
119,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with palpable T1-T2 invasive breast cancer were recruited,8e7d379bc116332307e54f6cef9d8d517b082952,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
119,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with palpable T1-T2 invasive breast cancer were recruited from six medical centres in the Netherlands,75db0374ad38f800d02b0e19ffb948f7dd7f37c6,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
120,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"patients with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer",a5ce4ad3a274bfe8aa55aadfaa00d7624f32c56d,False,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
120,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"patients with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer",a5ce4ad3a274bfe8aa55aadfaa00d7624f32c56d,False,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
122,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors,bcec87f427a1c6e6a336726d281fb67543d3cf78,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
122,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors,bcec87f427a1c6e6a336726d281fb67543d3cf78,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
123,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma",d57a0e70cd847b04f4eb56ebbf449fa9bc55841a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
123,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma",d57a0e70cd847b04f4eb56ebbf449fa9bc55841a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
124,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.",f01be5f907ffb3968529022574e3b780796c8912,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
124,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.",f01be5f907ffb3968529022574e3b780796c8912,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
125,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease, as defined by Response Evaluation Criteria In Solid Tumors version 1.1, had received at least one platinum-based regimen",6d1a87a3d2148833cdae7e2691ac258614cf0a5d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
125,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease,fbb28621ca792d0faff6a84d142934f1380805f2,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease,2013657070185ba51f4157a780dc6214d4a149b4,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease,2013657070185ba51f4157a780dc6214d4a149b4,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
127,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC were enrolled,f6ae1a7979a85cbb3361ae4ed55a331be7d7d488,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
127,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with resectable stage IIIA or IIIB (T3N2) NSCLC were enrolled,8a67bd68234b5be5e42e23c8be40fd3591fef96f,False,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
128,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",62a9896c1da9a80e07fb82397217a16d1d84584a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
128,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",62a9896c1da9a80e07fb82397217a16d1d84584a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
129,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
129,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
130,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm,4296d5fb72270e8341ca5ee07edb61cf79b35b50,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
130,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm,4296d5fb72270e8341ca5ee07edb61cf79b35b50,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
131,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
131,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
132,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"We conducted a randomized, open-label, noninferiority, postauthorization, safety end-point trial involving patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor.",e38390aaad285508fbd172229746be5928a3e2f5,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
132,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor,91bd9ce646c85b4c45e39bd471eb05419d1cc62e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
133,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with stage IV melanoma with no evidence of disease after resection or radiotherapy,e65618adae10e67174237fc8b646807da88c37e8,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
133,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
134,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level of 1% or more to receive nivolumab",42ad9b9e5fbcd4e67959609e6321d877e640a6d7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
134,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,patients with untreated stage IV or recurrent NSCLC,0c85b8487b0acb5a3977724399f64a26805c26c5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
135,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Among patients with high-risk relapsed metastatic neuroblastoma, oral β-glucan adjuvant during GD2/GD3 ganglioside vaccine boost has stimulated IgG antibody response",8deda0b2488b04e6850c168c5df2fc2cd550ea0f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
135,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"Among patients with high-risk relapsed metastatic neuroblastoma, oral β-glucan adjuvant during GD2/GD3 ganglioside vaccine boost has stimulated IgG antibody response",8deda0b2488b04e6850c168c5df2fc2cd550ea0f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
136,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre.,a6faddd453e53720422bf2bb801ad8dfcd687277,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
136,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre.,a6faddd453e53720422bf2bb801ad8dfcd687277,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
137,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Because of the inaccessibility of mediastinal nodal metastases, the left thoracoabdominal approach (LTA) has often been used to treat gastric cancer of the cardia or subcardia.",505584ec834af3150eb82845836a6a1791972f0e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,adults aged 18 years or older with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum that was refractory to previous standard therapy,af633a6944eb57692b1eedaba57650900c92a1b9,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,adults aged 18 years or older with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum that was refractory to previous standard therapy,af633a6944eb57692b1eedaba57650900c92a1b9,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"523 patients with curable stage T2b, T3, or T4 gastric cancer were randomly assigned during surgery to D2 lymphadenectomy alone (263 patients) or to D2 lymphadenectomy plus PAND (260 patients)",490954a6e6f8f512ac272d794f2793653b2bb8ac,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
139,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"523 patients with curable stage T2b, T3, or T4 gastric cancer were randomly assigned during surgery to D2 lymphadenectomy alone (263 patients) or to D2 lymphadenectomy plus PAND (260 patients)",490954a6e6f8f512ac272d794f2793653b2bb8ac,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
140,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
140,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
141,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression,187b46812f1d8adc55b45569e5fa26ef2e61a69a,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
141,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression,187b46812f1d8adc55b45569e5fa26ef2e61a69a,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
142,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)",22ba5ffce0ae91fc338c92ab90641a6944ad8acb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
142,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"This multicenter, double-blind, placebo-controlled phase 3 trial enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)",a91ba8c0d91ff17d0e6af1c40fd559be263bf262,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
143,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"Screening for its precursor, anal intraepithelial neoplasia (AIN), is subject of discussion.",3a464d27b3321c8001ba80fab558066c60e9a134,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
143,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"Screening for its precursor, anal intraepithelial neoplasia (AIN), is subject of discussion.",3a464d27b3321c8001ba80fab558066c60e9a134,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
144,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,spinal cord compression caused by metastatic cancer,8cb9910a1b04bc12e5d19bac259fcc3e2c21ab9a,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
144,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,spinal cord compression caused by metastatic cancer,8cb9910a1b04bc12e5d19bac259fcc3e2c21ab9a,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
145,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy",a68c0f30833a87517c04acc3c8114503aba73390,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
145,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision",9d69fb515579fc1983b1221d78ede77659cfc981,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
146,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States,74c9e84f875aaf64bd23ef59b2906c556e7e43aa,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
146,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,marine n-3 fatty acids (at a dose of 1 g per day) in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States,6637c1e973a270fa129945396421098300d68ccf,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
147,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.,69b842dffdbffa24b7350f9d02f2376643d86b1b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
147,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.,69b842dffdbffa24b7350f9d02f2376643d86b1b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
148,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
148,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
149,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.",5dd83413e5cf0f338a57224082e25970f5d5aa27,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
149,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.",5dd83413e5cf0f338a57224082e25970f5d5aa27,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
150,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with a histologically proven superficial basal-cell carcinoma,e8d4ba50a7b6fd5dcb3c9939a6f3043aa82a3107,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
150,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with a histologically proven superficial basal-cell carcinoma,e8d4ba50a7b6fd5dcb3c9939a6f3043aa82a3107,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
151,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.",12f0f83eee4f297d5b656a2bc3371efacee7671e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
151,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.",12f0f83eee4f297d5b656a2bc3371efacee7671e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
152,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,We included chemotherapy-naive men (aged ≥18 years) with mCRPC who had not been previously treated with androgen biosynthesis signalling inhibitors,234ef7b029d3c6b6fe6e4a16d75c5e4f63861090,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
152,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We included chemotherapy-naive men (aged ≥18 years) with mCRPC who had not been previously treated with androgen biosynthesis signalling inhibitors and were receiving ongoing androgen deprivation therapy,05deb733e7d9d49fc7d4383c5369da4a73d85928,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
153,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment",623aaaee2065b1baf7cf0c6d1adae0950ab244e3,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
153,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment",623aaaee2065b1baf7cf0c6d1adae0950ab244e3,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
154,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Women older than 18 years with histologically confirmed HER2-overexpressing breast cancer and CNS recurrence or progression as determined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) during or after treatment with trastuzumab, lapatinib, or both, were eligible.",25d39f9ae00ffa521ebe07ab3bb1d89b5117c54e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
154,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Patients with advanced HER2-positive breast cancer frequently develop CNS metastases. The metastases that progress after brain radiotherapy and HER2-targeted systemic therapy are a difficult therapeutic challenge.,804de7f2c4ca52ad32ac8c22c2f8e6981ec07e52,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
155,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
155,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
156,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery,497bfcf94eef00225dfe6be3ee39ac77b8c6b7a2,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
156,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery,497bfcf94eef00225dfe6be3ee39ac77b8c6b7a2,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
157,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,The primary end point was metastasis-free survival,3f799a018c6da63b630bf17cb51591206ce075f1,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
157,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less,7860fcacfb91af16f9e4ce1d620792df7883440f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
158,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
158,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
159,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,children and young adults (<30 years) with high-risk neuroblastoma were randomly assigned at diagnosis,b41ff7b720bc34fc428c92ded59893dd848cc9bb,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
159,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,children and young adults (<30 years) with high-risk neuroblastoma were randomly assigned at diagnosis,b41ff7b720bc34fc428c92ded59893dd848cc9bb,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
160,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy",05c2939dada0672749ec4cb4ea3d7457c7858303,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
160,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy",05c2939dada0672749ec4cb4ea3d7457c7858303,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
161,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"patients with previously untreated, FGFR2b-overexpressing, advanced gastric or gastro-oesophageal junction adenocarcinoma",c33c45777f5ddb41bc8337ed90d047903fbb774d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
161,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"previously untreated, FGFR2b-overexpressing, advanced gastric or gastro-oesophageal junction adenocarcinoma",4356af0ce9de80b48a9f001e5ff5ada783c5d8cc,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
162,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"pathologically proven, stage IIIA/N2 non-small-cell lung cancer",b7018211963328285fa59b411a7fde24c20729b8,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
162,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
163,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer from 81 Italian centres",42c2125c9d0d81288538f25dd8b3c047203713de,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
163,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer from 81 Italian centres",42c2125c9d0d81288538f25dd8b3c047203713de,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
164,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors.,ad666259a56de2edd15a2032e761dc69121c9de1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
164,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation,583a76088c72262449dac8aacd51fb58b93120b8,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
165,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"adult patients (aged ≥18 years) with advanced, progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal origin were enrolled",1097520aab3d197f4867ce88a13d038e7c72ae07,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
165,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"adult patients (aged ≥18 years) with advanced, progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal origin were enrolled",1097520aab3d197f4867ce88a13d038e7c72ae07,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane,246502d97693ff1bf8efb3c3018acc06eccbfa9d,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
166,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane,246502d97693ff1bf8efb3c3018acc06eccbfa9d,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
167,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.,5fc989ef5fe2c3d505652b55cb785026b6bb9235,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
167,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.,5fc989ef5fe2c3d505652b55cb785026b6bb9235,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
168,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"HR-positive, HER2-negative advanced breast cancer",faee86c53010ff6d9154771948e27e86ca8b279f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
168,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"HR-positive, HER2-negative advanced breast cancer",faee86c53010ff6d9154771948e27e86ca8b279f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
169,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,We enrolled female patients with HER2-overexpressing metastatic breast cancer who had progressed on or following adjuvant trastuzumab or first-line treatment of metastatic disease with trastuzumab.,e9c238aef87e34090486f21c9fb8626127670618,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
169,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We enrolled female patients with HER2-overexpressing metastatic breast cancer who had progressed on or following adjuvant trastuzumab or first-line treatment of metastatic disease with trastuzumab.,e9c238aef87e34090486f21c9fb8626127670618,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
170,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,We screened 3100 first-degree relatives of patients with gastric cancer. We randomly assigned 1838 participants with H. pylori infection to receive either eradication therapy...or placebo. The primary outcome was development of gastric cancer.,d87629d59bc12887eef7657e1a5eaaf115461d59,False,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
170,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,We screened 3100 first-degree relatives of patients with gastric cancer. We randomly assigned 1838 participants with H. pylori infection to receive either eradication therapy,66318eaa24dd72efbb8f2dd5ae9d892d620fe6db,False,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
171,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-positive early breast cancer in premenopausal women,e2e40fd85b9bba6397be29b29ac5c6c0bdfeea59,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
171,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-positive early breast cancer in premenopausal women,e2e40fd85b9bba6397be29b29ac5c6c0bdfeea59,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
173,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,To assess whether stereotactic body radiotherapy on a single tumor site preceding pembrolizumab treatment enhances tumor response in patients with metastatic NSCLC.,374e60a2a29d21ed4816c49171017e2b69b302d3,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
173,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,To assess whether stereotactic body radiotherapy on a single tumor site preceding pembrolizumab treatment enhances tumor response in patients with metastatic NSCLC.,374e60a2a29d21ed4816c49171017e2b69b302d3,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
174,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"Men and women, who had indicated on a previous questionnaire that they would probably attend screening if invited, were randomly assigned (1:2) to an intervention group (offered flexible sigmoidoscopy screening) or a control group",cb97a816b5b3cac53b18771afd7428f40aa973a8,False,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
174,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,Colorectal cancer is the third most common cancer worldwide. Previous analyses have only reported follow-up after flexible sigmoidoscopy for a maximum of 12 years. We aimed to examine colorectal cancer incidence and mortality after a single flexible sigmoidoscopy screening and 17 years of follow-up.,96770c141957debb83e0b58151ff6f98d9f0363e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
175,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who had been pretreated with platinum-based chemotherapy.,9e6203ad597e2d1e23acd743cea428eb86362819,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
175,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who had been pretreated with platinum-based chemotherapy.,9e6203ad597e2d1e23acd743cea428eb86362819,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
176,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"From 1993 through 2001, we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects).",529c7a2f02b5029cc173759afd736b6a80629cf1,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
176,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects)",c66df23d0610296fd455dd07268b825cf01af1ac,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
177,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.,70d475696cdc082bcacbd6384e423ff7da28aba6,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
177,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.,70d475696cdc082bcacbd6384e423ff7da28aba6,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
178,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"to demonstrate the efficacy of ivosidenib (AG-120)-a first-in-class, oral, small-molecule inhibitor of mutant IDH1-vs placebo for patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation",c9ddda61d7731bee7b9899c8f9a9f8c0924f2ccc,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
178,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"demonstrate the efficacy of ivosidenib (AG-120)-a first-in-class, oral, small-molecule inhibitor of mutant IDH1-vs placebo for patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation",160d6dd97964e72f3e4ee7ea40f2d3fc4f700252,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
179,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Patients (age 1-20 years) with neuroblastoma were eligible to be randomly assigned if they had completed a multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide with or without topotecan, vincristine, and doxorubicin) and achieved an adequate disease response.",0d65348acebaddbbcf21c23018e019f526dfc462,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,had previously untreated recurrent or metastatic nasopharyngeal carcinoma,bb06d0c31dc58f6a446b63ce25a67cb6e3404c9b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,had previously untreated recurrent or metastatic nasopharyngeal carcinoma,bb06d0c31dc58f6a446b63ce25a67cb6e3404c9b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
182,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more,8238f81c269109ba3c048924442cdc35631824df,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
182,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more,8238f81c269109ba3c048924442cdc35631824df,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
183,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with previously untreated stage II or stage III triple-negative breast cancer,df1fbc5bb5dcbf5062226f899b54c592cad0ffc2,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
183,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with previously untreated stage II or stage III triple-negative breast cancer,df1fbc5bb5dcbf5062226f899b54c592cad0ffc2,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
184,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer,823f122356f8f86a5e76455b661c9dd507b9fb64,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
184,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer,823f122356f8f86a5e76455b661c9dd507b9fb64,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
185,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,Eligible participants aged 1-18 years with newly diagnosed cancer and normal audiometry were randomly assigned (1:1) to receive sodium thiosulfate or observation (control group) in addition to their planned cisplatin-containing chemotherapy regimen,a8a037c85beae667177bdf82856f613163a24083,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
185,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,Eligible participants aged 1-18 years with newly diagnosed cancer and normal audiometry were randomly assigned (1:1) to receive sodium thiosulfate or observation (control group) in addition to their planned cisplatin-containing chemotherapy regimen,a8a037c85beae667177bdf82856f613163a24083,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
186,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
186,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
187,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"patients with locoregionally advanced, unresectable disease... stage III or stage IV disease and no distant metastases",67e772b38e26fbd01cfb432fd112411f8eea3964,False,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
187,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"patients with locoregionally advanced, unresectable disease...stage III or stage IV disease and no distant metastases",58fce206b6c9f3acee27f17ae91063cb7de45160,False,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
188,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent",406f22033394df460ac3a4a6de3cf7b661fbcc51,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
188,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent",406f22033394df460ac3a4a6de3cf7b661fbcc51,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
189,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"a randomised, placebo-controlled, double-blind trial of exemestane 25 mg a day for the primary prevention of breast cancer",775a173bb31c607563b6c7d1ad882376d7fc252f,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
189,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"a randomised, placebo-controlled, double-blind trial of exemestane 25 mg a day for the primary prevention of breast cancer",775a173bb31c607563b6c7d1ad882376d7fc252f,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
190,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer,1d5ab5aa44d4b9fe7746b357e8ac868cb49cd851,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
190,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer,1d5ab5aa44d4b9fe7746b357e8ac868cb49cd851,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
191,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
191,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
192,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer",32ca4d3fff954ed57510ab1bee98e9767a91dddc,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
192,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.",09698d0fe82df3f68e60864457c76c6e4c68b602,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
193,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Eligible patients were adults (aged 18 years or older) with progressive, advanced, well differentiated pancreatic NETs, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and progression on up to two kinds of previous systemic regimens for advanced disease.",345f51cc7a17b35f0e59c0d61c6219a51a9ba1b9,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
193,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Eligible patients were adults (aged 18 years or older) with progressive, advanced, well differentiated pancreatic NETs, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and progression on up to two kinds of previous systemic regimens for advanced disease.",345f51cc7a17b35f0e59c0d61c6219a51a9ba1b9,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
194,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions,83b241e5412ffc76522b5f4b1eb8c2ba5559c311,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
194,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions, Eastern Cooperative Oncology Group score of 0-1, and a life expectancy of at least 6 months were eligible.",a2bb26ee3f4690b802f9ac765f68896bb4dff919,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
195,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung who had progressed after at least four cycles of platinum-based-chemotherapy.,7b6c6e36b482f1636c166e4378de25d7832b70ee,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
195,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung who had progressed after at least four cycles of platinum-based-chemotherapy.,7b6c6e36b482f1636c166e4378de25d7832b70ee,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
196,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel",b0d5b8e000da10259a494d9d1d935a8a5098b10d,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
196,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel",b0d5b8e000da10259a494d9d1d935a8a5098b10d,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
197,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Patients aged 18 years and older with metastatic soft-tissue sarcomas,5aa95ecda2edcb243e6f1061f50ba6de22c5831e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
197,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Patients aged 18 years and older with metastatic soft-tissue sarcomas,5aa95ecda2edcb243e6f1061f50ba6de22c5831e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
198,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry.,0dba11ee514688d77c9254edf4807a4baff8b71f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
198,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry.,0dba11ee514688d77c9254edf4807a4baff8b71f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
199,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment,0278ffd332ca1b2e0bf80b280ebe480fb8d41250,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
199,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment,0278ffd332ca1b2e0bf80b280ebe480fb8d41250,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
0,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We randomly assigned patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual),fc7bb4a1f2e57bc303295fd86d2ec6c2c8ca0505,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
1,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma with prespecified FGFR alterations,0160b11634f2b30a9d244e76b12d448a9151fb57,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
2,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"In this phase 3 study, we aimed to compare overall survival in patients with advanced or metastatic soft-tissue sarcoma who received eribulin with that in patients who received dacarbazine",cf3614b788fdddf6d88bbe8c5a0531acbefc221b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
4,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,To investigate the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing after second-line or further treatment.,c9e609f99613768550cecda30d5261632a03cdcd,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.,095a4141eb262225a4f7a27dacfdcec099af798c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
6,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Localised prostate cancer is commonly treated with external beam radiotherapy,0c49d50c3d7e6e3b243439cb9d2a760b787b52c7,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"In this randomised controlled trial, we recruited postmenopausal women aged 50-74 years from 13 centres in National Health Service Trusts in England, Wales, and Northern Ireland.",c0b3f644539d5fce65e71e6ffad366dbfc3ba94e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
8,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,women had to be at increased risk of breast cancer (judged on the basis of specific criteria),f6e99365f989a7d0a77de7cdc0f7e02d7e48083c,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
9,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma",f7c8ae218aa2a3d30f7332ef5fdf9e777dc7d8dc,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
10,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab.",0591ee004c0def46184a426053dd9738f35bbfe6,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
11,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer.",d1e614fe7b5029804a8fbe3e3a04765c4bffb316,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
12,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1 to 3 prior regimens and performance status of 0 to 2.",f3409732cc7d4683f100ffbb4e6a413730016a80,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
13,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,5102 patients with HER2-positive early breast cancer,42e034cabf2625e843f4f5548b2fb5d4b396f648,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
14,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer,51ec0273befa1e47d1450daed3776964587877f4,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
15,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer were randomly assigned",84ec036d9366cf4a0250f89f04a963cb3b9da6ed,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
16,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.",7e1f10ae979f9c975e6f844c7d8c536f7403d433,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
17,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast",c6bec3db773bc407f94951fa1e0122a502885747,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
18,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,healthy women older than 25 years,7cef698a40287e43633ef9741ddf42790931b86d,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
20,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer,7705de340e41b57febb4d8971de9d1fa7442e04e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
21,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation,8558a85da1ba64adc29d0d287b8124a5c93b74ba,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"we randomly assigned 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations",32924e6cfd4d4f195549c678749a0c82e6d5b7ad,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
23,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,140 patients with early breast cancer were randomly assigned,bff69170118c768e1eb092596381a3c543eed253,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
25,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Barcelona Clinic Liver Cancer stage B or C disease,c7301b6296b7bdbecfa1ac7e161014afb25491ea,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
26,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,Women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing in combination with liquid-based cytology,bbda95a47068f488276798ce98cd978a28681a60,False,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
27,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned,bfee109a10676ba8e9aa75d74715bb869358dc39,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
30,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,1500 women with axillary node-positive or high-risk node-negative breast cancer,bcdd56e17d1a840c3afc168e772f2dc8dca708c5,True,LOCALIZED,gemini,gemini-3-flash-preview,"0 status or ""node-negative"" status refers to Stage",INVALID,False,
31,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously,324aade2b9dcc7564cab85ec6def80cff9e1bad4,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
32,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Patients with centrally confirmed HER2-positive gastric or gastroesophageal junction adenocarcinoma that had progressed while they were receiving at least two previous therapies, including trastuzumab",83e41a14d9cc5141b01a709074a904e7e85884b7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
33,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"In a multicenter, sham-controlled trial, we randomly assigned 127 patients with dysplastic Barrett's esophagus",32a9eef18cf13b2c780494445c6368dd83b84420,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
34,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Eligible patients were premenopausal women aged 18-59 years who had histologically or cytologically confirmed HR-positive, HER2-negative, advanced breast cancer",376bc86d88c5629dd3f7472a123ac28182d128a6,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
35,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy,5a943ca8e986a9372d87d3a446983858c218bfb1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
36,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned",bef7dc4daef6dba31ca7cb28ef2c7402a9b0617e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
37,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,eligible patients recruited in 138 clinics from 24 countries (aged ≥18 years with histologically or cytologically confirmed advanced non-small-cell lung cancer,dd4a2579bcb6d5baa7eb513d87860f580f708e7d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
38,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma",4dccde99f317d5f36d314601c66701d8accae702,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
39,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma,fcc8b382a999378f1e6c81cc8bc685b7d2fad526,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
40,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We sought to determine the efficacy and safety of sunitinib in patients with locoregional renal-cell carcinoma at high risk for tumor recurrence after nephrectomy.,c082bcd6fe87f693cd29a356941c7d8d288f67e6,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
41,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Standard first-line regimens for patients with metastatic gastroesophageal adenocarcinomas have an approximate 40% objective response rate (ORR).,43c6405e58d7844115495f18c7fbe2aafae3c296,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
42,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b,823afbdce5dc36ee194b7d774c5eaaf9d0366acf,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
43,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer and who had chosen surgery as their treatment approach,6c7bbb749c23a76c07155510f2a35c4213821cd1,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
44,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We assessed the effects of combined docetaxel and estramustine on relapse in patients with high-risk localised prostate cancer.,786ab75603b505994389571e11eaa12e57c099cc,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
45,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated,02d496a2dd8422ce71898eb8c05bed6bc7046068,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
46,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer without neuroendocrine differentiation,d8b422adbc7e21bce8ba462cb2cfd07fe0ae4df0,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
47,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen,e4721392778786e03d84fcd2855ac39157cedcdd,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
48,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we recruited patients aged 18 years or older who had received taxane therapy and undergone two or fewer previous chemotherapy regimens for metastatic breast cancer,c76e796fffd838f7d92822c2d1386d920f8b782c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
49,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer",cfbf220f019f4e538d01b925b7d7555d6a0e6e8a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
50,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we enrolled patients with stage IIIB or IV adenocarcinoma,0825e4d60d1fa4f662bb55c1140ae89e2cce2319,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
51,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer",97d6bfead549bd200270e4c195e1f70f5a675d31,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
53,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,adjuvant chemotherapy for operable node-positive breast cancer,d831e475033b14ff9450885da9a3f45addd83004,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
54,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy.,c02ea06c108110323e6de9212ef4743b789afcb7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
55,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"In the Prostate Cancer Prevention Trial (PCPT), finasteride significantly reduced the risk of prostate cancer",61f3e6a7146bfbb6e0c92599b2e3abca0e51ee7b,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
56,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,men treated with radiotherapy for prostate cancer,3785749ee005f17e910b4e193d9dfe606c193607,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
57,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,patients with radiologically confirmed painful bone metastases,86cb4376c17caed9db019d633d3111c8c42964c5,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
58,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer",98a8176ee5187d630adb8aeaa485ef5593c3909e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
59,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,We assessed the efficacy and safety of pertuzumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic gastric or gastro-oesophageal junction cancer.,c96be6c17272c3b6a08ee06032afbfaf76e684ab,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
60,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer,eb39c499b2390ac2dd1d4534274471899a2f3445,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
62,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease)",4d8a53f9ab4779215bbb08f3398f784bae600b5a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
63,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) who had disease progression after receiving EGFR tyrosine-kinase inhibitor therapy,c6ea67fb9b85a8261880f550b0ffcca8ee4134e5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
64,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,patients with advanced renal cell carcinoma and no previous systemic therapy,27873bec3229f421e7a00bd2e3a69d89aa463abb,True,BOTH,gemini,gemini-3-flash-preview,"IV).
    *   Does the quote *support",INVALID,False,
65,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease, children (≥365 days of age) who had stage 3 tumors with favorable histopathological features, and infants who had stage 4S disease with a diploid DNA index or unfavorable histopathological features.",e2f405aa914f41ce9361dcd11d7d73d45a94569d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
66,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment",92b54c29dfeb350fb3e61b31231bb4b6ae50a08e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
67,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned",0d6ba56beb6830ccb551ce364ac1ff2caf808724,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
68,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,patients aged 18 years or older with unresectable hepatocellular carcinoma,dafec26da4015cf84651f3e0d1d6c58a92a0471e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma,96d38b1bcb1aa5ffc0fdc50e988558ea509561ce,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
70,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Randomization was stratified based on site of metastasis (visceral, bone only, or other)",6ea62c972b956e36c633136528c0a1dd84c8e97a,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
71,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
72,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with resected stage III melanoma with BRAF V600E or V600K mutations,579a7383ae80b1ae9fe530ed163c8b19a1c1d3ec,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
73,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"This international, multicenter, open-label parallel-group phase 2 randomized clinical trial was conducted at 9 tertiary academic cancer centers in Canada and Australia and enrolled patients with T1-T2N0-2 p16-positive OPSCC",5f23cfb9eedad535fea0acd3ed0d3338419d02ae,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
74,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries,bf89fe51434b0d644946853de71f676f18751fd0,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
75,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors",705c0db343db93f7def5ac17051a9587b6be6529,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
76,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,Pragmatic randomized clinical trial from March 2013 to July 2016 among 5999 participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings.,55256a245d0faecee3ad6ecb733169dfa86e371e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
77,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,2f473300ee2ed5d6e679dd22a6fb62b3b64bf27b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
78,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer (cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer)",20f35dbfe1c2d4338016708f34248860a1dba4ce,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
79,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy",0405aa34a2137529c9041abdac3e50222c00c304,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
80,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment, enzalutamide significantly increased overall survival compared with placebo.",c34877d78c6b666cca66be8b0ea0be09064ed5e7,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
81,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
82,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,patients with untreated locally recurrent inoperable or metastatic triple-negative breast cancer,29fb90e05aab5f09411ed2d741d293bd2063769a,False,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
83,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients 18 to 75 years of age with resectable cancer of the middle or lower third of the esophagus,0baebef4cd924b3a4022d771beea312b006e770c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
84,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,previously untreated recurrent and/or metastatic ERBB2-positive breast cancer,710609f4c90c54721c6ff50e3f5906bc48e4cc5f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
85,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C,91cec28e5c907eadc7e24c39b2db70269724b18c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
86,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy",8ca5067dadf24757c361c89491a6f0977f3e888c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
87,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract",feac9e353db3a2317bbb6d8f79e649e29d2c384c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
88,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,840 patients with stage IB-IIIA NSCLC from 101 centres in 14 countries were randomly assigned to observation (n=433) or to 30 mg/m(2) vinorelbine plus 100 mg/m(2) cisplatin (n=407).,b63664706fb59899ae2ce5dda6f04bdf65982d18,True,LOCALIZED,gemini,gemini-3-flash-preview,"LOCALIZED
    *   QUOTE describes IB-II",INVALID,False,
89,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"histopathologically diagnosed with undifferentiated or differentiated, non-keratinising, locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus",6066226c122c0b9b37ac9622c8c2759dbd45608e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
90,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"To determine if the addition of celecoxib to adjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) improves disease-free survival in patients with stage III colon cancer.",49ff2f8d949d4746f41ca8d1a792d27bbe3dee1c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
91,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Sentinel-lymph-node biopsy is associated with increased melanoma-specific survival (i.e., survival until death from melanoma) among patients with node-positive intermediate-thickness melanomas (1.2 to 3.5 mm).",dd2ce66947ca9e027a74abf5aab423fca1f3744c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
92,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Eligible patients (aged ≥18 years) had histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma with first disease recurrence more than 6 months after first-line platinum-based chemotherapy",efb5c3a90dacb2bf43619b9c28e38d5779aa313f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
93,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence",c37659491a000415239367e1978caf776dc39280,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
94,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,comparing atezolizumab plus bevacizumab versus sunitinib in first-line metastatic renal cell carcinoma,2a9315e96c1d5e7fed9a565a224f05cb302f1a14,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
95,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
96,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment,7ad600db6616635fc16a44ff62e3125d220e6c0e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
97,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC",0b402dc18bfbf2b3abe6d6e47c3cc9b7ada85791,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
98,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy",dcbe702f34b4ba40177de4b6f4df1dd179f0d943,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
99,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs) and enrolled",b7e8d2cdc9533f4eb4de4a221f8b6dc7bd9167f1,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
100,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.",2bb4c508e081004e847881868ce95d43864f22fb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
101,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,locoregionally advanced nasopharyngeal carcinoma,2edcecb4d1b79b8fa4d89eb6411cb292d075cebd,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
102,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage.",9a226940bcf144b135766bfa4bf9bf3e09e0a381,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
103,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.,e17cfaf030de1c203c1c5a45a0f85f9ffc6a7796,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
104,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma,fa08345d653fe100e478be37169783281485351b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
105,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Randomisation was done via the minimisation method with biased-coin balancing for Eastern Cooperative Oncology Group performance status, disease stage at enrolment, and institution.",0cb6744cc662dde9e8f633cc0a52e5bbc16eee32,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
106,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
107,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer,925a41b4143b75a761a76d588e6b8fbc0d961442,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
108,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"patients with advanced cancer, aged at least 18 years, admitted to the palliative and supportive care unit at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), with refractory agitation",c39b3f6f7eb39a439e7f57b846d303f827a00ac0,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
109,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma",6f23b4ecc422bab373dea947e4bb3946b5ac0614,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
110,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease",42edce59222b2d92f7594e370656ad2a9f95330c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
111,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
112,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction,7764aacefa5c6343a21be2968247573405ba770c,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
113,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"we randomly assigned, in a 1:1 ratio, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to receive 500 mg of nicotinamide twice daily or placebo for 12 months",8d9b12c4a7e614356b0e109df4cf4ab5cfd9b92a,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
114,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment,4864296f7ae844ff2919e93269293aa144b83745,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
115,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy,2f7ab902b18cc5cdd9667c868b8ed71e403d9958,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
116,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma",4e9d1b2e87d328e571dc9c7e55c1d887aef3d569,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
117,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.,1e5a0d07bcab51fdb16ae60707f07703b41de616,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
118,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible patients were aged 18-75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)",666abb58c43dc6cbad55d9584c2ff02bb0c5a432,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
119,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with palpable T1-T2 invasive breast cancer were recruited,8e7d379bc116332307e54f6cef9d8d517b082952,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
120,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"patients with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer",a5ce4ad3a274bfe8aa55aadfaa00d7624f32c56d,False,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
122,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors,bcec87f427a1c6e6a336726d281fb67543d3cf78,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
123,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma",d57a0e70cd847b04f4eb56ebbf449fa9bc55841a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
124,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.",f01be5f907ffb3968529022574e3b780796c8912,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
125,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease,fbb28621ca792d0faff6a84d142934f1380805f2,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
126,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease,2013657070185ba51f4157a780dc6214d4a149b4,True,BOTH,gemini,gemini-3-flash-preview,"Decision: Does ""Stage IVB or recurrent or persistent",INVALID,False,
127,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC were enrolled,f6ae1a7979a85cbb3361ae4ed55a331be7d7d488,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
128,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",62a9896c1da9a80e07fb82397217a16d1d84584a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
129,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
130,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm,4296d5fb72270e8341ca5ee07edb61cf79b35b50,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
131,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
132,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor,91bd9ce646c85b4c45e39bd471eb05419d1cc62e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
133,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with stage IV melanoma with no evidence of disease after surgery or radiotherapy,f85f0257d1ab124153605d0bbffc6c0db04db633,False,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
134,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,patients with untreated stage IV or recurrent NSCLC,0c85b8487b0acb5a3977724399f64a26805c26c5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
135,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Among patients with high-risk relapsed metastatic neuroblastoma, oral β-glucan adjuvant during GD2/GD3 ganglioside vaccine boost has stimulated IgG antibody response",8deda0b2488b04e6850c168c5df2fc2cd550ea0f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
136,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre.,a6faddd453e53720422bf2bb801ad8dfcd687277,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
138,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,adults aged 18 years or older with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum that was refractory to previous standard therapy,af633a6944eb57692b1eedaba57650900c92a1b9,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"523 patients with curable stage T2b, T3, or T4 gastric cancer were randomly assigned during surgery to D2 lymphadenectomy alone (263 patients) or to D2 lymphadenectomy plus PAND (260 patients)",490954a6e6f8f512ac272d794f2793653b2bb8ac,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
140,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
141,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression,187b46812f1d8adc55b45569e5fa26ef2e61a69a,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
142,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)",22ba5ffce0ae91fc338c92ab90641a6944ad8acb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
143,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"Anal cancer is an increasing issue in HIV-positive men who have sex with men (MSM). Screening for its precursor, anal intraepithelial neoplasia (AIN), is subject of discussion.",353b737861e00823d1b60d2aba28bb14722c5e7e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
144,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,spinal cord compression caused by metastatic cancer,8cb9910a1b04bc12e5d19bac259fcc3e2c21ab9a,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
145,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"patients aged 18 years or older from 129 UK centres who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy",d9579960f4cb2a8af4b3cafdef8256e00fe93b8e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
146,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States,12f69eadbafed10c6733ff923755b0fb906407e0,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
147,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.,69b842dffdbffa24b7350f9d02f2376643d86b1b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
148,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
149,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.",5dd83413e5cf0f338a57224082e25970f5d5aa27,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
150,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Superficial basal-cell carcinoma is most commonly treated with topical non-surgical treatments,a1cbe9d785f284b52fca25573b8f8a6cc81dead9,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
151,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.",12f0f83eee4f297d5b656a2bc3371efacee7671e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
152,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,We included chemotherapy-naive men (aged ≥18 years) with mCRPC who had not been previously treated with androgen biosynthesis signalling inhibitors,234ef7b029d3c6b6fe6e4a16d75c5e4f63861090,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
153,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment",623aaaee2065b1baf7cf0c6d1adae0950ab244e3,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
154,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Women older than 18 years with histologically confirmed HER2-overexpressing breast cancer and CNS recurrence or progression as determined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) during or after treatment with trastuzumab, lapatinib, or both, were eligible.",25d39f9ae00ffa521ebe07ab3bb1d89b5117c54e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
155,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
156,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery,497bfcf94eef00225dfe6be3ee39ac77b8c6b7a2,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
157,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,we enrolled patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less,5c2cf0243d55d96dd4292233768c76e266a6f0e2,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
158,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
159,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,children and young adults (<30 years) with high-risk neuroblastoma were randomly assigned at diagnosis,b41ff7b720bc34fc428c92ded59893dd848cc9bb,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
160,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy",05c2939dada0672749ec4cb4ea3d7457c7858303,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
161,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Outcomes are poor in patients with HER2-negative, advanced gastric or gastro-oesophageal junction adenocarcinomas.",81f3a0d81fc79f36f8808045aceb3a981bf715f2,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
162,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
163,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer from 81 Italian centres",42c2125c9d0d81288538f25dd8b3c047203713de,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
164,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation,583a76088c72262449dac8aacd51fb58b93120b8,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
165,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"adult patients (aged ≥18 years) with advanced, progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal origin were enrolled",1097520aab3d197f4867ce88a13d038e7c72ae07,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"We conducted a phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of trastuzumab deruxtecan (a HER2 antibody-drug conjugate) with those of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.",e50544c83b7956b22ab1ac15fff8159eb88637bb,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
167,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.,5fc989ef5fe2c3d505652b55cb785026b6bb9235,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
168,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"HR-positive, HER2-negative advanced breast cancer",faee86c53010ff6d9154771948e27e86ca8b279f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
169,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,We enrolled female patients with HER2-overexpressing metastatic breast cancer who had progressed on or following adjuvant trastuzumab or first-line treatment of metastatic disease with trastuzumab.,e9c238aef87e34090486f21c9fb8626127670618,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
170,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,We randomly assigned 1838 participants with H. pylori infection to receive either eradication therapy,c3ed5167be671bd93f25be64ff45859e98ded5b5,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
171,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-positive early breast cancer in premenopausal women,e2e40fd85b9bba6397be29b29ac5c6c0bdfeea59,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
173,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,To assess whether stereotactic body radiotherapy on a single tumor site preceding pembrolizumab treatment enhances tumor response in patients with metastatic NSCLC.,374e60a2a29d21ed4816c49171017e2b69b302d3,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
174,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"Men and women, who had indicated on a previous questionnaire that they would probably attend screening if invited, were randomly assigned (1:2) to an intervention group (offered flexible sigmoidoscopy screening) or a control group (not contacted).",00be356bb6b02279d8af11c34900d2702dc5397f,False,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
175,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who had been pretreated with platinum-based chemotherapy.,9e6203ad597e2d1e23acd743cea428eb86362819,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
176,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"From 1993 through 2001, we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects).",529c7a2f02b5029cc173759afd736b6a80629cf1,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
177,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.,70d475696cdc082bcacbd6384e423ff7da28aba6,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
178,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"demonstrate the efficacy of ivosidenib (AG-120)-a first-in-class, oral, small-molecule inhibitor of mutant IDH1-vs placebo for patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation",160d6dd97964e72f3e4ee7ea40f2d3fc4f700252,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
179,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Patients (age 1-20 years) with neuroblastoma were eligible to be randomly assigned if they had completed a multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide with or without topotecan, vincristine, and doxorubicin) and achieved an adequate disease response.",0d65348acebaddbbcf21c23018e019f526dfc462,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,had previously untreated recurrent or metastatic nasopharyngeal carcinoma,bb06d0c31dc58f6a446b63ce25a67cb6e3404c9b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
182,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more,8238f81c269109ba3c048924442cdc35631824df,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
183,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with previously untreated stage II or stage III triple-negative breast cancer,df1fbc5bb5dcbf5062226f899b54c592cad0ffc2,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
184,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer,823f122356f8f86a5e76455b661c9dd507b9fb64,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
185,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,Eligible participants aged 1-18 years with newly diagnosed cancer and normal audiometry were randomly assigned (1:1) to receive sodium thiosulfate or observation (control group) in addition to their planned cisplatin-containing chemotherapy regimen,a8a037c85beae667177bdf82856f613163a24083,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
186,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
187,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"patients with locoregionally advanced, unresectable disease... stage III or stage IV disease and no distant metastases",67e772b38e26fbd01cfb432fd112411f8eea3964,False,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
188,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent",406f22033394df460ac3a4a6de3cf7b661fbcc51,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
189,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"a randomised, placebo-controlled, double-blind trial of exemestane 25 mg a day for the primary prevention of breast cancer",775a173bb31c607563b6c7d1ad882376d7fc252f,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
190,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer,1d5ab5aa44d4b9fe7746b357e8ac868cb49cd851,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
191,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
192,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer",32ca4d3fff954ed57510ab1bee98e9767a91dddc,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
193,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Eligible patients were adults (aged 18 years or older) with progressive, advanced, well differentiated pancreatic NETs",5203160dfb07efc646930d7c8a2ed8f5ea77ac99,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
194,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions,83b241e5412ffc76522b5f4b1eb8c2ba5559c311,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
195,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung who had progressed after at least four cycles of platinum-based-chemotherapy.,7b6c6e36b482f1636c166e4378de25d7832b70ee,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
196,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel",b0d5b8e000da10259a494d9d1d935a8a5098b10d,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
197,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Patients aged 18 years and older with metastatic soft-tissue sarcomas,5aa95ecda2edcb243e6f1061f50ba6de22c5831e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
198,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry.,0dba11ee514688d77c9254edf4807a4baff8b71f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
199,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment,0278ffd332ca1b2e0bf80b280ebe480fb8d41250,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
0,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We randomly assigned patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual),fc7bb4a1f2e57bc303295fd86d2ec6c2c8ca0505,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
0,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We randomly assigned patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual),fc7bb4a1f2e57bc303295fd86d2ec6c2c8ca0505,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
1,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma with prespecified FGFR alterations,0160b11634f2b30a9d244e76b12d448a9151fb57,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
1,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma with prespecified FGFR alterations,0160b11634f2b30a9d244e76b12d448a9151fb57,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
2,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"In this phase 3 study, we aimed to compare overall survival in patients with advanced or metastatic soft-tissue sarcoma who received eribulin with that in patients who received dacarbazine",cf3614b788fdddf6d88bbe8c5a0531acbefc221b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
2,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"In this phase 3 study, we aimed to compare overall survival in patients with advanced or metastatic soft-tissue sarcoma who received eribulin with that in patients who received dacarbazine",cf3614b788fdddf6d88bbe8c5a0531acbefc221b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
4,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,To investigate the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing after second-line or further treatment.,c9e609f99613768550cecda30d5261632a03cdcd,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
4,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,To investigate the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing after second-line or further treatment.,c9e609f99613768550cecda30d5261632a03cdcd,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
5,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.,095a4141eb262225a4f7a27dacfdcec099af798c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
5,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.,095a4141eb262225a4f7a27dacfdcec099af798c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
6,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Localised prostate cancer is commonly treated with external beam radiotherapy,0c49d50c3d7e6e3b243439cb9d2a760b787b52c7,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
6,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Localised prostate cancer is commonly treated with external beam radiotherapy,0c49d50c3d7e6e3b243439cb9d2a760b787b52c7,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"We recruited postmenopausal women aged 50-74 years from 13 centres in National Health Service Trusts in England, Wales, and Northern Ireland.",507ed5b5e16c7afa7515b71d2a45e6af6b23c385,False,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
7,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"We recruited postmenopausal women aged 50-74 years from 13 centres in National Health Service Trusts in England, Wales, and Northern Ireland.",507ed5b5e16c7afa7515b71d2a45e6af6b23c385,False,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
8,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,postmenopausal women who are at high risk of the disease,a29a8e17895852ca8a39d9cdf67189f8e9161a2e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
8,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"To be eligible, women had to be at increased risk of breast cancer",e23b8207c614a3044014c44d56f786b3d775384d,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
9,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma",f7c8ae218aa2a3d30f7332ef5fdf9e777dc7d8dc,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
9,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma",f7c8ae218aa2a3d30f7332ef5fdf9e777dc7d8dc,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
10,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab.",0591ee004c0def46184a426053dd9738f35bbfe6,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
10,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab.",0591ee004c0def46184a426053dd9738f35bbfe6,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
11,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer.",d1e614fe7b5029804a8fbe3e3a04765c4bffb316,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
11,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer.",d1e614fe7b5029804a8fbe3e3a04765c4bffb316,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
12,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1 to 3 prior regimens and performance status of 0 to 2.",f3409732cc7d4683f100ffbb4e6a413730016a80,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
12,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1 to 3 prior regimens and performance status of 0 to 2.",f3409732cc7d4683f100ffbb4e6a413730016a80,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
13,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,5102 patients with HER2-positive early breast cancer,42e034cabf2625e843f4f5548b2fb5d4b396f648,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
13,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,5102 patients with HER2-positive early breast cancer,42e034cabf2625e843f4f5548b2fb5d4b396f648,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
14,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer,51ec0273befa1e47d1450daed3776964587877f4,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
14,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer,51ec0273befa1e47d1450daed3776964587877f4,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
15,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer were randomly assigned",84ec036d9366cf4a0250f89f04a963cb3b9da6ed,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
15,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer were randomly assigned",84ec036d9366cf4a0250f89f04a963cb3b9da6ed,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
16,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.",7e1f10ae979f9c975e6f844c7d8c536f7403d433,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
16,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.",7e1f10ae979f9c975e6f844c7d8c536f7403d433,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
17,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast",c6bec3db773bc407f94951fa1e0122a502885747,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
17,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast",c6bec3db773bc407f94951fa1e0122a502885747,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
18,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,healthy women older than 25 years,7cef698a40287e43633ef9741ddf42790931b86d,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
18,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,healthy women older than 25 years,7cef698a40287e43633ef9741ddf42790931b86d,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
20,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer,7705de340e41b57febb4d8971de9d1fa7442e04e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
20,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"previously untreated (except for neoadjuvant or adjuvant chemotherapy completed ≥180 days before recurrence), HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer",82f9ae49f05c3afc0efa3efd85ae63994cee48e1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
21,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation,8558a85da1ba64adc29d0d287b8124a5c93b74ba,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
21,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation,8558a85da1ba64adc29d0d287b8124a5c93b74ba,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"we randomly assigned 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations",32924e6cfd4d4f195549c678749a0c82e6d5b7ad,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
22,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"we randomly assigned 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations",32924e6cfd4d4f195549c678749a0c82e6d5b7ad,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
23,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,140 patients with early breast cancer were randomly assigned,bff69170118c768e1eb092596381a3c543eed253,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
23,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,140 patients with early breast cancer,8dbe064277815c984c0fdd220e7ff087d90f2f09,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
25,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Barcelona Clinic Liver Cancer stage B or C disease,c7301b6296b7bdbecfa1ac7e161014afb25491ea,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
25,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Barcelona Clinic Liver Cancer stage B or C disease,c7301b6296b7bdbecfa1ac7e161014afb25491ea,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
26,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,Women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing,d85113a3698d87094482ce17b9c7375fc21bddad,False,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
26,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,Women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing,d85113a3698d87094482ce17b9c7375fc21bddad,False,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
27,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned,bfee109a10676ba8e9aa75d74715bb869358dc39,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
27,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned,bfee109a10676ba8e9aa75d74715bb869358dc39,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
30,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"we randomly assigned (centrally by computer; stratified by node status, HER2 status, and centre) 1500 women with axillary node-positive or high-risk node-negative breast cancer",51d14a3b6c6f874d36fada30f09e46b36132ee73,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
30,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,1500 women with axillary node-positive or high-risk node-negative breast cancer,bcdd56e17d1a840c3afc168e772f2dc8dca708c5,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
31,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously,324aade2b9dcc7564cab85ec6def80cff9e1bad4,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
31,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously,324aade2b9dcc7564cab85ec6def80cff9e1bad4,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
32,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Patients with centrally confirmed HER2-positive gastric or gastroesophageal junction adenocarcinoma that had progressed while they were receiving at least two previous therapies, including trastuzumab",83e41a14d9cc5141b01a709074a904e7e85884b7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
32,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Patients with centrally confirmed HER2-positive gastric or gastroesophageal junction adenocarcinoma that had progressed while they were receiving at least two previous therapies, including trastuzumab",83e41a14d9cc5141b01a709074a904e7e85884b7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
33,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"In a multicenter, sham-controlled trial, we randomly assigned 127 patients with dysplastic Barrett's esophagus",32a9eef18cf13b2c780494445c6368dd83b84420,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
33,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"In a multicenter, sham-controlled trial, we randomly assigned 127 patients with dysplastic Barrett's esophagus",32a9eef18cf13b2c780494445c6368dd83b84420,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
34,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Eligible patients were premenopausal women aged 18-59 years who had histologically or cytologically confirmed HR-positive, HER2-negative, advanced breast cancer",376bc86d88c5629dd3f7472a123ac28182d128a6,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
34,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"premenopausal women with hormone-receptor-positive, advanced breast cancer",b7f7973899cec2a7ea0e17bdc7fb5beca630fe8d,False,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
35,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,No treatments are presently available to increase survival in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy.,db9632759935187a78e1099978d7773d20859809,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
35,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy,5a943ca8e986a9372d87d3a446983858c218bfb1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
36,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned",bef7dc4daef6dba31ca7cb28ef2c7402a9b0617e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
36,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned",bef7dc4daef6dba31ca7cb28ef2c7402a9b0617e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
37,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,eligible patients recruited in 138 clinics from 24 countries (aged ≥18 years with histologically or cytologically confirmed advanced non-small-cell lung cancer,dd4a2579bcb6d5baa7eb513d87860f580f708e7d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
37,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,eligible patients recruited in 138 clinics from 24 countries (aged ≥18 years with histologically or cytologically confirmed advanced non-small-cell lung cancer,dd4a2579bcb6d5baa7eb513d87860f580f708e7d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
38,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma",4dccde99f317d5f36d314601c66701d8accae702,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
38,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma",4dccde99f317d5f36d314601c66701d8accae702,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
39,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma,fcc8b382a999378f1e6c81cc8bc685b7d2fad526,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
39,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma,fcc8b382a999378f1e6c81cc8bc685b7d2fad526,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
40,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with locoregional renal-cell carcinoma at high risk for tumor recurrence after nephrectomy,219ebaf5950154794a2f340f0970c3ee40bbd79a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
40,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We sought to determine the efficacy and safety of sunitinib in patients with locoregional renal-cell carcinoma at high risk for tumor recurrence after nephrectomy.,c082bcd6fe87f693cd29a356941c7d8d288f67e6,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
41,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Standard first-line regimens for patients with metastatic gastroesophageal adenocarcinomas have an approximate 40% objective response rate (ORR).,43c6405e58d7844115495f18c7fbe2aafae3c296,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
41,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Standard first-line regimens for patients with metastatic gastroesophageal adenocarcinomas have an approximate 40% objective response rate (ORR).,43c6405e58d7844115495f18c7fbe2aafae3c296,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
42,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627),b1c09b3e60339f032a3371c9409dd5cba859d47c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
42,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned,35ab9758ff3cbe8aab8a9ca6d7d0aebc9404d81a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
43,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer and who had chosen surgery as their treatment approach,6c7bbb749c23a76c07155510f2a35c4213821cd1,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
43,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer and who had chosen surgery as their treatment approach,6c7bbb749c23a76c07155510f2a35c4213821cd1,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
44,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We assessed the effects of combined docetaxel and estramustine on relapse in patients with high-risk localised prostate cancer.,786ab75603b505994389571e11eaa12e57c099cc,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
44,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We assessed the effects of combined docetaxel and estramustine on relapse in patients with high-risk localised prostate cancer.,786ab75603b505994389571e11eaa12e57c099cc,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
45,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated,02d496a2dd8422ce71898eb8c05bed6bc7046068,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
45,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated,02d496a2dd8422ce71898eb8c05bed6bc7046068,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
46,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer without neuroendocrine differentiation,d8b422adbc7e21bce8ba462cb2cfd07fe0ae4df0,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
46,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer without neuroendocrine differentiation,d8b422adbc7e21bce8ba462cb2cfd07fe0ae4df0,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
47,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen,e4721392778786e03d84fcd2855ac39157cedcdd,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
47,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen,e4721392778786e03d84fcd2855ac39157cedcdd,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
48,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,patients with previously treated metastatic breast cancer,d4d34620582aba440ad57f1a5e1e98bf67366997,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
48,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,two or fewer previous chemotherapy regimens for metastatic breast cancer,8d2244853502618d92c71778dd81ff892a6b294a,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
49,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer",cfbf220f019f4e538d01b925b7d7555d6a0e6e8a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
49,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer",cfbf220f019f4e538d01b925b7d7555d6a0e6e8a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
50,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we enrolled patients with stage IIIB or IV adenocarcinoma,0825e4d60d1fa4f662bb55c1140ae89e2cce2319,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
50,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we enrolled patients with stage IIIB or IV adenocarcinoma,0825e4d60d1fa4f662bb55c1140ae89e2cce2319,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
51,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer",97d6bfead549bd200270e4c195e1f70f5a675d31,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
51,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer",97d6bfead549bd200270e4c195e1f70f5a675d31,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
53,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,adjuvant chemotherapy for operable node-positive breast cancer,d831e475033b14ff9450885da9a3f45addd83004,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
53,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,adjuvant chemotherapy for operable node-positive breast cancer,d831e475033b14ff9450885da9a3f45addd83004,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
54,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy.,c02ea06c108110323e6de9212ef4743b789afcb7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
54,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy.,c02ea06c108110323e6de9212ef4743b789afcb7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
56,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,scheduled to receive radiotherapy for prostate cancer,2aff11e016c46ad17f1370f6028d113cc18b8f28,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
56,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Two hundred forty-two participants with intact erectile function scheduled to receive radiotherapy for prostate cancer were recruited,4dfc3c6bf55043377fadff9f1319f7b1fa5cb037,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
57,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,enrolled 160 patients with radiologically confirmed painful bone metastases,bf827c4b70a3b2c7f466645b23a47ece3ad69f79,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
57,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"This prospective, randomized, single-institution phase 2 noninferiority trial conducted at a tertiary cancer care center enrolled 160 patients with radiologically confirmed painful bone metastases",47914415954e0030186cf36c2cee2a69d12adcbe,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
58,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, who had received one or two previous systemic treatments for metastatic disease",146630f6cb4e92394cc4d3fde32029546edc2f5d,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
58,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer",98a8176ee5187d630adb8aeaa485ef5593c3909e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
59,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,We assessed the efficacy and safety of pertuzumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic gastric or gastro-oesophageal junction cancer.,c96be6c17272c3b6a08ee06032afbfaf76e684ab,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
59,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We assessed the efficacy and safety of pertuzumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic gastric or gastro-oesophageal junction cancer.,c96be6c17272c3b6a08ee06032afbfaf76e684ab,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
60,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer,eb39c499b2390ac2dd1d4534274471899a2f3445,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
60,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer,eb39c499b2390ac2dd1d4534274471899a2f3445,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
61,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,patients with symptoms suggestive of colorectal cancer,7885ebd7581b37dd829f169a8a87475b044c38d1,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
62,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease)",4d8a53f9ab4779215bbb08f3398f784bae600b5a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
62,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease)",4d8a53f9ab4779215bbb08f3398f784bae600b5a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
63,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) who had disease progression after receiving EGFR tyrosine-kinase inhibitor therapy,c5e339c43af4750dbfb418920c5f2588026bbffe,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
63,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) who had disease progression after receiving EGFR tyrosine-kinase inhibitor therapy,c6ea67fb9b85a8261880f550b0ffcca8ee4134e5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
64,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,patients with advanced renal cell carcinoma and no previous systemic therapy,27873bec3229f421e7a00bd2e3a69d89aa463abb,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
64,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,patients with advanced renal cell carcinoma and no previous systemic therapy,27873bec3229f421e7a00bd2e3a69d89aa463abb,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
65,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease, children (≥365 days of age) who had stage 3 tumors with favorable histopathological features, and infants who had stage 4S disease with a diploid DNA index or unfavorable histopathological features.",e2f405aa914f41ce9361dcd11d7d73d45a94569d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
65,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease, children (≥365 days of age) who had stage 3 tumors with favorable histopathological features, and infants who had stage 4S disease with a diploid DNA index or unfavorable histopathological features.",e2f405aa914f41ce9361dcd11d7d73d45a94569d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
66,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment",92b54c29dfeb350fb3e61b31231bb4b6ae50a08e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
66,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment",92b54c29dfeb350fb3e61b31231bb4b6ae50a08e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
67,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned",0d6ba56beb6830ccb551ce364ac1ff2caf808724,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
67,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned",0d6ba56beb6830ccb551ce364ac1ff2caf808724,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
68,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,patients aged 18 years or older with unresectable hepatocellular carcinoma,dafec26da4015cf84651f3e0d1d6c58a92a0471e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
68,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,patients aged 18 years or older with unresectable hepatocellular carcinoma,dafec26da4015cf84651f3e0d1d6c58a92a0471e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma,96d38b1bcb1aa5ffc0fdc50e988558ea509561ce,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma,96d38b1bcb1aa5ffc0fdc50e988558ea509561ce,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
70,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Randomization was stratified based on site of metastasis (visceral, bone only, or other) and resistance to prior ET (primary vs secondary).",e18234726dba6d1cc4bc57a45cb3ece481ff1ab1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
70,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Randomization was stratified based on site of metastasis (visceral, bone only, or other)",6ea62c972b956e36c633136528c0a1dd84c8e97a,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
71,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
71,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
72,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients who had resected stage III melanoma with BRAF V600E or V600K mutations,12ccaf4f82680f37fe37be42eec6ed337dfc63bc,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
72,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with resected stage III melanoma with BRAF V600E or V600K mutations,579a7383ae80b1ae9fe530ed163c8b19a1c1d3ec,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
73,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,T1-T2N0-2 p16-positive OPSCC,e13bde1e6308ed1b899f8f16b6d26c3a5e5a66ca,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
73,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,enrolled patients with T1-T2N0-2 p16-positive OPSCC,64ce7a66da3b9350c6ec61deff324c165f4fd575,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
74,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries,bf89fe51434b0d644946853de71f676f18751fd0,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
74,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited,0298c4ebd14147a2c51e15d5aff9edd861061538,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
75,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors",705c0db343db93f7def5ac17051a9587b6be6529,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
75,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors",705c0db343db93f7def5ac17051a9587b6be6529,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
76,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,among 5999 participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings,a84a329d9800aee76b206256d580ce80ed8d7b5b,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
76,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"Among persons aged 50 to 64 years receiving primary care at a safety-net institution, mailed outreach invitations offering FIT or colonoscopy compared with usual care increased the proportion completing CRC screening process within 3 years.",08f34ef91e10d3fff4c15c6ee368a53718cecf8c,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
77,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,2f473300ee2ed5d6e679dd22a6fb62b3b64bf27b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
77,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,2f473300ee2ed5d6e679dd22a6fb62b3b64bf27b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
78,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer (cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer)",20f35dbfe1c2d4338016708f34248860a1dba4ce,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
78,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer (cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer)",20f35dbfe1c2d4338016708f34248860a1dba4ce,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
79,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy",0405aa34a2137529c9041abdac3e50222c00c304,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
79,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy",0405aa34a2137529c9041abdac3e50222c00c304,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
80,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment, enzalutamide significantly increased overall survival compared with placebo.",c34877d78c6b666cca66be8b0ea0be09064ed5e7,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
80,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment, enzalutamide significantly increased overall survival compared with placebo.",c34877d78c6b666cca66be8b0ea0be09064ed5e7,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
81,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
81,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
82,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,randomly assigned patients 2:1 with untreated locally recurrent inoperable or metastatic triple-negative breast cancer,50a04a731744183c77c6309f4fd72c4f43944b0a,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
82,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,untreated locally recurrent inoperable or metastatic triple-negative breast cancer,4e05d39ea4883688eba77cc5809eb230ee88e5f7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
83,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients 18 to 75 years of age with resectable cancer of the middle or lower third of the esophagus,0baebef4cd924b3a4022d771beea312b006e770c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
83,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients 18 to 75 years of age with resectable cancer of the middle or lower third of the esophagus,0baebef4cd924b3a4022d771beea312b006e770c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
84,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized,2af9700c1ac362442bdb36b45f67e71d24763b0d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
84,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized,2af9700c1ac362442bdb36b45f67e71d24763b0d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
85,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C who had not received previous treatment with a KRAS G12C inhibitor,5f29fd8a3860573fff492e09ca4330436eb220a2,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
85,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C who had not received previous treatment with a KRAS G12C inhibitor,5f29fd8a3860573fff492e09ca4330436eb220a2,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
86,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy",44543fcedf1e506791ac2be2f6c729782b756273,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
86,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"enrolling patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy",a71040b3a8b377cf20ea24365216ca338c38a6ea,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
87,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract",feac9e353db3a2317bbb6d8f79e649e29d2c384c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
87,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract",feac9e353db3a2317bbb6d8f79e649e29d2c384c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
88,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,840 patients with stage IB-IIIA NSCLC from 101 centres in 14 countries were randomly assigned to observation (n=433) or to 30 mg/m(2) vinorelbine plus 100 mg/m(2) cisplatin (n=407).,b63664706fb59899ae2ce5dda6f04bdf65982d18,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
88,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,840 patients with stage IB-IIIA NSCLC from 101 centres in 14 countries were randomly assigned to observation (n=433) or to 30 mg/m(2) vinorelbine plus 100 mg/m(2) cisplatin (n=407).,b63664706fb59899ae2ce5dda6f04bdf65982d18,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
89,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus",72edf0593dcdbaa0c3bea1a320c43bf3f1472076,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
89,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus",72edf0593dcdbaa0c3bea1a320c43bf3f1472076,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
90,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with stage III colon cancer,edf15d4023c95bc0cedb01d9c45ec1dbf2dc2d03,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
90,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with stage III colon cancer,edf15d4023c95bc0cedb01d9c45ec1dbf2dc2d03,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
91,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with sentinel-node metastases detected by means of standard pathological assessment or a multimarker molecular assay,82d72671c923b8736e62499c5d98a618f2432ae2,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
91,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Sentinel-lymph-node biopsy is associated with increased melanoma-specific survival (i.e., survival until death from melanoma) among patients with node-positive intermediate-thickness melanomas (1.2 to 3.5 mm).",dd2ce66947ca9e027a74abf5aab423fca1f3744c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
93,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence",c37659491a000415239367e1978caf776dc39280,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
93,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence",c37659491a000415239367e1978caf776dc39280,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
94,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,a phase 3 trial comparing atezolizumab plus bevacizumab versus sunitinib in first-line metastatic renal cell carcinoma,ff75c2eee75a5b6c52756cac79f7af79ffc683dd,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
94,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,patients with previously untreated metastatic renal cell carcinoma,d39b284e062de97f1ada89226d8b6168e2099764,False,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
95,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
95,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
96,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment,7ad600db6616635fc16a44ff62e3125d220e6c0e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
96,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment,7ad600db6616635fc16a44ff62e3125d220e6c0e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
97,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC",0b402dc18bfbf2b3abe6d6e47c3cc9b7ada85791,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
97,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC",0b402dc18bfbf2b3abe6d6e47c3cc9b7ada85791,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
98,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy",dcbe702f34b4ba40177de4b6f4df1dd179f0d943,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
98,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 2:1 ratio",53a464af8f4765b601194c6ed2b698be42e8d2b2,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
99,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs) and enrolled",b7e8d2cdc9533f4eb4de4a221f8b6dc7bd9167f1,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
99,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs) and enrolled",b7e8d2cdc9533f4eb4de4a221f8b6dc7bd9167f1,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
100,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.",2bb4c508e081004e847881868ce95d43864f22fb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
100,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.",2bb4c508e081004e847881868ce95d43864f22fb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
101,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,locoregionally advanced nasopharyngeal carcinoma,2edcecb4d1b79b8fa4d89eb6411cb292d075cebd,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
101,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,locoregionally advanced nasopharyngeal carcinoma,2edcecb4d1b79b8fa4d89eb6411cb292d075cebd,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
102,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage.",9a226940bcf144b135766bfa4bf9bf3e09e0a381,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
102,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage.",9a226940bcf144b135766bfa4bf9bf3e09e0a381,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
103,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.,e17cfaf030de1c203c1c5a45a0f85f9ffc6a7796,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
103,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.,e17cfaf030de1c203c1c5a45a0f85f9ffc6a7796,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
104,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma,fa08345d653fe100e478be37169783281485351b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
104,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma and adequate cardiac, renal, and hepatic function.",47305802b893796a8363fba1844bb539f1eefa15,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
105,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Randomisation was done via the minimisation method with biased-coin balancing for Eastern Cooperative Oncology Group performance status, disease stage at enrolment, and institution.",0cb6744cc662dde9e8f633cc0a52e5bbc16eee32,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
105,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,Patients with small-cell lung cancer that responded to first-line treatment but showed evidence of disease relapse or progression at least 90 days after completion of the first-line treatment were eligible to participate.,7a675638797d3a81ba42bbb525134d8c2a5eaebf,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
106,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
106,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
107,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer,925a41b4143b75a761a76d588e6b8fbc0d961442,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
107,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer,925a41b4143b75a761a76d588e6b8fbc0d961442,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
108,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"patients with advanced cancer, aged at least 18 years, admitted to the palliative and supportive care unit at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), with refractory agitation",c39b3f6f7eb39a439e7f57b846d303f827a00ac0,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
108,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"patients with advanced cancer, aged at least 18 years, admitted to the palliative and supportive care unit at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), with refractory agitation, despite low-dose haloperidol",0b7f5d5aa0566c9284b0dc46892d61e4b77c7915,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
109,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma",6f23b4ecc422bab373dea947e4bb3946b5ac0614,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
109,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma",6f23b4ecc422bab373dea947e4bb3946b5ac0614,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
110,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease",42edce59222b2d92f7594e370656ad2a9f95330c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
110,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease",42edce59222b2d92f7594e370656ad2a9f95330c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
111,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
111,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
112,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction,7764aacefa5c6343a21be2968247573405ba770c,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
112,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction,7764aacefa5c6343a21be2968247573405ba770c,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
113,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"we randomly assigned, in a 1:1 ratio, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to receive 500 mg of nicotinamide twice daily or placebo for 12 months",8d9b12c4a7e614356b0e109df4cf4ab5cfd9b92a,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
113,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"we randomly assigned, in a 1:1 ratio, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to receive 500 mg of nicotinamide twice daily or placebo for 12 months",8d9b12c4a7e614356b0e109df4cf4ab5cfd9b92a,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
114,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment,4864296f7ae844ff2919e93269293aa144b83745,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
114,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment,4864296f7ae844ff2919e93269293aa144b83745,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
115,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy,2f7ab902b18cc5cdd9667c868b8ed71e403d9958,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
115,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy,2f7ab902b18cc5cdd9667c868b8ed71e403d9958,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
116,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma",4e9d1b2e87d328e571dc9c7e55c1d887aef3d569,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
116,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma",4e9d1b2e87d328e571dc9c7e55c1d887aef3d569,True,BOTH,gemini,gemini-3-flash-preview,"IIIC) and metastatic (IV) cases, labeling",INVALID,False,
117,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.,1e5a0d07bcab51fdb16ae60707f07703b41de616,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
117,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.,1e5a0d07bcab51fdb16ae60707f07703b41de616,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
118,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Eligible patients were aged 18-75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)",666abb58c43dc6cbad55d9584c2ff02bb0c5a432,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
118,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients were aged 18-75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)",666abb58c43dc6cbad55d9584c2ff02bb0c5a432,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
119,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with palpable T1-T2 invasive breast cancer were recruited,8e7d379bc116332307e54f6cef9d8d517b082952,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
119,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with palpable T1-T2 invasive breast cancer were recruited from six medical centres in the Netherlands,75db0374ad38f800d02b0e19ffb948f7dd7f37c6,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
120,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"patients with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer",a5ce4ad3a274bfe8aa55aadfaa00d7624f32c56d,False,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
120,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"patients with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer",a5ce4ad3a274bfe8aa55aadfaa00d7624f32c56d,False,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
122,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors,bcec87f427a1c6e6a336726d281fb67543d3cf78,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
122,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors,bcec87f427a1c6e6a336726d281fb67543d3cf78,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
123,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma",d57a0e70cd847b04f4eb56ebbf449fa9bc55841a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
123,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma",d57a0e70cd847b04f4eb56ebbf449fa9bc55841a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
124,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.",f01be5f907ffb3968529022574e3b780796c8912,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
124,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.",f01be5f907ffb3968529022574e3b780796c8912,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
125,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease, as defined by Response Evaluation Criteria In Solid Tumors version 1.1, had received at least one platinum-based regimen",6d1a87a3d2148833cdae7e2691ac258614cf0a5d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
125,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease,fbb28621ca792d0faff6a84d142934f1380805f2,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease,2013657070185ba51f4157a780dc6214d4a149b4,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease,2013657070185ba51f4157a780dc6214d4a149b4,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
127,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC were enrolled,f6ae1a7979a85cbb3361ae4ed55a331be7d7d488,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
127,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with resectable stage IIIA or IIIB (T3N2) NSCLC were enrolled,8a67bd68234b5be5e42e23c8be40fd3591fef96f,False,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
128,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",62a9896c1da9a80e07fb82397217a16d1d84584a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
128,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",62a9896c1da9a80e07fb82397217a16d1d84584a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
129,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
129,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
130,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm,4296d5fb72270e8341ca5ee07edb61cf79b35b50,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
130,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm,4296d5fb72270e8341ca5ee07edb61cf79b35b50,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
131,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
131,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
132,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"We conducted a randomized, open-label, noninferiority, postauthorization, safety end-point trial involving patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor.",e38390aaad285508fbd172229746be5928a3e2f5,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
132,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor,91bd9ce646c85b4c45e39bd471eb05419d1cc62e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
133,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with stage IV melanoma with no evidence of disease after resection or radiotherapy,e65618adae10e67174237fc8b646807da88c37e8,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
133,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
134,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level of 1% or more to receive nivolumab",42ad9b9e5fbcd4e67959609e6321d877e640a6d7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
134,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,patients with untreated stage IV or recurrent NSCLC,0c85b8487b0acb5a3977724399f64a26805c26c5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
135,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Among patients with high-risk relapsed metastatic neuroblastoma, oral β-glucan adjuvant during GD2/GD3 ganglioside vaccine boost has stimulated IgG antibody response",8deda0b2488b04e6850c168c5df2fc2cd550ea0f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
135,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"Among patients with high-risk relapsed metastatic neuroblastoma, oral β-glucan adjuvant during GD2/GD3 ganglioside vaccine boost has stimulated IgG antibody response",8deda0b2488b04e6850c168c5df2fc2cd550ea0f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
136,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre.,a6faddd453e53720422bf2bb801ad8dfcd687277,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
136,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre.,a6faddd453e53720422bf2bb801ad8dfcd687277,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
137,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Because of the inaccessibility of mediastinal nodal metastases, the left thoracoabdominal approach (LTA) has often been used to treat gastric cancer of the cardia or subcardia.",505584ec834af3150eb82845836a6a1791972f0e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,adults aged 18 years or older with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum that was refractory to previous standard therapy,af633a6944eb57692b1eedaba57650900c92a1b9,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,adults aged 18 years or older with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum that was refractory to previous standard therapy,af633a6944eb57692b1eedaba57650900c92a1b9,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"523 patients with curable stage T2b, T3, or T4 gastric cancer were randomly assigned during surgery to D2 lymphadenectomy alone (263 patients) or to D2 lymphadenectomy plus PAND (260 patients)",490954a6e6f8f512ac272d794f2793653b2bb8ac,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
139,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"523 patients with curable stage T2b, T3, or T4 gastric cancer were randomly assigned during surgery to D2 lymphadenectomy alone (263 patients) or to D2 lymphadenectomy plus PAND (260 patients)",490954a6e6f8f512ac272d794f2793653b2bb8ac,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
140,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
140,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
141,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression,187b46812f1d8adc55b45569e5fa26ef2e61a69a,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
141,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression,187b46812f1d8adc55b45569e5fa26ef2e61a69a,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
142,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)",22ba5ffce0ae91fc338c92ab90641a6944ad8acb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
142,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"This multicenter, double-blind, placebo-controlled phase 3 trial enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)",a91ba8c0d91ff17d0e6af1c40fd559be263bf262,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
143,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"Screening for its precursor, anal intraepithelial neoplasia (AIN), is subject of discussion.",3a464d27b3321c8001ba80fab558066c60e9a134,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
143,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"Screening for its precursor, anal intraepithelial neoplasia (AIN), is subject of discussion.",3a464d27b3321c8001ba80fab558066c60e9a134,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
144,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,spinal cord compression caused by metastatic cancer,8cb9910a1b04bc12e5d19bac259fcc3e2c21ab9a,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
144,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,spinal cord compression caused by metastatic cancer,8cb9910a1b04bc12e5d19bac259fcc3e2c21ab9a,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
145,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy",a68c0f30833a87517c04acc3c8114503aba73390,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
145,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision",9d69fb515579fc1983b1221d78ede77659cfc981,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
146,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States,74c9e84f875aaf64bd23ef59b2906c556e7e43aa,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
146,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,marine n-3 fatty acids (at a dose of 1 g per day) in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States,6637c1e973a270fa129945396421098300d68ccf,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
147,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.,69b842dffdbffa24b7350f9d02f2376643d86b1b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
147,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.,69b842dffdbffa24b7350f9d02f2376643d86b1b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
148,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
148,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
149,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.",5dd83413e5cf0f338a57224082e25970f5d5aa27,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
149,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.",5dd83413e5cf0f338a57224082e25970f5d5aa27,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
150,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with a histologically proven superficial basal-cell carcinoma,e8d4ba50a7b6fd5dcb3c9939a6f3043aa82a3107,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
150,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with a histologically proven superficial basal-cell carcinoma,e8d4ba50a7b6fd5dcb3c9939a6f3043aa82a3107,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
151,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.",12f0f83eee4f297d5b656a2bc3371efacee7671e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
151,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.",12f0f83eee4f297d5b656a2bc3371efacee7671e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
152,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,We included chemotherapy-naive men (aged ≥18 years) with mCRPC who had not been previously treated with androgen biosynthesis signalling inhibitors,234ef7b029d3c6b6fe6e4a16d75c5e4f63861090,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
152,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We included chemotherapy-naive men (aged ≥18 years) with mCRPC who had not been previously treated with androgen biosynthesis signalling inhibitors and were receiving ongoing androgen deprivation therapy,05deb733e7d9d49fc7d4383c5369da4a73d85928,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
153,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment",623aaaee2065b1baf7cf0c6d1adae0950ab244e3,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
153,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment",623aaaee2065b1baf7cf0c6d1adae0950ab244e3,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
154,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Women older than 18 years with histologically confirmed HER2-overexpressing breast cancer and CNS recurrence or progression as determined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) during or after treatment with trastuzumab, lapatinib, or both, were eligible.",25d39f9ae00ffa521ebe07ab3bb1d89b5117c54e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
154,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Patients with advanced HER2-positive breast cancer frequently develop CNS metastases. The metastases that progress after brain radiotherapy and HER2-targeted systemic therapy are a difficult therapeutic challenge.,804de7f2c4ca52ad32ac8c22c2f8e6981ec07e52,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
155,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
155,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
156,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery,497bfcf94eef00225dfe6be3ee39ac77b8c6b7a2,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
156,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery,497bfcf94eef00225dfe6be3ee39ac77b8c6b7a2,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
157,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,The primary end point was metastasis-free survival,3f799a018c6da63b630bf17cb51591206ce075f1,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
157,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less,7860fcacfb91af16f9e4ce1d620792df7883440f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
158,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
158,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
159,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,children and young adults (<30 years) with high-risk neuroblastoma were randomly assigned at diagnosis,b41ff7b720bc34fc428c92ded59893dd848cc9bb,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
159,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,children and young adults (<30 years) with high-risk neuroblastoma were randomly assigned at diagnosis,b41ff7b720bc34fc428c92ded59893dd848cc9bb,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
160,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy",05c2939dada0672749ec4cb4ea3d7457c7858303,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
160,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy",05c2939dada0672749ec4cb4ea3d7457c7858303,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
161,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"patients with previously untreated, FGFR2b-overexpressing, advanced gastric or gastro-oesophageal junction adenocarcinoma",c33c45777f5ddb41bc8337ed90d047903fbb774d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
161,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"previously untreated, FGFR2b-overexpressing, advanced gastric or gastro-oesophageal junction adenocarcinoma",4356af0ce9de80b48a9f001e5ff5ada783c5d8cc,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
162,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"pathologically proven, stage IIIA/N2 non-small-cell lung cancer",b7018211963328285fa59b411a7fde24c20729b8,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
162,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
163,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer from 81 Italian centres",42c2125c9d0d81288538f25dd8b3c047203713de,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
163,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer from 81 Italian centres",42c2125c9d0d81288538f25dd8b3c047203713de,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
164,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors.,ad666259a56de2edd15a2032e761dc69121c9de1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
164,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation,583a76088c72262449dac8aacd51fb58b93120b8,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
165,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"adult patients (aged ≥18 years) with advanced, progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal origin were enrolled",1097520aab3d197f4867ce88a13d038e7c72ae07,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
165,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"adult patients (aged ≥18 years) with advanced, progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal origin were enrolled",1097520aab3d197f4867ce88a13d038e7c72ae07,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane,246502d97693ff1bf8efb3c3018acc06eccbfa9d,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
166,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane,246502d97693ff1bf8efb3c3018acc06eccbfa9d,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
167,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.,5fc989ef5fe2c3d505652b55cb785026b6bb9235,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
167,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.,5fc989ef5fe2c3d505652b55cb785026b6bb9235,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
168,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"HR-positive, HER2-negative advanced breast cancer",faee86c53010ff6d9154771948e27e86ca8b279f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
168,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"HR-positive, HER2-negative advanced breast cancer",faee86c53010ff6d9154771948e27e86ca8b279f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
169,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,We enrolled female patients with HER2-overexpressing metastatic breast cancer who had progressed on or following adjuvant trastuzumab or first-line treatment of metastatic disease with trastuzumab.,e9c238aef87e34090486f21c9fb8626127670618,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
169,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We enrolled female patients with HER2-overexpressing metastatic breast cancer who had progressed on or following adjuvant trastuzumab or first-line treatment of metastatic disease with trastuzumab.,e9c238aef87e34090486f21c9fb8626127670618,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
170,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,We screened 3100 first-degree relatives of patients with gastric cancer. We randomly assigned 1838 participants with H. pylori infection to receive either eradication therapy...or placebo. The primary outcome was development of gastric cancer.,d87629d59bc12887eef7657e1a5eaaf115461d59,False,NEITHER,gemini,gemini-3-flash-preview,THER label because the participants do not have localized or,INVALID,False,
170,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,We screened 3100 first-degree relatives of patients with gastric cancer. We randomly assigned 1838 participants with H. pylori infection to receive either eradication therapy,66318eaa24dd72efbb8f2dd5ae9d892d620fe6db,False,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
171,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-positive early breast cancer in premenopausal women,e2e40fd85b9bba6397be29b29ac5c6c0bdfeea59,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
171,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-positive early breast cancer in premenopausal women,e2e40fd85b9bba6397be29b29ac5c6c0bdfeea59,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
173,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,To assess whether stereotactic body radiotherapy on a single tumor site preceding pembrolizumab treatment enhances tumor response in patients with metastatic NSCLC.,374e60a2a29d21ed4816c49171017e2b69b302d3,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
173,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,To assess whether stereotactic body radiotherapy on a single tumor site preceding pembrolizumab treatment enhances tumor response in patients with metastatic NSCLC.,374e60a2a29d21ed4816c49171017e2b69b302d3,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
174,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"Men and women, who had indicated on a previous questionnaire that they would probably attend screening if invited, were randomly assigned (1:2) to an intervention group (offered flexible sigmoidoscopy screening) or a control group",cb97a816b5b3cac53b18771afd7428f40aa973a8,False,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
174,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,Colorectal cancer is the third most common cancer worldwide. Previous analyses have only reported follow-up after flexible sigmoidoscopy for a maximum of 12 years. We aimed to examine colorectal cancer incidence and mortality after a single flexible sigmoidoscopy screening and 17 years of follow-up.,96770c141957debb83e0b58151ff6f98d9f0363e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
175,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who had been pretreated with platinum-based chemotherapy.,9e6203ad597e2d1e23acd743cea428eb86362819,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
175,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who had been pretreated with platinum-based chemotherapy.,9e6203ad597e2d1e23acd743cea428eb86362819,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
176,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"From 1993 through 2001, we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects).",529c7a2f02b5029cc173759afd736b6a80629cf1,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
176,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects)",c66df23d0610296fd455dd07268b825cf01af1ac,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
177,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.,70d475696cdc082bcacbd6384e423ff7da28aba6,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
177,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.,70d475696cdc082bcacbd6384e423ff7da28aba6,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
178,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"to demonstrate the efficacy of ivosidenib (AG-120)-a first-in-class, oral, small-molecule inhibitor of mutant IDH1-vs placebo for patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation",c9ddda61d7731bee7b9899c8f9a9f8c0924f2ccc,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
178,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"demonstrate the efficacy of ivosidenib (AG-120)-a first-in-class, oral, small-molecule inhibitor of mutant IDH1-vs placebo for patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation",160d6dd97964e72f3e4ee7ea40f2d3fc4f700252,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
179,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Patients (age 1-20 years) with neuroblastoma were eligible to be randomly assigned if they had completed a multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide with or without topotecan, vincristine, and doxorubicin) and achieved an adequate disease response.",0d65348acebaddbbcf21c23018e019f526dfc462,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,had previously untreated recurrent or metastatic nasopharyngeal carcinoma,bb06d0c31dc58f6a446b63ce25a67cb6e3404c9b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
181,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,had previously untreated recurrent or metastatic nasopharyngeal carcinoma,bb06d0c31dc58f6a446b63ce25a67cb6e3404c9b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
182,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more,8238f81c269109ba3c048924442cdc35631824df,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
182,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more,8238f81c269109ba3c048924442cdc35631824df,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
183,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with previously untreated stage II or stage III triple-negative breast cancer,df1fbc5bb5dcbf5062226f899b54c592cad0ffc2,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
183,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with previously untreated stage II or stage III triple-negative breast cancer,df1fbc5bb5dcbf5062226f899b54c592cad0ffc2,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
184,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer,823f122356f8f86a5e76455b661c9dd507b9fb64,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
184,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer,823f122356f8f86a5e76455b661c9dd507b9fb64,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
185,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,Eligible participants aged 1-18 years with newly diagnosed cancer and normal audiometry were randomly assigned (1:1) to receive sodium thiosulfate or observation (control group) in addition to their planned cisplatin-containing chemotherapy regimen,a8a037c85beae667177bdf82856f613163a24083,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
185,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,Eligible participants aged 1-18 years with newly diagnosed cancer and normal audiometry were randomly assigned (1:1) to receive sodium thiosulfate or observation (control group) in addition to their planned cisplatin-containing chemotherapy regimen,a8a037c85beae667177bdf82856f613163a24083,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
186,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
186,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
187,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"patients with locoregionally advanced, unresectable disease... stage III or stage IV disease and no distant metastases",67e772b38e26fbd01cfb432fd112411f8eea3964,False,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
187,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"patients with locoregionally advanced, unresectable disease...stage III or stage IV disease and no distant metastases",58fce206b6c9f3acee27f17ae91063cb7de45160,False,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
188,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent",406f22033394df460ac3a4a6de3cf7b661fbcc51,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
188,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent",406f22033394df460ac3a4a6de3cf7b661fbcc51,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
189,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"a randomised, placebo-controlled, double-blind trial of exemestane 25 mg a day for the primary prevention of breast cancer",775a173bb31c607563b6c7d1ad882376d7fc252f,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
189,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"a randomised, placebo-controlled, double-blind trial of exemestane 25 mg a day for the primary prevention of breast cancer",775a173bb31c607563b6c7d1ad882376d7fc252f,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
190,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer,1d5ab5aa44d4b9fe7746b357e8ac868cb49cd851,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
190,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer,1d5ab5aa44d4b9fe7746b357e8ac868cb49cd851,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
191,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
191,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
192,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer",32ca4d3fff954ed57510ab1bee98e9767a91dddc,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
192,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.",09698d0fe82df3f68e60864457c76c6e4c68b602,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
193,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Eligible patients were adults (aged 18 years or older) with progressive, advanced, well differentiated pancreatic NETs, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and progression on up to two kinds of previous systemic regimens for advanced disease.",345f51cc7a17b35f0e59c0d61c6219a51a9ba1b9,True,BOTH,gemini,gemini-3-flash-preview,"metastatic).
    *   The label """,INVALID,False,
193,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Eligible patients were adults (aged 18 years or older) with progressive, advanced, well differentiated pancreatic NETs, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and progression on up to two kinds of previous systemic regimens for advanced disease.",345f51cc7a17b35f0e59c0d61c6219a51a9ba1b9,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
194,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions,83b241e5412ffc76522b5f4b1eb8c2ba5559c311,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
194,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions, Eastern Cooperative Oncology Group score of 0-1, and a life expectancy of at least 6 months were eligible.",a2bb26ee3f4690b802f9ac765f68896bb4dff919,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
195,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung who had progressed after at least four cycles of platinum-based-chemotherapy.,7b6c6e36b482f1636c166e4378de25d7832b70ee,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
195,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung who had progressed after at least four cycles of platinum-based-chemotherapy.,7b6c6e36b482f1636c166e4378de25d7832b70ee,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
196,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel",b0d5b8e000da10259a494d9d1d935a8a5098b10d,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
196,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel",b0d5b8e000da10259a494d9d1d935a8a5098b10d,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
197,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Patients aged 18 years and older with metastatic soft-tissue sarcomas,5aa95ecda2edcb243e6f1061f50ba6de22c5831e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
197,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Patients aged 18 years and older with metastatic soft-tissue sarcomas,5aa95ecda2edcb243e6f1061f50ba6de22c5831e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
198,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry.,0dba11ee514688d77c9254edf4807a4baff8b71f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
198,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry.,0dba11ee514688d77c9254edf4807a4baff8b71f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
199,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment,0278ffd332ca1b2e0bf80b280ebe480fb8d41250,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
199,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment,0278ffd332ca1b2e0bf80b280ebe480fb8d41250,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
0,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We randomly assigned patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual),fc7bb4a1f2e57bc303295fd86d2ec6c2c8ca0505,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
1,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma with prespecified FGFR alterations,0160b11634f2b30a9d244e76b12d448a9151fb57,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
2,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"In this phase 3 study, we aimed to compare overall survival in patients with advanced or metastatic soft-tissue sarcoma who received eribulin with that in patients who received dacarbazine",cf3614b788fdddf6d88bbe8c5a0531acbefc221b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
3,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
4,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,To investigate the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing after second-line or further treatment.,c9e609f99613768550cecda30d5261632a03cdcd,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.,095a4141eb262225a4f7a27dacfdcec099af798c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
6,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Localised prostate cancer is commonly treated with external beam radiotherapy,0c49d50c3d7e6e3b243439cb9d2a760b787b52c7,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"In this randomised controlled trial, we recruited postmenopausal women aged 50-74 years from 13 centres in National Health Service Trusts in England, Wales, and Northern Ireland.",c0b3f644539d5fce65e71e6ffad366dbfc3ba94e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,women had to be at increased risk of breast cancer (judged on the basis of specific criteria),f6e99365f989a7d0a77de7cdc0f7e02d7e48083c,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
9,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma",f7c8ae218aa2a3d30f7332ef5fdf9e777dc7d8dc,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
10,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab.",0591ee004c0def46184a426053dd9738f35bbfe6,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
11,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer.",d1e614fe7b5029804a8fbe3e3a04765c4bffb316,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
12,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1 to 3 prior regimens and performance status of 0 to 2.",f3409732cc7d4683f100ffbb4e6a413730016a80,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
13,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,5102 patients with HER2-positive early breast cancer,42e034cabf2625e843f4f5548b2fb5d4b396f648,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
14,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer,51ec0273befa1e47d1450daed3776964587877f4,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
15,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer were randomly assigned",84ec036d9366cf4a0250f89f04a963cb3b9da6ed,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
16,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.",7e1f10ae979f9c975e6f844c7d8c536f7403d433,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
17,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast",c6bec3db773bc407f94951fa1e0122a502885747,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
18,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,healthy women older than 25 years,7cef698a40287e43633ef9741ddf42790931b86d,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
20,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer,7705de340e41b57febb4d8971de9d1fa7442e04e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
21,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation,8558a85da1ba64adc29d0d287b8124a5c93b74ba,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"we randomly assigned 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations",32924e6cfd4d4f195549c678749a0c82e6d5b7ad,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
23,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,140 patients with early breast cancer were randomly assigned,bff69170118c768e1eb092596381a3c543eed253,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
25,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Barcelona Clinic Liver Cancer stage B or C disease,c7301b6296b7bdbecfa1ac7e161014afb25491ea,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
26,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,Women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing in combination with liquid-based cytology,bbda95a47068f488276798ce98cd978a28681a60,False,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
27,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned,bfee109a10676ba8e9aa75d74715bb869358dc39,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
30,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,1500 women with axillary node-positive or high-risk node-negative breast cancer,bcdd56e17d1a840c3afc168e772f2dc8dca708c5,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
31,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously,324aade2b9dcc7564cab85ec6def80cff9e1bad4,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
32,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Patients with centrally confirmed HER2-positive gastric or gastroesophageal junction adenocarcinoma that had progressed while they were receiving at least two previous therapies, including trastuzumab",83e41a14d9cc5141b01a709074a904e7e85884b7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
33,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"In a multicenter, sham-controlled trial, we randomly assigned 127 patients with dysplastic Barrett's esophagus",32a9eef18cf13b2c780494445c6368dd83b84420,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
34,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Eligible patients were premenopausal women aged 18-59 years who had histologically or cytologically confirmed HR-positive, HER2-negative, advanced breast cancer",376bc86d88c5629dd3f7472a123ac28182d128a6,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
35,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy,5a943ca8e986a9372d87d3a446983858c218bfb1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
36,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned",bef7dc4daef6dba31ca7cb28ef2c7402a9b0617e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
37,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,eligible patients recruited in 138 clinics from 24 countries (aged ≥18 years with histologically or cytologically confirmed advanced non-small-cell lung cancer,dd4a2579bcb6d5baa7eb513d87860f580f708e7d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
38,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma",4dccde99f317d5f36d314601c66701d8accae702,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
39,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma,fcc8b382a999378f1e6c81cc8bc685b7d2fad526,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
40,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We sought to determine the efficacy and safety of sunitinib in patients with locoregional renal-cell carcinoma at high risk for tumor recurrence after nephrectomy.,c082bcd6fe87f693cd29a356941c7d8d288f67e6,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
41,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Standard first-line regimens for patients with metastatic gastroesophageal adenocarcinomas have an approximate 40% objective response rate (ORR).,43c6405e58d7844115495f18c7fbe2aafae3c296,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
42,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b,823afbdce5dc36ee194b7d774c5eaaf9d0366acf,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
43,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer and who had chosen surgery as their treatment approach,6c7bbb749c23a76c07155510f2a35c4213821cd1,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
44,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We assessed the effects of combined docetaxel and estramustine on relapse in patients with high-risk localised prostate cancer.,786ab75603b505994389571e11eaa12e57c099cc,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
45,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated,02d496a2dd8422ce71898eb8c05bed6bc7046068,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
46,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer without neuroendocrine differentiation,d8b422adbc7e21bce8ba462cb2cfd07fe0ae4df0,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
47,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen,e4721392778786e03d84fcd2855ac39157cedcdd,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
48,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we recruited patients aged 18 years or older who had received taxane therapy and undergone two or fewer previous chemotherapy regimens for metastatic breast cancer,c76e796fffd838f7d92822c2d1386d920f8b782c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
49,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer",cfbf220f019f4e538d01b925b7d7555d6a0e6e8a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
50,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we enrolled patients with stage IIIB or IV adenocarcinoma,0825e4d60d1fa4f662bb55c1140ae89e2cce2319,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
51,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer",97d6bfead549bd200270e4c195e1f70f5a675d31,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
53,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,adjuvant chemotherapy for operable node-positive breast cancer,d831e475033b14ff9450885da9a3f45addd83004,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
54,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy.,c02ea06c108110323e6de9212ef4743b789afcb7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
55,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"In the Prostate Cancer Prevention Trial (PCPT), finasteride significantly reduced the risk of prostate cancer",61f3e6a7146bfbb6e0c92599b2e3abca0e51ee7b,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
56,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,men treated with radiotherapy for prostate cancer,3785749ee005f17e910b4e193d9dfe606c193607,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
57,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,patients with radiologically confirmed painful bone metastases,86cb4376c17caed9db019d633d3111c8c42964c5,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
58,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer",98a8176ee5187d630adb8aeaa485ef5593c3909e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
59,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,We assessed the efficacy and safety of pertuzumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic gastric or gastro-oesophageal junction cancer.,c96be6c17272c3b6a08ee06032afbfaf76e684ab,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
60,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer,eb39c499b2390ac2dd1d4534274471899a2f3445,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
62,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease)",4d8a53f9ab4779215bbb08f3398f784bae600b5a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
63,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) who had disease progression after receiving EGFR tyrosine-kinase inhibitor therapy,c6ea67fb9b85a8261880f550b0ffcca8ee4134e5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
64,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,patients with advanced renal cell carcinoma and no previous systemic therapy,27873bec3229f421e7a00bd2e3a69d89aa463abb,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
65,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease, children (≥365 days of age) who had stage 3 tumors with favorable histopathological features, and infants who had stage 4S disease with a diploid DNA index or unfavorable histopathological features.",e2f405aa914f41ce9361dcd11d7d73d45a94569d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
66,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment",92b54c29dfeb350fb3e61b31231bb4b6ae50a08e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
67,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned",0d6ba56beb6830ccb551ce364ac1ff2caf808724,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
68,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,patients aged 18 years or older with unresectable hepatocellular carcinoma,dafec26da4015cf84651f3e0d1d6c58a92a0471e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma,96d38b1bcb1aa5ffc0fdc50e988558ea509561ce,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
70,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Randomization was stratified based on site of metastasis (visceral, bone only, or other)",6ea62c972b956e36c633136528c0a1dd84c8e97a,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
71,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
72,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with resected stage III melanoma with BRAF V600E or V600K mutations,579a7383ae80b1ae9fe530ed163c8b19a1c1d3ec,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
73,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"This international, multicenter, open-label parallel-group phase 2 randomized clinical trial was conducted at 9 tertiary academic cancer centers in Canada and Australia and enrolled patients with T1-T2N0-2 p16-positive OPSCC",5f23cfb9eedad535fea0acd3ed0d3338419d02ae,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
74,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries,bf89fe51434b0d644946853de71f676f18751fd0,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
75,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors",705c0db343db93f7def5ac17051a9587b6be6529,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
76,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,Pragmatic randomized clinical trial from March 2013 to July 2016 among 5999 participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings.,55256a245d0faecee3ad6ecb733169dfa86e371e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
77,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,2f473300ee2ed5d6e679dd22a6fb62b3b64bf27b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
78,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer (cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer)",20f35dbfe1c2d4338016708f34248860a1dba4ce,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
79,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy",0405aa34a2137529c9041abdac3e50222c00c304,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
80,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment, enzalutamide significantly increased overall survival compared with placebo.",c34877d78c6b666cca66be8b0ea0be09064ed5e7,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
81,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
82,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,patients with untreated locally recurrent inoperable or metastatic triple-negative breast cancer,29fb90e05aab5f09411ed2d741d293bd2063769a,False,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
83,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients 18 to 75 years of age with resectable cancer of the middle or lower third of the esophagus,0baebef4cd924b3a4022d771beea312b006e770c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
84,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,previously untreated recurrent and/or metastatic ERBB2-positive breast cancer,710609f4c90c54721c6ff50e3f5906bc48e4cc5f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
85,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C,91cec28e5c907eadc7e24c39b2db70269724b18c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
86,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy",8ca5067dadf24757c361c89491a6f0977f3e888c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
87,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract",feac9e353db3a2317bbb6d8f79e649e29d2c384c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
88,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,840 patients with stage IB-IIIA NSCLC from 101 centres in 14 countries were randomly assigned to observation (n=433) or to 30 mg/m(2) vinorelbine plus 100 mg/m(2) cisplatin (n=407).,b63664706fb59899ae2ce5dda6f04bdf65982d18,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
89,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"histopathologically diagnosed with undifferentiated or differentiated, non-keratinising, locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus",6066226c122c0b9b37ac9622c8c2759dbd45608e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
90,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"To determine if the addition of celecoxib to adjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) improves disease-free survival in patients with stage III colon cancer.",49ff2f8d949d4746f41ca8d1a792d27bbe3dee1c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
91,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Sentinel-lymph-node biopsy is associated with increased melanoma-specific survival (i.e., survival until death from melanoma) among patients with node-positive intermediate-thickness melanomas (1.2 to 3.5 mm).",dd2ce66947ca9e027a74abf5aab423fca1f3744c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
92,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Eligible patients (aged ≥18 years) had histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma with first disease recurrence more than 6 months after first-line platinum-based chemotherapy",efb5c3a90dacb2bf43619b9c28e38d5779aa313f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
93,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence",c37659491a000415239367e1978caf776dc39280,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
94,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,comparing atezolizumab plus bevacizumab versus sunitinib in first-line metastatic renal cell carcinoma,2a9315e96c1d5e7fed9a565a224f05cb302f1a14,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
95,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
96,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment,7ad600db6616635fc16a44ff62e3125d220e6c0e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
97,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC",0b402dc18bfbf2b3abe6d6e47c3cc9b7ada85791,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
98,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy",dcbe702f34b4ba40177de4b6f4df1dd179f0d943,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
99,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs) and enrolled",b7e8d2cdc9533f4eb4de4a221f8b6dc7bd9167f1,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
100,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.",2bb4c508e081004e847881868ce95d43864f22fb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
101,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,locoregionally advanced nasopharyngeal carcinoma,2edcecb4d1b79b8fa4d89eb6411cb292d075cebd,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
102,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage.",9a226940bcf144b135766bfa4bf9bf3e09e0a381,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.,e17cfaf030de1c203c1c5a45a0f85f9ffc6a7796,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
104,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma,fa08345d653fe100e478be37169783281485351b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
105,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Randomisation was done via the minimisation method with biased-coin balancing for Eastern Cooperative Oncology Group performance status, disease stage at enrolment, and institution.",0cb6744cc662dde9e8f633cc0a52e5bbc16eee32,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
106,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
107,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer,925a41b4143b75a761a76d588e6b8fbc0d961442,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
108,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"patients with advanced cancer, aged at least 18 years, admitted to the palliative and supportive care unit at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), with refractory agitation",c39b3f6f7eb39a439e7f57b846d303f827a00ac0,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
109,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma",6f23b4ecc422bab373dea947e4bb3946b5ac0614,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
110,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease",42edce59222b2d92f7594e370656ad2a9f95330c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
111,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
112,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction,7764aacefa5c6343a21be2968247573405ba770c,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
113,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"we randomly assigned, in a 1:1 ratio, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to receive 500 mg of nicotinamide twice daily or placebo for 12 months",8d9b12c4a7e614356b0e109df4cf4ab5cfd9b92a,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
114,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment,4864296f7ae844ff2919e93269293aa144b83745,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
115,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy,2f7ab902b18cc5cdd9667c868b8ed71e403d9958,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
116,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma",4e9d1b2e87d328e571dc9c7e55c1d887aef3d569,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
117,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.,1e5a0d07bcab51fdb16ae60707f07703b41de616,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
118,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible patients were aged 18-75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)",666abb58c43dc6cbad55d9584c2ff02bb0c5a432,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
119,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with palpable T1-T2 invasive breast cancer were recruited,8e7d379bc116332307e54f6cef9d8d517b082952,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
120,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"patients with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer",a5ce4ad3a274bfe8aa55aadfaa00d7624f32c56d,False,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
122,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors,bcec87f427a1c6e6a336726d281fb67543d3cf78,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
123,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma",d57a0e70cd847b04f4eb56ebbf449fa9bc55841a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
124,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.",f01be5f907ffb3968529022574e3b780796c8912,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
125,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease,fbb28621ca792d0faff6a84d142934f1380805f2,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease,2013657070185ba51f4157a780dc6214d4a149b4,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
127,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC were enrolled,f6ae1a7979a85cbb3361ae4ed55a331be7d7d488,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
128,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",62a9896c1da9a80e07fb82397217a16d1d84584a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
129,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
130,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm,4296d5fb72270e8341ca5ee07edb61cf79b35b50,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
131,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
132,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor,91bd9ce646c85b4c45e39bd471eb05419d1cc62e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
133,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with stage IV melanoma with no evidence of disease after surgery or radiotherapy,f85f0257d1ab124153605d0bbffc6c0db04db633,False,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
134,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,patients with untreated stage IV or recurrent NSCLC,0c85b8487b0acb5a3977724399f64a26805c26c5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
135,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Among patients with high-risk relapsed metastatic neuroblastoma, oral β-glucan adjuvant during GD2/GD3 ganglioside vaccine boost has stimulated IgG antibody response",8deda0b2488b04e6850c168c5df2fc2cd550ea0f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
136,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre.,a6faddd453e53720422bf2bb801ad8dfcd687277,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
138,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,adults aged 18 years or older with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum that was refractory to previous standard therapy,af633a6944eb57692b1eedaba57650900c92a1b9,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
139,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"523 patients with curable stage T2b, T3, or T4 gastric cancer were randomly assigned during surgery to D2 lymphadenectomy alone (263 patients) or to D2 lymphadenectomy plus PAND (260 patients)",490954a6e6f8f512ac272d794f2793653b2bb8ac,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
140,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
141,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression,187b46812f1d8adc55b45569e5fa26ef2e61a69a,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
142,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)",22ba5ffce0ae91fc338c92ab90641a6944ad8acb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
143,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"Anal cancer is an increasing issue in HIV-positive men who have sex with men (MSM). Screening for its precursor, anal intraepithelial neoplasia (AIN), is subject of discussion.",353b737861e00823d1b60d2aba28bb14722c5e7e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
144,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,spinal cord compression caused by metastatic cancer,8cb9910a1b04bc12e5d19bac259fcc3e2c21ab9a,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
145,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"patients aged 18 years or older from 129 UK centres who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy",d9579960f4cb2a8af4b3cafdef8256e00fe93b8e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
146,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States,12f69eadbafed10c6733ff923755b0fb906407e0,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
147,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.,69b842dffdbffa24b7350f9d02f2376643d86b1b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
148,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
149,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.",5dd83413e5cf0f338a57224082e25970f5d5aa27,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
150,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Superficial basal-cell carcinoma is most commonly treated with topical non-surgical treatments,a1cbe9d785f284b52fca25573b8f8a6cc81dead9,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
151,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.",12f0f83eee4f297d5b656a2bc3371efacee7671e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
152,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,We included chemotherapy-naive men (aged ≥18 years) with mCRPC who had not been previously treated with androgen biosynthesis signalling inhibitors,234ef7b029d3c6b6fe6e4a16d75c5e4f63861090,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
153,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment",623aaaee2065b1baf7cf0c6d1adae0950ab244e3,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
154,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Women older than 18 years with histologically confirmed HER2-overexpressing breast cancer and CNS recurrence or progression as determined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) during or after treatment with trastuzumab, lapatinib, or both, were eligible.",25d39f9ae00ffa521ebe07ab3bb1d89b5117c54e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
155,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
156,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery,497bfcf94eef00225dfe6be3ee39ac77b8c6b7a2,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
157,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,we enrolled patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less,5c2cf0243d55d96dd4292233768c76e266a6f0e2,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
158,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
159,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,children and young adults (<30 years) with high-risk neuroblastoma were randomly assigned at diagnosis,b41ff7b720bc34fc428c92ded59893dd848cc9bb,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
160,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy",05c2939dada0672749ec4cb4ea3d7457c7858303,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
161,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Outcomes are poor in patients with HER2-negative, advanced gastric or gastro-oesophageal junction adenocarcinomas.",81f3a0d81fc79f36f8808045aceb3a981bf715f2,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
162,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
163,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer from 81 Italian centres",42c2125c9d0d81288538f25dd8b3c047203713de,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
164,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation,583a76088c72262449dac8aacd51fb58b93120b8,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
165,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"adult patients (aged ≥18 years) with advanced, progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal origin were enrolled",1097520aab3d197f4867ce88a13d038e7c72ae07,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"We conducted a phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of trastuzumab deruxtecan (a HER2 antibody-drug conjugate) with those of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.",e50544c83b7956b22ab1ac15fff8159eb88637bb,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
167,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.,5fc989ef5fe2c3d505652b55cb785026b6bb9235,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
168,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"HR-positive, HER2-negative advanced breast cancer",faee86c53010ff6d9154771948e27e86ca8b279f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
169,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,We enrolled female patients with HER2-overexpressing metastatic breast cancer who had progressed on or following adjuvant trastuzumab or first-line treatment of metastatic disease with trastuzumab.,e9c238aef87e34090486f21c9fb8626127670618,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
170,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,We randomly assigned 1838 participants with H. pylori infection to receive either eradication therapy,c3ed5167be671bd93f25be64ff45859e98ded5b5,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
171,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-positive early breast cancer in premenopausal women,e2e40fd85b9bba6397be29b29ac5c6c0bdfeea59,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
173,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,To assess whether stereotactic body radiotherapy on a single tumor site preceding pembrolizumab treatment enhances tumor response in patients with metastatic NSCLC.,374e60a2a29d21ed4816c49171017e2b69b302d3,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
174,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"Men and women, who had indicated on a previous questionnaire that they would probably attend screening if invited, were randomly assigned (1:2) to an intervention group (offered flexible sigmoidoscopy screening) or a control group (not contacted).",00be356bb6b02279d8af11c34900d2702dc5397f,False,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
175,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who had been pretreated with platinum-based chemotherapy.,9e6203ad597e2d1e23acd743cea428eb86362819,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
176,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"From 1993 through 2001, we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects).",529c7a2f02b5029cc173759afd736b6a80629cf1,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
177,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.,70d475696cdc082bcacbd6384e423ff7da28aba6,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
178,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"demonstrate the efficacy of ivosidenib (AG-120)-a first-in-class, oral, small-molecule inhibitor of mutant IDH1-vs placebo for patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation",160d6dd97964e72f3e4ee7ea40f2d3fc4f700252,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
179,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,"Patients (age 1-20 years) with neuroblastoma were eligible to be randomly assigned if they had completed a multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide with or without topotecan, vincristine, and doxorubicin) and achieved an adequate disease response.",0d65348acebaddbbcf21c23018e019f526dfc462,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,had previously untreated recurrent or metastatic nasopharyngeal carcinoma,bb06d0c31dc58f6a446b63ce25a67cb6e3404c9b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
182,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more,8238f81c269109ba3c048924442cdc35631824df,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
183,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,patients with previously untreated stage II or stage III triple-negative breast cancer,df1fbc5bb5dcbf5062226f899b54c592cad0ffc2,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
184,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer,823f122356f8f86a5e76455b661c9dd507b9fb64,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
185,anthropic,claude-opus-4-5-20251101,evidence_required,1,BOTH,Eligible participants aged 1-18 years with newly diagnosed cancer and normal audiometry were randomly assigned (1:1) to receive sodium thiosulfate or observation (control group) in addition to their planned cisplatin-containing chemotherapy regimen,a8a037c85beae667177bdf82856f613163a24083,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
186,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
187,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,"patients with locoregionally advanced, unresectable disease... stage III or stage IV disease and no distant metastases",67e772b38e26fbd01cfb432fd112411f8eea3964,False,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
188,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent",406f22033394df460ac3a4a6de3cf7b661fbcc51,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
189,anthropic,claude-opus-4-5-20251101,evidence_required,1,NEITHER,"a randomised, placebo-controlled, double-blind trial of exemestane 25 mg a day for the primary prevention of breast cancer",775a173bb31c607563b6c7d1ad882376d7fc252f,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
190,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer,1d5ab5aa44d4b9fe7746b357e8ac868cb49cd851,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
191,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
192,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer",32ca4d3fff954ed57510ab1bee98e9767a91dddc,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
193,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"Eligible patients were adults (aged 18 years or older) with progressive, advanced, well differentiated pancreatic NETs",5203160dfb07efc646930d7c8a2ed8f5ea77ac99,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
194,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions,83b241e5412ffc76522b5f4b1eb8c2ba5559c311,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
195,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung who had progressed after at least four cycles of platinum-based-chemotherapy.,7b6c6e36b482f1636c166e4378de25d7832b70ee,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
196,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,"In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel",b0d5b8e000da10259a494d9d1d935a8a5098b10d,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
197,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,Patients aged 18 years and older with metastatic soft-tissue sarcomas,5aa95ecda2edcb243e6f1061f50ba6de22c5831e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
198,anthropic,claude-opus-4-5-20251101,evidence_required,1,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry.,0dba11ee514688d77c9254edf4807a4baff8b71f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
199,anthropic,claude-opus-4-5-20251101,evidence_required,1,METASTATIC,men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment,0278ffd332ca1b2e0bf80b280ebe480fb8d41250,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
0,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We randomly assigned patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual),fc7bb4a1f2e57bc303295fd86d2ec6c2c8ca0505,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
0,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We randomly assigned patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual),fc7bb4a1f2e57bc303295fd86d2ec6c2c8ca0505,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
1,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma with prespecified FGFR alterations,0160b11634f2b30a9d244e76b12d448a9151fb57,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
1,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma with prespecified FGFR alterations,0160b11634f2b30a9d244e76b12d448a9151fb57,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
2,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"In this phase 3 study, we aimed to compare overall survival in patients with advanced or metastatic soft-tissue sarcoma who received eribulin with that in patients who received dacarbazine",cf3614b788fdddf6d88bbe8c5a0531acbefc221b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
2,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"In this phase 3 study, we aimed to compare overall survival in patients with advanced or metastatic soft-tissue sarcoma who received eribulin with that in patients who received dacarbazine",cf3614b788fdddf6d88bbe8c5a0531acbefc221b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
4,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,To investigate the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing after second-line or further treatment.,c9e609f99613768550cecda30d5261632a03cdcd,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
4,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,To investigate the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing after second-line or further treatment.,c9e609f99613768550cecda30d5261632a03cdcd,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.,095a4141eb262225a4f7a27dacfdcec099af798c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
5,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.,095a4141eb262225a4f7a27dacfdcec099af798c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
6,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Localised prostate cancer is commonly treated with external beam radiotherapy,0c49d50c3d7e6e3b243439cb9d2a760b787b52c7,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
6,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Localised prostate cancer is commonly treated with external beam radiotherapy,0c49d50c3d7e6e3b243439cb9d2a760b787b52c7,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
7,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"We recruited postmenopausal women aged 50-74 years from 13 centres in National Health Service Trusts in England, Wales, and Northern Ireland.",507ed5b5e16c7afa7515b71d2a45e6af6b23c385,False,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"We recruited postmenopausal women aged 50-74 years from 13 centres in National Health Service Trusts in England, Wales, and Northern Ireland.",507ed5b5e16c7afa7515b71d2a45e6af6b23c385,False,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,postmenopausal women who are at high risk of the disease,a29a8e17895852ca8a39d9cdf67189f8e9161a2e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"To be eligible, women had to be at increased risk of breast cancer",e23b8207c614a3044014c44d56f786b3d775384d,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
9,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma",f7c8ae218aa2a3d30f7332ef5fdf9e777dc7d8dc,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
9,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma",f7c8ae218aa2a3d30f7332ef5fdf9e777dc7d8dc,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
10,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab.",0591ee004c0def46184a426053dd9738f35bbfe6,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
10,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab.",0591ee004c0def46184a426053dd9738f35bbfe6,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
11,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer.",d1e614fe7b5029804a8fbe3e3a04765c4bffb316,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
11,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer.",d1e614fe7b5029804a8fbe3e3a04765c4bffb316,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
12,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1 to 3 prior regimens and performance status of 0 to 2.",f3409732cc7d4683f100ffbb4e6a413730016a80,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
12,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1 to 3 prior regimens and performance status of 0 to 2.",f3409732cc7d4683f100ffbb4e6a413730016a80,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
13,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,5102 patients with HER2-positive early breast cancer,42e034cabf2625e843f4f5548b2fb5d4b396f648,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
13,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,5102 patients with HER2-positive early breast cancer,42e034cabf2625e843f4f5548b2fb5d4b396f648,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
14,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer,51ec0273befa1e47d1450daed3776964587877f4,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
14,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer,51ec0273befa1e47d1450daed3776964587877f4,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
15,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer were randomly assigned",84ec036d9366cf4a0250f89f04a963cb3b9da6ed,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
15,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer were randomly assigned",84ec036d9366cf4a0250f89f04a963cb3b9da6ed,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
16,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.",7e1f10ae979f9c975e6f844c7d8c536f7403d433,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
16,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.",7e1f10ae979f9c975e6f844c7d8c536f7403d433,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
17,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast",c6bec3db773bc407f94951fa1e0122a502885747,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
17,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast",c6bec3db773bc407f94951fa1e0122a502885747,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
18,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,healthy women older than 25 years,7cef698a40287e43633ef9741ddf42790931b86d,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
18,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,healthy women older than 25 years,7cef698a40287e43633ef9741ddf42790931b86d,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
20,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer,7705de340e41b57febb4d8971de9d1fa7442e04e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
20,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"previously untreated (except for neoadjuvant or adjuvant chemotherapy completed ≥180 days before recurrence), HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer",82f9ae49f05c3afc0efa3efd85ae63994cee48e1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
21,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation,8558a85da1ba64adc29d0d287b8124a5c93b74ba,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
21,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation,8558a85da1ba64adc29d0d287b8124a5c93b74ba,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"we randomly assigned 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations",32924e6cfd4d4f195549c678749a0c82e6d5b7ad,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
22,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"we randomly assigned 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations",32924e6cfd4d4f195549c678749a0c82e6d5b7ad,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
23,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,140 patients with early breast cancer were randomly assigned,bff69170118c768e1eb092596381a3c543eed253,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
23,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,140 patients with early breast cancer,8dbe064277815c984c0fdd220e7ff087d90f2f09,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
25,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Barcelona Clinic Liver Cancer stage B or C disease,c7301b6296b7bdbecfa1ac7e161014afb25491ea,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
25,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Barcelona Clinic Liver Cancer stage B or C disease,c7301b6296b7bdbecfa1ac7e161014afb25491ea,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
26,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,Women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing,d85113a3698d87094482ce17b9c7375fc21bddad,False,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
26,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,Women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing,d85113a3698d87094482ce17b9c7375fc21bddad,False,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
27,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned,bfee109a10676ba8e9aa75d74715bb869358dc39,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
27,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned,bfee109a10676ba8e9aa75d74715bb869358dc39,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
30,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"we randomly assigned (centrally by computer; stratified by node status, HER2 status, and centre) 1500 women with axillary node-positive or high-risk node-negative breast cancer",51d14a3b6c6f874d36fada30f09e46b36132ee73,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
30,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,1500 women with axillary node-positive or high-risk node-negative breast cancer,bcdd56e17d1a840c3afc168e772f2dc8dca708c5,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
31,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously,324aade2b9dcc7564cab85ec6def80cff9e1bad4,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
31,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously,324aade2b9dcc7564cab85ec6def80cff9e1bad4,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
32,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Patients with centrally confirmed HER2-positive gastric or gastroesophageal junction adenocarcinoma that had progressed while they were receiving at least two previous therapies, including trastuzumab",83e41a14d9cc5141b01a709074a904e7e85884b7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
32,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Patients with centrally confirmed HER2-positive gastric or gastroesophageal junction adenocarcinoma that had progressed while they were receiving at least two previous therapies, including trastuzumab",83e41a14d9cc5141b01a709074a904e7e85884b7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
33,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"In a multicenter, sham-controlled trial, we randomly assigned 127 patients with dysplastic Barrett's esophagus",32a9eef18cf13b2c780494445c6368dd83b84420,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
33,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"In a multicenter, sham-controlled trial, we randomly assigned 127 patients with dysplastic Barrett's esophagus",32a9eef18cf13b2c780494445c6368dd83b84420,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
34,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Eligible patients were premenopausal women aged 18-59 years who had histologically or cytologically confirmed HR-positive, HER2-negative, advanced breast cancer",376bc86d88c5629dd3f7472a123ac28182d128a6,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
34,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"premenopausal women with hormone-receptor-positive, advanced breast cancer",b7f7973899cec2a7ea0e17bdc7fb5beca630fe8d,False,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
35,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,No treatments are presently available to increase survival in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy.,db9632759935187a78e1099978d7773d20859809,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
35,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy,5a943ca8e986a9372d87d3a446983858c218bfb1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
36,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned",bef7dc4daef6dba31ca7cb28ef2c7402a9b0617e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
36,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned",bef7dc4daef6dba31ca7cb28ef2c7402a9b0617e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
37,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,eligible patients recruited in 138 clinics from 24 countries (aged ≥18 years with histologically or cytologically confirmed advanced non-small-cell lung cancer,dd4a2579bcb6d5baa7eb513d87860f580f708e7d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
37,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,eligible patients recruited in 138 clinics from 24 countries (aged ≥18 years with histologically or cytologically confirmed advanced non-small-cell lung cancer,dd4a2579bcb6d5baa7eb513d87860f580f708e7d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
38,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma",4dccde99f317d5f36d314601c66701d8accae702,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
38,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma",4dccde99f317d5f36d314601c66701d8accae702,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
39,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma,fcc8b382a999378f1e6c81cc8bc685b7d2fad526,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
39,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma,fcc8b382a999378f1e6c81cc8bc685b7d2fad526,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
40,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with locoregional renal-cell carcinoma at high risk for tumor recurrence after nephrectomy,219ebaf5950154794a2f340f0970c3ee40bbd79a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
40,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We sought to determine the efficacy and safety of sunitinib in patients with locoregional renal-cell carcinoma at high risk for tumor recurrence after nephrectomy.,c082bcd6fe87f693cd29a356941c7d8d288f67e6,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
41,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Standard first-line regimens for patients with metastatic gastroesophageal adenocarcinomas have an approximate 40% objective response rate (ORR).,43c6405e58d7844115495f18c7fbe2aafae3c296,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
41,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Standard first-line regimens for patients with metastatic gastroesophageal adenocarcinomas have an approximate 40% objective response rate (ORR).,43c6405e58d7844115495f18c7fbe2aafae3c296,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
42,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627),b1c09b3e60339f032a3371c9409dd5cba859d47c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
42,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned,35ab9758ff3cbe8aab8a9ca6d7d0aebc9404d81a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
43,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer and who had chosen surgery as their treatment approach,6c7bbb749c23a76c07155510f2a35c4213821cd1,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
43,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer and who had chosen surgery as their treatment approach,6c7bbb749c23a76c07155510f2a35c4213821cd1,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
44,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We assessed the effects of combined docetaxel and estramustine on relapse in patients with high-risk localised prostate cancer.,786ab75603b505994389571e11eaa12e57c099cc,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
44,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We assessed the effects of combined docetaxel and estramustine on relapse in patients with high-risk localised prostate cancer.,786ab75603b505994389571e11eaa12e57c099cc,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
45,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated,02d496a2dd8422ce71898eb8c05bed6bc7046068,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
45,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated,02d496a2dd8422ce71898eb8c05bed6bc7046068,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
46,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer without neuroendocrine differentiation,d8b422adbc7e21bce8ba462cb2cfd07fe0ae4df0,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
46,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer without neuroendocrine differentiation,d8b422adbc7e21bce8ba462cb2cfd07fe0ae4df0,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
47,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen,e4721392778786e03d84fcd2855ac39157cedcdd,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
47,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen,e4721392778786e03d84fcd2855ac39157cedcdd,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
48,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,patients with previously treated metastatic breast cancer,d4d34620582aba440ad57f1a5e1e98bf67366997,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
48,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,two or fewer previous chemotherapy regimens for metastatic breast cancer,8d2244853502618d92c71778dd81ff892a6b294a,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
49,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer",cfbf220f019f4e538d01b925b7d7555d6a0e6e8a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
49,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer",cfbf220f019f4e538d01b925b7d7555d6a0e6e8a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
50,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we enrolled patients with stage IIIB or IV adenocarcinoma,0825e4d60d1fa4f662bb55c1140ae89e2cce2319,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
50,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we enrolled patients with stage IIIB or IV adenocarcinoma,0825e4d60d1fa4f662bb55c1140ae89e2cce2319,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
51,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer",97d6bfead549bd200270e4c195e1f70f5a675d31,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
51,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer",97d6bfead549bd200270e4c195e1f70f5a675d31,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
53,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,adjuvant chemotherapy for operable node-positive breast cancer,d831e475033b14ff9450885da9a3f45addd83004,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
53,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,adjuvant chemotherapy for operable node-positive breast cancer,d831e475033b14ff9450885da9a3f45addd83004,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
54,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy.,c02ea06c108110323e6de9212ef4743b789afcb7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
54,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy.,c02ea06c108110323e6de9212ef4743b789afcb7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
56,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,scheduled to receive radiotherapy for prostate cancer,2aff11e016c46ad17f1370f6028d113cc18b8f28,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
56,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Two hundred forty-two participants with intact erectile function scheduled to receive radiotherapy for prostate cancer were recruited,4dfc3c6bf55043377fadff9f1319f7b1fa5cb037,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
57,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,enrolled 160 patients with radiologically confirmed painful bone metastases,bf827c4b70a3b2c7f466645b23a47ece3ad69f79,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
57,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"This prospective, randomized, single-institution phase 2 noninferiority trial conducted at a tertiary cancer care center enrolled 160 patients with radiologically confirmed painful bone metastases",47914415954e0030186cf36c2cee2a69d12adcbe,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
58,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, who had received one or two previous systemic treatments for metastatic disease",146630f6cb4e92394cc4d3fde32029546edc2f5d,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
58,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer",98a8176ee5187d630adb8aeaa485ef5593c3909e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
59,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,We assessed the efficacy and safety of pertuzumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic gastric or gastro-oesophageal junction cancer.,c96be6c17272c3b6a08ee06032afbfaf76e684ab,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
59,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We assessed the efficacy and safety of pertuzumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic gastric or gastro-oesophageal junction cancer.,c96be6c17272c3b6a08ee06032afbfaf76e684ab,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
60,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer,eb39c499b2390ac2dd1d4534274471899a2f3445,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
60,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer,eb39c499b2390ac2dd1d4534274471899a2f3445,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
61,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,patients with symptoms suggestive of colorectal cancer,7885ebd7581b37dd829f169a8a87475b044c38d1,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
62,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease)",4d8a53f9ab4779215bbb08f3398f784bae600b5a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
62,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease)",4d8a53f9ab4779215bbb08f3398f784bae600b5a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
63,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) who had disease progression after receiving EGFR tyrosine-kinase inhibitor therapy,c5e339c43af4750dbfb418920c5f2588026bbffe,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
63,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) who had disease progression after receiving EGFR tyrosine-kinase inhibitor therapy,c6ea67fb9b85a8261880f550b0ffcca8ee4134e5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
64,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,patients with advanced renal cell carcinoma and no previous systemic therapy,27873bec3229f421e7a00bd2e3a69d89aa463abb,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
64,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,patients with advanced renal cell carcinoma and no previous systemic therapy,27873bec3229f421e7a00bd2e3a69d89aa463abb,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
65,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease, children (≥365 days of age) who had stage 3 tumors with favorable histopathological features, and infants who had stage 4S disease with a diploid DNA index or unfavorable histopathological features.",e2f405aa914f41ce9361dcd11d7d73d45a94569d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
65,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease, children (≥365 days of age) who had stage 3 tumors with favorable histopathological features, and infants who had stage 4S disease with a diploid DNA index or unfavorable histopathological features.",e2f405aa914f41ce9361dcd11d7d73d45a94569d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
66,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment",92b54c29dfeb350fb3e61b31231bb4b6ae50a08e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
66,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment",92b54c29dfeb350fb3e61b31231bb4b6ae50a08e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
67,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned",0d6ba56beb6830ccb551ce364ac1ff2caf808724,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
67,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned",0d6ba56beb6830ccb551ce364ac1ff2caf808724,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
68,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,patients aged 18 years or older with unresectable hepatocellular carcinoma,dafec26da4015cf84651f3e0d1d6c58a92a0471e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
68,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,patients aged 18 years or older with unresectable hepatocellular carcinoma,dafec26da4015cf84651f3e0d1d6c58a92a0471e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma,96d38b1bcb1aa5ffc0fdc50e988558ea509561ce,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma,96d38b1bcb1aa5ffc0fdc50e988558ea509561ce,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
70,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Randomization was stratified based on site of metastasis (visceral, bone only, or other) and resistance to prior ET (primary vs secondary).",e18234726dba6d1cc4bc57a45cb3ece481ff1ab1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
70,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Randomization was stratified based on site of metastasis (visceral, bone only, or other)",6ea62c972b956e36c633136528c0a1dd84c8e97a,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
71,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
71,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
72,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients who had resected stage III melanoma with BRAF V600E or V600K mutations,12ccaf4f82680f37fe37be42eec6ed337dfc63bc,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
72,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with resected stage III melanoma with BRAF V600E or V600K mutations,579a7383ae80b1ae9fe530ed163c8b19a1c1d3ec,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
73,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,T1-T2N0-2 p16-positive OPSCC,e13bde1e6308ed1b899f8f16b6d26c3a5e5a66ca,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
73,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,enrolled patients with T1-T2N0-2 p16-positive OPSCC,64ce7a66da3b9350c6ec61deff324c165f4fd575,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
74,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries,bf89fe51434b0d644946853de71f676f18751fd0,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
74,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited,0298c4ebd14147a2c51e15d5aff9edd861061538,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
75,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors",705c0db343db93f7def5ac17051a9587b6be6529,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
75,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors",705c0db343db93f7def5ac17051a9587b6be6529,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
76,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,among 5999 participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings,a84a329d9800aee76b206256d580ce80ed8d7b5b,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
76,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"Among persons aged 50 to 64 years receiving primary care at a safety-net institution, mailed outreach invitations offering FIT or colonoscopy compared with usual care increased the proportion completing CRC screening process within 3 years.",08f34ef91e10d3fff4c15c6ee368a53718cecf8c,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
77,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,2f473300ee2ed5d6e679dd22a6fb62b3b64bf27b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
77,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,2f473300ee2ed5d6e679dd22a6fb62b3b64bf27b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
78,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer (cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer)",20f35dbfe1c2d4338016708f34248860a1dba4ce,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
78,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer (cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer)",20f35dbfe1c2d4338016708f34248860a1dba4ce,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
79,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy",0405aa34a2137529c9041abdac3e50222c00c304,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
79,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy",0405aa34a2137529c9041abdac3e50222c00c304,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
80,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment, enzalutamide significantly increased overall survival compared with placebo.",c34877d78c6b666cca66be8b0ea0be09064ed5e7,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
80,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment, enzalutamide significantly increased overall survival compared with placebo.",c34877d78c6b666cca66be8b0ea0be09064ed5e7,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
81,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
81,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
82,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,randomly assigned patients 2:1 with untreated locally recurrent inoperable or metastatic triple-negative breast cancer,50a04a731744183c77c6309f4fd72c4f43944b0a,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
82,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,untreated locally recurrent inoperable or metastatic triple-negative breast cancer,4e05d39ea4883688eba77cc5809eb230ee88e5f7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
83,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients 18 to 75 years of age with resectable cancer of the middle or lower third of the esophagus,0baebef4cd924b3a4022d771beea312b006e770c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
83,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients 18 to 75 years of age with resectable cancer of the middle or lower third of the esophagus,0baebef4cd924b3a4022d771beea312b006e770c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
84,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized,2af9700c1ac362442bdb36b45f67e71d24763b0d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
84,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized,2af9700c1ac362442bdb36b45f67e71d24763b0d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
85,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C who had not received previous treatment with a KRAS G12C inhibitor,5f29fd8a3860573fff492e09ca4330436eb220a2,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
85,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C who had not received previous treatment with a KRAS G12C inhibitor,5f29fd8a3860573fff492e09ca4330436eb220a2,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
86,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy",44543fcedf1e506791ac2be2f6c729782b756273,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
86,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"enrolling patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy",a71040b3a8b377cf20ea24365216ca338c38a6ea,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
87,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract",feac9e353db3a2317bbb6d8f79e649e29d2c384c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
87,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract",feac9e353db3a2317bbb6d8f79e649e29d2c384c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
88,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,840 patients with stage IB-IIIA NSCLC from 101 centres in 14 countries were randomly assigned to observation (n=433) or to 30 mg/m(2) vinorelbine plus 100 mg/m(2) cisplatin (n=407).,b63664706fb59899ae2ce5dda6f04bdf65982d18,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
88,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,840 patients with stage IB-IIIA NSCLC from 101 centres in 14 countries were randomly assigned to observation (n=433) or to 30 mg/m(2) vinorelbine plus 100 mg/m(2) cisplatin (n=407).,b63664706fb59899ae2ce5dda6f04bdf65982d18,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
89,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus",72edf0593dcdbaa0c3bea1a320c43bf3f1472076,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
89,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus",72edf0593dcdbaa0c3bea1a320c43bf3f1472076,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
90,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with stage III colon cancer,edf15d4023c95bc0cedb01d9c45ec1dbf2dc2d03,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
90,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with stage III colon cancer,edf15d4023c95bc0cedb01d9c45ec1dbf2dc2d03,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
91,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with sentinel-node metastases detected by means of standard pathological assessment or a multimarker molecular assay,82d72671c923b8736e62499c5d98a618f2432ae2,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
91,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Sentinel-lymph-node biopsy is associated with increased melanoma-specific survival (i.e., survival until death from melanoma) among patients with node-positive intermediate-thickness melanomas (1.2 to 3.5 mm).",dd2ce66947ca9e027a74abf5aab423fca1f3744c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
93,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence",c37659491a000415239367e1978caf776dc39280,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
93,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence",c37659491a000415239367e1978caf776dc39280,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
94,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,a phase 3 trial comparing atezolizumab plus bevacizumab versus sunitinib in first-line metastatic renal cell carcinoma,ff75c2eee75a5b6c52756cac79f7af79ffc683dd,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
94,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,patients with previously untreated metastatic renal cell carcinoma,d39b284e062de97f1ada89226d8b6168e2099764,False,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
95,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
95,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
96,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment,7ad600db6616635fc16a44ff62e3125d220e6c0e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
96,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment,7ad600db6616635fc16a44ff62e3125d220e6c0e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
97,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC",0b402dc18bfbf2b3abe6d6e47c3cc9b7ada85791,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
97,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC",0b402dc18bfbf2b3abe6d6e47c3cc9b7ada85791,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
98,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy",dcbe702f34b4ba40177de4b6f4df1dd179f0d943,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
98,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 2:1 ratio",53a464af8f4765b601194c6ed2b698be42e8d2b2,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
99,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs) and enrolled",b7e8d2cdc9533f4eb4de4a221f8b6dc7bd9167f1,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
99,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs) and enrolled",b7e8d2cdc9533f4eb4de4a221f8b6dc7bd9167f1,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
100,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.",2bb4c508e081004e847881868ce95d43864f22fb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
100,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.",2bb4c508e081004e847881868ce95d43864f22fb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
101,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,locoregionally advanced nasopharyngeal carcinoma,2edcecb4d1b79b8fa4d89eb6411cb292d075cebd,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
101,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,locoregionally advanced nasopharyngeal carcinoma,2edcecb4d1b79b8fa4d89eb6411cb292d075cebd,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
102,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage.",9a226940bcf144b135766bfa4bf9bf3e09e0a381,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
102,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage.",9a226940bcf144b135766bfa4bf9bf3e09e0a381,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.,e17cfaf030de1c203c1c5a45a0f85f9ffc6a7796,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
103,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.,e17cfaf030de1c203c1c5a45a0f85f9ffc6a7796,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
104,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma,fa08345d653fe100e478be37169783281485351b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
104,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma and adequate cardiac, renal, and hepatic function.",47305802b893796a8363fba1844bb539f1eefa15,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
105,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Randomisation was done via the minimisation method with biased-coin balancing for Eastern Cooperative Oncology Group performance status, disease stage at enrolment, and institution.",0cb6744cc662dde9e8f633cc0a52e5bbc16eee32,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
105,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,Patients with small-cell lung cancer that responded to first-line treatment but showed evidence of disease relapse or progression at least 90 days after completion of the first-line treatment were eligible to participate.,7a675638797d3a81ba42bbb525134d8c2a5eaebf,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
106,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
106,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
107,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer,925a41b4143b75a761a76d588e6b8fbc0d961442,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
107,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer,925a41b4143b75a761a76d588e6b8fbc0d961442,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
108,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"patients with advanced cancer, aged at least 18 years, admitted to the palliative and supportive care unit at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), with refractory agitation",c39b3f6f7eb39a439e7f57b846d303f827a00ac0,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
108,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"patients with advanced cancer, aged at least 18 years, admitted to the palliative and supportive care unit at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), with refractory agitation, despite low-dose haloperidol",0b7f5d5aa0566c9284b0dc46892d61e4b77c7915,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
109,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma",6f23b4ecc422bab373dea947e4bb3946b5ac0614,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
109,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma",6f23b4ecc422bab373dea947e4bb3946b5ac0614,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
110,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease",42edce59222b2d92f7594e370656ad2a9f95330c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
110,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease",42edce59222b2d92f7594e370656ad2a9f95330c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
111,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
111,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
112,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction,7764aacefa5c6343a21be2968247573405ba770c,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
112,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction,7764aacefa5c6343a21be2968247573405ba770c,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
113,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"we randomly assigned, in a 1:1 ratio, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to receive 500 mg of nicotinamide twice daily or placebo for 12 months",8d9b12c4a7e614356b0e109df4cf4ab5cfd9b92a,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
113,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"we randomly assigned, in a 1:1 ratio, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to receive 500 mg of nicotinamide twice daily or placebo for 12 months",8d9b12c4a7e614356b0e109df4cf4ab5cfd9b92a,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
114,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment,4864296f7ae844ff2919e93269293aa144b83745,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
114,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment,4864296f7ae844ff2919e93269293aa144b83745,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
115,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy,2f7ab902b18cc5cdd9667c868b8ed71e403d9958,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
115,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy,2f7ab902b18cc5cdd9667c868b8ed71e403d9958,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
116,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma",4e9d1b2e87d328e571dc9c7e55c1d887aef3d569,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
116,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma",4e9d1b2e87d328e571dc9c7e55c1d887aef3d569,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
117,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.,1e5a0d07bcab51fdb16ae60707f07703b41de616,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
117,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.,1e5a0d07bcab51fdb16ae60707f07703b41de616,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
118,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Eligible patients were aged 18-75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)",666abb58c43dc6cbad55d9584c2ff02bb0c5a432,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
118,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients were aged 18-75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)",666abb58c43dc6cbad55d9584c2ff02bb0c5a432,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
119,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with palpable T1-T2 invasive breast cancer were recruited,8e7d379bc116332307e54f6cef9d8d517b082952,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
119,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with palpable T1-T2 invasive breast cancer were recruited from six medical centres in the Netherlands,75db0374ad38f800d02b0e19ffb948f7dd7f37c6,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
120,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"patients with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer",a5ce4ad3a274bfe8aa55aadfaa00d7624f32c56d,False,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
120,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"patients with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer",a5ce4ad3a274bfe8aa55aadfaa00d7624f32c56d,False,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
122,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors,bcec87f427a1c6e6a336726d281fb67543d3cf78,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
122,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors,bcec87f427a1c6e6a336726d281fb67543d3cf78,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
123,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma",d57a0e70cd847b04f4eb56ebbf449fa9bc55841a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
123,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma",d57a0e70cd847b04f4eb56ebbf449fa9bc55841a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
124,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.",f01be5f907ffb3968529022574e3b780796c8912,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
124,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.",f01be5f907ffb3968529022574e3b780796c8912,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
125,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease, as defined by Response Evaluation Criteria In Solid Tumors version 1.1, had received at least one platinum-based regimen",6d1a87a3d2148833cdae7e2691ac258614cf0a5d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
125,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease,fbb28621ca792d0faff6a84d142934f1380805f2,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease,2013657070185ba51f4157a780dc6214d4a149b4,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease,2013657070185ba51f4157a780dc6214d4a149b4,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
127,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC were enrolled,f6ae1a7979a85cbb3361ae4ed55a331be7d7d488,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
127,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with resectable stage IIIA or IIIB (T3N2) NSCLC were enrolled,8a67bd68234b5be5e42e23c8be40fd3591fef96f,False,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
128,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",62a9896c1da9a80e07fb82397217a16d1d84584a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
128,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",62a9896c1da9a80e07fb82397217a16d1d84584a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
129,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
129,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
130,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm,4296d5fb72270e8341ca5ee07edb61cf79b35b50,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
130,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm,4296d5fb72270e8341ca5ee07edb61cf79b35b50,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
131,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
131,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
132,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"We conducted a randomized, open-label, noninferiority, postauthorization, safety end-point trial involving patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor.",e38390aaad285508fbd172229746be5928a3e2f5,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
132,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor,91bd9ce646c85b4c45e39bd471eb05419d1cc62e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
133,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with stage IV melanoma with no evidence of disease after resection or radiotherapy,e65618adae10e67174237fc8b646807da88c37e8,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
133,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
134,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level of 1% or more to receive nivolumab",42ad9b9e5fbcd4e67959609e6321d877e640a6d7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
134,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,patients with untreated stage IV or recurrent NSCLC,0c85b8487b0acb5a3977724399f64a26805c26c5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
135,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Among patients with high-risk relapsed metastatic neuroblastoma, oral β-glucan adjuvant during GD2/GD3 ganglioside vaccine boost has stimulated IgG antibody response",8deda0b2488b04e6850c168c5df2fc2cd550ea0f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
135,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"Among patients with high-risk relapsed metastatic neuroblastoma, oral β-glucan adjuvant during GD2/GD3 ganglioside vaccine boost has stimulated IgG antibody response",8deda0b2488b04e6850c168c5df2fc2cd550ea0f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
136,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre.,a6faddd453e53720422bf2bb801ad8dfcd687277,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
136,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre.,a6faddd453e53720422bf2bb801ad8dfcd687277,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
137,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Because of the inaccessibility of mediastinal nodal metastases, the left thoracoabdominal approach (LTA) has often been used to treat gastric cancer of the cardia or subcardia.",505584ec834af3150eb82845836a6a1791972f0e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,adults aged 18 years or older with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum that was refractory to previous standard therapy,af633a6944eb57692b1eedaba57650900c92a1b9,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,adults aged 18 years or older with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum that was refractory to previous standard therapy,af633a6944eb57692b1eedaba57650900c92a1b9,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"523 patients with curable stage T2b, T3, or T4 gastric cancer were randomly assigned during surgery to D2 lymphadenectomy alone (263 patients) or to D2 lymphadenectomy plus PAND (260 patients)",490954a6e6f8f512ac272d794f2793653b2bb8ac,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
139,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"523 patients with curable stage T2b, T3, or T4 gastric cancer were randomly assigned during surgery to D2 lymphadenectomy alone (263 patients) or to D2 lymphadenectomy plus PAND (260 patients)",490954a6e6f8f512ac272d794f2793653b2bb8ac,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
140,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
140,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
141,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression,187b46812f1d8adc55b45569e5fa26ef2e61a69a,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
141,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression,187b46812f1d8adc55b45569e5fa26ef2e61a69a,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
142,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)",22ba5ffce0ae91fc338c92ab90641a6944ad8acb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
142,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"This multicenter, double-blind, placebo-controlled phase 3 trial enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)",a91ba8c0d91ff17d0e6af1c40fd559be263bf262,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
143,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"Screening for its precursor, anal intraepithelial neoplasia (AIN), is subject of discussion.",3a464d27b3321c8001ba80fab558066c60e9a134,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
143,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"Screening for its precursor, anal intraepithelial neoplasia (AIN), is subject of discussion.",3a464d27b3321c8001ba80fab558066c60e9a134,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
144,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,spinal cord compression caused by metastatic cancer,8cb9910a1b04bc12e5d19bac259fcc3e2c21ab9a,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
144,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,spinal cord compression caused by metastatic cancer,8cb9910a1b04bc12e5d19bac259fcc3e2c21ab9a,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
145,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy",a68c0f30833a87517c04acc3c8114503aba73390,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
145,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision",9d69fb515579fc1983b1221d78ede77659cfc981,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
146,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States,74c9e84f875aaf64bd23ef59b2906c556e7e43aa,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
146,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,marine n-3 fatty acids (at a dose of 1 g per day) in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States,6637c1e973a270fa129945396421098300d68ccf,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
147,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.,69b842dffdbffa24b7350f9d02f2376643d86b1b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
147,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.,69b842dffdbffa24b7350f9d02f2376643d86b1b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
148,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
148,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
149,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.",5dd83413e5cf0f338a57224082e25970f5d5aa27,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
149,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.",5dd83413e5cf0f338a57224082e25970f5d5aa27,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
150,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with a histologically proven superficial basal-cell carcinoma,e8d4ba50a7b6fd5dcb3c9939a6f3043aa82a3107,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
150,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with a histologically proven superficial basal-cell carcinoma,e8d4ba50a7b6fd5dcb3c9939a6f3043aa82a3107,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
151,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.",12f0f83eee4f297d5b656a2bc3371efacee7671e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
151,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.",12f0f83eee4f297d5b656a2bc3371efacee7671e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
152,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,We included chemotherapy-naive men (aged ≥18 years) with mCRPC who had not been previously treated with androgen biosynthesis signalling inhibitors,234ef7b029d3c6b6fe6e4a16d75c5e4f63861090,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
152,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We included chemotherapy-naive men (aged ≥18 years) with mCRPC who had not been previously treated with androgen biosynthesis signalling inhibitors and were receiving ongoing androgen deprivation therapy,05deb733e7d9d49fc7d4383c5369da4a73d85928,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
153,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment",623aaaee2065b1baf7cf0c6d1adae0950ab244e3,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
153,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment",623aaaee2065b1baf7cf0c6d1adae0950ab244e3,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
154,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Women older than 18 years with histologically confirmed HER2-overexpressing breast cancer and CNS recurrence or progression as determined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) during or after treatment with trastuzumab, lapatinib, or both, were eligible.",25d39f9ae00ffa521ebe07ab3bb1d89b5117c54e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
154,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Patients with advanced HER2-positive breast cancer frequently develop CNS metastases. The metastases that progress after brain radiotherapy and HER2-targeted systemic therapy are a difficult therapeutic challenge.,804de7f2c4ca52ad32ac8c22c2f8e6981ec07e52,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
155,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
155,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
156,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery,497bfcf94eef00225dfe6be3ee39ac77b8c6b7a2,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
156,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery,497bfcf94eef00225dfe6be3ee39ac77b8c6b7a2,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
157,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,The primary end point was metastasis-free survival,3f799a018c6da63b630bf17cb51591206ce075f1,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
157,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less,7860fcacfb91af16f9e4ce1d620792df7883440f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
158,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
158,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
159,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,children and young adults (<30 years) with high-risk neuroblastoma were randomly assigned at diagnosis,b41ff7b720bc34fc428c92ded59893dd848cc9bb,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
159,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,children and young adults (<30 years) with high-risk neuroblastoma were randomly assigned at diagnosis,b41ff7b720bc34fc428c92ded59893dd848cc9bb,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
160,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy",05c2939dada0672749ec4cb4ea3d7457c7858303,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
160,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy",05c2939dada0672749ec4cb4ea3d7457c7858303,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
161,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"patients with previously untreated, FGFR2b-overexpressing, advanced gastric or gastro-oesophageal junction adenocarcinoma",c33c45777f5ddb41bc8337ed90d047903fbb774d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
161,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"previously untreated, FGFR2b-overexpressing, advanced gastric or gastro-oesophageal junction adenocarcinoma",4356af0ce9de80b48a9f001e5ff5ada783c5d8cc,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
162,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"pathologically proven, stage IIIA/N2 non-small-cell lung cancer",b7018211963328285fa59b411a7fde24c20729b8,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
162,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
163,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer from 81 Italian centres",42c2125c9d0d81288538f25dd8b3c047203713de,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
163,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer from 81 Italian centres",42c2125c9d0d81288538f25dd8b3c047203713de,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
164,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors.,ad666259a56de2edd15a2032e761dc69121c9de1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
164,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation,583a76088c72262449dac8aacd51fb58b93120b8,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
165,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"adult patients (aged ≥18 years) with advanced, progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal origin were enrolled",1097520aab3d197f4867ce88a13d038e7c72ae07,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
165,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"adult patients (aged ≥18 years) with advanced, progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal origin were enrolled",1097520aab3d197f4867ce88a13d038e7c72ae07,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane,246502d97693ff1bf8efb3c3018acc06eccbfa9d,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
166,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane,246502d97693ff1bf8efb3c3018acc06eccbfa9d,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
167,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.,5fc989ef5fe2c3d505652b55cb785026b6bb9235,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
167,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.,5fc989ef5fe2c3d505652b55cb785026b6bb9235,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
168,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"HR-positive, HER2-negative advanced breast cancer",faee86c53010ff6d9154771948e27e86ca8b279f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
168,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"HR-positive, HER2-negative advanced breast cancer",faee86c53010ff6d9154771948e27e86ca8b279f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
169,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,We enrolled female patients with HER2-overexpressing metastatic breast cancer who had progressed on or following adjuvant trastuzumab or first-line treatment of metastatic disease with trastuzumab.,e9c238aef87e34090486f21c9fb8626127670618,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
169,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We enrolled female patients with HER2-overexpressing metastatic breast cancer who had progressed on or following adjuvant trastuzumab or first-line treatment of metastatic disease with trastuzumab.,e9c238aef87e34090486f21c9fb8626127670618,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
170,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,We screened 3100 first-degree relatives of patients with gastric cancer. We randomly assigned 1838 participants with H. pylori infection to receive either eradication therapy...or placebo. The primary outcome was development of gastric cancer.,d87629d59bc12887eef7657e1a5eaaf115461d59,False,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
170,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,We screened 3100 first-degree relatives of patients with gastric cancer. We randomly assigned 1838 participants with H. pylori infection to receive either eradication therapy,66318eaa24dd72efbb8f2dd5ae9d892d620fe6db,False,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
171,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-positive early breast cancer in premenopausal women,e2e40fd85b9bba6397be29b29ac5c6c0bdfeea59,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
171,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-positive early breast cancer in premenopausal women,e2e40fd85b9bba6397be29b29ac5c6c0bdfeea59,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
173,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,To assess whether stereotactic body radiotherapy on a single tumor site preceding pembrolizumab treatment enhances tumor response in patients with metastatic NSCLC.,374e60a2a29d21ed4816c49171017e2b69b302d3,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
173,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,To assess whether stereotactic body radiotherapy on a single tumor site preceding pembrolizumab treatment enhances tumor response in patients with metastatic NSCLC.,374e60a2a29d21ed4816c49171017e2b69b302d3,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
174,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"Men and women, who had indicated on a previous questionnaire that they would probably attend screening if invited, were randomly assigned (1:2) to an intervention group (offered flexible sigmoidoscopy screening) or a control group",cb97a816b5b3cac53b18771afd7428f40aa973a8,False,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
174,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,Colorectal cancer is the third most common cancer worldwide. Previous analyses have only reported follow-up after flexible sigmoidoscopy for a maximum of 12 years. We aimed to examine colorectal cancer incidence and mortality after a single flexible sigmoidoscopy screening and 17 years of follow-up.,96770c141957debb83e0b58151ff6f98d9f0363e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
175,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who had been pretreated with platinum-based chemotherapy.,9e6203ad597e2d1e23acd743cea428eb86362819,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
175,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who had been pretreated with platinum-based chemotherapy.,9e6203ad597e2d1e23acd743cea428eb86362819,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
176,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"From 1993 through 2001, we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects).",529c7a2f02b5029cc173759afd736b6a80629cf1,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
176,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects)",c66df23d0610296fd455dd07268b825cf01af1ac,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
177,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.,70d475696cdc082bcacbd6384e423ff7da28aba6,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
177,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.,70d475696cdc082bcacbd6384e423ff7da28aba6,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
178,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"to demonstrate the efficacy of ivosidenib (AG-120)-a first-in-class, oral, small-molecule inhibitor of mutant IDH1-vs placebo for patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation",c9ddda61d7731bee7b9899c8f9a9f8c0924f2ccc,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
178,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,"demonstrate the efficacy of ivosidenib (AG-120)-a first-in-class, oral, small-molecule inhibitor of mutant IDH1-vs placebo for patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation",160d6dd97964e72f3e4ee7ea40f2d3fc4f700252,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
179,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"Patients (age 1-20 years) with neuroblastoma were eligible to be randomly assigned if they had completed a multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide with or without topotecan, vincristine, and doxorubicin) and achieved an adequate disease response.",0d65348acebaddbbcf21c23018e019f526dfc462,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,had previously untreated recurrent or metastatic nasopharyngeal carcinoma,bb06d0c31dc58f6a446b63ce25a67cb6e3404c9b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
181,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,had previously untreated recurrent or metastatic nasopharyngeal carcinoma,bb06d0c31dc58f6a446b63ce25a67cb6e3404c9b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
182,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more,8238f81c269109ba3c048924442cdc35631824df,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
182,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more,8238f81c269109ba3c048924442cdc35631824df,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
183,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,patients with previously untreated stage II or stage III triple-negative breast cancer,df1fbc5bb5dcbf5062226f899b54c592cad0ffc2,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
183,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,patients with previously untreated stage II or stage III triple-negative breast cancer,df1fbc5bb5dcbf5062226f899b54c592cad0ffc2,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
184,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer,823f122356f8f86a5e76455b661c9dd507b9fb64,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
184,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer,823f122356f8f86a5e76455b661c9dd507b9fb64,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
185,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,Eligible participants aged 1-18 years with newly diagnosed cancer and normal audiometry were randomly assigned (1:1) to receive sodium thiosulfate or observation (control group) in addition to their planned cisplatin-containing chemotherapy regimen,a8a037c85beae667177bdf82856f613163a24083,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
185,anthropic,claude-opus-4-5-20251101,evidence_required,3,BOTH,Eligible participants aged 1-18 years with newly diagnosed cancer and normal audiometry were randomly assigned (1:1) to receive sodium thiosulfate or observation (control group) in addition to their planned cisplatin-containing chemotherapy regimen,a8a037c85beae667177bdf82856f613163a24083,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
186,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
186,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
187,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,"patients with locoregionally advanced, unresectable disease... stage III or stage IV disease and no distant metastases",67e772b38e26fbd01cfb432fd112411f8eea3964,False,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
187,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,"patients with locoregionally advanced, unresectable disease...stage III or stage IV disease and no distant metastases",58fce206b6c9f3acee27f17ae91063cb7de45160,False,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
188,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent",406f22033394df460ac3a4a6de3cf7b661fbcc51,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
188,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent",406f22033394df460ac3a4a6de3cf7b661fbcc51,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
189,anthropic,claude-opus-4-5-20251101,evidence_required,2,NEITHER,"a randomised, placebo-controlled, double-blind trial of exemestane 25 mg a day for the primary prevention of breast cancer",775a173bb31c607563b6c7d1ad882376d7fc252f,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
189,anthropic,claude-opus-4-5-20251101,evidence_required,3,NEITHER,"a randomised, placebo-controlled, double-blind trial of exemestane 25 mg a day for the primary prevention of breast cancer",775a173bb31c607563b6c7d1ad882376d7fc252f,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
190,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer,1d5ab5aa44d4b9fe7746b357e8ac868cb49cd851,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
190,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer,1d5ab5aa44d4b9fe7746b357e8ac868cb49cd851,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
191,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
191,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
192,anthropic,claude-opus-4-5-20251101,evidence_required,2,BOTH,"postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer",32ca4d3fff954ed57510ab1bee98e9767a91dddc,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
192,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.",09698d0fe82df3f68e60864457c76c6e4c68b602,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
193,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"Eligible patients were adults (aged 18 years or older) with progressive, advanced, well differentiated pancreatic NETs, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and progression on up to two kinds of previous systemic regimens for advanced disease.",345f51cc7a17b35f0e59c0d61c6219a51a9ba1b9,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
193,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Eligible patients were adults (aged 18 years or older) with progressive, advanced, well differentiated pancreatic NETs, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and progression on up to two kinds of previous systemic regimens for advanced disease.",345f51cc7a17b35f0e59c0d61c6219a51a9ba1b9,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
194,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions,83b241e5412ffc76522b5f4b1eb8c2ba5559c311,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
194,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions, Eastern Cooperative Oncology Group score of 0-1, and a life expectancy of at least 6 months were eligible.",a2bb26ee3f4690b802f9ac765f68896bb4dff919,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
195,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung who had progressed after at least four cycles of platinum-based-chemotherapy.,7b6c6e36b482f1636c166e4378de25d7832b70ee,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
195,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung who had progressed after at least four cycles of platinum-based-chemotherapy.,7b6c6e36b482f1636c166e4378de25d7832b70ee,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
196,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,"In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel",b0d5b8e000da10259a494d9d1d935a8a5098b10d,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
196,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,"In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel",b0d5b8e000da10259a494d9d1d935a8a5098b10d,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
197,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,Patients aged 18 years and older with metastatic soft-tissue sarcomas,5aa95ecda2edcb243e6f1061f50ba6de22c5831e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
197,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,Patients aged 18 years and older with metastatic soft-tissue sarcomas,5aa95ecda2edcb243e6f1061f50ba6de22c5831e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
198,anthropic,claude-opus-4-5-20251101,evidence_required,2,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry.,0dba11ee514688d77c9254edf4807a4baff8b71f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
198,anthropic,claude-opus-4-5-20251101,evidence_required,3,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry.,0dba11ee514688d77c9254edf4807a4baff8b71f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
199,anthropic,claude-opus-4-5-20251101,evidence_required,2,METASTATIC,men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment,0278ffd332ca1b2e0bf80b280ebe480fb8d41250,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
199,anthropic,claude-opus-4-5-20251101,evidence_required,3,METASTATIC,men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment,0278ffd332ca1b2e0bf80b280ebe480fb8d41250,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
0,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual),85e156f895f3ed503c4178addd4d94580bebde85,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
1,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we enrolled patients who had locally advanced and unresectable or metastatic,aa41afcfd0d25b8d3f4bc8fbef7869c1c9d86a37,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
2,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,advanced or metastatic soft-tissue sarcoma,d28b1db6a124af08f9f65e1287ad6406871299d6,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
4,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,those who had centrally located squamous cell carcinoma with cavitary,14348ecd6150694f35998f13a9b61ff576c513fe,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.,095a4141eb262225a4f7a27dacfdcec099af798c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
6,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Localised prostate cancer is commonly treated with external beam radiotherapy and moderate,93a011d4fea905c8f60e6d5512d87f998750d89e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
7,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,Exclusion criteria were previous bilateral oophorectomy or ovarian,738b55450f305ebb6083f9550ce0d793bb275d13,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,We assessed the efficacy and safety of the aromatase inhibitor anastro,bc88e62143bc0c9f7397e9ce30b587a20003568a,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
9,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we recruited patients aged 18 years or older with,ca4a0d30874b0052ef92684b33263b9379859a4a,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
10,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab.",0591ee004c0def46184a426053dd9738f35bbfe6,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
11,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Patients aged at least 18 years with previously untreated,0b407e11d8e70f359fdc350bd85a3017c6a794e8,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
12,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fallopian tube",9d680e16f279da24617cb2dded0f2f148e428a14,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
13,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,5102 patients with HER2-positive,6e8f583e331ae97b039b4274289f9cc76de51694,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
14,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer,51ec0273befa1e47d1450daed3776964587877f4,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
16,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible patients were women aged 18 years or older with unilateral,fa828c664e4d6915e3b826d995dda65ee5a24afe,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
17,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive,",68e45bf2723aaf85c62974581393b33f08376601,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
18,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,"In this phase 3, multinational, double-blind,",d62a4ca5af50b33b775e30a113eab79034e9c464,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
19,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligible patients were adult women (aged ≥18 years,dfea16ed826e19dac78d07a31edc2219984a297d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
21,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"In this trial, we randomly assigned 556 patients",5a367c4e58fb6e9cfa55fbb7a21840df3dc5edc7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations",5bc192c8ba270a07267a65bb5a3800b98362e9a3,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
23,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,140 patients with early breast cancer were randomly assigned,bff69170118c768e1eb092596381a3c543eed253,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
25,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,randomized clinical trial enrolled systemic therapy-naive adults with histologically confirmed,8cbe559a5132c3510d3a7004165b477c7d5d0d59,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
26,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,women aged 25-60 years were randomly assigned,ef016a5eb2328ee48078573c31cefca9d5af9dac,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
27,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Patients (aged 18-80 years,bbab1c3921c2657b0258898e56f6bb32b91c1e35,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
28,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Treatment for patients with recurrent ovarian cancer has been mainly based on,69248b845a348504f04bdc025f5bcb0b2c20ad4c,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
29,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,measurable or evaluable high-grade serous or endometri,56e72dca2422ca084705cc335eb6899ddc062337,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
30,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,1500 women with axillary node-positive or high-risk node-negative breast cancer,bcdd56e17d1a840c3afc168e772f2dc8dca708c5,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
31,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,A total of 424 survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously were screened,5808aec2aa6f127482bcc1304d8c6a36f777e807,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
32,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,The drug may have efficacy in patients with HER2-positive advanced gastric,b62e995489b9d85619a85cb51b2f3cd258d41728,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
33,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,we randomly assigned 127 patients with dysplastic Barrett,45abd30338224ac4c9a6497a3d70732625e71aa7,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
34,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible patients were premenopausal women aged 18-59 years,5f840835219fab2ba5517b0ca1e10975f184285b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
35,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,recurrent or metastatic squamous-cell carcinoma of the head and,821b13e93a3d74436c5c87b76e94d2e1b7090bc3,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
36,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"patients with chemotherapy-naive, stage IIIB or IV, non-",665ffd8ffb4b29e86141481a76f6b55b985c8905,False,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
37,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,histologically or cytologically confirmed advanced non-small-cell lung cancer,25e69c709826bca84b2a20a3de52d1e666cec5d8,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
38,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma",4dccde99f317d5f36d314601c66701d8accae702,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
39,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma were randomly assigned,8a5c047c35aa6f50c18f52b683e7dbd2d05b54ef,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
40,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"we assigned 615 patients with locoregional, high",d05f59ff3e74720ef323d38196d4b51e50a5f85c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
41,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Standard first-line regimens for patients with metastatic gastroes,ffcc32a8347280ddf65b415bdb0b315d7e6f9fb5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
42,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,1256 patients with resected stage III,a75e6175509c8dd0fc4c56efdb8cb1dddffd3cf9,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
43,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer,59a3763c94c3f0cac7eec1001ce3b4f98d515821,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
45,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated,02d496a2dd8422ce71898eb8c05bed6bc7046068,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
46,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer,45921d9ab9b48290b5485d58823453be5f06f07f,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
47,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,We compared the efficacy and safety of a modified FOLFIRINO,c7e38e489e7e4c0cfabd626a1d68e773ab7ef786,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
48,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,patients with previously treated metastatic breast cancer,d4d34620582aba440ad57f1a5e1e98bf67366997,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
49,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"women with hormone-receptor-positive, human epidermal",660ec951f268ff99e8f633c71740a58391fbb24f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
50,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we enrolled patients with stage IIIB or IV adenocarcinoma,0825e4d60d1fa4f662bb55c1140ae89e2cce2319,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
51,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"advanced hormone-receptor-positive, human epidermal growth factor receptor",75062dc8fd420b4d90a15aa24dff341a910eba27,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
52,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,"The study involved 182,16",e2260312646af6e3a013c14a9e868225bfa5f955,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
53,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,adjuvant chemotherapy for operable node-positive breast cancer,d831e475033b14ff9450885da9a3f45addd83004,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
54,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC,83ebc0f9d457c6f7c84b8d584fad5230449ae643,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
55,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,"In the Prostate Cancer Prevention Trial (PCPT), finaster",e827fd6ed9cedd5ab4e5cbc7022788b3a4a0e5fd,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
56,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,One hundred twenty-one participants were assigned 5 mg,26caef53683d157edf9fcc2c68943199fd491164,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
57,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,enrolled 160 patients with radiologically confirmed painful bone metastases,bf827c4b70a3b2c7f466645b23a47ece3ad69f79,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
58,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"Patients aged 18 years or older, with centrally confirmed",54d212a011d4743b2d9a68211839fe112c75c56b,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
59,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"JACOB was a double-blind, placebo-controlled, randomised, multicentre, phase 3 trial in patients aged 18 years or older with HER2-positive metastatic gastric or gastro-oesophageal junction cancer.",3775d984868f90f69a99a5af7c3928c8895cb059,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
60,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer,eb39c499b2390ac2dd1d4534274471899a2f3445,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
62,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible participants were aged 18 year or older with hist,17ac88b62929c763b814fad909cd05cef8dd3b7b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
63,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible participants were adults aged 18-75 years,a284feb82a6e5df208e4e25d38860653ef9b572f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
64,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,patients with advanced renal cell carcinoma and no previous systemic therapy,27873bec3229f421e7a00bd2e3a69d89aa463abb,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
66,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment",92b54c29dfeb350fb3e61b31231bb4b6ae50a08e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
67,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV6",946ae7f2594fcb5b1278330be651f5a678f112bd,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma,96d38b1bcb1aa5ffc0fdc50e988558ea509561ce,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
70,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Randomization was stratified based on site of metastasis (visceral,",7e5d8909a7017653bee2a7ee71c3a15fbfd4ef5a,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
71,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer",90d37de0fe857b85ec9ed0126051eeeee05f0b83,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
72,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with resected stage III melanoma with BRAF,b13d3a946fa5c810b63d343d5366f5ef75be3a0a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
74,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited,0298c4ebd14147a2c51e15d5aff9edd861061538,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
75,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We randomly assigned 229 patients who had well-,e0526438dca7bd0aeb7e575d88e860c2c7f3c0cd,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
76,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,participants aged 50 to 64 years,149f3b2aa1ad1813e70c34c3616ee7ebfba3641c,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
77,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,25ecd584e5b4a56896c4eee319b874a2c1548069,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
78,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we randomly assigned patients (in a 1:1 ratio),224ad0306ecbdbb1e61819f96cfa6b02a6c6432a,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
79,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,patients with clear-cell renal-cell carcinoma who were,c6babd6926440ac4f820f5e7788cef20ae867f98,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
80,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,In the AFFIRM trial of patients with metastatic castration-,1f22e8954c181e8838473310c0291d1ab3de519c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
81,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
82,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we randomly assigned patients 2:1 with untreated locally recurrent inoper,3a9f5b0b65c6f36108ec7f5d7fc6bde649c0412f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
83,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,resectable cancer of the middle or lower third of the esophagus,4aa815917ed986cf18485917b5df7dc4af2ec9fd,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
84,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,479 women with previously untreated recurrent and/or,c49459eba9aa9ecdfef521f28238db8bbe0e3921,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
85,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with,76ecfde963edc5c5c6a0eeb6fc4c8a3e28420fc9,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
86,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"enrolling patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy",a71040b3a8b377cf20ea24365216ca338c38a6ea,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
87,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract.",fb9278c2791a54c475e36e439cc3e33ec9537dfc,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
88,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,840 patients with stage IB-IIIA NSCLC from 101 centres in 14 countries were randomly assigned to observation (n=433) or to 30 mg/m(2) vinorelbine plus 100 mg/m(2) cisplatin (n=,d30822da13e718c3273975bc1d5efb70ec9cd52c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
89,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"histopathologically diagnosed with undifferentiated or differentiated,",e2e958e3041d7e8b4b0f0715fd6b068113dbd303,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
90,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,A total of 2526 patients with stage,20b26158d7a0628d0b37c8b266cb526c76134c1b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
91,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,we randomly assigned patients with sentinel-node metastases detected,3463d51815e11d2c9977e70d51b8753dcabc12c1,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
92,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma",20a8ac2d2d7de84a786ae92ba2577331d911dc21,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
93,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence",c37659491a000415239367e1978caf776dc39280,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
94,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,patients with previously untreated metastatic renal cell carcinoma,d39b284e062de97f1ada89226d8b6168e2099764,False,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
95,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
96,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment,7ad600db6616635fc16a44ff62e3125d220e6c0e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
97,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC_",55ebd3b04a126fe1121ac652d0282f2a257f96f8,False,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
98,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation,2f0b234c6ef62442bf7acce140fa215447af0a7e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
99,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,Individuals aged 30 to 64 years with female sex,da09b4c276fe2322676bdbd8b37adbb00c70bf31,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
100,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Adults with rectal cancer that had been clinically staged as T2,f969a5a891673495161c9f5f7e376d6350d0ddbf,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
101,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Patients with previously untreated, stage III-IVB (",1b445e0a2831f1d8e8ffcf9964fc0ad3cae15294,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
102,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Randomization was stratified according to programmed death ligand 1 (PD,e7b6c4f52bcc307bc9ed05593e0b38ae5a3f5aa8,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,To evaluate the safety and efficacy of adjuvant girentuximab on,312c321bd5b8c4c52e1ab61e8a73cc6ff6014ac8,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
104,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible patients had pathological stage high-grade T1b,6822e7e9cdef0ffa3134eed0944d04b382e91bd0,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
105,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Randomisation was done via the minimisation method with biased-,2c2b486879566150e58b1377d31ae7971f6219a8,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
106,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
107,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"We conducted a phase 3, double-blind",fc3d4c2967ce694aaa180320370661673eb91c51,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
108,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"patients with advanced cancer, aged at least 18",994ffb7c194d2b0a1798216a5d30c4aa72ae22ff,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
109,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"locally advanced, unresectable, or metastatic cutaneous melanoma",40560de174934256c1341f83c94e1cc40eddd7ae,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
110,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"in patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease",493177c96434c0b68b8132d84e12d76eb974e196,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
111,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
112,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we enrolled adults aged 18 years or older with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction.,076c11304025f27e18daf7fb5b082e983e0f3670,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
113,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,386 participants who had had at least two,7a75b65b112895dc818d1db21dd487e4bf6059a1,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
114,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with squamous-cell carcinoma of the head and neck who,b2181e086b7a75dc8c7522280f687a16131d7a4a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
115,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we randomly assigned patients with unresectable stage IIIC or IV melanoma,9c74be094483dd16b5b51d18d71153ac0f52a093,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
116,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Patients with advanced, unresectable, American Joint Committee on Cancer stage",67adbb9742b225071eb18b5a7f2ca3aec3922ce5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
117,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,We compared letrozole with tamoxifen as adjuvant treatment,49168eb16df68e889387ece63de234cd5ebe6370,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
118,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible patients were aged 18-75,b7d3ab477e2281821eca96aa1c27369a3b79f353,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
119,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with palpable T1-T2 invasive breast cancer,cb8a20c15fe2c7f29c70bbdd83082bcecf3eb382,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
120,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"patients aged 18 years or older, with previously untreated, hist",d685b73a550ae1884ecdf14be67b0d1071a6a235,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
122,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with FIGO (International Federation of Gynecology and Obstetrics),898d0d9c4730a3a3b473d1b7c30432405e5269fa,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
123,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible patients were aged 18 years or older,b28b5f3ef72e5860a6d72add16b504b580daae25,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
124,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.",f01be5f907ffb3968529022574e3b780796c8912,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
125,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible patients were aged 18 years or older with recurrent low-,1a5d29608d27231c110464f71862e72dfe1be02a,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible adult participants (aged ≥18 years) had primary stage,595c13a7df2ba392d69037646fef21e6456a83ad,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
127,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients aged 18 to 70 years with re,04376809b47363de3a6796ccf12cba919a09baf9,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
128,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Participants were aged 18 years and older, had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",a2901e7a0e6ecc70978ec646a7e92e9bd0370ff6,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
129,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligible patients were aged 18-80 years,23a13725bade9e440e355e30fcc2bddbc3ecc72e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
130,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual,4e7c6aeeb2970456a0aee1c5d8e245d4ece8b380,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
131,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
132,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,patients with active rheumatoid arthritis despite methotrexate treatment who were,a29e135e0d7ae70a83d2afb8315d23773b59f466,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
133,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
134,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"we randomly assigned, in a 1:1 ratio,",d8aeb23400b810b4ec1f3a911af426ebf6dffc6b,False,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
136,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre.,a6faddd453e53720422bf2bb801ad8dfcd687277,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
137,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Because of the inaccessibility of mediastinal nodal metastases, the left",d71a6a19b62287a8c87044ba79468ee7ee91dca6,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,adults aged 18 years or older with histologically or,a7d1499c9ee0b79e19ec3fa8b4a3d394ad2407c5,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"523 patients with curable stage T2b,",0d51129c6fa571a99cf0d77fabed1c42749871f9,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
140,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
141,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area.",90b8b1ce26881f1a262c409c0be08f786debc092,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
142,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)",22ba5ffce0ae91fc338c92ab90641a6944ad8acb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
143,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,"Screening for its precursor, anal intraepithelial neoplasia",5beb370f7bca7917da96597bf3268e3493f960c0,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
144,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we randomly assigned patients with spinal cord compression caused by metastatic,090973cbdcc1cd84e5ba5c262556df3885ed3059,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
145,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"patients aged 18 years or older from 129 UK centres who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy.",d596171e05c1467d3cae8198a94cac5e82ad45a1,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
146,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States.,0b8a0885898b71126aa8a73937c694188bb6ff1c,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
147,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,To determine whether nab-paclitaxel improves the,fb9e76a7b49023b705e92a5d472b486aa84ce78e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
148,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
149,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly",c9186e1a53e7f758fef12ddb31fb25dd6368a34f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
150,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,we enrolled patients with a histologically proven superficial basal-cell carcinoma,3d9bef131d356c2d728d9fc8d0397676cc4e5712,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
151,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,"Patients aged 18 years or older, diagnosed with un",277803b484baf3002791db4f1f0b2df599ac5b0f,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
152,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We included chemotherapy-naive men (aged ≥18 years),26d9bdcdee233175800dde94e23b0b96b3d08f6b,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
153,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"patients with stage 0, I, and IIA breast cancer",39d54b7fda4846a420f13a6d7bddc9681a1f78cf,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
154,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Women older than 18 years with histologically confirmed HER,9d8c254694955e1e925281d78ba3e01f2fc0cb33,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
155,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
156,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery,497bfcf94eef00225dfe6be3ee39ac77b8c6b7a2,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
157,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"In this phase 3 trial, we enrolled patients with prostate cancer",eca0abaf59cb5f8c34cdf06773c50748825df0ac,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
158,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
159,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Randomisation was done in blocks stratified by International Neuroblastoma Staging System,82560fd0e57d6e14f4d1a81377b782ff356ab625,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
160,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy",05c2939dada0672749ec4cb4ea3d7457c7858303,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
161,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Outcomes are poor in patients with HER2-negative, advanced gastric",8bf475c1883351d59b81ea8bf3a22e9637a1fcc8,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
162,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
163,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,we enrolled patients aged 18-70 years with operable,361aca067096fdcf9e4414bb4d9f147d84b0671e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
164,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Patients who have unresectable or metastatic melanoma with a BRAF V,7db3bf36cf3fd002728a008b97171b9465cb5fc7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
165,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"adult patients (aged ≥18 years) with advanced, progressive,",9d627e5b828a1e9487d0d3a1144093e73f7a24cc,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane,ba494453b87af5027c59b2f08eaff54dadac5a1f,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
167,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,We aimed to assess ipilimumab as adjuvant therapy for patients,ebddf69df90f6bd0b69c8c8975852fa1fa885f48,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
168,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"HR-positive, HER2-negative advanced breast cancer who had received",3769f3d3d40d3900152c84e1040dba5f1f6577a7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
169,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We enrolled female patients with HER2-overexpressing metastatic breast,096983cb493d121b856dc5f92d825c9cb763b6ff,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
170,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,we screened 3100 first-degree relatives of,ff93519f9209262eea30b0db94a7a9622ad14b32,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
171,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Suppression of ovarian estrogen production reduces the recurrence of hormone-,a92a02769fe8cbe2ee204656c4a9ca440c9ad9a0,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
173,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,To assess whether stereotactic body radiotherapy on a single tumor,b4fc1f94e39fb209e6368c90d1dc68f2cdbd7cbb,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
174,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,170 432,36aa4528777ba80b6853a2d08b496fb35f52e88f,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
175,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,locally advanced or metastatic non-small-cell lung cancer,6e24b1c3586fff2364349bb1c8e959a166d8299d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
176,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,From 1993 through 2001,19cb282f719974dd500ab898c016c19933530b16,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
177,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,in patients with stage III or IVA endometrial carcinoma.,48f3743584d803d62172a9a128422d891fd91513,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
178,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,aimed to demonstrate the efficacy of ivosidenib (AG,22339d0519bf4bd384730f1543379a2775a467e6,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
179,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Patients (age 1-20 years) with neuroblastoma,6b1897a7f2285c40aada0282dd21cdc4cc355d99,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,had previously untreated recurrent or metastatic nasopharyngeal carcinoma.,f624bba9f68f856f6bf4d587b8f050ae9b066143,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
182,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we randomly assigned patients with stage IV or recurrent NS,609c513140e211273fe2852df5ae9ed386974508,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
183,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer,f33d8d6555d1c7356f81cb353a4c7a81669df708,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
184,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer,823f122356f8f86a5e76455b661c9dd507b9fb64,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
185,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible participants aged 1-18 years with newly diagnosed cancer,cc1aeb9962f648a43797bb2c25cb0194b75ca5cc,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
186,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
187,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,stage III or stage IV disease and no distant metastases,4e125bf1bdb004c65a01c2857ead93a7069be002,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
188,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes,45a629579ffe04604931a5af649703de002388f9,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
189,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,primary prevention of breast cancer,a4273a11d881b39d97e17b7c3e3d320c0e8f3224,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
190,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"ABCSG-12 is a randomised, controlled, open-",9a38a31f44246f309db4fb72f28ebdf01289eb5b,False,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
191,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
192,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"hormone receptor (HR)-positive, human epidermal growth factor",c2593e947af909435f318d451fd8c2ffaf328ceb,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
193,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible patients were adults (aged 18 years or older,c7638d6d44df055338c1b1d50449c811d0b38a1d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
194,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions, Eastern Cooperative Oncology Group score of 0-1, and a life expectancy of at least 6 months were eligible.",a2bb26ee3f4690b802f9ac765f68896bb4dff919,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
195,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung,fc43a5e41e52c882b1483b7240e1d1e78c9226d5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
196,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination.,b115d94518768d5f9b795d5db83ebfc4ffac9bc6,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
197,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Patients aged 18 years and older with metastatic soft-tissue sarcomas,5aa95ecda2edcb243e6f1061f50ba6de22c5831e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
198,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal,398671c8395e086ccd4ecafa5bd50584792142bb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
199,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,patients with metastatic castration-resistant prostate cancer that progressed after docetaxel chemotherapy,c6cab3e89f16f961f2900cb7b4a7282338f4772f,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
0,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual),7797aa481fbba7100152347a5a0e1f99810e5bec,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
0,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,We randomly assigned patients with resectable NSCLC (,1e7a5cd362035f4f5429e42105ce3ed3e1b231ef,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
1,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma,aa5907779d1e8cda3850878a7a3f4fe2aa54d877,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
1,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma with prespecified,23b5382dff493f59f8b3ff4abbf314ce9cd3c554,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
2,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we aimed to compare overall survival in patients with advanced or metastatic soft,a79b53593cb622fc42459ab021b914997ac73f1b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
2,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,advanced or metastatic soft-tissue sarcoma,d28b1db6a124af08f9f65e1287ad6406871299d6,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
3,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
4,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,those who had centrally located squamous cell carcinoma with cavitary features or brain,4581332fa356182fdbc4195f9070caae09c4ea6d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
4,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Those aged 18 to 75 years who had histologically,7e6f4965d61ebc7a17987656d8405f84d8d9940c,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive,3813f30a61e6d1b5ded36f69628e5b79a499b9b0,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.,095a4141eb262225a4f7a27dacfdcec099af798c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
6,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Localised prostate cancer is commonly treated with external beam radiotherapy and moderate,93a011d4fea905c8f60e6d5512d87f998750d89e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
7,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,Exclusion criteria were previous bilateral oophorectomy or ovarian,738b55450f305ebb6083f9550ce0d793bb275d13,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,we recruited postmenopausal women aged 50-74,59d5840f3d20e6313613f827e1c12ea5e2c935b2,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,"To be eligible, women had to be at increased risk",ac66b1d521e8833f031f86a6dd82ebc6ba84b8dd,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,"To be eligible, women had to be at increased risk of breast cancer (judged on the",55a8a024f7f97542e151b1a1c2b737ce68e77d3e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
9,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma",f7c8ae218aa2a3d30f7332ef5fdf9e777dc7d8dc,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
9,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we recruited patients aged 18 years or older with metastatic,a81509646c8882f451e1fe85afb33f3be7106fc8,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
10,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We randomly assigned patients with node-positive or high,0d9f305f39383eeeb0789757b5cdbfe46a699388,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
10,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,We randomly assigned patients with node-positive or high-risk,fe01e176a79eb80fa42b300d83c062bdbdd059df,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
11,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Patients aged at least 18 years with previously untreated locally advanced,cde1af8589fd6ba5273725bb157dfa624de203bd,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
11,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Patients aged at least 18 years with previously untreated locally,23e036c902cf8e826e0acd329388acb68302024a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
12,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fall",8d6b94d99d7c72ba2c479af281af6ba00d1688b5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
12,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fallopian",18e442bb43b46dc8a35c42b80664679eec4279ab,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
13,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,5102 patients with HER2-positive early breast cancer.,eabc2e51526a815b77f818267896a16616d06cf0,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
13,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,5102 patients with HER2-positive early breast cancer,42e034cabf2625e843f4f5548b2fb5d4b396f648,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
14,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,had stage I-III histologically proven and operable invasive hormone receptor,5b9ee52e251a53719de81e76e6283f55f756ae9a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
14,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Women were eligible if they were postmenopausal at the time of study entry, had stage I–III histologically proven and operable invasive hormone receptor-positive breast cancer",f78986d9d995a6349bf6385f91103c1ec9f72ebb,False,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
15,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Patients with HER2-positive, operable, locally advanced or inflammatory",6e1ad67f3e8d33499c3aee0e947d1036f7910da9,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
15,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Patients with HER2-positive, operable, locally",451810189a8afd011ecb26957b5e40f83d318b3f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
16,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserv",d9f2000319ca8edc336fc183aa58fd79474e418c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
17,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive, non-",a9a8a95023ba41ec615f3ec51e32d13452d31dc3,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
17,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast",c6bec3db773bc407f94951fa1e0122a502885747,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
18,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,healthy women older than 25 years,7cef698a40287e43633ef9741ddf42790931b86d,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
18,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,we randomly assigned healthy women older than 25 years to the,0eaa7f7eb7b9a0da076a2780133e5c1c1ba96962,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
19,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were adult women (aged ≥18 years),2dbeb45f15bcd82c3ca10830cb32ecf4fbb2a77e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
19,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Eligible patients were adult women (aged ≥18 years,dfea16ed826e19dac78d07a31edc2219984a297d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
20,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"unresectable, advanced or recurrent gastric or gastro-",9449cdb90017a665fadd57f7ea091b7ed26d7cc1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
21,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,EGFR mutation-positive advanced non-small-cell lung cancer (NS,348874b7e6cb6409db9ed53570887eae49945c9e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
21,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,patients with EGFR mutation-positive advanced non-small-cell,88eda38c0440f60021fb60ea45b35be12abd8873,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"870 patients with completely resected, stage III melanoma",bbfc1945313c370d67dbb5064c7f106fba34aad9,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
22,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"we randomly assigned 870 patients with completely resected, stage III melanoma",a1f2d33b3461ec586aa3319b5e73a66e74762328,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
23,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,140 patients with early breast cancer were randomly assigned,bff69170118c768e1eb092596381a3c543eed253,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
23,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,140 patients with early breast cancer were randomly assigned in,1045ea51473e1e2d16f116337a94d1f3a847e398,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
24,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"platinum-sensitive, recurrent ovarian cancer",7ad89581d28ad793e39d5ef1c9e62c2301831dae,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
24,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"platinum-sensitive, recurrent ovarian cancer",7ad89581d28ad793e39d5ef1c9e62c2301831dae,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
25,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Barcelona Clinic Liver Cancer stage B or C disease,c7301b6296b7bdbecfa1ac7e161014afb25491ea,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
25,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Barcelona Clinic Liver Cancer stage B or C disease,c7301b6296b7bdbecfa1ac7e161014afb25491ea,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
26,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,women aged 25-60 years were randomly,db0840a6e37e9843a6bd17f88296e0b065d5371e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
26,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,women aged 25-60 years were randomly assigned,ef016a5eb2328ee48078573c31cefca9d5af9dac,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
27,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Patients (aged 18-80 years) with c,633fc721ee59354ce34b0b441df21f9c7e1d9b72,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
27,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Patients (aged 18–80 years) with,ba6d099e0776ae7cd32407214c97da244e5284cd,False,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
28,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Treatment for patients with recurrent ovarian cancer has been mainly based on systemic,031f346bf2e9264b9cc4ace4eeac064ef24ce5e4,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
28,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"In women with recurrent ovarian cancer, cytoreductive surgery followed",73e898b83cfa288d872a43058d829bdc1d900dff,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
29,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,measurable or evaluable high-grade serous or endometrioid platinum,09a95fb0b5814bd0f5b34484fa4d5af4d5282854,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
30,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,1500 women with axillary node-positive or high-risk node-negative breast cancer,bcdd56e17d1a840c3afc168e772f2dc8dca708c5,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
30,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,1500 women with axillary node-positive or high-risk node-negative breast cancer,bcdd56e17d1a840c3afc168e772f2dc8dca708c5,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
31,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,A total of 424 survivors of stages 0 to,f34262a2a6d0fc80549a96fa819958009ad653ef,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
31,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,A total of 424 survivors of stages 0 to,f34262a2a6d0fc80549a96fa819958009ad653ef,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
32,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,The drug may have efficacy in patients with HER2-positive advanced gastric,b62e995489b9d85619a85cb51b2f3cd258d41728,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
32,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,The drug may have efficacy in patients with HER2-positive advanced,82b0862578382b2e6a677e64e71e3d1d652f1c0a,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
33,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,we randomly assigned 127 patients with dysplastic,3be1d7bf864e2fc4676bc7a4f1695a44bf1e90c5,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
33,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,we randomly assigned 127 patients with dys,c7143d240a5f8bb67b5a041bc0a20510cd1902d8,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
34,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were premenopausal women aged 18-59 years,5f840835219fab2ba5517b0ca1e10975f184285b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
34,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,premenopausal women aged 18-59 years who,b0f9323691c3a9c9ced7599c6f4d0ac31cf0edb3,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
35,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,recurrent or metastatic squamous-cell carcinoma of the head and neck,36052cc4a9b1e356b0b0f8617f6d0b79df84ea9f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
35,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,patients with recurrent or metastatic squamous-cell carcinoma of the head and neck,fbe1abd1d2d29c459ac519e0ebf66154064c91bf,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
36,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned",bef7dc4daef6dba31ca7cb28ef2c7402a9b0617e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
36,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Patients with chemotherapy-naive, stage IIIB or IV,",49952265bb8cd55fb837d23553d346a6072504fb,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
37,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,histologically or cytologically confirmed advanced non-small-cell lung cancer,25e69c709826bca84b2a20a3de52d1e666cec5d8,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
37,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,histologically or cytologically confirmed advanced non-small-,acc11f99279dad3ee4be15d5e418360b8bd91281,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
38,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma",4dccde99f317d5f36d314601c66701d8accae702,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
38,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"Eligible patients were male, aged 18 years or",1ef9b288ad7281068aca1f77c1b337fa569b9ea1,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
39,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable,60a1dbde588b70a3406119fae83d54be29cbeb76,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
39,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma,44c4c1fa6eb8791e09c71900f02c27af6980f4cf,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
40,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"we assigned 615 patients with locoregional, high",d05f59ff3e74720ef323d38196d4b51e50a5f85c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
40,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients with locoregional renal-cell carcinoma at high risk for,337060494b3da572159260da07c18886e95ea387,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
41,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Standard first-line regimens for patients with metastatic gastroes,ffcc32a8347280ddf65b415bdb0b315d7e6f9fb5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
41,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Standard first-line regimens for patients with metastatic gastroesophageal aden,2856b243479961f0815a43f20b00bf9a77d2cf0a,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
42,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627),b1c09b3e60339f032a3371c9409dd5cba859d47c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
42,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,1256 patients with resected stage III,a75e6175509c8dd0fc4c56efdb8cb1dddffd3cf9,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
43,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer and who had chosen surgery as their treatment approach,6c7bbb749c23a76c07155510f2a35c4213821cd1,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
43,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer,59a3763c94c3f0cac7eec1001ce3b4f98d515821,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
44,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,We assessed the effects of combined docetaxel and estram,c8e934911aeca9b9e480fa44876037aaa2280a78,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
45,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated (1 to 1) by minimisation to receive interferon alfa-2a alone or combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil.",7d0ba771cb0ab2735f66a46a3304a322d427e97e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
45,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated,02d496a2dd8422ce71898eb8c05bed6bc7046068,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
46,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer,45921d9ab9b48290b5485d58823453be5f06f07f,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
46,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer,45921d9ab9b48290b5485d58823453be5f06f07f,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
47,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer.,8066acb22185685f4794b84d85bf2c95a2903b69,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
47,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,We compared the efficacy and safety of a modified FOLF,b3927e0854918b0a338783c432c575a4a0316266,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
48,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,patients with previously treated metastatic breast cancer,d4d34620582aba440ad57f1a5e1e98bf67366997,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
48,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,patients with previously treated metastatic breast cancer,d4d34620582aba440ad57f1a5e1e98bf67366997,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
49,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"women with hormone-receptor-positive, human epidermal growth factor",1fefeee94fff14fedea59c1d1daa40937bb2aa3a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
49,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"We performed a prospective trial involving 10,2",36dc612e72f7b6642735a1b3657f79aff5cbb3fd,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
50,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we enrolled patients with stage IIIB or IV adenocarcinoma Identification of early cognitive,0cbe1864804f75d076b7d18fedb85eda7d506bd9,False,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
50,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,we enrolled patients with stage IIIB or IV adenocarcinoma,0825e4d60d1fa4f662bb55c1140ae89e2cce2319,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
51,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,premenopausal or perimenopausal patients with advanced hormone-receptor-,049b5abfa1eed87e9fb026687850e573d2168a76,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
51,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"advanced hormone-receptor-positive, human epidermal growth factor receptor",75062dc8fd420b4d90a15aa24dff341a910eba27,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
52,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,"The study involved 182,160",bee76e7dd23507023629b0faf13a418cb8473c6e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
52,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,"The study involved 182,160 men",e1b8695b6a884d1566963916899ec18bbb17ee5f,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
53,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,adjuvant chemotherapy for operable node-positive breast cancer,d831e475033b14ff9450885da9a3f45addd83004,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
54,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC that was not,62cba847b8421fdd30417995a4a9eb46c5a63b9f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
54,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy.,c02ea06c108110323e6de9212ef4743b789afcb7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
55,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,"In the Prostate Cancer Prevention Trial (PCPT), fin",3b1957189f5b5c63db37365865a862948ef64fdc,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
56,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,One hundred twenty-one participants were assigned 5 mg,26caef53683d157edf9fcc2c68943199fd491164,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
56,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Two hundred forty-two participants with intact erectile function scheduled,3dee2c7e99d97c4cf6b2b63ca5346d1cb43aab6a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
57,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,enrolled 160 patients with radiologically confirmed painful bone metastases,bf827c4b70a3b2c7f466645b23a47ece3ad69f79,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
57,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,enrolled 160 patients with radiologically confirmed painful bone metastases,bf827c4b70a3b2c7f466645b23a47ece3ad69f79,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
58,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, who had received one or two previous systemic treatments for metastatic disease, had progression on their most recent therapy, and had previous treatment with an anthracycline or taxane were eligible.",4ffb2b75b7f3fcb5a5ec2fac9e64baf94e3ddbb7,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
58,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"Patients aged 18 years or older, with centrally confirmed metastatic",aeac996b0170dccfbce94c605f0f19e81cdca24e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
59,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"JACOB was a double-blind, placebo-controlled, randomised",c4d2076bc961d1dbba572c7d107e0d77ee3c54e5,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
59,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"JACOB was a double-blind, placebo-",1fec106e597c3c46d31570a9458f9b9148f63586,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
60,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,premenopausal and postmenopausal women 35-70 years,2c1d320253967327999c0d9d34009f5dcc608090,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
60,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,premenopausal and postmenopausal women 35-70 years,2c1d320253967327999c0d9d34009f5dcc608090,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
61,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,Eligible patients were aged 55 years or older and regarded by,d0b5f3c51c4302faefbc5466e38de05cf087b53d,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
61,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,recruited patients with symptoms suggestive of colorectal cancer from 21 UK,e373e54cd03db423f059cb189450a0f0a0c0a239,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
62,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Eligible participants were aged 18 year or older with hist,17ac88b62929c763b814fad909cd05cef8dd3b7b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
62,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Eligible participants were aged 18 year or older with hist,17ac88b62929c763b814fad909cd05cef8dd3b7b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
63,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible participants were adults aged 18-75 years,a284feb82a6e5df208e4e25d38860653ef9b572f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
63,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Eligible participants were adults aged 18-75 years with locally advanced or metastatic NSCLC得以进行研究。,a536d5e43edc1db6d8db663123a55d26032a987b,False,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
64,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,patients with advanced renal cell carcinoma and no previous systemic therapy,27873bec3229f421e7a00bd2e3a69d89aa463abb,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
65,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,these patients included infants (<365 days of age),c1bc8450180527177e16dffc91a606f3e34723b5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
66,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer",540a6dbd666afb7ee6d0b7e5b7f3da7b959389ca,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
66,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment",92b54c29dfeb350fb3e61b31231bb4b6ae50a08e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
67,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV6",946ae7f2594fcb5b1278330be651f5a678f112bd,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
68,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Randomisation was stratified by geographical region, macrovascular portal vein",03653e98b86887295aff242004de9437be76371e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
68,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Randomisation was stratified by geographical region, macrovascular portal vein invasion or",7f5f22b05df9837265308749b355f87d10b2585c,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma,cf0305d73607fee89ad537787a8bab73a002e622,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,we randomly assigned previously untreated patients in East Asia who had advanced pulmonary,7917ea945add31fa3a11074806f3e212c8151eea,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
70,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"Randomization was stratified based on site of metastasis (visceral,",7e5d8909a7017653bee2a7ee71c3a15fbfd4ef5a,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
70,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Randomization was stratified based on site of metastasis (visceral,2385b6398f7f157a111dd6680aac3092b7e60415,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
71,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligible patients were aged 18 years or older,b28b5f3ef72e5860a6d72add16b504b580daae25,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
71,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
72,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We randomly assigned 870 patients who had,c087e6adf70564ed78e85a3b8b4bd44da92976fa,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
72,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients who had resected stage III melanoma with BRAF,fb35ca6c38f7c2adad2bcd51d1da7a909751edbe,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
73,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,enrolled patients with T1-T2N0-2 p,262ec6c5f79c5e808237988ff2527f805e3a822d,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
73,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,enrolled patients with T1-T2N0-2 p,262ec6c5f79c5e808237988ff2527f805e3a822d,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
74,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited,0298c4ebd14147a2c51e15d5aff9edd861061538,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
74,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited,0298c4ebd14147a2c51e15d5aff9edd861061538,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
75,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We randomly assigned 229 patients who had well-d,1462f338ecc30763fd3431c80fc0190797dc70ed,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
75,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors",705c0db343db93f7def5ac17051a9587b6be6529,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
76,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,5999 participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings.,fdf44af83ac37b872df2156a1683d452a28f959b,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
76,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,5999 participants aged 50,0ab850d62bc4237aa3148aca192f902456682e7c,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
77,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Participants (N = 51,61f06ef6bac554a46a5f00d4abffc19f1d2c1712,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
77,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,25ecd584e5b4a56896c4eee319b874a2c1548069,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
78,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we randomly assigned patients (in a 1:,369a3f45bdc861652167bf352a26c33bb5d79f80,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
78,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we randomly assigned patients (in a 1:1,f740974ade697b1863f08214abf1418a96f14857,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
79,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,patients with clear-cell renal-cell carcinoma who were at,7cf20d92d8928d6e30e1ec5ae287cbdca90b369c,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
79,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,patients with clear-cell renal-cell carcinoma who were at high risk,35163ceeb4e89de03fa27cdb88023b6a841f9646,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
80,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,patients with metastatic castration-resistant prostate cancer,059b16131770d5c692e8fbdf168f4aa81d9dc888,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
80,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment,9cc321336738a035abca85558916448bb1b64de9,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
81,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
81,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
82,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we randomly assigned patients 2:1 with untreated locally,8079d97beae8060155533989d3d3726a60c33f51,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
82,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,untreated locally recurrent inoperable or metastatic triple-negative breast cancer,4e05d39ea4883688eba77cc5809eb230ee88e5f7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
83,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,resectable cancer of the middle or lower third of the,190bb51d091ddf505ffd61ceb9c88fb72b981d8e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
83,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients 18 to 75 years of age with resectable cancer of the middle or lower third of the esophagus.,f048ddcaac4f282de7afb4ad6a448fc464bf0a99,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
84,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,479 women with previously untreated recurrent and/,0cedd55c3811d422b46c2dab0f7e7ebf1981afdc,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
84,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,479 women with previously untreated recurrent and/or metastatic,2226e937fed5ddd3e88c6f24dc023700bf0801a6,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
85,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C,91cec28e5c907eadc7e24c39b2db70269724b18c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
85,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C,91cec28e5c907eadc7e24c39b2db70269724b18c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
86,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,enrolling patients with at least one risk factor (pathological T-,7e6ba65017b6c90e6c2931815880c17bf5ef6c9b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
86,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"enrolling patients with at least one risk factor (pathological T-stage 3 or 4,",4b67d31ef8e2fde90f9f38b233a9633bf6689102,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
87,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"eligible patients had histologically confirmed, radiologically evident m",dd3f5f5c565e58432614d0545d1f48c97eb4c484,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
87,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract.",fb9278c2791a54c475e36e439cc3e33ec9537dfc,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
88,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,840 patients with stage IB-IIIA,cdfd7938c0cc30be00207ffcf82937e6b0bf3774,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
88,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,840 patients with stage IB-IIIA,cdfd7938c0cc30be00207ffcf82937e6b0bf3774,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
89,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We included patients aged 18-70 years,42223a5169601e31b3b579efe907b53d7a9a9022,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
89,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"locally recurrent NPC with tumours confined to the nasopharyngeal cavity,",a5c9e7d28d571be01c5adcfb942e90448b603d72,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
90,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"The effect of celecoxib, a COX-2 inhibitor",1abc6df0543ac6e981b88bd38d610198d6d70240,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
90,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"The effect of celecoxib, a COX-2 inhibitor",1abc6df0543ac6e981b88bd38d610198d6d70240,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
91,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,we randomly assigned patients with sentinel-node metastases detected by means,61e24361e4c7ec4f64426c09f89bd25dd42bd2d8,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
91,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,we randomly assigned patients with sentinel-node metastases detected by,2cbc1c4a696135b5344dc97d8dbb5130112cc660,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
92,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients (aged ≥18 years) had histologically confirmed epithelial,34c908724525f37f42c1be4643ac9c9d7f5c5d0b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
93,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,adult patients (aged ≥18 years) who had,f6aa31ea2b90aaf4da8a35d9fd40961ca5b37e3d,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
94,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,first-line metastatic renal cell carcinoma.,0b5e34470c16e4afaf2664de39af21c77e24db66,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
94,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,atezolizumab plus bevacizumab versus sunitinib in first-line metastatic renal cell carcinoma.,e762e14aa0fb56fe8d26f169b60276dce548894c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
95,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
95,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
96,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer that had,6ca3c9a52c2fba93cd925fe3e4d0d6084444d369,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
96,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer,5d5155847f5bd926214d2cd5e8b09aeba15723f7,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
97,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC",0b402dc18bfbf2b3abe6d6e47c3cc9b7ada85791,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
97,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC",0b402dc18bfbf2b3abe6d6e47c3cc9b7ada85791,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
98,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we randomly assigned 322 patients who had,3f575d57cc42c6c0e42de469da84e441c6bdf9f1,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
99,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,Individuals aged 30 to 64 years with female sex,da09b4c276fe2322676bdbd8b37adbb00c70bf31,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
99,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,Individuals aged 30 to 64 years with,0b4c5b075968aa016dcec5b53062569a82188949,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
100,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.",2bb4c508e081004e847881868ce95d43864f22fb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
100,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.",2bb4c508e081004e847881868ce95d43864f22fb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
101,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Patients with previously untreated, stage III-IVB (except",a7cae986e82c256071b923884e51d3404c48fc39,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
101,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Patients with previously untreated, stage III-IVB",bc344dd2fccfb636492f974a73e3a5d217092800,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
102,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Randomization was stratified according to programmed death ligand 1 (,8a40c19e0ebbc18ea1de4b1f51539a0d4e4816e8,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,To evaluate the safety and efficacy of adjuvant girent,1bae6dfffc0a5aa56bcf89719679c495566ee48e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Eligible adult patients had undergone partial or radical nephrectomy,c34b599e310ea2a740b14a182df17c7e7f0c245b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
104,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Eligible patients had pathological stage high-grade T1,9fb978dfc17f2da9acb25f70d7320adc3fa07af6,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
104,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma,fa08345d653fe100e478be37169783281485351b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
105,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,disease stage at enrolment,9a136c4b28b0ceaa6ee70aa995398e0884fd436f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
105,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Randomisation was done via the minimisation method with biased-coin,c0345caf4e1b4a1d526b92ece50a5313687772f8,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
106,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
106,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
107,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"We conducted a phase 3, double-blind,",169cf34b3f7bafd0e11860f5f47691a003d05b58,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
107,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"We conducted a phase 3, double-blind,",169cf34b3f7bafd0e11860f5f47691a003d05b58,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
108,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"patients with advanced cancer, aged at least 18 years",d58f8bbe597f8dc117a48218e33ea3388f99fcf5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
108,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"patients with advanced cancer, aged at least 18",994ffb7c194d2b0a1798216a5d30c4aa72ae22ff,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
109,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were aged at least 18 years with histologically,af5270228efa0020a5244874017f8a54e66ed6ec,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
109,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"locally advanced, unresectable, or metastatic cutaneous melanoma",40560de174934256c1341f83c94e1cc40eddd7ae,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
110,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"in patients with histologically proven, HER2-positive metastatic",85ab1998a3dd73a68e6a7d0c04d53765d53fa707,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
110,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"in patients with histologically proven, HER2-positive metastatic breast cancer",9f34a4e281d85a1a18b56d2da1cb165df7dd713b,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
111,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
111,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
112,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction,13a237312af3eebf8e1b4c49da4f1658b1899b21,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
112,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,enrolled adults aged 18 years or older with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction.,7dc65b0e848bd37b186397eec9230c3027f55412,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
113,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,386 participants who had had at least two nonmel,6cbf02402571542ac7b4847238bde8b18e3dd86c,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
113,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,386 participants who had had at least two non,922e0a80b0251760a4052417d678a80e5decd772,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
114,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,squamous-cell carcinoma of the head and neck who have advanced,7e07421875264cc5a0d9db8c2f41e978f3d4b339,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
115,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we randomly assigned patients with unresectable stage IIIC or IV melanoma,9c74be094483dd16b5b51d18d71153ac0f52a093,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
115,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,we randomly assigned patients with unresectable stage IIIC or IV,b1c133813cb9787f08c732ca7c20951529b4bb51,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
116,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma",4e9d1b2e87d328e571dc9c7e55c1d887aef3d569,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
116,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma",4e9d1b2e87d328e571dc9c7e55c1d887aef3d569,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
117,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.,1e5a0d07bcab51fdb16ae60707f07703b41de616,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
117,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,postmenopausal women with early breast cancer,90a9744ff44d78efb1add493d765580a9eef470c,False,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
118,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease",956a14b0bd45bfc6a8f74ce071549a2f12f5e735,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
118,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Eligible patients were aged 18-75 years,c1b78c0d232a322c7a79bb845f5c6dcd3753ce3e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
119,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,patients with palpable T1-T2 invasive breast cancer were,54eee157e1069fe29b4ba528c0234c145de7bcb5,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
119,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients with palpable T1-T2 invasive breast,e4d6156c46b5b389125577e483203b3b76dacb98,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
120,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"unresectable, locally advanced or metastatic triple-negative breast cancer",12be568af4ded2ccd5fb071fbf2267ce4d701476,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
120,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"patients aged 18 years or older, with previously",bb0df9e6d8e77371d73825ff2f6bcb0b8d53d8e2,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
122,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized 1:1:1 to receive adjuvant RT, CCRT, or SCRT.",8957dd67add6f88a78128c6347bf1d0e6a996aa8,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
122,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized 1:1:1 to receive adjuvant RT, CCRT, or SCRT.",8957dd67add6f88a78128c6347bf1d0e6a996aa8,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
123,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma",d57a0e70cd847b04f4eb56ebbf449fa9bc55841a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
123,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma",d57a0e70cd847b04f4eb56ebbf449fa9bc55841a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
124,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Adults (aged ≥18 years) with locally advanced soft,54cb968a582ec2f6d436ae26bbcc2945897fc24d,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
124,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.",f01be5f907ffb3968529022574e3b780796c8912,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
125,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were aged 18 years or older with recurrent,f47b1abdd2067378584524abae6842ee42ceb742,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible adult participants (aged ≥18 years) had primary stage,595c13a7df2ba392d69037646fef21e6456a83ad,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Eligible adult participants (aged ≥18 years) had primary stage,595c13a7df2ba392d69037646fef21e6456a83ad,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
127,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients aged 18 to 70 years,ad57000091ba176064dc3bbafea94a6b4c114346,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
128,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Participants were aged 18 years and older, had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",a2901e7a0e6ecc70978ec646a7e92e9bd0370ff6,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
128,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",ddbb59f329d0519e114ab00542bc0c308ab849a7,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
129,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
130,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal,066f5c9c3300f35dd46935fcd44d8a38c86fdf4d,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
130,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal,066f5c9c3300f35dd46935fcd44d8a38c86fdf4d,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
131,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
131,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
132,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,involving patients with active rheumatoid arthritis despite methotrexate treatment who were 5,49262def5e6886a8fa32d521d5ea0aacb848b69e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
132,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,involving patients with active rheumatoid arthritis despite methotrexate treatment who were 5,49262def5e6886a8fa32d521d5ea0aacb848b69e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
133,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
133,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligible patients were aged 18-80 years with stage,f0d23247e554045b99e8c13fceb2e4f7f71a937b,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
134,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we compared first-line nivolumab with chemotherapy in patients with,70e2550ff9ca1377d8e25401fe280185cda030d7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
134,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,patients with untreated stage IV or recurrent NSCLC,0c85b8487b0acb5a3977724399f64a26805c26c5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
135,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,both groups were also comparable in their first remission status at study entry (,cea7f11537876b871f139b544830915c388874fd,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
135,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,both groups were also comparable in their first remission status at study entry,ba5189ccae8d8069f39157c1d82686bc1bc47ea2,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
136,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,All patients starting adjuvant or neoadjuvant chemotherapy for early stage,32e9e9a87b5ee72a0c8df16600d68bf5af27c5db,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
136,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,adjuvant or neoadjuvant chemotherapy for early stage breast cancer,1ecaa8b535b85180464b3997ee1542bb1814f020,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
137,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Because of the inaccessibility of mediastinal nodal metastases,",64fbfd8c4faf805467bfe23731fcd47f1773672c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
137,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Because of the inaccessibility of mediastinal nodal metastases, the left",d71a6a19b62287a8c87044ba79468ee7ee91dca6,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Regorafenib confers an overall survival benefit in patients,470fe82309cad8ea3657e18086e7b2452dbcbb5f,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Regorafenib confers an overall survival benefit in patients with refractory,653f3c3078b6d2936838bd8ef9c448128d4c5ea9,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"523 patients with curable stage T2b,",0d51129c6fa571a99cf0d77fabed1c42749871f9,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
140,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
140,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
141,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression,187b46812f1d8adc55b45569e5fa26ef2e61a69a,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
141,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligible patients (n =,8556bb1cf71a95201f654710b9555f594a96da09,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
142,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0) and primary tumor larger than 2 cm",d324a09f85840d997b19ae0ef62132b034505322,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
142,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Asian patients with ERBB2-positive early or,736e81f2e407b49a588edd767227dad3e0e21a66,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
143,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,"Screening for its precursor, anal intraepithelial neoplasia (",4b1baf3f25eaf60158587f8cf2b8458e12e9a331,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
143,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Patients with histologically confirmed AIN were randomly assigned to receive either,89ee4ab56f1c5a83eb85bafebc781462ebfa93a7,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
144,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we randomly assigned patients with spinal cord compression caused by metastatic cancer to either surgery followed by radiotherapy,fd3dfc0dc6b97db075ea14265678448bd50a1b62,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
144,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we randomly assigned patients with spinal cord compression caused by metastatic,090973cbdcc1cd84e5ba5c262556df3885ed3059,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
145,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"enrolled patients aged 18 years or older from 129 UK centres who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy.",ddf7b949c332b2defeb48a223ad7a46d43b73d09,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
145,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"node-positive or high-risk node-negative operable breast cancer, had undergone complete excision",ffd4733d5e788c755802230a867239a8c8c5f4fb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
146,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older,f0986623f747b44a8a974f8d0a311f6cb9100fd4,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
146,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States.,69ba34b09a80f9f8d9b1da2620a0ac6d68b55e6d,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
147,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.,69b842dffdbffa24b7350f9d02f2376643d86b1b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
147,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,To determine whether nab-paclitaxel improves the outcomes,01a27b38a2f4c1f74ebff981013cdee97c60e999,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
148,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
148,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
149,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly recurrent soft",c0b393e9bc2c8efbf533f7ccaffdad99a43d2d74,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
149,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.",5dd83413e5cf0f338a57224082e25970f5d5aa27,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
150,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,we enrolled patients with a histologically proven superficial basal-,3fe0776db64f2a719a850ce9731a9669b088a680,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
150,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,we enrolled patients with a histologically proven superficial basal-,3fe0776db64f2a719a850ce9731a9669b088a680,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
151,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,diagnosed with unprovoked venous thromboembolism (,8b39079668fe1d794b1853c338d77ba0411b4c66,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
151,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,"Patients aged 18 years or older, diagnosed with",2bb9f5785ee3151b1ed43c628b64875409bbbece,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
152,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We included chemotherapy-naive men (aged ≥1,8c4ea9ef2d124f4b7266b8bd801ec7e0b8ec5321,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
152,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,We included chemotherapy-naive men (aged ≥18 years),26d9bdcdee233175800dde94e23b0b96b3d08f6b,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
153,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,accelerated partial breast irradiation (APBI) for patients with stage,8567b1680eabdb7fe7532d59c8a8f51caf8906e4,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
153,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,accelerated partial breast irradiation (APBI) for patients with stage,8567b1680eabdb7fe7532d59c8a8f51caf8906e4,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
154,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Women older than 18 years with histologically confirmed HER,9d8c254694955e1e925281d78ba3e01f2fc0cb33,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
154,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Women older than 18 years with histologically,bac4769ee263e3a852a26081491097451333de10,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
155,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
155,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
156,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical,7c938534564b931449ed7d031cfb787a89e0b3d2,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
156,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery,497bfcf94eef00225dfe6be3ee39ac77b8c6b7a2,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
157,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,we enrolled patients with prostate cancer who had high-,eb11b92332c31e237ac13d3f1b865591cd8e9984,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
157,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,we enrolled patients with prostate cancer who had high-risk biochemical,53d6e4231290b98b4824f5b7eb50798f1e06a50b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
158,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease,4cc0c0ba02fd8fd04ad1a7e0752c9f253813fbd0,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
158,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
159,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,radiation therapy to the primary tumour site plus meta-iodobenzylguan,ef1eb6ea15d910133452313e4eee12a472bcc504,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
159,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"All patients were treated with six cycles of induction chemotherapy, myelo",6f21f2edd2d79b19a6b8305f2d1068a3bbbd70d2,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
160,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,women aged 18 years or older with hormone-receptor-,bf07db9d8f2ec9e1e8376b23240a781d101311d0,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
160,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer",c6a5bfe53f897b58d7a4e4700d69d71805fb3518,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
161,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Outcomes are poor in patients with HER2-negative, advanced",ec99240daf0632aa96205f810bd55fb54f659301,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
161,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Outcomes are poor in patients with HER2-negative,",4d45530dce4bfeb6946bdab6c4b2a5cd8b4f5505,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
162,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
162,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
163,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer",27df1e3a1113bef9b17cbfd8c1811894c37fafeb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
163,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"We enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer from 81 Italian centres.",323f84eab7da85319403771ffcf28ceea7ecaa59,False,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
164,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Patients who have unresectable or metastatic melanoma with a BRAF V,7db3bf36cf3fd002728a008b97171b9465cb5fc7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
165,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were randomly assigned in a 2:1 ratio,fb890edaf5d17c50f8c0cfb8ff15dfc856394181,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
165,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"adult patients (aged ≥18 years) with advanced, progressive",6c3149585afbf22265750068eed99bbb99bde25c,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.,0d0051c9a89f4850fe4794c8eed127f0ea0d9b17,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
166,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,patients with HER2-positive metastatic breast cancer previously treated with,9eb20b9e5be060872e6cdc4d1381ab41c1ef0fae,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
167,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,completely resected stage III melanoma at high risk of,59abffb731a1a76ffd6e228a8237bb6817027db1,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
168,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"in patients with HR-positive, HER2-negative advanced breast",0557a86da69e4df5fdf45d098532285a44890405,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
168,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"HR-positive, HER2-negative advanced breast cancer who",c4c2394d95974be179d12e25ec61d06b5f9acf92,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
169,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We enrolled female patients with HER2-overexpressing,f02e3cad6b9e5d36a2eae2ad765d5b748b03d5fe,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
169,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,We enrolled female patients with HER2-overexpressing metastatic,005048b41dd909db688f376fe307a54088d2c9fd,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
170,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,we screened 3100 first-degree relatives,8a7d132df4e12f22de20710430842a1744ff55d4,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
170,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,we screened 3100 first-degree relatives of,ff93519f9209262eea30b0db94a7a9622ad14b32,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
171,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,early breast cancer,d04e2d195abacd3a6db2384ad741abd39c1d4382,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
171,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-,2be7e0bce175fd4709bdc2e78ffa82150d0b09bf,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
173,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,To assess whether stereotactic body radiotherapy on a single tumor site,6f151cbb3e6cce6fa99622a2c44f58a4558de4b3,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
173,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,To assess whether stereotactic body radiotherapy on a,dde7fed95e6e2c5c2b6db525a389f4d4ff4f9901,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
174,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,170 432 eligible,a0f425c126919277317dabf8e19d596ae8e20cdd,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
174,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,170 432 eligible,a0f425c126919277317dabf8e19d596ae8e20cdd,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
175,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who,87d94dc31f87d6290677024d897e395667e58d02,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
175,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,locally advanced or metastatic,e7894e52acb07b735ae47a10d6beec8e1beedc5f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
176,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,"we randomly assigned 76,693",335459b7e6ca8c55ce67f2196a21bc07dfce92a0,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
176,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,"we randomly assigned 76,693 men at",7bb29b7eb4719bde7281f54ab61e213d4e067465,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
177,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,patients with stage III or IVA endometrial carcinoma,83a4d8c6e02ba20c4a7daf2f202feaf6def357af,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
177,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,in patients with stage III or IVA endometrial carcinoma,2002feb6dec076ebeb70d6a9900497c6c4955e6d,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
178,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,unresectable or metastatic cholangiocarcinoma,a90ac0ded24bb405865cd960c1faa2f1aa15ea2b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
178,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"aimed to demonstrate the efficacy of ivosidenib (AG-120)-a first-in-class, oral, small-molecule inhibitor of mutant IDH1-vs placebo for patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation.",c3734cfc43a7a509e7101c7502c2435306a512ae,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
179,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Patients were randomly assigned (1:1) to busulfan and,5b754efafe0ab94c1fec057a3f425fe1573c5272,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
179,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"balancing age at diagnosis, stage, MYCN amplification, and national",c417922175cbd219427dd03b0d52e1e1458725a3,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,patients were eligible if they were aged 18-7,c3cc6e090ca39f3532710bcd6b82ed864eae7898,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,patients were eligible if they were aged 18-,08b1f1d4e5ad6e76214595216aef4e15844f0959,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
182,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we randomly assigned patients with stage IV or recurrent NSCLC,7e148c6a8909bf1c9ba9c524125e35afc58618aa,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
182,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we randomly assigned patients with stage IV or recurrent NSCLC,7e148c6a8909bf1c9ba9c524125e35afc58618aa,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
183,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,patients with previously untreated stage II or stage III triple-negative breast cancer,df1fbc5bb5dcbf5062226f899b54c592cad0ffc2,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
183,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer,f33d8d6555d1c7356f81cb353a4c7a81669df708,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
184,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer.,8bf79f9205710ed68b6bfcad25eeb9f02b4518f9,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
184,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer,823f122356f8f86a5e76455b661c9dd507b9fb64,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
186,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
186,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
187,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We randomly assigned eligible patients between the ages of,9c6db607e0b4a0d263c71b29f9bb7bec68b852a5,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
187,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients between the ages of 18 and,069c79195586d2d060a6ac49c5a8b06cd6135885,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
188,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes,45a629579ffe04604931a5af649703de002388f9,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
188,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes,45a629579ffe04604931a5af649703de002388f9,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
189,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,exemestane 25 mg a day for the primary prevention of breast cancer,0d52001903e864e0ca1353e01d67caebfee3e508,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
189,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,primary prevention of breast cancer,a4273a11d881b39d97e17b7c3e3d320c0e8f3224,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
190,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"ABCSG-12 is a randomised, controlled, open",03e5172a589ede017e1d2900e13e43a074435ab2,False,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
191,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
191,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
192,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"hormone receptor (HR)-positive, human epidermal growth factor receptor 2",18d8797c8fd87f6e8c4a2a30fd361a6d9c802e00,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
193,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were adults (aged 18 years or,ed0b2f7d885707876cf209788eb0181185634542,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
193,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Eligible patients were adults (aged 18 years or older) with,bdbae9c9a8a7ac5f9d91885d2a033c05c0008f84,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
194,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Patients aged 18 or older with a controlled primary tumour,8579ff0827711712d691347c159338df3583ccab,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
194,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Patients aged 18 or older with a controlled primary tumour,8579ff0827711712d691347c159338df3583ccab,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
195,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung,fc43a5e41e52c882b1483b7240e1d1e78c9226d5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
195,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung who had progressed after at least four cycles of platinum-based-chemotherapy.,7b6c6e36b482f1636c166e4378de25d7832b70ee,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
196,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination.,b115d94518768d5f9b795d5db83ebfc4ffac9bc6,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
196,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination.,b115d94518768d5f9b795d5db83ebfc4ffac9bc6,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
197,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Patients aged 18 years and older with metastatic soft-tissue sarcomas,5aa95ecda2edcb243e6f1061f50ba6de22c5831e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
197,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Patients aged 18 years and older with metastatic soft,86eb6a5a948f3912c43569f11c623d3dcb14b4bb,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
198,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry.,0dba11ee514688d77c9254edf4807a4baff8b71f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
198,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour,76a09e20d2d740bdabd2af21bb950f49cb219034,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
199,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment were randomly assigned,37778d79b23f24354dccbd63cc0fc49a6013ae65,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
199,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Our aim was to assess the use of ipilimumab after,563803f93742a5ad0e54d611a129fb162ce55595,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
0,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual),85e156f895f3ed503c4178addd4d94580bebde85,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
1,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we enrolled patients who had locally advanced and unresectable or metastatic,aa41afcfd0d25b8d3f4bc8fbef7869c1c9d86a37,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
2,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,advanced or metastatic soft-tissue sarcoma,d28b1db6a124af08f9f65e1287ad6406871299d6,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
3,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
4,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,those who had centrally located squamous cell carcinoma with cavitary,14348ecd6150694f35998f13a9b61ff576c513fe,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.,095a4141eb262225a4f7a27dacfdcec099af798c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
6,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Localised prostate cancer is commonly treated with external beam radiotherapy and moderate,93a011d4fea905c8f60e6d5512d87f998750d89e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
7,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,Exclusion criteria were previous bilateral oophorectomy or ovarian,738b55450f305ebb6083f9550ce0d793bb275d13,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,We assessed the efficacy and safety of the aromatase inhibitor anastro,bc88e62143bc0c9f7397e9ce30b587a20003568a,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
9,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we recruited patients aged 18 years or older with,ca4a0d30874b0052ef92684b33263b9379859a4a,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
10,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab.",0591ee004c0def46184a426053dd9738f35bbfe6,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
11,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Patients aged at least 18 years with previously untreated,0b407e11d8e70f359fdc350bd85a3017c6a794e8,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
12,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fallopian tube",9d680e16f279da24617cb2dded0f2f148e428a14,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
13,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,5102 patients with HER2-positive,6e8f583e331ae97b039b4274289f9cc76de51694,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
14,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer,51ec0273befa1e47d1450daed3776964587877f4,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
16,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible patients were women aged 18 years or older with unilateral,fa828c664e4d6915e3b826d995dda65ee5a24afe,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
17,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive,",68e45bf2723aaf85c62974581393b33f08376601,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
18,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,"In this phase 3, multinational, double-blind,",d62a4ca5af50b33b775e30a113eab79034e9c464,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
19,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligible patients were adult women (aged ≥18 years,dfea16ed826e19dac78d07a31edc2219984a297d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
21,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"In this trial, we randomly assigned 556 patients",5a367c4e58fb6e9cfa55fbb7a21840df3dc5edc7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations",5bc192c8ba270a07267a65bb5a3800b98362e9a3,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
23,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,140 patients with early breast cancer were randomly assigned,bff69170118c768e1eb092596381a3c543eed253,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
25,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,randomized clinical trial enrolled systemic therapy-naive adults with histologically confirmed,8cbe559a5132c3510d3a7004165b477c7d5d0d59,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
26,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,women aged 25-60 years were randomly assigned,ef016a5eb2328ee48078573c31cefca9d5af9dac,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
27,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Patients (aged 18-80 years,bbab1c3921c2657b0258898e56f6bb32b91c1e35,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
28,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Treatment for patients with recurrent ovarian cancer has been mainly based on,69248b845a348504f04bdc025f5bcb0b2c20ad4c,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
29,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,measurable or evaluable high-grade serous or endometri,56e72dca2422ca084705cc335eb6899ddc062337,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
30,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,1500 women with axillary node-positive or high-risk node-negative breast cancer,bcdd56e17d1a840c3afc168e772f2dc8dca708c5,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
31,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,A total of 424 survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously were screened,5808aec2aa6f127482bcc1304d8c6a36f777e807,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
32,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,The drug may have efficacy in patients with HER2-positive advanced gastric,b62e995489b9d85619a85cb51b2f3cd258d41728,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
33,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,we randomly assigned 127 patients with dysplastic Barrett,45abd30338224ac4c9a6497a3d70732625e71aa7,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
34,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible patients were premenopausal women aged 18-59 years,5f840835219fab2ba5517b0ca1e10975f184285b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
35,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,recurrent or metastatic squamous-cell carcinoma of the head and,821b13e93a3d74436c5c87b76e94d2e1b7090bc3,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
36,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"patients with chemotherapy-naive, stage IIIB or IV, non-",665ffd8ffb4b29e86141481a76f6b55b985c8905,False,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
37,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,histologically or cytologically confirmed advanced non-small-cell lung cancer,25e69c709826bca84b2a20a3de52d1e666cec5d8,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
38,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma",4dccde99f317d5f36d314601c66701d8accae702,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
39,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma were randomly assigned,8a5c047c35aa6f50c18f52b683e7dbd2d05b54ef,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
40,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"we assigned 615 patients with locoregional, high",d05f59ff3e74720ef323d38196d4b51e50a5f85c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
41,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Standard first-line regimens for patients with metastatic gastroes,ffcc32a8347280ddf65b415bdb0b315d7e6f9fb5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
42,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,1256 patients with resected stage III,a75e6175509c8dd0fc4c56efdb8cb1dddffd3cf9,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
43,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer,59a3763c94c3f0cac7eec1001ce3b4f98d515821,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
45,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated,02d496a2dd8422ce71898eb8c05bed6bc7046068,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
46,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer,45921d9ab9b48290b5485d58823453be5f06f07f,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
47,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,We compared the efficacy and safety of a modified FOLFIRINO,c7e38e489e7e4c0cfabd626a1d68e773ab7ef786,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
48,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,patients with previously treated metastatic breast cancer,d4d34620582aba440ad57f1a5e1e98bf67366997,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
49,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"women with hormone-receptor-positive, human epidermal",660ec951f268ff99e8f633c71740a58391fbb24f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
50,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we enrolled patients with stage IIIB or IV adenocarcinoma,0825e4d60d1fa4f662bb55c1140ae89e2cce2319,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
51,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"advanced hormone-receptor-positive, human epidermal growth factor receptor",75062dc8fd420b4d90a15aa24dff341a910eba27,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
52,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,"The study involved 182,16",e2260312646af6e3a013c14a9e868225bfa5f955,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
53,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,adjuvant chemotherapy for operable node-positive breast cancer,d831e475033b14ff9450885da9a3f45addd83004,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
54,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC,83ebc0f9d457c6f7c84b8d584fad5230449ae643,True,BOTH,gemini,gemini-3-flash-preview,"usually metastatic or treated as such.
    *",INVALID,False,
55,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,"In the Prostate Cancer Prevention Trial (PCPT), finaster",e827fd6ed9cedd5ab4e5cbc7022788b3a4a0e5fd,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
56,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,One hundred twenty-one participants were assigned 5 mg,26caef53683d157edf9fcc2c68943199fd491164,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
57,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,enrolled 160 patients with radiologically confirmed painful bone metastases,bf827c4b70a3b2c7f466645b23a47ece3ad69f79,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
58,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"Patients aged 18 years or older, with centrally confirmed",54d212a011d4743b2d9a68211839fe112c75c56b,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
59,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"JACOB was a double-blind, placebo-controlled, randomised, multicentre, phase 3 trial in patients aged 18 years or older with HER2-positive metastatic gastric or gastro-oesophageal junction cancer.",3775d984868f90f69a99a5af7c3928c8895cb059,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
60,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer,eb39c499b2390ac2dd1d4534274471899a2f3445,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
62,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible participants were aged 18 year or older with hist,17ac88b62929c763b814fad909cd05cef8dd3b7b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
63,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible participants were adults aged 18-75 years,a284feb82a6e5df208e4e25d38860653ef9b572f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
64,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,patients with advanced renal cell carcinoma and no previous systemic therapy,27873bec3229f421e7a00bd2e3a69d89aa463abb,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
66,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment",92b54c29dfeb350fb3e61b31231bb4b6ae50a08e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
67,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV6",946ae7f2594fcb5b1278330be651f5a678f112bd,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
69,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma,96d38b1bcb1aa5ffc0fdc50e988558ea509561ce,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
70,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Randomization was stratified based on site of metastasis (visceral,",7e5d8909a7017653bee2a7ee71c3a15fbfd4ef5a,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
71,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer",90d37de0fe857b85ec9ed0126051eeeee05f0b83,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
72,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with resected stage III melanoma with BRAF,b13d3a946fa5c810b63d343d5366f5ef75be3a0a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
74,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited,0298c4ebd14147a2c51e15d5aff9edd861061538,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
75,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We randomly assigned 229 patients who had well-,e0526438dca7bd0aeb7e575d88e860c2c7f3c0cd,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
76,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,participants aged 50 to 64 years,149f3b2aa1ad1813e70c34c3616ee7ebfba3641c,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
77,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,25ecd584e5b4a56896c4eee319b874a2c1548069,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
78,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we randomly assigned patients (in a 1:1 ratio),224ad0306ecbdbb1e61819f96cfa6b02a6c6432a,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
79,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,patients with clear-cell renal-cell carcinoma who were,c6babd6926440ac4f820f5e7788cef20ae867f98,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
80,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,In the AFFIRM trial of patients with metastatic castration-,1f22e8954c181e8838473310c0291d1ab3de519c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
81,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
82,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we randomly assigned patients 2:1 with untreated locally recurrent inoper,3a9f5b0b65c6f36108ec7f5d7fc6bde649c0412f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
83,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,resectable cancer of the middle or lower third of the esophagus,4aa815917ed986cf18485917b5df7dc4af2ec9fd,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
84,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,479 women with previously untreated recurrent and/or,c49459eba9aa9ecdfef521f28238db8bbe0e3921,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
85,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with,76ecfde963edc5c5c6a0eeb6fc4c8a3e28420fc9,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
86,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"enrolling patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy",a71040b3a8b377cf20ea24365216ca338c38a6ea,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
87,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract.",fb9278c2791a54c475e36e439cc3e33ec9537dfc,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
88,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,840 patients with stage IB-IIIA NSCLC from 101 centres in 14 countries were randomly assigned to observation (n=433) or to 30 mg/m(2) vinorelbine plus 100 mg/m(2) cisplatin (n=,d30822da13e718c3273975bc1d5efb70ec9cd52c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
89,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"histopathologically diagnosed with undifferentiated or differentiated,",e2e958e3041d7e8b4b0f0715fd6b068113dbd303,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
90,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,A total of 2526 patients with stage,20b26158d7a0628d0b37c8b266cb526c76134c1b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
91,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,we randomly assigned patients with sentinel-node metastases detected,3463d51815e11d2c9977e70d51b8753dcabc12c1,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
92,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma",20a8ac2d2d7de84a786ae92ba2577331d911dc21,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
93,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence",c37659491a000415239367e1978caf776dc39280,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
94,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,patients with previously untreated metastatic renal cell carcinoma,d39b284e062de97f1ada89226d8b6168e2099764,False,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
95,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
96,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment,7ad600db6616635fc16a44ff62e3125d220e6c0e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
97,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC_",55ebd3b04a126fe1121ac652d0282f2a257f96f8,False,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
98,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation,2f0b234c6ef62442bf7acce140fa215447af0a7e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
99,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,Individuals aged 30 to 64 years with female sex,da09b4c276fe2322676bdbd8b37adbb00c70bf31,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
100,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Adults with rectal cancer that had been clinically staged as T2,f969a5a891673495161c9f5f7e376d6350d0ddbf,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
101,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Patients with previously untreated, stage III-IVB (",1b445e0a2831f1d8e8ffcf9964fc0ad3cae15294,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
102,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Randomization was stratified according to programmed death ligand 1 (PD,e7b6c4f52bcc307bc9ed05593e0b38ae5a3f5aa8,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,To evaluate the safety and efficacy of adjuvant girentuximab on,312c321bd5b8c4c52e1ab61e8a73cc6ff6014ac8,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
104,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible patients had pathological stage high-grade T1b,6822e7e9cdef0ffa3134eed0944d04b382e91bd0,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
105,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Randomisation was done via the minimisation method with biased-,2c2b486879566150e58b1377d31ae7971f6219a8,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
106,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
107,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"We conducted a phase 3, double-blind",fc3d4c2967ce694aaa180320370661673eb91c51,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
108,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"patients with advanced cancer, aged at least 18",994ffb7c194d2b0a1798216a5d30c4aa72ae22ff,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
109,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"locally advanced, unresectable, or metastatic cutaneous melanoma",40560de174934256c1341f83c94e1cc40eddd7ae,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
110,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"in patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease",493177c96434c0b68b8132d84e12d76eb974e196,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
111,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
112,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we enrolled adults aged 18 years or older with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction.,076c11304025f27e18daf7fb5b082e983e0f3670,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
113,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,386 participants who had had at least two,7a75b65b112895dc818d1db21dd487e4bf6059a1,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
114,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with squamous-cell carcinoma of the head and neck who,b2181e086b7a75dc8c7522280f687a16131d7a4a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
115,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we randomly assigned patients with unresectable stage IIIC or IV melanoma,9c74be094483dd16b5b51d18d71153ac0f52a093,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
116,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Patients with advanced, unresectable, American Joint Committee on Cancer stage",67adbb9742b225071eb18b5a7f2ca3aec3922ce5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
117,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,We compared letrozole with tamoxifen as adjuvant treatment,49168eb16df68e889387ece63de234cd5ebe6370,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
118,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible patients were aged 18-75,b7d3ab477e2281821eca96aa1c27369a3b79f353,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
119,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with palpable T1-T2 invasive breast cancer,cb8a20c15fe2c7f29c70bbdd83082bcecf3eb382,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
120,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"patients aged 18 years or older, with previously untreated, hist",d685b73a550ae1884ecdf14be67b0d1071a6a235,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
122,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with FIGO (International Federation of Gynecology and Obstetrics),898d0d9c4730a3a3b473d1b7c30432405e5269fa,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
123,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible patients were aged 18 years or older,b28b5f3ef72e5860a6d72add16b504b580daae25,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
124,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.",f01be5f907ffb3968529022574e3b780796c8912,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
125,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible patients were aged 18 years or older with recurrent low-,1a5d29608d27231c110464f71862e72dfe1be02a,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible adult participants (aged ≥18 years) had primary stage,595c13a7df2ba392d69037646fef21e6456a83ad,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
127,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients aged 18 to 70 years with re,04376809b47363de3a6796ccf12cba919a09baf9,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
128,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Participants were aged 18 years and older, had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",a2901e7a0e6ecc70978ec646a7e92e9bd0370ff6,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
129,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligible patients were aged 18-80 years,23a13725bade9e440e355e30fcc2bddbc3ecc72e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
130,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual,4e7c6aeeb2970456a0aee1c5d8e245d4ece8b380,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
131,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
132,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,patients with active rheumatoid arthritis despite methotrexate treatment who were,a29e135e0d7ae70a83d2afb8315d23773b59f466,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
133,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
134,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"we randomly assigned, in a 1:1 ratio,",d8aeb23400b810b4ec1f3a911af426ebf6dffc6b,False,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
136,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre.,a6faddd453e53720422bf2bb801ad8dfcd687277,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
137,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Because of the inaccessibility of mediastinal nodal metastases, the left",d71a6a19b62287a8c87044ba79468ee7ee91dca6,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,adults aged 18 years or older with histologically or,a7d1499c9ee0b79e19ec3fa8b4a3d394ad2407c5,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"523 patients with curable stage T2b,",0d51129c6fa571a99cf0d77fabed1c42749871f9,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
140,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
141,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area.",90b8b1ce26881f1a262c409c0be08f786debc092,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
142,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)",22ba5ffce0ae91fc338c92ab90641a6944ad8acb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
143,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,"Screening for its precursor, anal intraepithelial neoplasia",5beb370f7bca7917da96597bf3268e3493f960c0,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
144,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we randomly assigned patients with spinal cord compression caused by metastatic,090973cbdcc1cd84e5ba5c262556df3885ed3059,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
145,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"patients aged 18 years or older from 129 UK centres who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy.",d596171e05c1467d3cae8198a94cac5e82ad45a1,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
146,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States.,0b8a0885898b71126aa8a73937c694188bb6ff1c,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
147,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,To determine whether nab-paclitaxel improves the,fb9e76a7b49023b705e92a5d472b486aa84ce78e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
148,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
149,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly",c9186e1a53e7f758fef12ddb31fb25dd6368a34f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
150,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,we enrolled patients with a histologically proven superficial basal-cell carcinoma,3d9bef131d356c2d728d9fc8d0397676cc4e5712,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
151,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,"Patients aged 18 years or older, diagnosed with un",277803b484baf3002791db4f1f0b2df599ac5b0f,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
152,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We included chemotherapy-naive men (aged ≥18 years),26d9bdcdee233175800dde94e23b0b96b3d08f6b,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
153,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"patients with stage 0, I, and IIA breast cancer",39d54b7fda4846a420f13a6d7bddc9681a1f78cf,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
154,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Women older than 18 years with histologically confirmed HER,9d8c254694955e1e925281d78ba3e01f2fc0cb33,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
155,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
156,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery,497bfcf94eef00225dfe6be3ee39ac77b8c6b7a2,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
157,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"In this phase 3 trial, we enrolled patients with prostate cancer",eca0abaf59cb5f8c34cdf06773c50748825df0ac,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
158,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
159,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Randomisation was done in blocks stratified by International Neuroblastoma Staging System,82560fd0e57d6e14f4d1a81377b782ff356ab625,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
160,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy",05c2939dada0672749ec4cb4ea3d7457c7858303,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
161,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Outcomes are poor in patients with HER2-negative, advanced gastric",8bf475c1883351d59b81ea8bf3a22e9637a1fcc8,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
162,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
163,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,we enrolled patients aged 18-70 years with operable,361aca067096fdcf9e4414bb4d9f147d84b0671e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
164,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Patients who have unresectable or metastatic melanoma with a BRAF V,7db3bf36cf3fd002728a008b97171b9465cb5fc7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
165,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"adult patients (aged ≥18 years) with advanced, progressive,",9d627e5b828a1e9487d0d3a1144093e73f7a24cc,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane,ba494453b87af5027c59b2f08eaff54dadac5a1f,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
167,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,We aimed to assess ipilimumab as adjuvant therapy for patients,ebddf69df90f6bd0b69c8c8975852fa1fa885f48,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
168,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"HR-positive, HER2-negative advanced breast cancer who had received",3769f3d3d40d3900152c84e1040dba5f1f6577a7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
169,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We enrolled female patients with HER2-overexpressing metastatic breast,096983cb493d121b856dc5f92d825c9cb763b6ff,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
170,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,we screened 3100 first-degree relatives of,ff93519f9209262eea30b0db94a7a9622ad14b32,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
171,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Suppression of ovarian estrogen production reduces the recurrence of hormone-,a92a02769fe8cbe2ee204656c4a9ca440c9ad9a0,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
173,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,To assess whether stereotactic body radiotherapy on a single tumor,b4fc1f94e39fb209e6368c90d1dc68f2cdbd7cbb,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
174,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,170 432,36aa4528777ba80b6853a2d08b496fb35f52e88f,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
175,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,locally advanced or metastatic non-small-cell lung cancer,6e24b1c3586fff2364349bb1c8e959a166d8299d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
176,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,From 1993 through 2001,19cb282f719974dd500ab898c016c19933530b16,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
177,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,in patients with stage III or IVA endometrial carcinoma.,48f3743584d803d62172a9a128422d891fd91513,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
178,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,aimed to demonstrate the efficacy of ivosidenib (AG,22339d0519bf4bd384730f1543379a2775a467e6,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
179,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Patients (age 1-20 years) with neuroblastoma,6b1897a7f2285c40aada0282dd21cdc4cc355d99,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
181,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,had previously untreated recurrent or metastatic nasopharyngeal carcinoma.,f624bba9f68f856f6bf4d587b8f050ae9b066143,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
182,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we randomly assigned patients with stage IV or recurrent NS,609c513140e211273fe2852df5ae9ed386974508,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
183,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer,f33d8d6555d1c7356f81cb353a4c7a81669df708,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
184,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer,823f122356f8f86a5e76455b661c9dd507b9fb64,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
185,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible participants aged 1-18 years with newly diagnosed cancer,cc1aeb9962f648a43797bb2c25cb0194b75ca5cc,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
186,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
187,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,stage III or stage IV disease and no distant metastases,4e125bf1bdb004c65a01c2857ead93a7069be002,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
188,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes,45a629579ffe04604931a5af649703de002388f9,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
189,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,primary prevention of breast cancer,a4273a11d881b39d97e17b7c3e3d320c0e8f3224,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
190,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"ABCSG-12 is a randomised, controlled, open-",9a38a31f44246f309db4fb72f28ebdf01289eb5b,False,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
191,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
192,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"hormone receptor (HR)-positive, human epidermal growth factor",c2593e947af909435f318d451fd8c2ffaf328ceb,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
193,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible patients were adults (aged 18 years or older,c7638d6d44df055338c1b1d50449c811d0b38a1d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
194,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions, Eastern Cooperative Oncology Group score of 0-1, and a life expectancy of at least 6 months were eligible.",a2bb26ee3f4690b802f9ac765f68896bb4dff919,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
195,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung,fc43a5e41e52c882b1483b7240e1d1e78c9226d5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
196,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination.,b115d94518768d5f9b795d5db83ebfc4ffac9bc6,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
197,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Patients aged 18 years and older with metastatic soft-tissue sarcomas,5aa95ecda2edcb243e6f1061f50ba6de22c5831e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
198,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal,398671c8395e086ccd4ecafa5bd50584792142bb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
199,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,patients with metastatic castration-resistant prostate cancer that progressed after docetaxel chemotherapy,c6cab3e89f16f961f2900cb7b4a7282338f4772f,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
0,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual),7797aa481fbba7100152347a5a0e1f99810e5bec,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
0,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,We randomly assigned patients with resectable NSCLC (,1e7a5cd362035f4f5429e42105ce3ed3e1b231ef,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
1,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma,aa5907779d1e8cda3850878a7a3f4fe2aa54d877,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
1,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma with prespecified,23b5382dff493f59f8b3ff4abbf314ce9cd3c554,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
2,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we aimed to compare overall survival in patients with advanced or metastatic soft,a79b53593cb622fc42459ab021b914997ac73f1b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
2,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,advanced or metastatic soft-tissue sarcoma,d28b1db6a124af08f9f65e1287ad6406871299d6,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
3,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
3,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
4,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,those who had centrally located squamous cell carcinoma with cavitary features or brain,4581332fa356182fdbc4195f9070caae09c4ea6d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
4,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Those aged 18 to 75 years who had histologically,7e6f4965d61ebc7a17987656d8405f84d8d9940c,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive,3813f30a61e6d1b5ded36f69628e5b79a499b9b0,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.,095a4141eb262225a4f7a27dacfdcec099af798c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
6,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Localised prostate cancer is commonly treated with external beam radiotherapy and moderate,93a011d4fea905c8f60e6d5512d87f998750d89e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,Exclusion criteria were previous bilateral oophorectomy or ovarian,738b55450f305ebb6083f9550ce0d793bb275d13,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,we recruited postmenopausal women aged 50-74,59d5840f3d20e6313613f827e1c12ea5e2c935b2,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,"To be eligible, women had to be at increased risk",ac66b1d521e8833f031f86a6dd82ebc6ba84b8dd,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
8,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,"To be eligible, women had to be at increased risk of breast cancer (judged on the",55a8a024f7f97542e151b1a1c2b737ce68e77d3e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
9,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma",f7c8ae218aa2a3d30f7332ef5fdf9e777dc7d8dc,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
9,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we recruited patients aged 18 years or older with metastatic,a81509646c8882f451e1fe85afb33f3be7106fc8,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
10,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We randomly assigned patients with node-positive or high,0d9f305f39383eeeb0789757b5cdbfe46a699388,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
10,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,We randomly assigned patients with node-positive or high-risk,fe01e176a79eb80fa42b300d83c062bdbdd059df,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
11,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Patients aged at least 18 years with previously untreated locally advanced,cde1af8589fd6ba5273725bb157dfa624de203bd,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
11,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Patients aged at least 18 years with previously untreated locally,23e036c902cf8e826e0acd329388acb68302024a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
12,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fall",8d6b94d99d7c72ba2c479af281af6ba00d1688b5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
12,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fallopian",18e442bb43b46dc8a35c42b80664679eec4279ab,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
13,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,5102 patients with HER2-positive early breast cancer.,eabc2e51526a815b77f818267896a16616d06cf0,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
13,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,5102 patients with HER2-positive early breast cancer,42e034cabf2625e843f4f5548b2fb5d4b396f648,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
14,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,had stage I-III histologically proven and operable invasive hormone receptor,5b9ee52e251a53719de81e76e6283f55f756ae9a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
14,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Women were eligible if they were postmenopausal at the time of study entry, had stage I–III histologically proven and operable invasive hormone receptor-positive breast cancer",f78986d9d995a6349bf6385f91103c1ec9f72ebb,False,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
15,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Patients with HER2-positive, operable, locally advanced or inflammatory",6e1ad67f3e8d33499c3aee0e947d1036f7910da9,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
15,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Patients with HER2-positive, operable, locally",451810189a8afd011ecb26957b5e40f83d318b3f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
16,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserv",d9f2000319ca8edc336fc183aa58fd79474e418c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
17,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive, non-",a9a8a95023ba41ec615f3ec51e32d13452d31dc3,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
17,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast",c6bec3db773bc407f94951fa1e0122a502885747,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
18,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,healthy women older than 25 years,7cef698a40287e43633ef9741ddf42790931b86d,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
18,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,we randomly assigned healthy women older than 25 years to the,0eaa7f7eb7b9a0da076a2780133e5c1c1ba96962,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
19,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were adult women (aged ≥18 years),2dbeb45f15bcd82c3ca10830cb32ecf4fbb2a77e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
19,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Eligible patients were adult women (aged ≥18 years,dfea16ed826e19dac78d07a31edc2219984a297d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
20,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"unresectable, advanced or recurrent gastric or gastro-",9449cdb90017a665fadd57f7ea091b7ed26d7cc1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
21,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,EGFR mutation-positive advanced non-small-cell lung cancer (NS,348874b7e6cb6409db9ed53570887eae49945c9e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
21,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,patients with EGFR mutation-positive advanced non-small-cell,88eda38c0440f60021fb60ea45b35be12abd8873,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
22,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"870 patients with completely resected, stage III melanoma",bbfc1945313c370d67dbb5064c7f106fba34aad9,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
22,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"we randomly assigned 870 patients with completely resected, stage III melanoma",a1f2d33b3461ec586aa3319b5e73a66e74762328,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
23,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,140 patients with early breast cancer were randomly assigned,bff69170118c768e1eb092596381a3c543eed253,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
23,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,140 patients with early breast cancer were randomly assigned in,1045ea51473e1e2d16f116337a94d1f3a847e398,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
24,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"platinum-sensitive, recurrent ovarian cancer",7ad89581d28ad793e39d5ef1c9e62c2301831dae,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
24,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"platinum-sensitive, recurrent ovarian cancer",7ad89581d28ad793e39d5ef1c9e62c2301831dae,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
25,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Barcelona Clinic Liver Cancer stage B or C disease,c7301b6296b7bdbecfa1ac7e161014afb25491ea,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
25,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Barcelona Clinic Liver Cancer stage B or C disease,c7301b6296b7bdbecfa1ac7e161014afb25491ea,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
26,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,women aged 25-60 years were randomly,db0840a6e37e9843a6bd17f88296e0b065d5371e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
26,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,women aged 25-60 years were randomly assigned,ef016a5eb2328ee48078573c31cefca9d5af9dac,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
27,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Patients (aged 18-80 years) with c,633fc721ee59354ce34b0b441df21f9c7e1d9b72,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
27,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Patients (aged 18–80 years) with,ba6d099e0776ae7cd32407214c97da244e5284cd,False,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
28,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Treatment for patients with recurrent ovarian cancer has been mainly based on systemic,031f346bf2e9264b9cc4ace4eeac064ef24ce5e4,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
28,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"In women with recurrent ovarian cancer, cytoreductive surgery followed",73e898b83cfa288d872a43058d829bdc1d900dff,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
29,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,measurable or evaluable high-grade serous or endometrioid platinum,09a95fb0b5814bd0f5b34484fa4d5af4d5282854,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
30,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,1500 women with axillary node-positive or high-risk node-negative breast cancer,bcdd56e17d1a840c3afc168e772f2dc8dca708c5,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
30,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,1500 women with axillary node-positive or high-risk node-negative breast cancer,bcdd56e17d1a840c3afc168e772f2dc8dca708c5,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
31,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,A total of 424 survivors of stages 0 to,f34262a2a6d0fc80549a96fa819958009ad653ef,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
31,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,A total of 424 survivors of stages 0 to,f34262a2a6d0fc80549a96fa819958009ad653ef,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
32,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,The drug may have efficacy in patients with HER2-positive advanced gastric,b62e995489b9d85619a85cb51b2f3cd258d41728,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
32,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,The drug may have efficacy in patients with HER2-positive advanced,82b0862578382b2e6a677e64e71e3d1d652f1c0a,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
33,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,we randomly assigned 127 patients with dysplastic,3be1d7bf864e2fc4676bc7a4f1695a44bf1e90c5,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
33,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,we randomly assigned 127 patients with dys,c7143d240a5f8bb67b5a041bc0a20510cd1902d8,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
34,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were premenopausal women aged 18-59 years,5f840835219fab2ba5517b0ca1e10975f184285b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
34,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,premenopausal women aged 18-59 years who,b0f9323691c3a9c9ced7599c6f4d0ac31cf0edb3,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
35,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,recurrent or metastatic squamous-cell carcinoma of the head and neck,36052cc4a9b1e356b0b0f8617f6d0b79df84ea9f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
35,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,patients with recurrent or metastatic squamous-cell carcinoma of the head and neck,fbe1abd1d2d29c459ac519e0ebf66154064c91bf,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
36,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned",bef7dc4daef6dba31ca7cb28ef2c7402a9b0617e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
36,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Patients with chemotherapy-naive, stage IIIB or IV,",49952265bb8cd55fb837d23553d346a6072504fb,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
37,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,histologically or cytologically confirmed advanced non-small-cell lung cancer,25e69c709826bca84b2a20a3de52d1e666cec5d8,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
37,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,histologically or cytologically confirmed advanced non-small-,acc11f99279dad3ee4be15d5e418360b8bd91281,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
38,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma",4dccde99f317d5f36d314601c66701d8accae702,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
38,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"Eligible patients were male, aged 18 years or",1ef9b288ad7281068aca1f77c1b337fa569b9ea1,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
39,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable,60a1dbde588b70a3406119fae83d54be29cbeb76,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
39,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma,44c4c1fa6eb8791e09c71900f02c27af6980f4cf,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
40,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"we assigned 615 patients with locoregional, high",d05f59ff3e74720ef323d38196d4b51e50a5f85c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
40,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients with locoregional renal-cell carcinoma at high risk for,337060494b3da572159260da07c18886e95ea387,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
41,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Standard first-line regimens for patients with metastatic gastroes,ffcc32a8347280ddf65b415bdb0b315d7e6f9fb5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
41,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Standard first-line regimens for patients with metastatic gastroesophageal aden,2856b243479961f0815a43f20b00bf9a77d2cf0a,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
42,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627),b1c09b3e60339f032a3371c9409dd5cba859d47c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
42,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,1256 patients with resected stage III,a75e6175509c8dd0fc4c56efdb8cb1dddffd3cf9,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
43,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer and who had chosen surgery as their treatment approach,6c7bbb749c23a76c07155510f2a35c4213821cd1,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
43,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer,59a3763c94c3f0cac7eec1001ce3b4f98d515821,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
44,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,We assessed the effects of combined docetaxel and estram,c8e934911aeca9b9e480fa44876037aaa2280a78,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
45,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated (1 to 1) by minimisation to receive interferon alfa-2a alone or combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil.",7d0ba771cb0ab2735f66a46a3304a322d427e97e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
45,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated,02d496a2dd8422ce71898eb8c05bed6bc7046068,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
46,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer,45921d9ab9b48290b5485d58823453be5f06f07f,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
46,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer,45921d9ab9b48290b5485d58823453be5f06f07f,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
47,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer.,8066acb22185685f4794b84d85bf2c95a2903b69,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
47,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,We compared the efficacy and safety of a modified FOLF,b3927e0854918b0a338783c432c575a4a0316266,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
48,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,patients with previously treated metastatic breast cancer,d4d34620582aba440ad57f1a5e1e98bf67366997,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
48,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,patients with previously treated metastatic breast cancer,d4d34620582aba440ad57f1a5e1e98bf67366997,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
49,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"women with hormone-receptor-positive, human epidermal growth factor",1fefeee94fff14fedea59c1d1daa40937bb2aa3a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
49,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"We performed a prospective trial involving 10,2",36dc612e72f7b6642735a1b3657f79aff5cbb3fd,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
50,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we enrolled patients with stage IIIB or IV adenocarcinoma Identification of early cognitive,0cbe1864804f75d076b7d18fedb85eda7d506bd9,False,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
50,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,we enrolled patients with stage IIIB or IV adenocarcinoma,0825e4d60d1fa4f662bb55c1140ae89e2cce2319,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
51,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,premenopausal or perimenopausal patients with advanced hormone-receptor-,049b5abfa1eed87e9fb026687850e573d2168a76,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
51,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"advanced hormone-receptor-positive, human epidermal growth factor receptor",75062dc8fd420b4d90a15aa24dff341a910eba27,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
52,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,"The study involved 182,160",bee76e7dd23507023629b0faf13a418cb8473c6e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
52,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,"The study involved 182,160 men",e1b8695b6a884d1566963916899ec18bbb17ee5f,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
53,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,adjuvant chemotherapy for operable node-positive breast cancer,d831e475033b14ff9450885da9a3f45addd83004,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
54,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC that was not,62cba847b8421fdd30417995a4a9eb46c5a63b9f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
54,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy.,c02ea06c108110323e6de9212ef4743b789afcb7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
55,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,"In the Prostate Cancer Prevention Trial (PCPT), fin",3b1957189f5b5c63db37365865a862948ef64fdc,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
56,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,One hundred twenty-one participants were assigned 5 mg,26caef53683d157edf9fcc2c68943199fd491164,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
56,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Two hundred forty-two participants with intact erectile function scheduled,3dee2c7e99d97c4cf6b2b63ca5346d1cb43aab6a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
57,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,enrolled 160 patients with radiologically confirmed painful bone metastases,bf827c4b70a3b2c7f466645b23a47ece3ad69f79,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
57,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,enrolled 160 patients with radiologically confirmed painful bone metastases,bf827c4b70a3b2c7f466645b23a47ece3ad69f79,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
58,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, who had received one or two previous systemic treatments for metastatic disease, had progression on their most recent therapy, and had previous treatment with an anthracycline or taxane were eligible.",4ffb2b75b7f3fcb5a5ec2fac9e64baf94e3ddbb7,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
58,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"Patients aged 18 years or older, with centrally confirmed metastatic",aeac996b0170dccfbce94c605f0f19e81cdca24e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
59,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"JACOB was a double-blind, placebo-controlled, randomised",c4d2076bc961d1dbba572c7d107e0d77ee3c54e5,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
59,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"JACOB was a double-blind, placebo-",1fec106e597c3c46d31570a9458f9b9148f63586,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
60,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,premenopausal and postmenopausal women 35-70 years,2c1d320253967327999c0d9d34009f5dcc608090,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
60,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,premenopausal and postmenopausal women 35-70 years,2c1d320253967327999c0d9d34009f5dcc608090,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
61,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,Eligible patients were aged 55 years or older and regarded by,d0b5f3c51c4302faefbc5466e38de05cf087b53d,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
61,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,recruited patients with symptoms suggestive of colorectal cancer from 21 UK,e373e54cd03db423f059cb189450a0f0a0c0a239,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
62,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Eligible participants were aged 18 year or older with hist,17ac88b62929c763b814fad909cd05cef8dd3b7b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
62,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Eligible participants were aged 18 year or older with hist,17ac88b62929c763b814fad909cd05cef8dd3b7b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
63,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible participants were adults aged 18-75 years,a284feb82a6e5df208e4e25d38860653ef9b572f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
63,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Eligible participants were adults aged 18-75 years with locally advanced or metastatic NSCLC得以进行研究。,a536d5e43edc1db6d8db663123a55d26032a987b,False,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
64,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,patients with advanced renal cell carcinoma and no previous systemic therapy,27873bec3229f421e7a00bd2e3a69d89aa463abb,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
65,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,these patients included infants (<365 days of age),c1bc8450180527177e16dffc91a606f3e34723b5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
66,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer",540a6dbd666afb7ee6d0b7e5b7f3da7b959389ca,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
66,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment",92b54c29dfeb350fb3e61b31231bb4b6ae50a08e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
67,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV6",946ae7f2594fcb5b1278330be651f5a678f112bd,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
68,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Randomisation was stratified by geographical region, macrovascular portal vein",03653e98b86887295aff242004de9437be76371e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
68,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Randomisation was stratified by geographical region, macrovascular portal vein invasion or",7f5f22b05df9837265308749b355f87d10b2585c,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma,cf0305d73607fee89ad537787a8bab73a002e622,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
69,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,we randomly assigned previously untreated patients in East Asia who had advanced pulmonary,7917ea945add31fa3a11074806f3e212c8151eea,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
70,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"Randomization was stratified based on site of metastasis (visceral,",7e5d8909a7017653bee2a7ee71c3a15fbfd4ef5a,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
70,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Randomization was stratified based on site of metastasis (visceral,2385b6398f7f157a111dd6680aac3092b7e60415,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
71,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligible patients were aged 18 years or older,b28b5f3ef72e5860a6d72add16b504b580daae25,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
71,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
72,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We randomly assigned 870 patients who had,c087e6adf70564ed78e85a3b8b4bd44da92976fa,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
72,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients who had resected stage III melanoma with BRAF,fb35ca6c38f7c2adad2bcd51d1da7a909751edbe,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
73,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,enrolled patients with T1-T2N0-2 p,262ec6c5f79c5e808237988ff2527f805e3a822d,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
73,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,enrolled patients with T1-T2N0-2 p,262ec6c5f79c5e808237988ff2527f805e3a822d,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
74,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited,0298c4ebd14147a2c51e15d5aff9edd861061538,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
74,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited,0298c4ebd14147a2c51e15d5aff9edd861061538,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
75,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We randomly assigned 229 patients who had well-d,1462f338ecc30763fd3431c80fc0190797dc70ed,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
75,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors",705c0db343db93f7def5ac17051a9587b6be6529,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
76,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,5999 participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings.,fdf44af83ac37b872df2156a1683d452a28f959b,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
76,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,5999 participants aged 50,0ab850d62bc4237aa3148aca192f902456682e7c,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
77,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Participants (N = 51,61f06ef6bac554a46a5f00d4abffc19f1d2c1712,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
77,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,25ecd584e5b4a56896c4eee319b874a2c1548069,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
78,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we randomly assigned patients (in a 1:,369a3f45bdc861652167bf352a26c33bb5d79f80,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
78,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we randomly assigned patients (in a 1:1,f740974ade697b1863f08214abf1418a96f14857,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
79,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,patients with clear-cell renal-cell carcinoma who were at,7cf20d92d8928d6e30e1ec5ae287cbdca90b369c,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
79,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,patients with clear-cell renal-cell carcinoma who were at high risk,35163ceeb4e89de03fa27cdb88023b6a841f9646,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
80,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,patients with metastatic castration-resistant prostate cancer,059b16131770d5c692e8fbdf168f4aa81d9dc888,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
80,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment,9cc321336738a035abca85558916448bb1b64de9,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
81,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
81,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
82,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we randomly assigned patients 2:1 with untreated locally,8079d97beae8060155533989d3d3726a60c33f51,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
82,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,untreated locally recurrent inoperable or metastatic triple-negative breast cancer,4e05d39ea4883688eba77cc5809eb230ee88e5f7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
83,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,resectable cancer of the middle or lower third of the,190bb51d091ddf505ffd61ceb9c88fb72b981d8e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
83,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients 18 to 75 years of age with resectable cancer of the middle or lower third of the esophagus.,f048ddcaac4f282de7afb4ad6a448fc464bf0a99,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
84,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,479 women with previously untreated recurrent and/,0cedd55c3811d422b46c2dab0f7e7ebf1981afdc,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
84,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,479 women with previously untreated recurrent and/or metastatic,2226e937fed5ddd3e88c6f24dc023700bf0801a6,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
85,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C,91cec28e5c907eadc7e24c39b2db70269724b18c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
85,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C,91cec28e5c907eadc7e24c39b2db70269724b18c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
86,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,enrolling patients with at least one risk factor (pathological T-,7e6ba65017b6c90e6c2931815880c17bf5ef6c9b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
86,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"enrolling patients with at least one risk factor (pathological T-stage 3 or 4,",4b67d31ef8e2fde90f9f38b233a9633bf6689102,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
87,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"eligible patients had histologically confirmed, radiologically evident m",dd3f5f5c565e58432614d0545d1f48c97eb4c484,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
87,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract.",fb9278c2791a54c475e36e439cc3e33ec9537dfc,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
88,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,840 patients with stage IB-IIIA,cdfd7938c0cc30be00207ffcf82937e6b0bf3774,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
88,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,840 patients with stage IB-IIIA,cdfd7938c0cc30be00207ffcf82937e6b0bf3774,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
89,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We included patients aged 18-70 years,42223a5169601e31b3b579efe907b53d7a9a9022,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
89,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"locally recurrent NPC with tumours confined to the nasopharyngeal cavity,",a5c9e7d28d571be01c5adcfb942e90448b603d72,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
90,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"The effect of celecoxib, a COX-2 inhibitor",1abc6df0543ac6e981b88bd38d610198d6d70240,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
90,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"The effect of celecoxib, a COX-2 inhibitor",1abc6df0543ac6e981b88bd38d610198d6d70240,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
91,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,we randomly assigned patients with sentinel-node metastases detected by means,61e24361e4c7ec4f64426c09f89bd25dd42bd2d8,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
91,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,we randomly assigned patients with sentinel-node metastases detected by,2cbc1c4a696135b5344dc97d8dbb5130112cc660,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
92,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients (aged ≥18 years) had histologically confirmed epithelial,34c908724525f37f42c1be4643ac9c9d7f5c5d0b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
93,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,adult patients (aged ≥18 years) who had,f6aa31ea2b90aaf4da8a35d9fd40961ca5b37e3d,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
94,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,first-line metastatic renal cell carcinoma.,0b5e34470c16e4afaf2664de39af21c77e24db66,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
94,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,atezolizumab plus bevacizumab versus sunitinib in first-line metastatic renal cell carcinoma.,e762e14aa0fb56fe8d26f169b60276dce548894c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
95,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
95,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
96,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer that had,6ca3c9a52c2fba93cd925fe3e4d0d6084444d369,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
96,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer,5d5155847f5bd926214d2cd5e8b09aeba15723f7,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
97,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC",0b402dc18bfbf2b3abe6d6e47c3cc9b7ada85791,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
97,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC",0b402dc18bfbf2b3abe6d6e47c3cc9b7ada85791,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
98,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we randomly assigned 322 patients who had,3f575d57cc42c6c0e42de469da84e441c6bdf9f1,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
99,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,Individuals aged 30 to 64 years with female sex,da09b4c276fe2322676bdbd8b37adbb00c70bf31,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
99,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,Individuals aged 30 to 64 years with,0b4c5b075968aa016dcec5b53062569a82188949,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
100,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.",2bb4c508e081004e847881868ce95d43864f22fb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
100,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.",2bb4c508e081004e847881868ce95d43864f22fb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
101,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Patients with previously untreated, stage III-IVB (except",a7cae986e82c256071b923884e51d3404c48fc39,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
101,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Patients with previously untreated, stage III-IVB",bc344dd2fccfb636492f974a73e3a5d217092800,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
102,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Randomization was stratified according to programmed death ligand 1 (,8a40c19e0ebbc18ea1de4b1f51539a0d4e4816e8,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,To evaluate the safety and efficacy of adjuvant girent,1bae6dfffc0a5aa56bcf89719679c495566ee48e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
103,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Eligible adult patients had undergone partial or radical nephrectomy,c34b599e310ea2a740b14a182df17c7e7f0c245b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
104,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Eligible patients had pathological stage high-grade T1,9fb978dfc17f2da9acb25f70d7320adc3fa07af6,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
104,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma,fa08345d653fe100e478be37169783281485351b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
105,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,disease stage at enrolment,9a136c4b28b0ceaa6ee70aa995398e0884fd436f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
105,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Randomisation was done via the minimisation method with biased-coin,c0345caf4e1b4a1d526b92ece50a5313687772f8,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
106,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
106,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
107,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"We conducted a phase 3, double-blind,",169cf34b3f7bafd0e11860f5f47691a003d05b58,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
107,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"We conducted a phase 3, double-blind,",169cf34b3f7bafd0e11860f5f47691a003d05b58,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
108,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"patients with advanced cancer, aged at least 18 years",d58f8bbe597f8dc117a48218e33ea3388f99fcf5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
108,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"patients with advanced cancer, aged at least 18",994ffb7c194d2b0a1798216a5d30c4aa72ae22ff,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
109,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were aged at least 18 years with histologically,af5270228efa0020a5244874017f8a54e66ed6ec,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
109,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"locally advanced, unresectable, or metastatic cutaneous melanoma",40560de174934256c1341f83c94e1cc40eddd7ae,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
110,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"in patients with histologically proven, HER2-positive metastatic",85ab1998a3dd73a68e6a7d0c04d53765d53fa707,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
110,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"in patients with histologically proven, HER2-positive metastatic breast cancer",9f34a4e281d85a1a18b56d2da1cb165df7dd713b,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
111,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
111,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
112,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction,13a237312af3eebf8e1b4c49da4f1658b1899b21,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
112,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,enrolled adults aged 18 years or older with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction.,7dc65b0e848bd37b186397eec9230c3027f55412,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
113,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,386 participants who had had at least two nonmel,6cbf02402571542ac7b4847238bde8b18e3dd86c,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
113,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,386 participants who had had at least two non,922e0a80b0251760a4052417d678a80e5decd772,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
114,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,squamous-cell carcinoma of the head and neck who have advanced,7e07421875264cc5a0d9db8c2f41e978f3d4b339,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
115,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we randomly assigned patients with unresectable stage IIIC or IV melanoma,9c74be094483dd16b5b51d18d71153ac0f52a093,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
115,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,we randomly assigned patients with unresectable stage IIIC or IV,b1c133813cb9787f08c732ca7c20951529b4bb51,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
116,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma",4e9d1b2e87d328e571dc9c7e55c1d887aef3d569,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
116,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma",4e9d1b2e87d328e571dc9c7e55c1d887aef3d569,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
117,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.,1e5a0d07bcab51fdb16ae60707f07703b41de616,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
117,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,postmenopausal women with early breast cancer,90a9744ff44d78efb1add493d765580a9eef470c,False,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
118,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease",956a14b0bd45bfc6a8f74ce071549a2f12f5e735,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
118,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Eligible patients were aged 18-75 years,c1b78c0d232a322c7a79bb845f5c6dcd3753ce3e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
119,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,patients with palpable T1-T2 invasive breast cancer were,54eee157e1069fe29b4ba528c0234c145de7bcb5,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
119,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients with palpable T1-T2 invasive breast,e4d6156c46b5b389125577e483203b3b76dacb98,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
120,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"unresectable, locally advanced or metastatic triple-negative breast cancer",12be568af4ded2ccd5fb071fbf2267ce4d701476,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
120,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"patients aged 18 years or older, with previously",bb0df9e6d8e77371d73825ff2f6bcb0b8d53d8e2,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
122,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized 1:1:1 to receive adjuvant RT, CCRT, or SCRT.",8957dd67add6f88a78128c6347bf1d0e6a996aa8,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
122,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized 1:1:1 to receive adjuvant RT, CCRT, or SCRT.",8957dd67add6f88a78128c6347bf1d0e6a996aa8,True,LOCALIZED,gemini,gemini-3-flash-preview,"A cervical cancer"" support the ""LOCALIZED"" label",INVALID,False,
123,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma",d57a0e70cd847b04f4eb56ebbf449fa9bc55841a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
123,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma",d57a0e70cd847b04f4eb56ebbf449fa9bc55841a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
124,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Adults (aged ≥18 years) with locally advanced soft,54cb968a582ec2f6d436ae26bbcc2945897fc24d,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
124,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.",f01be5f907ffb3968529022574e3b780796c8912,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
125,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were aged 18 years or older with recurrent,f47b1abdd2067378584524abae6842ee42ceb742,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible adult participants (aged ≥18 years) had primary stage,595c13a7df2ba392d69037646fef21e6456a83ad,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Eligible adult participants (aged ≥18 years) had primary stage,595c13a7df2ba392d69037646fef21e6456a83ad,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
127,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients aged 18 to 70 years,ad57000091ba176064dc3bbafea94a6b4c114346,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
128,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Participants were aged 18 years and older, had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",a2901e7a0e6ecc70978ec646a7e92e9bd0370ff6,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
128,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",ddbb59f329d0519e114ab00542bc0c308ab849a7,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
129,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
130,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal,066f5c9c3300f35dd46935fcd44d8a38c86fdf4d,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
130,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal,066f5c9c3300f35dd46935fcd44d8a38c86fdf4d,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
131,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
131,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
132,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,involving patients with active rheumatoid arthritis despite methotrexate treatment who were 5,49262def5e6886a8fa32d521d5ea0aacb848b69e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
132,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,involving patients with active rheumatoid arthritis despite methotrexate treatment who were 5,49262def5e6886a8fa32d521d5ea0aacb848b69e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
133,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
133,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligible patients were aged 18-80 years with stage,f0d23247e554045b99e8c13fceb2e4f7f71a937b,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
134,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we compared first-line nivolumab with chemotherapy in patients with,70e2550ff9ca1377d8e25401fe280185cda030d7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
134,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,patients with untreated stage IV or recurrent NSCLC,0c85b8487b0acb5a3977724399f64a26805c26c5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
135,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,both groups were also comparable in their first remission status at study entry (,cea7f11537876b871f139b544830915c388874fd,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
135,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,both groups were also comparable in their first remission status at study entry,ba5189ccae8d8069f39157c1d82686bc1bc47ea2,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
136,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,All patients starting adjuvant or neoadjuvant chemotherapy for early stage,32e9e9a87b5ee72a0c8df16600d68bf5af27c5db,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
136,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,adjuvant or neoadjuvant chemotherapy for early stage breast cancer,1ecaa8b535b85180464b3997ee1542bb1814f020,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
137,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Because of the inaccessibility of mediastinal nodal metastases,",64fbfd8c4faf805467bfe23731fcd47f1773672c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
137,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Because of the inaccessibility of mediastinal nodal metastases, the left",d71a6a19b62287a8c87044ba79468ee7ee91dca6,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Regorafenib confers an overall survival benefit in patients,470fe82309cad8ea3657e18086e7b2452dbcbb5f,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Regorafenib confers an overall survival benefit in patients with refractory,653f3c3078b6d2936838bd8ef9c448128d4c5ea9,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"523 patients with curable stage T2b,",0d51129c6fa571a99cf0d77fabed1c42749871f9,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
140,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
140,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
141,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression,187b46812f1d8adc55b45569e5fa26ef2e61a69a,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
141,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligible patients (n =,8556bb1cf71a95201f654710b9555f594a96da09,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
142,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0) and primary tumor larger than 2 cm",d324a09f85840d997b19ae0ef62132b034505322,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
142,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Asian patients with ERBB2-positive early or,736e81f2e407b49a588edd767227dad3e0e21a66,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
143,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,"Screening for its precursor, anal intraepithelial neoplasia (",4b1baf3f25eaf60158587f8cf2b8458e12e9a331,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
143,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Patients with histologically confirmed AIN were randomly assigned to receive either,89ee4ab56f1c5a83eb85bafebc781462ebfa93a7,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
144,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we randomly assigned patients with spinal cord compression caused by metastatic cancer to either surgery followed by radiotherapy,fd3dfc0dc6b97db075ea14265678448bd50a1b62,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
144,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we randomly assigned patients with spinal cord compression caused by metastatic,090973cbdcc1cd84e5ba5c262556df3885ed3059,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
145,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"enrolled patients aged 18 years or older from 129 UK centres who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy.",ddf7b949c332b2defeb48a223ad7a46d43b73d09,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
145,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"node-positive or high-risk node-negative operable breast cancer, had undergone complete excision",ffd4733d5e788c755802230a867239a8c8c5f4fb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
146,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older,f0986623f747b44a8a974f8d0a311f6cb9100fd4,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
146,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States.,69ba34b09a80f9f8d9b1da2620a0ac6d68b55e6d,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
147,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.,69b842dffdbffa24b7350f9d02f2376643d86b1b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
147,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,To determine whether nab-paclitaxel improves the outcomes,01a27b38a2f4c1f74ebff981013cdee97c60e999,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
148,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
148,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
149,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly recurrent soft",c0b393e9bc2c8efbf533f7ccaffdad99a43d2d74,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
149,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.",5dd83413e5cf0f338a57224082e25970f5d5aa27,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
150,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,we enrolled patients with a histologically proven superficial basal-,3fe0776db64f2a719a850ce9731a9669b088a680,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
150,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,we enrolled patients with a histologically proven superficial basal-,3fe0776db64f2a719a850ce9731a9669b088a680,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
151,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,diagnosed with unprovoked venous thromboembolism (,8b39079668fe1d794b1853c338d77ba0411b4c66,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
151,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,"Patients aged 18 years or older, diagnosed with",2bb9f5785ee3151b1ed43c628b64875409bbbece,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
152,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We included chemotherapy-naive men (aged ≥1,8c4ea9ef2d124f4b7266b8bd801ec7e0b8ec5321,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
152,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,We included chemotherapy-naive men (aged ≥18 years),26d9bdcdee233175800dde94e23b0b96b3d08f6b,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
153,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,accelerated partial breast irradiation (APBI) for patients with stage,8567b1680eabdb7fe7532d59c8a8f51caf8906e4,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
153,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,accelerated partial breast irradiation (APBI) for patients with stage,8567b1680eabdb7fe7532d59c8a8f51caf8906e4,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
154,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Women older than 18 years with histologically confirmed HER,9d8c254694955e1e925281d78ba3e01f2fc0cb33,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
154,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Women older than 18 years with histologically,bac4769ee263e3a852a26081491097451333de10,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
155,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
155,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
156,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical,7c938534564b931449ed7d031cfb787a89e0b3d2,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
156,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery,497bfcf94eef00225dfe6be3ee39ac77b8c6b7a2,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
157,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,we enrolled patients with prostate cancer who had high-,eb11b92332c31e237ac13d3f1b865591cd8e9984,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
157,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,we enrolled patients with prostate cancer who had high-risk biochemical,53d6e4231290b98b4824f5b7eb50798f1e06a50b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
158,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease,4cc0c0ba02fd8fd04ad1a7e0752c9f253813fbd0,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
158,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
159,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,radiation therapy to the primary tumour site plus meta-iodobenzylguan,ef1eb6ea15d910133452313e4eee12a472bcc504,True,BOTH,gemini,gemini-3-flash-preview,"guan"" is too weak/ambiguous to confirm",INVALID,False,
159,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"All patients were treated with six cycles of induction chemotherapy, myelo",6f21f2edd2d79b19a6b8305f2d1068a3bbbd70d2,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
160,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,women aged 18 years or older with hormone-receptor-,bf07db9d8f2ec9e1e8376b23240a781d101311d0,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
160,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer",c6a5bfe53f897b58d7a4e4700d69d71805fb3518,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
161,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Outcomes are poor in patients with HER2-negative, advanced",ec99240daf0632aa96205f810bd55fb54f659301,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
161,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Outcomes are poor in patients with HER2-negative,",4d45530dce4bfeb6946bdab6c4b2a5cd8b4f5505,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
162,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,gemini,gemini-3-flash-preview,"IA/N2 localized? Yes.
    *",INVALID,False,
162,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
163,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer",27df1e3a1113bef9b17cbfd8c1811894c37fafeb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
163,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"We enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer from 81 Italian centres.",323f84eab7da85319403771ffcf28ceea7ecaa59,False,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
164,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Patients who have unresectable or metastatic melanoma with a BRAF V,7db3bf36cf3fd002728a008b97171b9465cb5fc7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
165,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were randomly assigned in a 2:1 ratio,fb890edaf5d17c50f8c0cfb8ff15dfc856394181,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
165,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"adult patients (aged ≥18 years) with advanced, progressive",6c3149585afbf22265750068eed99bbb99bde25c,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
166,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.,0d0051c9a89f4850fe4794c8eed127f0ea0d9b17,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
166,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,patients with HER2-positive metastatic breast cancer previously treated with,9eb20b9e5be060872e6cdc4d1381ab41c1ef0fae,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
167,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,completely resected stage III melanoma at high risk of,59abffb731a1a76ffd6e228a8237bb6817027db1,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
168,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"in patients with HR-positive, HER2-negative advanced breast",0557a86da69e4df5fdf45d098532285a44890405,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
168,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"HR-positive, HER2-negative advanced breast cancer who",c4c2394d95974be179d12e25ec61d06b5f9acf92,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
169,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We enrolled female patients with HER2-overexpressing,f02e3cad6b9e5d36a2eae2ad765d5b748b03d5fe,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
169,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,We enrolled female patients with HER2-overexpressing metastatic,005048b41dd909db688f376fe307a54088d2c9fd,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
170,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,we screened 3100 first-degree relatives,8a7d132df4e12f22de20710430842a1744ff55d4,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
170,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,we screened 3100 first-degree relatives of,ff93519f9209262eea30b0db94a7a9622ad14b32,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
171,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,early breast cancer,d04e2d195abacd3a6db2384ad741abd39c1d4382,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
171,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-,2be7e0bce175fd4709bdc2e78ffa82150d0b09bf,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
173,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,To assess whether stereotactic body radiotherapy on a single tumor site,6f151cbb3e6cce6fa99622a2c44f58a4558de4b3,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
173,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,To assess whether stereotactic body radiotherapy on a,dde7fed95e6e2c5c2b6db525a389f4d4ff4f9901,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
174,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,170 432 eligible,a0f425c126919277317dabf8e19d596ae8e20cdd,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
174,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,170 432 eligible,a0f425c126919277317dabf8e19d596ae8e20cdd,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
175,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who,87d94dc31f87d6290677024d897e395667e58d02,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
175,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,locally advanced or metastatic,e7894e52acb07b735ae47a10d6beec8e1beedc5f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
176,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,"we randomly assigned 76,693",335459b7e6ca8c55ce67f2196a21bc07dfce92a0,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
176,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,"we randomly assigned 76,693 men at",7bb29b7eb4719bde7281f54ab61e213d4e067465,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
177,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,patients with stage III or IVA endometrial carcinoma,83a4d8c6e02ba20c4a7daf2f202feaf6def357af,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
177,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,in patients with stage III or IVA endometrial carcinoma,2002feb6dec076ebeb70d6a9900497c6c4955e6d,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
178,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,unresectable or metastatic cholangiocarcinoma,a90ac0ded24bb405865cd960c1faa2f1aa15ea2b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
178,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"aimed to demonstrate the efficacy of ivosidenib (AG-120)-a first-in-class, oral, small-molecule inhibitor of mutant IDH1-vs placebo for patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation.",c3734cfc43a7a509e7101c7502c2435306a512ae,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
179,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Patients were randomly assigned (1:1) to busulfan and,5b754efafe0ab94c1fec057a3f425fe1573c5272,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
179,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"balancing age at diagnosis, stage, MYCN amplification, and national",c417922175cbd219427dd03b0d52e1e1458725a3,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,patients were eligible if they were aged 18-7,c3cc6e090ca39f3532710bcd6b82ed864eae7898,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,patients were eligible if they were aged 18-,08b1f1d4e5ad6e76214595216aef4e15844f0959,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
182,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we randomly assigned patients with stage IV or recurrent NSCLC,7e148c6a8909bf1c9ba9c524125e35afc58618aa,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
182,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we randomly assigned patients with stage IV or recurrent NSCLC,7e148c6a8909bf1c9ba9c524125e35afc58618aa,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
183,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,patients with previously untreated stage II or stage III triple-negative breast cancer,df1fbc5bb5dcbf5062226f899b54c592cad0ffc2,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
183,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer,f33d8d6555d1c7356f81cb353a4c7a81669df708,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
184,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer.,8bf79f9205710ed68b6bfcad25eeb9f02b4518f9,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
184,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer,823f122356f8f86a5e76455b661c9dd507b9fb64,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
186,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
186,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
187,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We randomly assigned eligible patients between the ages of,9c6db607e0b4a0d263c71b29f9bb7bec68b852a5,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
187,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients between the ages of 18 and,069c79195586d2d060a6ac49c5a8b06cd6135885,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
188,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes,45a629579ffe04604931a5af649703de002388f9,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
188,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes,45a629579ffe04604931a5af649703de002388f9,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
189,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,exemestane 25 mg a day for the primary prevention of breast cancer,0d52001903e864e0ca1353e01d67caebfee3e508,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
189,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,primary prevention of breast cancer,a4273a11d881b39d97e17b7c3e3d320c0e8f3224,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
190,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"ABCSG-12 is a randomised, controlled, open",03e5172a589ede017e1d2900e13e43a074435ab2,False,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
191,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
191,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
192,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"hormone receptor (HR)-positive, human epidermal growth factor receptor 2",18d8797c8fd87f6e8c4a2a30fd361a6d9c802e00,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
193,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were adults (aged 18 years or,ed0b2f7d885707876cf209788eb0181185634542,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
193,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Eligible patients were adults (aged 18 years or older) with,bdbae9c9a8a7ac5f9d91885d2a033c05c0008f84,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
194,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Patients aged 18 or older with a controlled primary tumour,8579ff0827711712d691347c159338df3583ccab,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
194,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Patients aged 18 or older with a controlled primary tumour,8579ff0827711712d691347c159338df3583ccab,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
195,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung,fc43a5e41e52c882b1483b7240e1d1e78c9226d5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
195,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung who had progressed after at least four cycles of platinum-based-chemotherapy.,7b6c6e36b482f1636c166e4378de25d7832b70ee,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
196,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination.,b115d94518768d5f9b795d5db83ebfc4ffac9bc6,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
196,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination.,b115d94518768d5f9b795d5db83ebfc4ffac9bc6,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
197,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Patients aged 18 years and older with metastatic soft-tissue sarcomas,5aa95ecda2edcb243e6f1061f50ba6de22c5831e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
197,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Patients aged 18 years and older with metastatic soft,86eb6a5a948f3912c43569f11c623d3dcb14b4bb,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
198,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry.,0dba11ee514688d77c9254edf4807a4baff8b71f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
198,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour,76a09e20d2d740bdabd2af21bb950f49cb219034,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
199,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment were randomly assigned,37778d79b23f24354dccbd63cc0fc49a6013ae65,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
199,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Our aim was to assess the use of ipilimumab after,563803f93742a5ad0e54d611a129fb162ce55595,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
0,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual),85e156f895f3ed503c4178addd4d94580bebde85,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
1,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we enrolled patients who had locally advanced and unresectable or metastatic,aa41afcfd0d25b8d3f4bc8fbef7869c1c9d86a37,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
2,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,advanced or metastatic soft-tissue sarcoma,d28b1db6a124af08f9f65e1287ad6406871299d6,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
4,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,those who had centrally located squamous cell carcinoma with cavitary,14348ecd6150694f35998f13a9b61ff576c513fe,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.,095a4141eb262225a4f7a27dacfdcec099af798c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
6,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Localised prostate cancer is commonly treated with external beam radiotherapy and moderate,93a011d4fea905c8f60e6d5512d87f998750d89e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,Exclusion criteria were previous bilateral oophorectomy or ovarian,738b55450f305ebb6083f9550ce0d793bb275d13,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,We assessed the efficacy and safety of the aromatase inhibitor anastro,bc88e62143bc0c9f7397e9ce30b587a20003568a,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
9,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we recruited patients aged 18 years or older with,ca4a0d30874b0052ef92684b33263b9379859a4a,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
10,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab.",0591ee004c0def46184a426053dd9738f35bbfe6,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
11,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Patients aged at least 18 years with previously untreated,0b407e11d8e70f359fdc350bd85a3017c6a794e8,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
12,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fallopian tube",9d680e16f279da24617cb2dded0f2f148e428a14,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
13,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,5102 patients with HER2-positive,6e8f583e331ae97b039b4274289f9cc76de51694,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
14,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer,51ec0273befa1e47d1450daed3776964587877f4,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
16,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible patients were women aged 18 years or older with unilateral,fa828c664e4d6915e3b826d995dda65ee5a24afe,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
17,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive,",68e45bf2723aaf85c62974581393b33f08376601,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
18,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,"In this phase 3, multinational, double-blind,",d62a4ca5af50b33b775e30a113eab79034e9c464,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
19,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligible patients were adult women (aged ≥18 years,dfea16ed826e19dac78d07a31edc2219984a297d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
21,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"In this trial, we randomly assigned 556 patients",5a367c4e58fb6e9cfa55fbb7a21840df3dc5edc7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations",5bc192c8ba270a07267a65bb5a3800b98362e9a3,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
23,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,140 patients with early breast cancer were randomly assigned,bff69170118c768e1eb092596381a3c543eed253,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
25,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,randomized clinical trial enrolled systemic therapy-naive adults with histologically confirmed,8cbe559a5132c3510d3a7004165b477c7d5d0d59,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
26,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,women aged 25-60 years were randomly assigned,ef016a5eb2328ee48078573c31cefca9d5af9dac,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
27,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Patients (aged 18-80 years,bbab1c3921c2657b0258898e56f6bb32b91c1e35,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
28,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Treatment for patients with recurrent ovarian cancer has been mainly based on,69248b845a348504f04bdc025f5bcb0b2c20ad4c,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
29,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,measurable or evaluable high-grade serous or endometri,56e72dca2422ca084705cc335eb6899ddc062337,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
30,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,1500 women with axillary node-positive or high-risk node-negative breast cancer,bcdd56e17d1a840c3afc168e772f2dc8dca708c5,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
31,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,A total of 424 survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously were screened,5808aec2aa6f127482bcc1304d8c6a36f777e807,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
32,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,The drug may have efficacy in patients with HER2-positive advanced gastric,b62e995489b9d85619a85cb51b2f3cd258d41728,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
33,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,we randomly assigned 127 patients with dysplastic Barrett,45abd30338224ac4c9a6497a3d70732625e71aa7,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
34,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible patients were premenopausal women aged 18-59 years,5f840835219fab2ba5517b0ca1e10975f184285b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
35,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,recurrent or metastatic squamous-cell carcinoma of the head and,821b13e93a3d74436c5c87b76e94d2e1b7090bc3,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
36,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"patients with chemotherapy-naive, stage IIIB or IV, non-",665ffd8ffb4b29e86141481a76f6b55b985c8905,False,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
37,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,histologically or cytologically confirmed advanced non-small-cell lung cancer,25e69c709826bca84b2a20a3de52d1e666cec5d8,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
38,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma",4dccde99f317d5f36d314601c66701d8accae702,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
39,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma were randomly assigned,8a5c047c35aa6f50c18f52b683e7dbd2d05b54ef,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
40,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"we assigned 615 patients with locoregional, high",d05f59ff3e74720ef323d38196d4b51e50a5f85c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
41,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Standard first-line regimens for patients with metastatic gastroes,ffcc32a8347280ddf65b415bdb0b315d7e6f9fb5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
42,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,1256 patients with resected stage III,a75e6175509c8dd0fc4c56efdb8cb1dddffd3cf9,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
43,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer,59a3763c94c3f0cac7eec1001ce3b4f98d515821,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
45,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated,02d496a2dd8422ce71898eb8c05bed6bc7046068,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
46,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer,45921d9ab9b48290b5485d58823453be5f06f07f,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
47,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,We compared the efficacy and safety of a modified FOLFIRINO,c7e38e489e7e4c0cfabd626a1d68e773ab7ef786,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
48,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,patients with previously treated metastatic breast cancer,d4d34620582aba440ad57f1a5e1e98bf67366997,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
49,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"women with hormone-receptor-positive, human epidermal",660ec951f268ff99e8f633c71740a58391fbb24f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
50,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we enrolled patients with stage IIIB or IV adenocarcinoma,0825e4d60d1fa4f662bb55c1140ae89e2cce2319,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
51,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"advanced hormone-receptor-positive, human epidermal growth factor receptor",75062dc8fd420b4d90a15aa24dff341a910eba27,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
52,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,"The study involved 182,16",e2260312646af6e3a013c14a9e868225bfa5f955,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
53,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,adjuvant chemotherapy for operable node-positive breast cancer,d831e475033b14ff9450885da9a3f45addd83004,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
54,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC,83ebc0f9d457c6f7c84b8d584fad5230449ae643,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
55,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,"In the Prostate Cancer Prevention Trial (PCPT), finaster",e827fd6ed9cedd5ab4e5cbc7022788b3a4a0e5fd,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
56,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,One hundred twenty-one participants were assigned 5 mg,26caef53683d157edf9fcc2c68943199fd491164,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
57,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,enrolled 160 patients with radiologically confirmed painful bone metastases,bf827c4b70a3b2c7f466645b23a47ece3ad69f79,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
58,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"Patients aged 18 years or older, with centrally confirmed",54d212a011d4743b2d9a68211839fe112c75c56b,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
59,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"JACOB was a double-blind, placebo-controlled, randomised, multicentre, phase 3 trial in patients aged 18 years or older with HER2-positive metastatic gastric or gastro-oesophageal junction cancer.",3775d984868f90f69a99a5af7c3928c8895cb059,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
60,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer,eb39c499b2390ac2dd1d4534274471899a2f3445,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
62,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible participants were aged 18 year or older with hist,17ac88b62929c763b814fad909cd05cef8dd3b7b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
63,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible participants were adults aged 18-75 years,a284feb82a6e5df208e4e25d38860653ef9b572f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
64,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,patients with advanced renal cell carcinoma and no previous systemic therapy,27873bec3229f421e7a00bd2e3a69d89aa463abb,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
66,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment",92b54c29dfeb350fb3e61b31231bb4b6ae50a08e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
67,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV6",946ae7f2594fcb5b1278330be651f5a678f112bd,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma,96d38b1bcb1aa5ffc0fdc50e988558ea509561ce,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
70,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Randomization was stratified based on site of metastasis (visceral,",7e5d8909a7017653bee2a7ee71c3a15fbfd4ef5a,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
71,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer",90d37de0fe857b85ec9ed0126051eeeee05f0b83,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
72,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with resected stage III melanoma with BRAF,b13d3a946fa5c810b63d343d5366f5ef75be3a0a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
74,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited,0298c4ebd14147a2c51e15d5aff9edd861061538,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
75,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We randomly assigned 229 patients who had well-,e0526438dca7bd0aeb7e575d88e860c2c7f3c0cd,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
76,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,participants aged 50 to 64 years,149f3b2aa1ad1813e70c34c3616ee7ebfba3641c,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
77,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,25ecd584e5b4a56896c4eee319b874a2c1548069,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
78,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we randomly assigned patients (in a 1:1 ratio),224ad0306ecbdbb1e61819f96cfa6b02a6c6432a,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
79,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,patients with clear-cell renal-cell carcinoma who were,c6babd6926440ac4f820f5e7788cef20ae867f98,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
80,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,In the AFFIRM trial of patients with metastatic castration-,1f22e8954c181e8838473310c0291d1ab3de519c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
81,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
82,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we randomly assigned patients 2:1 with untreated locally recurrent inoper,3a9f5b0b65c6f36108ec7f5d7fc6bde649c0412f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
83,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,resectable cancer of the middle or lower third of the esophagus,4aa815917ed986cf18485917b5df7dc4af2ec9fd,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
84,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,479 women with previously untreated recurrent and/or,c49459eba9aa9ecdfef521f28238db8bbe0e3921,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
85,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with,76ecfde963edc5c5c6a0eeb6fc4c8a3e28420fc9,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
86,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"enrolling patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy",a71040b3a8b377cf20ea24365216ca338c38a6ea,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
87,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract.",fb9278c2791a54c475e36e439cc3e33ec9537dfc,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
88,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,840 patients with stage IB-IIIA NSCLC from 101 centres in 14 countries were randomly assigned to observation (n=433) or to 30 mg/m(2) vinorelbine plus 100 mg/m(2) cisplatin (n=,d30822da13e718c3273975bc1d5efb70ec9cd52c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
89,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"histopathologically diagnosed with undifferentiated or differentiated,",e2e958e3041d7e8b4b0f0715fd6b068113dbd303,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
90,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,A total of 2526 patients with stage,20b26158d7a0628d0b37c8b266cb526c76134c1b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
91,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,we randomly assigned patients with sentinel-node metastases detected,3463d51815e11d2c9977e70d51b8753dcabc12c1,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
92,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma",20a8ac2d2d7de84a786ae92ba2577331d911dc21,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
93,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence",c37659491a000415239367e1978caf776dc39280,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
94,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,patients with previously untreated metastatic renal cell carcinoma,d39b284e062de97f1ada89226d8b6168e2099764,False,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
95,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
96,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment,7ad600db6616635fc16a44ff62e3125d220e6c0e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
97,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC_",55ebd3b04a126fe1121ac652d0282f2a257f96f8,False,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
98,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation,2f0b234c6ef62442bf7acce140fa215447af0a7e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
99,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,Individuals aged 30 to 64 years with female sex,da09b4c276fe2322676bdbd8b37adbb00c70bf31,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
100,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Adults with rectal cancer that had been clinically staged as T2,f969a5a891673495161c9f5f7e376d6350d0ddbf,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
101,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Patients with previously untreated, stage III-IVB (",1b445e0a2831f1d8e8ffcf9964fc0ad3cae15294,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
102,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Randomization was stratified according to programmed death ligand 1 (PD,e7b6c4f52bcc307bc9ed05593e0b38ae5a3f5aa8,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,To evaluate the safety and efficacy of adjuvant girentuximab on,312c321bd5b8c4c52e1ab61e8a73cc6ff6014ac8,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
104,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible patients had pathological stage high-grade T1b,6822e7e9cdef0ffa3134eed0944d04b382e91bd0,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
105,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Randomisation was done via the minimisation method with biased-,2c2b486879566150e58b1377d31ae7971f6219a8,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
106,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
107,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"We conducted a phase 3, double-blind",fc3d4c2967ce694aaa180320370661673eb91c51,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
108,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"patients with advanced cancer, aged at least 18",994ffb7c194d2b0a1798216a5d30c4aa72ae22ff,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
109,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"locally advanced, unresectable, or metastatic cutaneous melanoma",40560de174934256c1341f83c94e1cc40eddd7ae,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
110,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"in patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease",493177c96434c0b68b8132d84e12d76eb974e196,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
111,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
112,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we enrolled adults aged 18 years or older with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction.,076c11304025f27e18daf7fb5b082e983e0f3670,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
113,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,386 participants who had had at least two,7a75b65b112895dc818d1db21dd487e4bf6059a1,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
114,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with squamous-cell carcinoma of the head and neck who,b2181e086b7a75dc8c7522280f687a16131d7a4a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
115,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we randomly assigned patients with unresectable stage IIIC or IV melanoma,9c74be094483dd16b5b51d18d71153ac0f52a093,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
116,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Patients with advanced, unresectable, American Joint Committee on Cancer stage",67adbb9742b225071eb18b5a7f2ca3aec3922ce5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
117,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,We compared letrozole with tamoxifen as adjuvant treatment,49168eb16df68e889387ece63de234cd5ebe6370,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
118,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible patients were aged 18-75,b7d3ab477e2281821eca96aa1c27369a3b79f353,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
119,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with palpable T1-T2 invasive breast cancer,cb8a20c15fe2c7f29c70bbdd83082bcecf3eb382,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
120,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"patients aged 18 years or older, with previously untreated, hist",d685b73a550ae1884ecdf14be67b0d1071a6a235,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
122,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with FIGO (International Federation of Gynecology and Obstetrics),898d0d9c4730a3a3b473d1b7c30432405e5269fa,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
123,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible patients were aged 18 years or older,b28b5f3ef72e5860a6d72add16b504b580daae25,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
124,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.",f01be5f907ffb3968529022574e3b780796c8912,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
125,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible patients were aged 18 years or older with recurrent low-,1a5d29608d27231c110464f71862e72dfe1be02a,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible adult participants (aged ≥18 years) had primary stage,595c13a7df2ba392d69037646fef21e6456a83ad,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
127,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients aged 18 to 70 years with re,04376809b47363de3a6796ccf12cba919a09baf9,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
128,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Participants were aged 18 years and older, had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",a2901e7a0e6ecc70978ec646a7e92e9bd0370ff6,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
129,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligible patients were aged 18-80 years,23a13725bade9e440e355e30fcc2bddbc3ecc72e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
130,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual,4e7c6aeeb2970456a0aee1c5d8e245d4ece8b380,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
131,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
132,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,patients with active rheumatoid arthritis despite methotrexate treatment who were,a29e135e0d7ae70a83d2afb8315d23773b59f466,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
133,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
134,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"we randomly assigned, in a 1:1 ratio,",d8aeb23400b810b4ec1f3a911af426ebf6dffc6b,False,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
136,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre.,a6faddd453e53720422bf2bb801ad8dfcd687277,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
137,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Because of the inaccessibility of mediastinal nodal metastases, the left",d71a6a19b62287a8c87044ba79468ee7ee91dca6,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,adults aged 18 years or older with histologically or,a7d1499c9ee0b79e19ec3fa8b4a3d394ad2407c5,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"523 patients with curable stage T2b,",0d51129c6fa571a99cf0d77fabed1c42749871f9,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
140,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
141,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area.",90b8b1ce26881f1a262c409c0be08f786debc092,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
142,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)",22ba5ffce0ae91fc338c92ab90641a6944ad8acb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
143,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,"Screening for its precursor, anal intraepithelial neoplasia",5beb370f7bca7917da96597bf3268e3493f960c0,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
144,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we randomly assigned patients with spinal cord compression caused by metastatic,090973cbdcc1cd84e5ba5c262556df3885ed3059,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
145,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"patients aged 18 years or older from 129 UK centres who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy.",d596171e05c1467d3cae8198a94cac5e82ad45a1,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
146,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States.,0b8a0885898b71126aa8a73937c694188bb6ff1c,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
147,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,To determine whether nab-paclitaxel improves the,fb9e76a7b49023b705e92a5d472b486aa84ce78e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
148,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
149,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly",c9186e1a53e7f758fef12ddb31fb25dd6368a34f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
150,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,we enrolled patients with a histologically proven superficial basal-cell carcinoma,3d9bef131d356c2d728d9fc8d0397676cc4e5712,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
151,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,"Patients aged 18 years or older, diagnosed with un",277803b484baf3002791db4f1f0b2df599ac5b0f,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
152,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We included chemotherapy-naive men (aged ≥18 years),26d9bdcdee233175800dde94e23b0b96b3d08f6b,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
153,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"patients with stage 0, I, and IIA breast cancer",39d54b7fda4846a420f13a6d7bddc9681a1f78cf,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
154,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Women older than 18 years with histologically confirmed HER,9d8c254694955e1e925281d78ba3e01f2fc0cb33,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
155,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
156,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery,497bfcf94eef00225dfe6be3ee39ac77b8c6b7a2,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
157,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"In this phase 3 trial, we enrolled patients with prostate cancer",eca0abaf59cb5f8c34cdf06773c50748825df0ac,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
158,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
159,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Randomisation was done in blocks stratified by International Neuroblastoma Staging System,82560fd0e57d6e14f4d1a81377b782ff356ab625,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
160,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy",05c2939dada0672749ec4cb4ea3d7457c7858303,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
161,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"Outcomes are poor in patients with HER2-negative, advanced gastric",8bf475c1883351d59b81ea8bf3a22e9637a1fcc8,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
162,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
163,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,we enrolled patients aged 18-70 years with operable,361aca067096fdcf9e4414bb4d9f147d84b0671e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
164,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Patients who have unresectable or metastatic melanoma with a BRAF V,7db3bf36cf3fd002728a008b97171b9465cb5fc7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
165,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"adult patients (aged ≥18 years) with advanced, progressive,",9d627e5b828a1e9487d0d3a1144093e73f7a24cc,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane,ba494453b87af5027c59b2f08eaff54dadac5a1f,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
167,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,We aimed to assess ipilimumab as adjuvant therapy for patients,ebddf69df90f6bd0b69c8c8975852fa1fa885f48,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
168,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"HR-positive, HER2-negative advanced breast cancer who had received",3769f3d3d40d3900152c84e1040dba5f1f6577a7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
169,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We enrolled female patients with HER2-overexpressing metastatic breast,096983cb493d121b856dc5f92d825c9cb763b6ff,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
170,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,we screened 3100 first-degree relatives of,ff93519f9209262eea30b0db94a7a9622ad14b32,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
171,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Suppression of ovarian estrogen production reduces the recurrence of hormone-,a92a02769fe8cbe2ee204656c4a9ca440c9ad9a0,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
173,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,To assess whether stereotactic body radiotherapy on a single tumor,b4fc1f94e39fb209e6368c90d1dc68f2cdbd7cbb,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
174,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,170 432,36aa4528777ba80b6853a2d08b496fb35f52e88f,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
175,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,locally advanced or metastatic non-small-cell lung cancer,6e24b1c3586fff2364349bb1c8e959a166d8299d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
176,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,From 1993 through 2001,19cb282f719974dd500ab898c016c19933530b16,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
177,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,in patients with stage III or IVA endometrial carcinoma.,48f3743584d803d62172a9a128422d891fd91513,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
178,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,aimed to demonstrate the efficacy of ivosidenib (AG,22339d0519bf4bd384730f1543379a2775a467e6,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
179,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Patients (age 1-20 years) with neuroblastoma,6b1897a7f2285c40aada0282dd21cdc4cc355d99,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,had previously untreated recurrent or metastatic nasopharyngeal carcinoma.,f624bba9f68f856f6bf4d587b8f050ae9b066143,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
182,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,we randomly assigned patients with stage IV or recurrent NS,609c513140e211273fe2852df5ae9ed386974508,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
183,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer,f33d8d6555d1c7356f81cb353a4c7a81669df708,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
184,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer,823f122356f8f86a5e76455b661c9dd507b9fb64,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
185,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible participants aged 1-18 years with newly diagnosed cancer,cc1aeb9962f648a43797bb2c25cb0194b75ca5cc,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
186,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
187,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,stage III or stage IV disease and no distant metastases,4e125bf1bdb004c65a01c2857ead93a7069be002,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
188,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes,45a629579ffe04604931a5af649703de002388f9,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
189,gemini,gemini-3-flash-preview,evidence_required,1,NEITHER,primary prevention of breast cancer,a4273a11d881b39d97e17b7c3e3d320c0e8f3224,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
190,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,"ABCSG-12 is a randomised, controlled, open-",9a38a31f44246f309db4fb72f28ebdf01289eb5b,False,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
191,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
192,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,"hormone receptor (HR)-positive, human epidermal growth factor",c2593e947af909435f318d451fd8c2ffaf328ceb,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
193,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,Eligible patients were adults (aged 18 years or older,c7638d6d44df055338c1b1d50449c811d0b38a1d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
194,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,"Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions, Eastern Cooperative Oncology Group score of 0-1, and a life expectancy of at least 6 months were eligible.",a2bb26ee3f4690b802f9ac765f68896bb4dff919,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
195,gemini,gemini-3-flash-preview,evidence_required,1,BOTH,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung,fc43a5e41e52c882b1483b7240e1d1e78c9226d5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
196,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination.,b115d94518768d5f9b795d5db83ebfc4ffac9bc6,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
197,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,Patients aged 18 years and older with metastatic soft-tissue sarcomas,5aa95ecda2edcb243e6f1061f50ba6de22c5831e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
198,gemini,gemini-3-flash-preview,evidence_required,1,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal,398671c8395e086ccd4ecafa5bd50584792142bb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
199,gemini,gemini-3-flash-preview,evidence_required,1,METASTATIC,patients with metastatic castration-resistant prostate cancer that progressed after docetaxel chemotherapy,c6cab3e89f16f961f2900cb7b4a7282338f4772f,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
0,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual),7797aa481fbba7100152347a5a0e1f99810e5bec,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
0,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,We randomly assigned patients with resectable NSCLC (,1e7a5cd362035f4f5429e42105ce3ed3e1b231ef,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
1,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma,aa5907779d1e8cda3850878a7a3f4fe2aa54d877,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
1,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma with prespecified,23b5382dff493f59f8b3ff4abbf314ce9cd3c554,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
2,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we aimed to compare overall survival in patients with advanced or metastatic soft,a79b53593cb622fc42459ab021b914997ac73f1b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
2,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,advanced or metastatic soft-tissue sarcoma,d28b1db6a124af08f9f65e1287ad6406871299d6,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
3,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned,3d24cd87c74831431b75447b0066652f058d4220,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
4,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,those who had centrally located squamous cell carcinoma with cavitary features or brain,4581332fa356182fdbc4195f9070caae09c4ea6d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
4,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Those aged 18 to 75 years who had histologically,7e6f4965d61ebc7a17987656d8405f84d8d9940c,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive,3813f30a61e6d1b5ded36f69628e5b79a499b9b0,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.,095a4141eb262225a4f7a27dacfdcec099af798c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
6,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Localised prostate cancer is commonly treated with external beam radiotherapy and moderate,93a011d4fea905c8f60e6d5512d87f998750d89e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,Exclusion criteria were previous bilateral oophorectomy or ovarian,738b55450f305ebb6083f9550ce0d793bb275d13,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,we recruited postmenopausal women aged 50-74,59d5840f3d20e6313613f827e1c12ea5e2c935b2,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,"To be eligible, women had to be at increased risk",ac66b1d521e8833f031f86a6dd82ebc6ba84b8dd,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,"To be eligible, women had to be at increased risk of breast cancer (judged on the",55a8a024f7f97542e151b1a1c2b737ce68e77d3e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
9,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma",f7c8ae218aa2a3d30f7332ef5fdf9e777dc7d8dc,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
9,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we recruited patients aged 18 years or older with metastatic,a81509646c8882f451e1fe85afb33f3be7106fc8,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
10,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We randomly assigned patients with node-positive or high,0d9f305f39383eeeb0789757b5cdbfe46a699388,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
10,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,We randomly assigned patients with node-positive or high-risk,fe01e176a79eb80fa42b300d83c062bdbdd059df,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
11,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Patients aged at least 18 years with previously untreated locally advanced,cde1af8589fd6ba5273725bb157dfa624de203bd,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
11,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Patients aged at least 18 years with previously untreated locally,23e036c902cf8e826e0acd329388acb68302024a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
12,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fall",8d6b94d99d7c72ba2c479af281af6ba00d1688b5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
12,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Participants were patients with persistent or recurrent epithelial ovarian, fallopian",18e442bb43b46dc8a35c42b80664679eec4279ab,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
13,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,5102 patients with HER2-positive early breast cancer.,eabc2e51526a815b77f818267896a16616d06cf0,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
13,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,5102 patients with HER2-positive early breast cancer,42e034cabf2625e843f4f5548b2fb5d4b396f648,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
14,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,had stage I-III histologically proven and operable invasive hormone receptor,5b9ee52e251a53719de81e76e6283f55f756ae9a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
14,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Women were eligible if they were postmenopausal at the time of study entry, had stage I–III histologically proven and operable invasive hormone receptor-positive breast cancer",f78986d9d995a6349bf6385f91103c1ec9f72ebb,False,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
15,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Patients with HER2-positive, operable, locally advanced or inflammatory",6e1ad67f3e8d33499c3aee0e947d1036f7910da9,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
15,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Patients with HER2-positive, operable, locally",451810189a8afd011ecb26957b5e40f83d318b3f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
16,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserv",d9f2000319ca8edc336fc183aa58fd79474e418c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
17,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive, non-",a9a8a95023ba41ec615f3ec51e32d13452d31dc3,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
17,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast",c6bec3db773bc407f94951fa1e0122a502885747,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
18,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,healthy women older than 25 years,7cef698a40287e43633ef9741ddf42790931b86d,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
18,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,we randomly assigned healthy women older than 25 years to the,0eaa7f7eb7b9a0da076a2780133e5c1c1ba96962,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
19,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were adult women (aged ≥18 years),2dbeb45f15bcd82c3ca10830cb32ecf4fbb2a77e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
19,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Eligible patients were adult women (aged ≥18 years,dfea16ed826e19dac78d07a31edc2219984a297d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
20,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"unresectable, advanced or recurrent gastric or gastro-",9449cdb90017a665fadd57f7ea091b7ed26d7cc1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
21,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,EGFR mutation-positive advanced non-small-cell lung cancer (NS,348874b7e6cb6409db9ed53570887eae49945c9e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
21,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,patients with EGFR mutation-positive advanced non-small-cell,88eda38c0440f60021fb60ea45b35be12abd8873,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"870 patients with completely resected, stage III melanoma",bbfc1945313c370d67dbb5064c7f106fba34aad9,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
22,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"we randomly assigned 870 patients with completely resected, stage III melanoma",a1f2d33b3461ec586aa3319b5e73a66e74762328,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
23,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,140 patients with early breast cancer were randomly assigned,bff69170118c768e1eb092596381a3c543eed253,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
23,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,140 patients with early breast cancer were randomly assigned in,1045ea51473e1e2d16f116337a94d1f3a847e398,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
24,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"platinum-sensitive, recurrent ovarian cancer",7ad89581d28ad793e39d5ef1c9e62c2301831dae,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
24,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"platinum-sensitive, recurrent ovarian cancer",7ad89581d28ad793e39d5ef1c9e62c2301831dae,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
25,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Barcelona Clinic Liver Cancer stage B or C disease,c7301b6296b7bdbecfa1ac7e161014afb25491ea,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
25,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Barcelona Clinic Liver Cancer stage B or C disease,c7301b6296b7bdbecfa1ac7e161014afb25491ea,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
26,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,women aged 25-60 years were randomly,db0840a6e37e9843a6bd17f88296e0b065d5371e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
26,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,women aged 25-60 years were randomly assigned,ef016a5eb2328ee48078573c31cefca9d5af9dac,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
27,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Patients (aged 18-80 years) with c,633fc721ee59354ce34b0b441df21f9c7e1d9b72,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
27,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Patients (aged 18–80 years) with,ba6d099e0776ae7cd32407214c97da244e5284cd,False,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
28,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Treatment for patients with recurrent ovarian cancer has been mainly based on systemic,031f346bf2e9264b9cc4ace4eeac064ef24ce5e4,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
28,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"In women with recurrent ovarian cancer, cytoreductive surgery followed",73e898b83cfa288d872a43058d829bdc1d900dff,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
29,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,measurable or evaluable high-grade serous or endometrioid platinum,09a95fb0b5814bd0f5b34484fa4d5af4d5282854,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
30,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,1500 women with axillary node-positive or high-risk node-negative breast cancer,bcdd56e17d1a840c3afc168e772f2dc8dca708c5,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
30,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,1500 women with axillary node-positive or high-risk node-negative breast cancer,bcdd56e17d1a840c3afc168e772f2dc8dca708c5,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
31,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,A total of 424 survivors of stages 0 to,f34262a2a6d0fc80549a96fa819958009ad653ef,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
31,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,A total of 424 survivors of stages 0 to,f34262a2a6d0fc80549a96fa819958009ad653ef,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
32,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,The drug may have efficacy in patients with HER2-positive advanced gastric,b62e995489b9d85619a85cb51b2f3cd258d41728,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
32,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,The drug may have efficacy in patients with HER2-positive advanced,82b0862578382b2e6a677e64e71e3d1d652f1c0a,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
33,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,we randomly assigned 127 patients with dysplastic,3be1d7bf864e2fc4676bc7a4f1695a44bf1e90c5,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
33,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,we randomly assigned 127 patients with dys,c7143d240a5f8bb67b5a041bc0a20510cd1902d8,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
34,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were premenopausal women aged 18-59 years,5f840835219fab2ba5517b0ca1e10975f184285b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
34,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,premenopausal women aged 18-59 years who,b0f9323691c3a9c9ced7599c6f4d0ac31cf0edb3,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
35,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,recurrent or metastatic squamous-cell carcinoma of the head and neck,36052cc4a9b1e356b0b0f8617f6d0b79df84ea9f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
35,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,patients with recurrent or metastatic squamous-cell carcinoma of the head and neck,fbe1abd1d2d29c459ac519e0ebf66154064c91bf,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
36,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned",bef7dc4daef6dba31ca7cb28ef2c7402a9b0617e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
36,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Patients with chemotherapy-naive, stage IIIB or IV,",49952265bb8cd55fb837d23553d346a6072504fb,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
37,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,histologically or cytologically confirmed advanced non-small-cell lung cancer,25e69c709826bca84b2a20a3de52d1e666cec5d8,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
37,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,histologically or cytologically confirmed advanced non-small-,acc11f99279dad3ee4be15d5e418360b8bd91281,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
38,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma",4dccde99f317d5f36d314601c66701d8accae702,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
38,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"Eligible patients were male, aged 18 years or",1ef9b288ad7281068aca1f77c1b337fa569b9ea1,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
39,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable,60a1dbde588b70a3406119fae83d54be29cbeb76,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
39,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma,44c4c1fa6eb8791e09c71900f02c27af6980f4cf,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
40,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"we assigned 615 patients with locoregional, high",d05f59ff3e74720ef323d38196d4b51e50a5f85c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
40,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients with locoregional renal-cell carcinoma at high risk for,337060494b3da572159260da07c18886e95ea387,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
41,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Standard first-line regimens for patients with metastatic gastroes,ffcc32a8347280ddf65b415bdb0b315d7e6f9fb5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
41,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Standard first-line regimens for patients with metastatic gastroesophageal aden,2856b243479961f0815a43f20b00bf9a77d2cf0a,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
42,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627),b1c09b3e60339f032a3371c9409dd5cba859d47c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
42,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,1256 patients with resected stage III,a75e6175509c8dd0fc4c56efdb8cb1dddffd3cf9,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
43,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer and who had chosen surgery as their treatment approach,6c7bbb749c23a76c07155510f2a35c4213821cd1,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
43,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer,59a3763c94c3f0cac7eec1001ce3b4f98d515821,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
44,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,We assessed the effects of combined docetaxel and estram,c8e934911aeca9b9e480fa44876037aaa2280a78,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
45,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated (1 to 1) by minimisation to receive interferon alfa-2a alone or combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil.",7d0ba771cb0ab2735f66a46a3304a322d427e97e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
45,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated,02d496a2dd8422ce71898eb8c05bed6bc7046068,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
46,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer,45921d9ab9b48290b5485d58823453be5f06f07f,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
46,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer,45921d9ab9b48290b5485d58823453be5f06f07f,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
47,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer.,8066acb22185685f4794b84d85bf2c95a2903b69,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
47,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,We compared the efficacy and safety of a modified FOLF,b3927e0854918b0a338783c432c575a4a0316266,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
48,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,patients with previously treated metastatic breast cancer,d4d34620582aba440ad57f1a5e1e98bf67366997,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
48,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,patients with previously treated metastatic breast cancer,d4d34620582aba440ad57f1a5e1e98bf67366997,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
49,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"women with hormone-receptor-positive, human epidermal growth factor",1fefeee94fff14fedea59c1d1daa40937bb2aa3a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
49,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"We performed a prospective trial involving 10,2",36dc612e72f7b6642735a1b3657f79aff5cbb3fd,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
50,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we enrolled patients with stage IIIB or IV adenocarcinoma Identification of early cognitive,0cbe1864804f75d076b7d18fedb85eda7d506bd9,False,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
50,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,we enrolled patients with stage IIIB or IV adenocarcinoma,0825e4d60d1fa4f662bb55c1140ae89e2cce2319,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
51,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,premenopausal or perimenopausal patients with advanced hormone-receptor-,049b5abfa1eed87e9fb026687850e573d2168a76,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
51,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"advanced hormone-receptor-positive, human epidermal growth factor receptor",75062dc8fd420b4d90a15aa24dff341a910eba27,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
52,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,"The study involved 182,160",bee76e7dd23507023629b0faf13a418cb8473c6e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
52,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,"The study involved 182,160 men",e1b8695b6a884d1566963916899ec18bbb17ee5f,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
53,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,adjuvant chemotherapy for operable node-positive breast cancer,d831e475033b14ff9450885da9a3f45addd83004,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
54,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC that was not,62cba847b8421fdd30417995a4a9eb46c5a63b9f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
54,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy.,c02ea06c108110323e6de9212ef4743b789afcb7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
55,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,"In the Prostate Cancer Prevention Trial (PCPT), fin",3b1957189f5b5c63db37365865a862948ef64fdc,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
56,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,One hundred twenty-one participants were assigned 5 mg,26caef53683d157edf9fcc2c68943199fd491164,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
56,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Two hundred forty-two participants with intact erectile function scheduled,3dee2c7e99d97c4cf6b2b63ca5346d1cb43aab6a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
57,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,enrolled 160 patients with radiologically confirmed painful bone metastases,bf827c4b70a3b2c7f466645b23a47ece3ad69f79,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
57,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,enrolled 160 patients with radiologically confirmed painful bone metastases,bf827c4b70a3b2c7f466645b23a47ece3ad69f79,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
58,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, who had received one or two previous systemic treatments for metastatic disease, had progression on their most recent therapy, and had previous treatment with an anthracycline or taxane were eligible.",4ffb2b75b7f3fcb5a5ec2fac9e64baf94e3ddbb7,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
58,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"Patients aged 18 years or older, with centrally confirmed metastatic",aeac996b0170dccfbce94c605f0f19e81cdca24e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
59,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"JACOB was a double-blind, placebo-controlled, randomised",c4d2076bc961d1dbba572c7d107e0d77ee3c54e5,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
59,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"JACOB was a double-blind, placebo-",1fec106e597c3c46d31570a9458f9b9148f63586,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
60,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,premenopausal and postmenopausal women 35-70 years,2c1d320253967327999c0d9d34009f5dcc608090,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
60,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,premenopausal and postmenopausal women 35-70 years,2c1d320253967327999c0d9d34009f5dcc608090,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
61,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,Eligible patients were aged 55 years or older and regarded by,d0b5f3c51c4302faefbc5466e38de05cf087b53d,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
61,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,recruited patients with symptoms suggestive of colorectal cancer from 21 UK,e373e54cd03db423f059cb189450a0f0a0c0a239,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
62,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Eligible participants were aged 18 year or older with hist,17ac88b62929c763b814fad909cd05cef8dd3b7b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
62,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Eligible participants were aged 18 year or older with hist,17ac88b62929c763b814fad909cd05cef8dd3b7b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
63,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible participants were adults aged 18-75 years,a284feb82a6e5df208e4e25d38860653ef9b572f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
63,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Eligible participants were adults aged 18-75 years with locally advanced or metastatic NSCLC得以进行研究。,a536d5e43edc1db6d8db663123a55d26032a987b,False,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
64,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,patients with advanced renal cell carcinoma and no previous systemic therapy,27873bec3229f421e7a00bd2e3a69d89aa463abb,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
65,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,these patients included infants (<365 days of age),c1bc8450180527177e16dffc91a606f3e34723b5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
66,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer",540a6dbd666afb7ee6d0b7e5b7f3da7b959389ca,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
66,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment",92b54c29dfeb350fb3e61b31231bb4b6ae50a08e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
67,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV6",946ae7f2594fcb5b1278330be651f5a678f112bd,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
68,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Randomisation was stratified by geographical region, macrovascular portal vein",03653e98b86887295aff242004de9437be76371e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
68,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Randomisation was stratified by geographical region, macrovascular portal vein invasion or",7f5f22b05df9837265308749b355f87d10b2585c,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma,cf0305d73607fee89ad537787a8bab73a002e622,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
69,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,we randomly assigned previously untreated patients in East Asia who had advanced pulmonary,7917ea945add31fa3a11074806f3e212c8151eea,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
70,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"Randomization was stratified based on site of metastasis (visceral,",7e5d8909a7017653bee2a7ee71c3a15fbfd4ef5a,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
70,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Randomization was stratified based on site of metastasis (visceral,2385b6398f7f157a111dd6680aac3092b7e60415,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
71,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligible patients were aged 18 years or older,b28b5f3ef72e5860a6d72add16b504b580daae25,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
71,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
72,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We randomly assigned 870 patients who had,c087e6adf70564ed78e85a3b8b4bd44da92976fa,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
72,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients who had resected stage III melanoma with BRAF,fb35ca6c38f7c2adad2bcd51d1da7a909751edbe,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
73,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,enrolled patients with T1-T2N0-2 p,262ec6c5f79c5e808237988ff2527f805e3a822d,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
73,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,enrolled patients with T1-T2N0-2 p,262ec6c5f79c5e808237988ff2527f805e3a822d,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
74,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited,0298c4ebd14147a2c51e15d5aff9edd861061538,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
74,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited,0298c4ebd14147a2c51e15d5aff9edd861061538,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
75,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We randomly assigned 229 patients who had well-d,1462f338ecc30763fd3431c80fc0190797dc70ed,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
75,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors",705c0db343db93f7def5ac17051a9587b6be6529,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
76,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,5999 participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings.,fdf44af83ac37b872df2156a1683d452a28f959b,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
76,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,5999 participants aged 50,0ab850d62bc4237aa3148aca192f902456682e7c,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
77,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Participants (N = 51,61f06ef6bac554a46a5f00d4abffc19f1d2c1712,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
77,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,25ecd584e5b4a56896c4eee319b874a2c1548069,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
78,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we randomly assigned patients (in a 1:,369a3f45bdc861652167bf352a26c33bb5d79f80,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
78,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we randomly assigned patients (in a 1:1,f740974ade697b1863f08214abf1418a96f14857,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
79,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,patients with clear-cell renal-cell carcinoma who were at,7cf20d92d8928d6e30e1ec5ae287cbdca90b369c,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
79,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,patients with clear-cell renal-cell carcinoma who were at high risk,35163ceeb4e89de03fa27cdb88023b6a841f9646,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
80,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,patients with metastatic castration-resistant prostate cancer,059b16131770d5c692e8fbdf168f4aa81d9dc888,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
80,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment,9cc321336738a035abca85558916448bb1b64de9,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
81,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
81,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter,160152c25a7ab010da6980b7b21b6fc4632b87bf,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
82,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we randomly assigned patients 2:1 with untreated locally,8079d97beae8060155533989d3d3726a60c33f51,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
82,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,untreated locally recurrent inoperable or metastatic triple-negative breast cancer,4e05d39ea4883688eba77cc5809eb230ee88e5f7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
83,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,resectable cancer of the middle or lower third of the,190bb51d091ddf505ffd61ceb9c88fb72b981d8e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
83,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients 18 to 75 years of age with resectable cancer of the middle or lower third of the esophagus.,f048ddcaac4f282de7afb4ad6a448fc464bf0a99,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
84,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,479 women with previously untreated recurrent and/,0cedd55c3811d422b46c2dab0f7e7ebf1981afdc,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
84,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,479 women with previously untreated recurrent and/or metastatic,2226e937fed5ddd3e88c6f24dc023700bf0801a6,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
85,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C,91cec28e5c907eadc7e24c39b2db70269724b18c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
85,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C,91cec28e5c907eadc7e24c39b2db70269724b18c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
86,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,enrolling patients with at least one risk factor (pathological T-,7e6ba65017b6c90e6c2931815880c17bf5ef6c9b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
86,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"enrolling patients with at least one risk factor (pathological T-stage 3 or 4,",4b67d31ef8e2fde90f9f38b233a9633bf6689102,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
87,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"eligible patients had histologically confirmed, radiologically evident m",dd3f5f5c565e58432614d0545d1f48c97eb4c484,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
87,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract.",fb9278c2791a54c475e36e439cc3e33ec9537dfc,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
88,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,840 patients with stage IB-IIIA,cdfd7938c0cc30be00207ffcf82937e6b0bf3774,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
88,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,840 patients with stage IB-IIIA,cdfd7938c0cc30be00207ffcf82937e6b0bf3774,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
89,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We included patients aged 18-70 years,42223a5169601e31b3b579efe907b53d7a9a9022,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
89,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"locally recurrent NPC with tumours confined to the nasopharyngeal cavity,",a5c9e7d28d571be01c5adcfb942e90448b603d72,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
90,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"The effect of celecoxib, a COX-2 inhibitor",1abc6df0543ac6e981b88bd38d610198d6d70240,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
90,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"The effect of celecoxib, a COX-2 inhibitor",1abc6df0543ac6e981b88bd38d610198d6d70240,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
91,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,we randomly assigned patients with sentinel-node metastases detected by means,61e24361e4c7ec4f64426c09f89bd25dd42bd2d8,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
91,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,we randomly assigned patients with sentinel-node metastases detected by,2cbc1c4a696135b5344dc97d8dbb5130112cc660,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
92,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients (aged ≥18 years) had histologically confirmed epithelial,34c908724525f37f42c1be4643ac9c9d7f5c5d0b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
93,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,adult patients (aged ≥18 years) who had,f6aa31ea2b90aaf4da8a35d9fd40961ca5b37e3d,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
94,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,first-line metastatic renal cell carcinoma.,0b5e34470c16e4afaf2664de39af21c77e24db66,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
94,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,atezolizumab plus bevacizumab versus sunitinib in first-line metastatic renal cell carcinoma.,e762e14aa0fb56fe8d26f169b60276dce548894c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
95,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
95,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
96,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer that had,6ca3c9a52c2fba93cd925fe3e4d0d6084444d369,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
96,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,men with radiographically documented metastatic castration-resistant prostate cancer,5d5155847f5bd926214d2cd5e8b09aeba15723f7,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
97,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC",0b402dc18bfbf2b3abe6d6e47c3cc9b7ada85791,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
97,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC",0b402dc18bfbf2b3abe6d6e47c3cc9b7ada85791,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
98,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we randomly assigned 322 patients who had,3f575d57cc42c6c0e42de469da84e441c6bdf9f1,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
99,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,Individuals aged 30 to 64 years with female sex,da09b4c276fe2322676bdbd8b37adbb00c70bf31,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
99,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,Individuals aged 30 to 64 years with,0b4c5b075968aa016dcec5b53062569a82188949,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
100,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.",2bb4c508e081004e847881868ce95d43864f22fb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
100,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.",2bb4c508e081004e847881868ce95d43864f22fb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
101,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Patients with previously untreated, stage III-IVB (except",a7cae986e82c256071b923884e51d3404c48fc39,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
101,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Patients with previously untreated, stage III-IVB",bc344dd2fccfb636492f974a73e3a5d217092800,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
102,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Randomization was stratified according to programmed death ligand 1 (,8a40c19e0ebbc18ea1de4b1f51539a0d4e4816e8,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,To evaluate the safety and efficacy of adjuvant girent,1bae6dfffc0a5aa56bcf89719679c495566ee48e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Eligible adult patients had undergone partial or radical nephrectomy,c34b599e310ea2a740b14a182df17c7e7f0c245b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
104,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Eligible patients had pathological stage high-grade T1,9fb978dfc17f2da9acb25f70d7320adc3fa07af6,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
104,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma,fa08345d653fe100e478be37169783281485351b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
105,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,disease stage at enrolment,9a136c4b28b0ceaa6ee70aa995398e0884fd436f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
105,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Randomisation was done via the minimisation method with biased-coin,c0345caf4e1b4a1d526b92ece50a5313687772f8,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
106,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
106,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
107,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"We conducted a phase 3, double-blind,",169cf34b3f7bafd0e11860f5f47691a003d05b58,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
107,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"We conducted a phase 3, double-blind,",169cf34b3f7bafd0e11860f5f47691a003d05b58,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
108,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"patients with advanced cancer, aged at least 18 years",d58f8bbe597f8dc117a48218e33ea3388f99fcf5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
108,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"patients with advanced cancer, aged at least 18",994ffb7c194d2b0a1798216a5d30c4aa72ae22ff,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
109,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were aged at least 18 years with histologically,af5270228efa0020a5244874017f8a54e66ed6ec,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
109,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"locally advanced, unresectable, or metastatic cutaneous melanoma",40560de174934256c1341f83c94e1cc40eddd7ae,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
110,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"in patients with histologically proven, HER2-positive metastatic",85ab1998a3dd73a68e6a7d0c04d53765d53fa707,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
110,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"in patients with histologically proven, HER2-positive metastatic breast cancer",9f34a4e281d85a1a18b56d2da1cb165df7dd713b,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
111,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
111,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.,271c2d9f63fff90efc8728cb816095315591e6e1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
112,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction,13a237312af3eebf8e1b4c49da4f1658b1899b21,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
112,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,enrolled adults aged 18 years or older with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction.,7dc65b0e848bd37b186397eec9230c3027f55412,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
113,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,386 participants who had had at least two nonmel,6cbf02402571542ac7b4847238bde8b18e3dd86c,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
113,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,386 participants who had had at least two non,922e0a80b0251760a4052417d678a80e5decd772,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
114,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,squamous-cell carcinoma of the head and neck who have advanced,7e07421875264cc5a0d9db8c2f41e978f3d4b339,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
115,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we randomly assigned patients with unresectable stage IIIC or IV melanoma,9c74be094483dd16b5b51d18d71153ac0f52a093,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
115,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,we randomly assigned patients with unresectable stage IIIC or IV,b1c133813cb9787f08c732ca7c20951529b4bb51,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
116,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma",4e9d1b2e87d328e571dc9c7e55c1d887aef3d569,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
116,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma",4e9d1b2e87d328e571dc9c7e55c1d887aef3d569,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
117,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.,1e5a0d07bcab51fdb16ae60707f07703b41de616,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
117,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,postmenopausal women with early breast cancer,90a9744ff44d78efb1add493d765580a9eef470c,False,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
118,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease",956a14b0bd45bfc6a8f74ce071549a2f12f5e735,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
118,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Eligible patients were aged 18-75 years,c1b78c0d232a322c7a79bb845f5c6dcd3753ce3e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
119,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,patients with palpable T1-T2 invasive breast cancer were,54eee157e1069fe29b4ba528c0234c145de7bcb5,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
119,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients with palpable T1-T2 invasive breast,e4d6156c46b5b389125577e483203b3b76dacb98,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
120,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"unresectable, locally advanced or metastatic triple-negative breast cancer",12be568af4ded2ccd5fb071fbf2267ce4d701476,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
120,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"patients aged 18 years or older, with previously",bb0df9e6d8e77371d73825ff2f6bcb0b8d53d8e2,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
122,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized 1:1:1 to receive adjuvant RT, CCRT, or SCRT.",8957dd67add6f88a78128c6347bf1d0e6a996aa8,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
122,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized 1:1:1 to receive adjuvant RT, CCRT, or SCRT.",8957dd67add6f88a78128c6347bf1d0e6a996aa8,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
123,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma",d57a0e70cd847b04f4eb56ebbf449fa9bc55841a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
123,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma",d57a0e70cd847b04f4eb56ebbf449fa9bc55841a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
124,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Adults (aged ≥18 years) with locally advanced soft,54cb968a582ec2f6d436ae26bbcc2945897fc24d,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
124,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.",f01be5f907ffb3968529022574e3b780796c8912,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
125,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were aged 18 years or older with recurrent,f47b1abdd2067378584524abae6842ee42ceb742,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible adult participants (aged ≥18 years) had primary stage,595c13a7df2ba392d69037646fef21e6456a83ad,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
126,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Eligible adult participants (aged ≥18 years) had primary stage,595c13a7df2ba392d69037646fef21e6456a83ad,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
127,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients aged 18 to 70 years,ad57000091ba176064dc3bbafea94a6b4c114346,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
128,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Participants were aged 18 years and older, had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",a2901e7a0e6ecc70978ec646a7e92e9bd0370ff6,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
128,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer",ddbb59f329d0519e114ab00542bc0c308ab849a7,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
129,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
130,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal,066f5c9c3300f35dd46935fcd44d8a38c86fdf4d,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
130,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal,066f5c9c3300f35dd46935fcd44d8a38c86fdf4d,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
131,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
131,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
132,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,involving patients with active rheumatoid arthritis despite methotrexate treatment who were 5,49262def5e6886a8fa32d521d5ea0aacb848b69e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
132,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,involving patients with active rheumatoid arthritis despite methotrexate treatment who were 5,49262def5e6886a8fa32d521d5ea0aacb848b69e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
133,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.,de6ab41b9a72e031f23e734d3b3eec4e3d6f64da,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
133,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligible patients were aged 18-80 years with stage,f0d23247e554045b99e8c13fceb2e4f7f71a937b,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
134,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we compared first-line nivolumab with chemotherapy in patients with,70e2550ff9ca1377d8e25401fe280185cda030d7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
134,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,patients with untreated stage IV or recurrent NSCLC,0c85b8487b0acb5a3977724399f64a26805c26c5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
135,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,both groups were also comparable in their first remission status at study entry (,cea7f11537876b871f139b544830915c388874fd,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
135,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,both groups were also comparable in their first remission status at study entry,ba5189ccae8d8069f39157c1d82686bc1bc47ea2,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
136,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,All patients starting adjuvant or neoadjuvant chemotherapy for early stage,32e9e9a87b5ee72a0c8df16600d68bf5af27c5db,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
136,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,adjuvant or neoadjuvant chemotherapy for early stage breast cancer,1ecaa8b535b85180464b3997ee1542bb1814f020,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
137,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Because of the inaccessibility of mediastinal nodal metastases,",64fbfd8c4faf805467bfe23731fcd47f1773672c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
137,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Because of the inaccessibility of mediastinal nodal metastases, the left",d71a6a19b62287a8c87044ba79468ee7ee91dca6,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Regorafenib confers an overall survival benefit in patients,470fe82309cad8ea3657e18086e7b2452dbcbb5f,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Regorafenib confers an overall survival benefit in patients with refractory,653f3c3078b6d2936838bd8ef9c448128d4c5ea9,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"523 patients with curable stage T2b,",0d51129c6fa571a99cf0d77fabed1c42749871f9,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
140,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
140,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.",32be2eebc0a9c19551555f1b28d74de10592d571,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
141,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression,187b46812f1d8adc55b45569e5fa26ef2e61a69a,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
141,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Eligible patients (n =,8556bb1cf71a95201f654710b9555f594a96da09,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
142,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0) and primary tumor larger than 2 cm",d324a09f85840d997b19ae0ef62132b034505322,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
142,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Asian patients with ERBB2-positive early or,736e81f2e407b49a588edd767227dad3e0e21a66,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
143,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,"Screening for its precursor, anal intraepithelial neoplasia (",4b1baf3f25eaf60158587f8cf2b8458e12e9a331,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
143,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Patients with histologically confirmed AIN were randomly assigned to receive either,89ee4ab56f1c5a83eb85bafebc781462ebfa93a7,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
144,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we randomly assigned patients with spinal cord compression caused by metastatic cancer to either surgery followed by radiotherapy,fd3dfc0dc6b97db075ea14265678448bd50a1b62,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
144,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we randomly assigned patients with spinal cord compression caused by metastatic,090973cbdcc1cd84e5ba5c262556df3885ed3059,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
145,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"enrolled patients aged 18 years or older from 129 UK centres who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy.",ddf7b949c332b2defeb48a223ad7a46d43b73d09,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
145,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"node-positive or high-risk node-negative operable breast cancer, had undergone complete excision",ffd4733d5e788c755802230a867239a8c8c5f4fb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
146,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older,f0986623f747b44a8a974f8d0a311f6cb9100fd4,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
146,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States.,69ba34b09a80f9f8d9b1da2620a0ac6d68b55e6d,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
147,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.,69b842dffdbffa24b7350f9d02f2376643d86b1b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
147,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,To determine whether nab-paclitaxel improves the outcomes,01a27b38a2f4c1f74ebff981013cdee97c60e999,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
148,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
148,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.,52cc3c52a9f573991c377f9593364e426cf861d2,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
149,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly recurrent soft",c0b393e9bc2c8efbf533f7ccaffdad99a43d2d74,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
149,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.",5dd83413e5cf0f338a57224082e25970f5d5aa27,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
150,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,we enrolled patients with a histologically proven superficial basal-,3fe0776db64f2a719a850ce9731a9669b088a680,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
150,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,we enrolled patients with a histologically proven superficial basal-,3fe0776db64f2a719a850ce9731a9669b088a680,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
151,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,diagnosed with unprovoked venous thromboembolism (,8b39079668fe1d794b1853c338d77ba0411b4c66,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
151,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,"Patients aged 18 years or older, diagnosed with",2bb9f5785ee3151b1ed43c628b64875409bbbece,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
152,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We included chemotherapy-naive men (aged ≥1,8c4ea9ef2d124f4b7266b8bd801ec7e0b8ec5321,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
152,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,We included chemotherapy-naive men (aged ≥18 years),26d9bdcdee233175800dde94e23b0b96b3d08f6b,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
153,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,accelerated partial breast irradiation (APBI) for patients with stage,8567b1680eabdb7fe7532d59c8a8f51caf8906e4,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
153,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,accelerated partial breast irradiation (APBI) for patients with stage,8567b1680eabdb7fe7532d59c8a8f51caf8906e4,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
154,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Women older than 18 years with histologically confirmed HER,9d8c254694955e1e925281d78ba3e01f2fc0cb33,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
154,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Women older than 18 years with histologically,bac4769ee263e3a852a26081491097451333de10,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
155,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
155,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer,8181c9da031d7b7cd80f17e377d1bcb05f7af4e5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
156,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical,7c938534564b931449ed7d031cfb787a89e0b3d2,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
156,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery,497bfcf94eef00225dfe6be3ee39ac77b8c6b7a2,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
157,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,we enrolled patients with prostate cancer who had high-,eb11b92332c31e237ac13d3f1b865591cd8e9984,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
157,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,we enrolled patients with prostate cancer who had high-risk biochemical,53d6e4231290b98b4824f5b7eb50798f1e06a50b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
158,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease,4cc0c0ba02fd8fd04ad1a7e0752c9f253813fbd0,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
158,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
159,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,radiation therapy to the primary tumour site plus meta-iodobenzylguan,ef1eb6ea15d910133452313e4eee12a472bcc504,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
159,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"All patients were treated with six cycles of induction chemotherapy, myelo",6f21f2edd2d79b19a6b8305f2d1068a3bbbd70d2,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
160,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,women aged 18 years or older with hormone-receptor-,bf07db9d8f2ec9e1e8376b23240a781d101311d0,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
160,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer",c6a5bfe53f897b58d7a4e4700d69d71805fb3518,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
161,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"Outcomes are poor in patients with HER2-negative, advanced",ec99240daf0632aa96205f810bd55fb54f659301,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
161,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"Outcomes are poor in patients with HER2-negative,",4d45530dce4bfeb6946bdab6c4b2a5cd8b4f5505,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
162,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
162,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
163,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer",27df1e3a1113bef9b17cbfd8c1811894c37fafeb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
163,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,"We enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer from 81 Italian centres.",323f84eab7da85319403771ffcf28ceea7ecaa59,False,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
164,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Patients who have unresectable or metastatic melanoma with a BRAF V,7db3bf36cf3fd002728a008b97171b9465cb5fc7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
165,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were randomly assigned in a 2:1 ratio,fb890edaf5d17c50f8c0cfb8ff15dfc856394181,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
165,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"adult patients (aged ≥18 years) with advanced, progressive",6c3149585afbf22265750068eed99bbb99bde25c,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.,0d0051c9a89f4850fe4794c8eed127f0ea0d9b17,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
166,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,patients with HER2-positive metastatic breast cancer previously treated with,9eb20b9e5be060872e6cdc4d1381ab41c1ef0fae,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
167,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,completely resected stage III melanoma at high risk of,59abffb731a1a76ffd6e228a8237bb6817027db1,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
168,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,"in patients with HR-positive, HER2-negative advanced breast",0557a86da69e4df5fdf45d098532285a44890405,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
168,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"HR-positive, HER2-negative advanced breast cancer who",c4c2394d95974be179d12e25ec61d06b5f9acf92,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
169,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We enrolled female patients with HER2-overexpressing,f02e3cad6b9e5d36a2eae2ad765d5b748b03d5fe,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
169,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,We enrolled female patients with HER2-overexpressing metastatic,005048b41dd909db688f376fe307a54088d2c9fd,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
170,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,we screened 3100 first-degree relatives,8a7d132df4e12f22de20710430842a1744ff55d4,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
170,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,we screened 3100 first-degree relatives of,ff93519f9209262eea30b0db94a7a9622ad14b32,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
171,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,early breast cancer,d04e2d195abacd3a6db2384ad741abd39c1d4382,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
171,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-,2be7e0bce175fd4709bdc2e78ffa82150d0b09bf,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
173,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,To assess whether stereotactic body radiotherapy on a single tumor site,6f151cbb3e6cce6fa99622a2c44f58a4558de4b3,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
173,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,To assess whether stereotactic body radiotherapy on a,dde7fed95e6e2c5c2b6db525a389f4d4ff4f9901,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
174,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,170 432 eligible,a0f425c126919277317dabf8e19d596ae8e20cdd,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
174,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,170 432 eligible,a0f425c126919277317dabf8e19d596ae8e20cdd,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
175,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who,87d94dc31f87d6290677024d897e395667e58d02,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
175,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,locally advanced or metastatic,e7894e52acb07b735ae47a10d6beec8e1beedc5f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
176,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,"we randomly assigned 76,693",335459b7e6ca8c55ce67f2196a21bc07dfce92a0,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
176,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,"we randomly assigned 76,693 men at",7bb29b7eb4719bde7281f54ab61e213d4e067465,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
177,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,patients with stage III or IVA endometrial carcinoma,83a4d8c6e02ba20c4a7daf2f202feaf6def357af,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
177,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,in patients with stage III or IVA endometrial carcinoma,2002feb6dec076ebeb70d6a9900497c6c4955e6d,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
178,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,unresectable or metastatic cholangiocarcinoma,a90ac0ded24bb405865cd960c1faa2f1aa15ea2b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
178,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"aimed to demonstrate the efficacy of ivosidenib (AG-120)-a first-in-class, oral, small-molecule inhibitor of mutant IDH1-vs placebo for patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation.",c3734cfc43a7a509e7101c7502c2435306a512ae,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
179,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Patients were randomly assigned (1:1) to busulfan and,5b754efafe0ab94c1fec057a3f425fe1573c5272,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
179,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"balancing age at diagnosis, stage, MYCN amplification, and national",c417922175cbd219427dd03b0d52e1e1458725a3,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,patients were eligible if they were aged 18-7,c3cc6e090ca39f3532710bcd6b82ed864eae7898,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,patients were eligible if they were aged 18-,08b1f1d4e5ad6e76214595216aef4e15844f0959,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
182,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,we randomly assigned patients with stage IV or recurrent NSCLC,7e148c6a8909bf1c9ba9c524125e35afc58618aa,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
182,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,we randomly assigned patients with stage IV or recurrent NSCLC,7e148c6a8909bf1c9ba9c524125e35afc58618aa,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
183,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,patients with previously untreated stage II or stage III triple-negative breast cancer,df1fbc5bb5dcbf5062226f899b54c592cad0ffc2,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
183,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer,f33d8d6555d1c7356f81cb353a4c7a81669df708,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
184,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer.,8bf79f9205710ed68b6bfcad25eeb9f02b4518f9,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
184,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,women with HER2-positive locally advanced or inflammatory breast cancer,823f122356f8f86a5e76455b661c9dd507b9fb64,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
186,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
186,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,patients with a history of colorectal adenomas,6fc2d1f414dad3766ae3f48f4df1cdaa7867adeb,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
187,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,We randomly assigned eligible patients between the ages of,9c6db607e0b4a0d263c71b29f9bb7bec68b852a5,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
187,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,patients between the ages of 18 and,069c79195586d2d060a6ac49c5a8b06cd6135885,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
188,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes,45a629579ffe04604931a5af649703de002388f9,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
188,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes,45a629579ffe04604931a5af649703de002388f9,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
189,gemini,gemini-3-flash-preview,evidence_required,2,NEITHER,exemestane 25 mg a day for the primary prevention of breast cancer,0d52001903e864e0ca1353e01d67caebfee3e508,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
189,gemini,gemini-3-flash-preview,evidence_required,3,NEITHER,primary prevention of breast cancer,a4273a11d881b39d97e17b7c3e3d320c0e8f3224,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
190,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,"ABCSG-12 is a randomised, controlled, open",03e5172a589ede017e1d2900e13e43a074435ab2,False,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
191,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
191,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,documented local recurrence after surgery followed by chemotherapy,0f09fe303ab3ed28a24a6a52fb11371df9173f0b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
192,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,"hormone receptor (HR)-positive, human epidermal growth factor receptor 2",18d8797c8fd87f6e8c4a2a30fd361a6d9c802e00,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
193,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,Eligible patients were adults (aged 18 years or,ed0b2f7d885707876cf209788eb0181185634542,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
193,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,Eligible patients were adults (aged 18 years or older) with,bdbae9c9a8a7ac5f9d91885d2a033c05c0008f84,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
194,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Patients aged 18 or older with a controlled primary tumour,8579ff0827711712d691347c159338df3583ccab,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
194,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Patients aged 18 or older with a controlled primary tumour,8579ff0827711712d691347c159338df3583ccab,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
195,gemini,gemini-3-flash-preview,evidence_required,2,BOTH,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung,fc43a5e41e52c882b1483b7240e1d1e78c9226d5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
195,gemini,gemini-3-flash-preview,evidence_required,3,BOTH,We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung who had progressed after at least four cycles of platinum-based-chemotherapy.,7b6c6e36b482f1636c166e4378de25d7832b70ee,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
196,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination.,b115d94518768d5f9b795d5db83ebfc4ffac9bc6,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
196,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination.,b115d94518768d5f9b795d5db83ebfc4ffac9bc6,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
197,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,Patients aged 18 years and older with metastatic soft-tissue sarcomas,5aa95ecda2edcb243e6f1061f50ba6de22c5831e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
197,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Patients aged 18 years and older with metastatic soft,86eb6a5a948f3912c43569f11c623d3dcb14b4bb,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
198,gemini,gemini-3-flash-preview,evidence_required,2,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry.,0dba11ee514688d77c9254edf4807a4baff8b71f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
198,gemini,gemini-3-flash-preview,evidence_required,3,LOCALIZED,Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour,76a09e20d2d740bdabd2af21bb950f49cb219034,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
199,gemini,gemini-3-flash-preview,evidence_required,2,METASTATIC,men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment were randomly assigned,37778d79b23f24354dccbd63cc0fc49a6013ae65,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
199,gemini,gemini-3-flash-preview,evidence_required,3,METASTATIC,Our aim was to assess the use of ipilimumab after,563803f93742a5ad0e54d611a129fb162ce55595,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
0,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual)""",4ff1015be14e55a6dc027019ecdd60952f227167,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
1,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma""",7eb95ff89d5d04f295084806378003c157ff248d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
2,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""advanced or metastatic soft-tissue sarcoma""",1295da81802a04e9192cf06aca1745cbf170765d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned to receive conventional treatment,a221ae2f909a5817edac074c80bb2975fac17cd6,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
4,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with advanced NSCLC""",92a4edc4f6099300b9741ae88ef7a1c2b68d4c69,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases""",791525825cbc2e242e5954ea5e81577322076b7b,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
6,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Localised prostate cancer is commonly treated with external beam radiotherapy""",2075df6469616478ab5333572552170c2af23e40,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""we recruited postmenopausal women aged 50-74 years""",825205e9fd92724e1f3afae503bd0345dc57ba91,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""we recruited postmenopausal women aged 40-70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer""",8f5a19f63c284bc566b6b3e23aa0480586670f83,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
9,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma""",bcf0f43a2e7712526ff22f78c8fb384de1bd41c9,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
10,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with HER2-positive early breast cancer""",dff881889bad66db1f693bfe1291b8f93fc1e172,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
11,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"Patients aged at least 18 years with previously untreated locally advanced cervical cancer (adenocarcinoma, squamous, or adenosquamous; International Federation of Gynaecology and Obstetrics [FIGO] 2009 stage IB2-IIB lymph node positive, stage ≥III any lymph node status)",7e0be13bc11e4041ebbd22e9f6a9233c2df3c9aa,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
13,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""5102 patients with HER2-positive early breast cancer.""",6fc60fbc97fb2b7457a5764c0b27d30038e35dd9,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
14,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer""",6e818b07a0449f0743df642ae68dcb5da4241f3a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
15,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer were randomly assigned""",236ca6b96c0ee52756b2e4c598c9b1714840e32c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
16,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.""",42230f67e81e4ec2f07ed82ff6bfb4f61ed2ba5b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
17,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast""",8fc6d07c6cb975cbfd9de12dd6da07ac5b37df01,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
18,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""we randomly assigned healthy women older than 25 years to the HPV 16/18 vaccine or control (1:1)""",caf882292f3c3b0622828cfda4e10574f5663d9e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
19,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer""",3543e5de7079dc26de26adcdc748a01b230c07cb,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
20,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer""",c789aa1f5231e28b683f55b63cc4140b811ab8f8,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations""",503d85a8a9b21b9bc5c1803cd126ceaae88989b1,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
23,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""140 patients with early breast cancer were randomly assigned""",0890677652b8ad2594a3f8720f35149d58544372,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
25,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Barcelona Clinic Liver Cancer stage B or C disease""",ee6acf7308c5058279ee836172140f729acd5690,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
26,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing""",44fac3ea7abefbd5ffca2844d5e92f5c0d6eb117,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
27,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy""",4ff243088b2431b1801bac35f0da031f143cc04e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
30,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""1500 women with axillary node-positive or high-risk node-negative breast cancer""",1ac326d32b2ff256f3ee5a674f7d25f48073a7bb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
31,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""survivors of stages 0 to III breast cancer""",d9e13e8f7c44b394195489cd210728974e1d924e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
33,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""127 patients with dysplastic Barrett's esophagus""",3f420387f846c04acbea6c4fafaf82e586317038,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
35,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy""",9a594005618b79231adb6e89183647cf9b16471f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
36,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1)",87eb828e0f5c5ff35683b3720117d5791cba812b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
38,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma""",1835ed02d5f7f875c5c2c3809f13328736c01a50,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
39,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma""",c83298140f73497cbe3fd0d573745f64b422ce3b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
40,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""615 patients with locoregional, high-risk clear-cell renal-cell carcinoma""",6fb1710a633ca3fa26cb79307bd06252c9850c07,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
42,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b""",a8469e5e1f5c48c19f8ff0ee1de2c99d3557d6ea,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
43,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""men who had newly diagnosed clinically localised prostate cancer""",3b8b754f054461eccf15f981c69dad8883b2ed11,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
44,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""We assessed the effects of combined docetaxel and estramustine on relapse in patients with high-risk localised prostate cancer.""",831b31123235a67340fdb8f3f20f175a66654602,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
45,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma""",a7c93949a9d3fbab608305bfe5f51f22e1412639,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
46,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer""",27b0089ec3d86bbc95e0452d452fbe8401a13826,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
47,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer.""",b68f41ac601a8152689fd5a890798d46b3191ab5,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
48,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we recruited patients aged 18 years or older who had received taxane therapy and undergone two or fewer previous chemotherapy regimens for metastatic breast cancer""",b32da692d78dc577beec180916efb843271fdbc7,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
49,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer""",18ee24010628b521ae0527651fcd2b316c7fb195,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
50,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""we enrolled patients with stage IIIB or IV adenocarcinoma""",85b58150810f2c94fd05d87cf5a0a2db971acf6f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
52,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""The study involved 182,160 men between the ages of 50 and 74 years at entry""",dd7ec2ad87380013f7e156ae4bde2d39ea299042,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
53,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""as adjuvant chemotherapy for operable node-positive breast cancer.""",42578a7a4ea77d80be5d931d0b83628b435dfb14,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
54,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We enrolled patients with stage IV or recurrent NSCLC""",e61aeea04d0bb3f0cbe10067e2e4c6ce9aae2699,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
55,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""finasteride significantly reduced the risk of prostate cancer""",83ff318fc4650375f1b4414008971f066b7db94a,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
57,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"enrolled 160 patients with radiologically confirmed painful bone metastases from September 19, 2014, through June 19, 2018.",e84e0a676af3c6a18e31e7f32ecc7f5faec3063b,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
58,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer""",1d7e7caf17ecbeabbf80e1bd20d1c6066b07cfda,False,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
59,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""trial in patients aged 18 years or older with HER2-positive metastatic gastric or gastro-oesophageal junction cancer.""",f6a8046916bc56ff598ee96fa82e5ff4ef08d99d,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
60,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer""",e0fa8b194e03484d945e29c1e793232b6c72eb22,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
62,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Standard treatment for locally advanced cervical cancer is chemoradiotherapy""",de0ced2cdeae5015e4c49c760fbc5c55b696318c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
63,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC)""",cab9b9359cdd091819a44ebda0376b8b814f4f7b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
65,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease""",05b5f21c2a9a961bc6d7ddd2e808e046a9c662a9,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
66,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment in this phase 3, open-label, randomised controlled trial at 85 centres in Japan.",f11560fc87d66b2648cd745c74c8a4f4b3cd1c5f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
67,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned 1:1 to 28-day cycles of atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) or atezolizumab placebo, vemurafenib, and cobimetinib (control group).",6e694d8175e339756455833fbee51942070e78bc,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
68,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Randomisation was stratified by geographical region, macrovascular portal vein invasion or extrahepatic spread or both""",323ad07c4ab7b5e2a9ed9c6bdf6472037b4c2063,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
70,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Randomization was stratified based on site of metastasis (visceral, bone only, or other)""",9eed8f758a2b678bc01936613f1603a1b183f34b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
71,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
72,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with resected stage III melanoma with BRAF V600E or V600K mutations""",f09bd903e0dfa51bbf2dec8755fa6a0b8e75c47e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
73,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,enrolled patients with T1-T2N0-2 p16-positive OPSCC,64ce7a66da3b9350c6ec61deff324c165f4fd575,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
74,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries.,bb30ac3795423051d209f329381c670f0141d023,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
75,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors""",2f960d29830303309d25eab7b6bd69ffb4550918,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
76,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings.""",f28d16785a4224a97a7d072f680b7ac63dd7f856,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
77,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,25ecd584e5b4a56896c4eee319b874a2c1548069,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
78,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer""",d4f1677604d7c50818a77525aa336404fce8ef1b,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
79,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy""",f907c613faa56569b97218213b1edc9110fc1e17,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
80,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment""",9c1c59183a809bbed82997ce1ee4fc2f5a1a89d8,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
81,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter""",5ce23330d473062f0ce23e20dc7ed49bcc1ded13,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
82,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""we randomly assigned patients 2:1 with untreated locally recurrent inoperable or metastatic triple-negative breast cancer""",530e59e039a361aef6bdecda01be6b4cd7510fc1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
84,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""479 women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized""",52154624a7bf58441edc21d252ab42fd1add94d1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
85,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C""",45347dceca54ce09502c27162d8f9f436b795435,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
86,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy""",43fafd8fd169e7e412bc5896801c0826d5433f6f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
87,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract.",fb9278c2791a54c475e36e439cc3e33ec9537dfc,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
88,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""840 patients with stage IB-IIIA NSCLC""",ce78fa129ae36d8c9267d85106f8126118809625,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
89,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus.""",40f6afe613aca56f68ab3bbb18c3f500a1b69a68,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
90,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""The effect of celecoxib, a COX-2 inhibitor, as treatment for nonmetastatic colon cancer is unknown.""",1b8615d8bdf5c122d0d522339f8a426f5d4b21d8,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
91,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""among patients with melanoma and sentinel-node metastases.""",31976c44d8beb7057dd01cfeda1040912cd5d055,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
93,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence""",54c87f68e178017ae71c2252c76ab5b05323e444,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
94,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""first-line metastatic renal cell carcinoma""",3b52cda5e6eb1229aa3ce0bc75f2c10c70a0e731,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
95,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.""",da26953ee9836d64a30801cbc76a8f15a34ef5cf,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
96,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment""",256301c3da375be8c27f88ea8f0a655c3764e1a5,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
97,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""559 patients with untreated metastatic, squamous NSCLC""",14fc370f6e6034383eb771e6f8ecdccd20262c1e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
98,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation""",b69757cb065eea51fec87605d464eaf5e3f0dc69,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
99,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs)""",47dc5286e6633cb5f65052d2bba85b86d4c9b1c7,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
100,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.""",5732978a51d07233e109bcf444d9665e0f649d1a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
101,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Patients with previously untreated, stage III-IVB (except T3-4N0) nasopharyngeal carcinoma""",27f431a1408d64a891a7d22386bf7834dfe5c42f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
102,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients with previously untreated advanced melanoma""",dcaafc830eeb03c41dba153034529b1ebd830749,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""in patients with localized completely resected high-risk ccRCC.""",230e584283d41f8f6bb09d3f43e5463330fcafaf,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
104,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma""",03f415f9e33719b9adb0cb3c466d86448460cf3f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
106,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
107,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer""",ae793456338175ac0995428dbffbcf6ede75070c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
109,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma""",2e0bcb209b02b1b660c6a753e0515329ed98f44a,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
110,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients with histologically proven, HER2-positive metastatic breast cancer""",7d38d0d335c6d9abf8e7892f675042ba2ad46716,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
111,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,previously untreated unresectable stage IIIc or stage IV melanoma,7af32f2ec7b0ed3174df20894f2640738b8c50ca,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
112,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction.""",b6b33fbea15254056651dbe04f18605c3038f275,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
113,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years""",b71ecc1d16307f4ff61eb107be177c20037a4c25,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
114,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment""",96d6cc4a08801a90159b5e658c102adb5e7835c9,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
115,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with unresectable stage IIIC or IV melanoma""",11e9fadb85f681011f47d41123159358b2f90f2e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
116,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma""",79688df7aa50c025910aa3d2513317840804f731,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
117,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.""",3a8c2754f3b5ccf378f544a227beb00f99c88c68,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
118,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)""",caaf6fda6d566b2b781edeea2c54d96dd2e78659,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
119,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with palpable T1-T2 invasive breast cancer were recruited""",311094d80875682ad3b9a873613b0d56bce94208,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
120,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients aged 18 years or older, with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer""",10a8723a2bc47bb9c825741765682babdd541ce9,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
122,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized 1:1:1 to receive adjuvant RT, CCRT, or SCRT.""",734dfc66f1a369321dfd350d3c09b5795b01455e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
123,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma""",f4800827bd42e0a3e5e59ad63c6149db83c954a0,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
124,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.""",4243d0159b95e7d66eb9410fc86a4c85f5bc2ab0,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
126,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease""",456d88c271f3025523520b59eca94989f3b9a335,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
127,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC""",d330098c362527c8c0fc9f25c22d5618dc2226da,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
128,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer""",9b4f77e8b257977fef01387baf76bcd45a32f29d,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
129,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
130,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm""",4b19644d2fc3138efbdaf7cf5376c61135fdd12f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
131,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligibility criteria included ERBB2-negative metastatic breast cancer""",8e2b228dffb6f528d7174895349654162c1ef4ae,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
132,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""trial involving patients with active rheumatoid arthritis despite methotrexate treatment""",bfeeb4985e01d3761ba4fcbc929bb4e827db9696,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
133,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
134,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients with untreated stage IV or recurrent NSCLC""",33efff137a6cd58155eb0d0d06ddeaa6a6b5bbdc,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
136,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer""",1f3739a104351deb9cde24ec13e40cdeba09639f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
138,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""advanced or metastatic adenocarcinoma of the colon or rectum""",2f19e2fd818508132ff39279f49c89226f4f738e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""523 patients with curable stage T2b, T3, or T4 gastric cancer were randomly assigned during surgery""",969146b64131c36e8a070b398cf99a135c5e63cd,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
140,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.""",9f49cb21a38ac744574562f94df408518e7822eb,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
141,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area.",705c3aed868ba525fe510bf294707e35c3b98be4,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
142,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)""",57432a17cb7aa7053bce98336d373103324c88a2,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
143,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""Patients with histologically confirmed AIN were randomly assigned to receive either 16 weeks of imiquimod (three times a week), 16 weeks of topical fluorouracil (twice a week), or monthly electrocautery for 4 months.""",3644f7e378d6917fcef3310ada90d9c1e849df3c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
144,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we randomly assigned patients with spinal cord compression caused by metastatic cancer""",d933ed9e6709b3f5a2a7a261a9b531930b09239f,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
145,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy""",c16f8ca3f52c3e17d98b2dc99ec9c1c0f86d16d7,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
146,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States.""",2de6fa28760472b06638f1df555b31547cda6827,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
147,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer""",fa1bb5d29986a28699551aa5d0ae119e6d357b3a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
148,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.""",c390a3924587575a18fc4500a3e002711ed3b588,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
149,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors""",1b94424e45a3b69efd550d8b620f81a8d5230a3c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
151,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.""",517d694e1af036d28860bf23f2b13b022b9d374d,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
152,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We included chemotherapy-naive men (aged ≥18 years) with mCRPC""",6a69fccdc6d285db6f76d7fe85ca6e9ce2a50b95,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
153,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment""",8089587e09d6b5b20f8e34a02dc3430bea3ee904,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
154,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""women with HER2-positive breast cancer with progressive brain metastases""",027def017940daf376745d22ea8451fbe5d502ae,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
155,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer""",e3a7b0ad7b355e68aa420df618198a97d0f53237,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
156,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""with clinical stage I endometrial or cervical cancer undergoing curative surgery""",36282199e9cda6ec27e20b233714f9e1b3d6fd8a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
157,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""we enrolled patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less.""",b6a4e63ddc3092b491cbfd3a3aba2357a1961169,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
158,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
159,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""radiation therapy to the primary tumour site plus meta-iodobenzylguanidine avid metastases present before myeloablative therapy""",e9855d32d7ae7db785abe78e7ff0610f27348f3b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
160,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy""",40c89ddac97d040b0724fb4ed9135a8d69f35e12,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
162,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer""",6f72cb8719293462c54d0b73e23deb8569b9bd01,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
163,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer""",1c478e87dcc88406a02c20f5e45dd56a4374079e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
164,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation""",e1bba7b445c37298184b0a7b6cb77e1f1b6c0bf7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane""",fd1996c52fb6536a44bea5442ef04ebdc1934485,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
167,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.""",5a600a145b0b23da959e2f2c6af55a88b1431263,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
169,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We enrolled female patients with HER2-overexpressing metastatic breast cancer who had progressed on or following adjuvant trastuzumab or first-line treatment of metastatic disease with trastuzumab.""",0d325e453020e66c3f8ef2b413d1da33dadf5178,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
170,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""we screened 3100 first-degree relatives of patients with gastric cancer.""",4f257a0c5636f406a7ecea0d4091181f7217f9d6,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
171,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""recurrence of hormone-receptor-positive early breast cancer in premenopausal women""",a6d7365e9384eb318b8b4c200674399212017498,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
173,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""enhances tumor response in patients with metastatic NSCLC.""",bdccdcc2c0c155c20ed9f49856df4e4491d2179d,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
174,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""170 432 eligible men and women, who had indicated on a previous questionnaire that they would probably attend screening if invited, were randomly assigned (1:2) to an intervention group (offered flexible sigmoidoscopy screening) or a control group (not contacted).""",5393df4c4d1977a61d517ef534c97e034eddc3a1,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
175,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with locally advanced or metastatic non-small-cell lung cancer""",92c818e306e91a3da2710903d9574f6827920ace,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
176,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects)""",770000892fd7ee126223181170b34b8cde3a4396,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
177,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with stage III or IVA endometrial carcinoma""",65d8b67032e4ffdaaeb25be205b7e6e3a085afaa,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
178,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation""",ce20f456354b9a522ddb9e03e0fadb605a61a244,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
181,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""had previously untreated recurrent or metastatic nasopharyngeal carcinoma""",91abde46da8b29dc47ddc94b6d5e595cd01b9f6f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
182,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we randomly assigned patients with stage IV or recurrent NSCLC""",d44806a07a0dda22a5893639e1f7bbc4aade300f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
183,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with previously untreated stage II or stage III triple-negative breast cancer""",f725748278e482f51738e0b84dbf4f3ca0fb0824,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
184,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""women with HER2-positive locally advanced or inflammatory breast cancer""",9522ac15bc3bf324d82e62b97e23700b8120a2fc,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
186,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""patients with a history of colorectal adenomas""",d88c4488a5a21870904c26faf3c3df13379d9f83,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
187,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""stage III or stage IV disease and no distant metastases""",dc4e44d8380b38d0f13e206aa4e1af05a0f19370,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
188,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""among men with metastatic castration-resistant prostate cancer""",97f90d7254165d3ceb68535581bd315cc294b933,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
189,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""exemestane 25 mg a day for the primary prevention of breast cancer""",e0b645dad4ec20095c75603a4b97ee642abbdc99,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
190,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""1803 premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer""",4299d90c351f4db3a5af8b3a783ff310c85d911f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
191,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""documented local recurrence after surgery followed by chemotherapy""",403b61665eeee66ab251ed6a89e9f4f19d469416,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
194,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions, Eastern Cooperative Oncology Group score of 0-1, and a life expectancy of at least 6 months were eligible.",a2bb26ee3f4690b802f9ac765f68896bb4dff919,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
195,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung""",6feeb3bf467f7d4292e3de8de361ec5ed5a73151,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
196,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We randomly assigned patients with metastatic breast cancer""",d3b009e709a41c64bb273fe64b92969349640d6b,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
197,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"Patients aged 18 years and older with metastatic soft-tissue sarcomas, an Eastern Cooperative Oncology Group performance status of 0-2, and who had previously received treatment with anthracycline and ifosfamide were randomly assigned (1:1)",702058ff4ccf56d803acf4dc9cf4fd8f894af711,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
198,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""after resection of localised, primary gastrointestinal stromal tumour""",118164528b0984e5ad7e0a28b4b7cce51855afa8,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
199,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment""",2d8dcda2f7c12b6ee1dd9f79923ed5e82e4c5885,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
0,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with resectable NSCLC (stage II to IIIB [N2 node stage]""",bf2ab166578945b59702e53b56dec487b809e250,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
0,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual)""",8652d19d3af47554676d4d308bfa861684af24ea,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
1,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma""",7eb95ff89d5d04f295084806378003c157ff248d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
1,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma""",7eb95ff89d5d04f295084806378003c157ff248d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
2,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""advanced or metastatic soft-tissue sarcoma""",1295da81802a04e9192cf06aca1745cbf170765d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
2,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""advanced or metastatic soft-tissue sarcoma""",1295da81802a04e9192cf06aca1745cbf170765d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned to receive conventional treatment,a221ae2f909a5817edac074c80bb2975fac17cd6,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
3,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned to receive conventional treatment,a221ae2f909a5817edac074c80bb2975fac17cd6,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
4,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with advanced NSCLC progressing after second-line or further treatment.""",dcae6cbb68d38e056dc1e1ccb363860095c3acf6,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
5,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases""",791525825cbc2e242e5954ea5e81577322076b7b,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
5,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases""",1513f8bc2b47bf531ab2184f5d460982913a8172,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
6,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Localised prostate cancer is commonly treated with external beam radiotherapy""",2075df6469616478ab5333572552170c2af23e40,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
6,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Localised prostate cancer is commonly treated with external beam radiotherapy""",2075df6469616478ab5333572552170c2af23e40,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""we recruited postmenopausal women aged 50-74 years""",825205e9fd92724e1f3afae503bd0345dc57ba91,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""we recruited postmenopausal women aged 50-74 years""",825205e9fd92724e1f3afae503bd0345dc57ba91,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""we recruited postmenopausal women aged 40-70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer""",8f5a19f63c284bc566b6b3e23aa0480586670f83,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
8,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""we recruited postmenopausal women aged 40-70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer""",8f5a19f63c284bc566b6b3e23aa0480586670f83,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
9,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma""",bcf0f43a2e7712526ff22f78c8fb384de1bd41c9,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
9,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma""",bcf0f43a2e7712526ff22f78c8fb384de1bd41c9,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
10,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer""",1cb68dbec11268ea57f620e713080ed3c582315c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
10,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer""",1cb68dbec11268ea57f620e713080ed3c582315c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
11,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"Patients aged at least 18 years with previously untreated locally advanced cervical cancer (adenocarcinoma, squamous, or adenosquamous; International Federation of Gynaecology and Obstetrics [FIGO] 2009 stage IB2-IIB lymph node positive, stage ≥III any lymph node status)",7e0be13bc11e4041ebbd22e9f6a9233c2df3c9aa,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
11,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"Patients aged at least 18 years with previously untreated locally advanced cervical cancer (adenocarcinoma, squamous, or adenosquamous; International Federation of Gynaecology and Obstetrics [FIGO] 2009 stage IB2-IIB lymph node positive, stage ≥III any lymph node status)",7e0be13bc11e4041ebbd22e9f6a9233c2df3c9aa,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
13,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""5102 patients with HER2-positive early breast cancer""",5ef2820aaf9ab4b1d097210517a38aba2c89338e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
13,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""5102 patients with HER2-positive early breast cancer""",5ef2820aaf9ab4b1d097210517a38aba2c89338e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
14,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer""",6e818b07a0449f0743df642ae68dcb5da4241f3a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
14,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer""",6e818b07a0449f0743df642ae68dcb5da4241f3a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
15,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer""",c85bb6f05c217b7b29f7980927c7792a658c531e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
15,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer""",c85bb6f05c217b7b29f7980927c7792a658c531e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
16,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.""",42230f67e81e4ec2f07ed82ff6bfb4f61ed2ba5b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
16,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.""",42230f67e81e4ec2f07ed82ff6bfb4f61ed2ba5b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
17,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast""",8fc6d07c6cb975cbfd9de12dd6da07ac5b37df01,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
17,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast""",8fc6d07c6cb975cbfd9de12dd6da07ac5b37df01,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
18,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""we randomly assigned healthy women older than 25 years to the HPV 16/18 vaccine or control (1:1)""",caf882292f3c3b0622828cfda4e10574f5663d9e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
18,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""we randomly assigned healthy women older than 25 years to the HPV 16/18 vaccine or control (1:1)""",caf882292f3c3b0622828cfda4e10574f5663d9e,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
19,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer""",3543e5de7079dc26de26adcdc748a01b230c07cb,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
19,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer""",3543e5de7079dc26de26adcdc748a01b230c07cb,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
20,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer""",c789aa1f5231e28b683f55b63cc4140b811ab8f8,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
20,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer""",c789aa1f5231e28b683f55b63cc4140b811ab8f8,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
21,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with previously untreated advanced NSCLC with an EGFR mutation""",b904abcb80c192af806439fedd28334b12cb7362,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations""",503d85a8a9b21b9bc5c1803cd126ceaae88989b1,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
22,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations""",503d85a8a9b21b9bc5c1803cd126ceaae88989b1,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
23,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""140 patients with early breast cancer were randomly assigned""",0890677652b8ad2594a3f8720f35149d58544372,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
23,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""140 patients with early breast cancer were randomly assigned""",0890677652b8ad2594a3f8720f35149d58544372,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
25,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Barcelona Clinic Liver Cancer stage B or C disease""",ee6acf7308c5058279ee836172140f729acd5690,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
25,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""Barcelona Clinic Liver Cancer stage B or C disease""",ee6acf7308c5058279ee836172140f729acd5690,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
26,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing""",44fac3ea7abefbd5ffca2844d5e92f5c0d6eb117,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
26,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing""",44fac3ea7abefbd5ffca2844d5e92f5c0d6eb117,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
27,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned (1:1) to receive either open or laparoscopic surgery.""",40a3b1148cd4ea4f88bebde1187024c10a289d06,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
27,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned (1:1) to receive either open or laparoscopic surgery.""",40a3b1148cd4ea4f88bebde1187024c10a289d06,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
30,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""1500 women with axillary node-positive or high-risk node-negative breast cancer""",1ac326d32b2ff256f3ee5a674f7d25f48073a7bb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
30,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""1500 women with axillary node-positive or high-risk node-negative breast cancer""",1ac326d32b2ff256f3ee5a674f7d25f48073a7bb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
31,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""survivors of stages 0 to III breast cancer""",d9e13e8f7c44b394195489cd210728974e1d924e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
31,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously""",bd5381973db04fcb2f620532631dfa8594a97fc8,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
33,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""127 patients with dysplastic Barrett's esophagus""",3f420387f846c04acbea6c4fafaf82e586317038,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
33,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""127 patients with dysplastic Barrett's esophagus""",3f420387f846c04acbea6c4fafaf82e586317038,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
35,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy.""",b49797e3c8aff38eda554e235d45aedee9cda2f7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
35,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy""",9a594005618b79231adb6e89183647cf9b16471f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
36,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1)",87eb828e0f5c5ff35683b3720117d5791cba812b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
36,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations""",f60504f6eb8415503d2a93b7858cf6f864a52a74,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
38,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma""",1835ed02d5f7f875c5c2c3809f13328736c01a50,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
38,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma""",1835ed02d5f7f875c5c2c3809f13328736c01a50,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
39,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma""",c83298140f73497cbe3fd0d573745f64b422ce3b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
39,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""unresectable stage IIIC or stage IV melanoma""",412941f42a2ca5bddcd1f26cf8d863909f8031c5,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
40,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""we assigned 615 patients with locoregional, high-risk clear-cell renal-cell carcinoma""",c0d0b60854063ddcdca9d044704023816c0aaa0b,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
40,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with locoregional, high-risk clear-cell renal-cell carcinoma""",427a61fdf11c46b8799716a9bf8e7bfbc01bbea0,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
42,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627),b1c09b3e60339f032a3371c9409dd5cba859d47c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
42,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627),b1c09b3e60339f032a3371c9409dd5cba859d47c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
43,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""men who had newly diagnosed clinically localised prostate cancer""",3b8b754f054461eccf15f981c69dad8883b2ed11,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
43,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer,59a3763c94c3f0cac7eec1001ce3b4f98d515821,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
44,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""We enrolled patients with treatment-naive prostate cancer and at least one risk factor (ie, stage T3-T4 disease, Gleason score of ≥8, prostate-specific antigen concentration >20 ng/mL, or pathological node-positive).""",d7662cb65997ad633274a61028c2e3b0363bb7b5,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
44,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""We enrolled patients with treatment-naive prostate cancer and at least one risk factor (ie, stage T3-T4 disease, Gleason score of ≥8, prostate-specific antigen concentration >20 ng/mL, or pathological node-positive).""",d7662cb65997ad633274a61028c2e3b0363bb7b5,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
45,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma""",a7c93949a9d3fbab608305bfe5f51f22e1412639,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
45,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma""",a7c93949a9d3fbab608305bfe5f51f22e1412639,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
46,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer""",27b0089ec3d86bbc95e0452d452fbe8401a13826,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
46,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer""",27b0089ec3d86bbc95e0452d452fbe8401a13826,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
47,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""adjuvant therapy in patients with resected pancreatic cancer.""",2d40581a4469011e734edddaf5efc0c7000bf8cb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
47,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with resected pancreatic cancer""",3ef34bfff309c5c5a47a9c2162c50f3840172a20,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
48,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with previously treated metastatic breast cancer""",90363ddf8d53793a44c0f22d3cf63252f7e41c5b,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
48,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we recruited patients aged 18 years or older who had received taxane therapy and undergone two or fewer previous chemotherapy regimens for metastatic breast cancer""",b32da692d78dc577beec180916efb843271fdbc7,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
49,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer""",18ee24010628b521ae0527651fcd2b316c7fb195,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
49,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer""",18ee24010628b521ae0527651fcd2b316c7fb195,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
50,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""we enrolled patients with stage IIIB or IV adenocarcinoma""",85b58150810f2c94fd05d87cf5a0a2db971acf6f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
50,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""we enrolled patients with stage IIIB or IV adenocarcinoma""",85b58150810f2c94fd05d87cf5a0a2db971acf6f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
52,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""The study involved 182,160 men between the ages of 50 and 74 years at entry""",dd7ec2ad87380013f7e156ae4bde2d39ea299042,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
52,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""The study involved 182,160 men between the ages of 50 and 74 years at entry""",dd7ec2ad87380013f7e156ae4bde2d39ea299042,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
53,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""as adjuvant chemotherapy for operable node-positive breast cancer.""",42578a7a4ea77d80be5d931d0b83628b435dfb14,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
53,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""as adjuvant chemotherapy for operable node-positive breast cancer.""",42578a7a4ea77d80be5d931d0b83628b435dfb14,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
54,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We enrolled patients with stage IV or recurrent NSCLC""",e61aeea04d0bb3f0cbe10067e2e4c6ce9aae2699,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
54,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""We enrolled patients with stage IV or recurrent NSCLC""",e61aeea04d0bb3f0cbe10067e2e4c6ce9aae2699,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
55,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""finasteride significantly reduced the risk of prostate cancer""",83ff318fc4650375f1b4414008971f066b7db94a,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
55,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""Finasteride reduced the risk of prostate cancer""",c18e39615052e8159df5e84392902eab4f877f47,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
57,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""enrolled 160 patients with radiologically confirmed painful bone metastases""",66dfe16afde749c512f3a9f75ab7f8a67e75f055,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
57,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""enrolled 160 patients with radiologically confirmed painful bone metastases""",66dfe16afde749c512f3a9f75ab7f8a67e75f055,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
58,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer""",1d7e7caf17ecbeabbf80e1bd20d1c6066b07cfda,False,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
58,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer""",6d607229d8c616539211c9914e6f8c6205324446,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
59,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""trial in patients aged 18 years or older with HER2-positive metastatic gastric or gastro-oesophageal junction cancer.""",f6a8046916bc56ff598ee96fa82e5ff4ef08d99d,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
59,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""trial in patients aged 18 years or older with HER2-positive metastatic gastric or gastro-oesophageal junction cancer.""",f6a8046916bc56ff598ee96fa82e5ff4ef08d99d,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
60,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer""",e0fa8b194e03484d945e29c1e793232b6c72eb22,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
60,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer""",e0fa8b194e03484d945e29c1e793232b6c72eb22,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
62,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease)""",0a2d4bf3ff1786514a13b2152a4b67a437955f1d,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
62,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease)""",0a2d4bf3ff1786514a13b2152a4b67a437955f1d,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
63,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC)""",cab9b9359cdd091819a44ebda0376b8b814f4f7b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
63,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) who had disease progression after receiving EGFR tyrosine-kinase inhibitor therapy.""",138a6be02add95b59b03464abbb7f916204520a1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
65,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""these patients included infants (<365 days of age) who had stage 3 or 4 disease""",1925825c4892fc3f99c27c6143b3201d6c3e886c,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
65,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""these patients included infants (<365 days of age) who had stage 3 or 4 disease""",1925825c4892fc3f99c27c6143b3201d6c3e886c,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
66,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment in this phase 3, open-label, randomised controlled trial at 85 centres in Japan.",f11560fc87d66b2648cd745c74c8a4f4b3cd1c5f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
66,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment in this phase 3, open-label, randomised controlled trial at 85 centres in Japan.",f11560fc87d66b2648cd745c74c8a4f4b3cd1c5f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
67,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma""",d560c77a9e6e10afd91ea8edeb1b77e5446919ce,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
67,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned 1:1 to 28-day cycles of atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) or atezolizumab placebo, vemurafenib, and cobimetinib (control group).",6e694d8175e339756455833fbee51942070e78bc,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
68,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Randomisation was stratified by geographical region, macrovascular portal vein invasion or extrahepatic spread or both""",323ad07c4ab7b5e2a9ed9c6bdf6472037b4c2063,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
68,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""macrovascular portal vein invasion or extrahepatic spread or both""",bc50d7f7d96fef6c6a77c7bc83c8c32e96d1415e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
70,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Randomization was stratified based on site of metastasis (visceral, bone only, or other)""",9eed8f758a2b678bc01936613f1603a1b183f34b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
70,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Randomization was stratified based on site of metastasis (visceral, bone only, or other)""",9eed8f758a2b678bc01936613f1603a1b183f34b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
71,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer""",fa5e203b4aad68d3d2f144bfed4da58e9b60ed6c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
71,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
72,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with resected stage III melanoma with BRAF V600E or V600K mutations""",f09bd903e0dfa51bbf2dec8755fa6a0b8e75c47e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
72,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients who had resected stage III melanoma with BRAF V600E or V600K mutations""",2fc9d6cd70ee123c59df87c0bbaa58a1f4743652,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
73,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,enrolled patients with T1-T2N0-2 p16-positive OPSCC,64ce7a66da3b9350c6ec61deff324c165f4fd575,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
73,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,enrolled patients with T1-T2N0-2 p16-positive OPSCC,64ce7a66da3b9350c6ec61deff324c165f4fd575,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
74,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries.,bb30ac3795423051d209f329381c670f0141d023,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
74,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries.,bb30ac3795423051d209f329381c670f0141d023,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
75,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors""",2f960d29830303309d25eab7b6bd69ffb4550918,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
75,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors""",2f960d29830303309d25eab7b6bd69ffb4550918,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
76,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""among 5999 participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings.""",6f0710a8947e4176e0c54f32b4c48a190e1ff1ba,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
76,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings.""",f28d16785a4224a97a7d072f680b7ac63dd7f856,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
77,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,25ecd584e5b4a56896c4eee319b874a2c1548069,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
77,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,25ecd584e5b4a56896c4eee319b874a2c1548069,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
78,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer""",d4f1677604d7c50818a77525aa336404fce8ef1b,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
78,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer""",d4f1677604d7c50818a77525aa336404fce8ef1b,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
79,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy""",f907c613faa56569b97218213b1edc9110fc1e17,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
79,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy""",f907c613faa56569b97218213b1edc9110fc1e17,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
80,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment""",9c1c59183a809bbed82997ce1ee4fc2f5a1a89d8,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
80,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment""",4a8cf56ab851cfbf7e54607b9045867dc1eb2395,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
81,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter""",5ce23330d473062f0ce23e20dc7ed49bcc1ded13,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
81,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter""",5ce23330d473062f0ce23e20dc7ed49bcc1ded13,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
82,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""patients with untreated locally recurrent inoperable or metastatic triple-negative breast cancer""",e023d806bb4b160c343f708723a2cd2e3e257ddb,False,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
82,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""untreated locally recurrent inoperable or metastatic triple-negative breast cancer""",92e265c019e9cb321c2a50d2b720940bf1075e7a,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
84,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""479 women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized""",52154624a7bf58441edc21d252ab42fd1add94d1,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
84,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""479 women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized to 1 of 2 treatment arms""",9c9a7b7a9d505120eaf392a74757c1df810ee5b2,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
85,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C""",45347dceca54ce09502c27162d8f9f436b795435,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
85,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C""",45347dceca54ce09502c27162d8f9f436b795435,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
86,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy""",43fafd8fd169e7e412bc5896801c0826d5433f6f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
86,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""enrolling patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy""",9203da80d71bcd97750ef00459f7237628a25f13,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
87,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract.",fb9278c2791a54c475e36e439cc3e33ec9537dfc,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
87,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract.""",1eeb2256f4273bd4645c2d33b7cc91a36a14ae76,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
88,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""840 patients with stage IB-IIIA NSCLC""",ce78fa129ae36d8c9267d85106f8126118809625,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
88,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""840 patients with stage IB-IIIA NSCLC""",ce78fa129ae36d8c9267d85106f8126118809625,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
89,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus.""",40f6afe613aca56f68ab3bbb18c3f500a1b69a68,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
89,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus.""",40f6afe613aca56f68ab3bbb18c3f500a1b69a68,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
90,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""A total of 2526 patients with stage III colon cancer were enrolled""",ad65bb9951f13ac2dcb8fd34ea1c3097eb6f0223,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
90,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""The effect of celecoxib, a COX-2 inhibitor, as treatment for nonmetastatic colon cancer is unknown.""",1b8615d8bdf5c122d0d522339f8a426f5d4b21d8,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
91,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with node-positive intermediate-thickness melanomas (1.2 to 3.5 mm)""",4b914be7299eb8af652df239e8615613d9f6493e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
91,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""among patients with melanoma and sentinel-node metastases""",df2a91818bb71d7537b5152d1ff46b88d703f914,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
93,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence""",54c87f68e178017ae71c2252c76ab5b05323e444,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
93,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence""",54c87f68e178017ae71c2252c76ab5b05323e444,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
94,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""first-line metastatic renal cell carcinoma""",3b52cda5e6eb1229aa3ce0bc75f2c10c70a0e731,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
94,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""first-line metastatic renal cell carcinoma""",3b52cda5e6eb1229aa3ce0bc75f2c10c70a0e731,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
95,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
95,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.""",da26953ee9836d64a30801cbc76a8f15a34ef5cf,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
96,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment""",256301c3da375be8c27f88ea8f0a655c3764e1a5,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
96,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment""",256301c3da375be8c27f88ea8f0a655c3764e1a5,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
97,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""559 patients with untreated metastatic, squamous NSCLC""",14fc370f6e6034383eb771e6f8ecdccd20262c1e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
97,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""559 patients with untreated metastatic, squamous NSCLC""",14fc370f6e6034383eb771e6f8ecdccd20262c1e,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
98,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation""",b69757cb065eea51fec87605d464eaf5e3f0dc69,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
98,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation""",b69757cb065eea51fec87605d464eaf5e3f0dc69,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
99,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs)""",47dc5286e6633cb5f65052d2bba85b86d4c9b1c7,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
99,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs)""",47dc5286e6633cb5f65052d2bba85b86d4c9b1c7,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
100,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.""",5732978a51d07233e109bcf444d9665e0f649d1a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
100,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.""",5732978a51d07233e109bcf444d9665e0f649d1a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
101,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Patients with previously untreated, stage III-IVB (except T3-4N0) nasopharyngeal carcinoma""",27f431a1408d64a891a7d22386bf7834dfe5c42f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
101,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Patients with previously untreated, stage III-IVB (except T3-4N0) nasopharyngeal carcinoma""",27f431a1408d64a891a7d22386bf7834dfe5c42f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
102,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with previously untreated advanced melanoma""",dcaafc830eeb03c41dba153034529b1ebd830749,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
102,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with previously untreated advanced melanoma""",dcaafc830eeb03c41dba153034529b1ebd830749,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.""",ff106cff6f82e4af66967d2e4c4adb0d35c78b76,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
103,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.""",ff106cff6f82e4af66967d2e4c4adb0d35c78b76,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
104,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma""",03f415f9e33719b9adb0cb3c466d86448460cf3f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
104,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma""",03f415f9e33719b9adb0cb3c466d86448460cf3f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
105,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Patients with small-cell lung cancer that responded to first-line treatment but showed evidence of disease relapse or progression at least 90 days after completion of the first-line treatment were eligible to participate.""",5172d251905a57d43546372b9791091e40b8c64c,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
106,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible patients had newly diagnosed metastatic prostate cancer.""",92bf4c8c181840c1e6b85ede53e4e6a7b2565bca,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
106,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
107,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer""",ae793456338175ac0995428dbffbcf6ede75070c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
107,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer""",ae793456338175ac0995428dbffbcf6ede75070c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
109,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma""",2e0bcb209b02b1b660c6a753e0515329ed98f44a,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
109,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma""",2e0bcb209b02b1b660c6a753e0515329ed98f44a,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
110,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with histologically proven, HER2-positive metastatic breast cancer""",7d38d0d335c6d9abf8e7892f675042ba2ad46716,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
110,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""in patients with histologically proven, HER2-positive metastatic breast cancer""",0bda1878459cf8910a5d3f04a849e0ef09fe988d,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
111,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""previously untreated unresectable stage IIIc or stage IV melanoma""",e46dd441c00b51d1b55e22d4973575c6d3d877ae,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
111,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""with previously untreated unresectable stage IIIc or stage IV melanoma""",81d68cc660739cbe06410243d084d719c6b4bc19,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
112,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction""",7dd6043baeec8a77b8812eec4208a6e9bc4b25a4,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
112,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction.""",b6b33fbea15254056651dbe04f18605c3038f275,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
113,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years""",b71ecc1d16307f4ff61eb107be177c20037a4c25,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
113,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years""",b71ecc1d16307f4ff61eb107be177c20037a4c25,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
114,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment""",96d6cc4a08801a90159b5e658c102adb5e7835c9,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
114,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment""",96d6cc4a08801a90159b5e658c102adb5e7835c9,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
115,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""patients with unresectable stage IIIC or IV melanoma""",11e9fadb85f681011f47d41123159358b2f90f2e,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
115,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""we randomly assigned patients with unresectable stage IIIC or IV melanoma""",8ac745e2e3d1ff6895195e2efee2f8b719930830,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
116,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma""",79688df7aa50c025910aa3d2513317840804f731,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
116,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma""",79688df7aa50c025910aa3d2513317840804f731,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
117,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.""",3a8c2754f3b5ccf378f544a227beb00f99c88c68,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
117,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.""",3a8c2754f3b5ccf378f544a227beb00f99c88c68,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
118,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Eligible patients were aged 18-75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)""",57880f1da72449c8aac9386dacfdba30d8619b10,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
118,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)""",caaf6fda6d566b2b781edeea2c54d96dd2e78659,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
119,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with palpable T1-T2 invasive breast cancer were recruited""",311094d80875682ad3b9a873613b0d56bce94208,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
119,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with palpable T1-T2 invasive breast cancer""",798e1eb45dec97bef742ad0128671785a60c2856,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
120,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer""",f90c6498c663cd41f570061741fcfc0aa989693f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
120,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""patients aged 18 years or older, with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer""",10a8723a2bc47bb9c825741765682babdd541ce9,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
122,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized""",b80a615ca2d43e6e4e50908741fd05deb0cb2e8c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
122,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized 1:1:1 to receive adjuvant RT, CCRT, or SCRT.""",734dfc66f1a369321dfd350d3c09b5795b01455e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
123,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma""",f4800827bd42e0a3e5e59ad63c6149db83c954a0,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
123,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma""",f4800827bd42e0a3e5e59ad63c6149db83c954a0,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
124,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall""",af4b8599baca419dc0def290cb5edb0da963922f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
124,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.""",4243d0159b95e7d66eb9410fc86a4c85f5bc2ab0,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
126,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease""",456d88c271f3025523520b59eca94989f3b9a335,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
126,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease""",456d88c271f3025523520b59eca94989f3b9a335,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
127,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC""",d330098c362527c8c0fc9f25c22d5618dc2226da,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
127,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC were enrolled""",d91146e6bb9b20c83651761dc559f57c95629cdb,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
128,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer""",9b4f77e8b257977fef01387baf76bcd45a32f29d,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
128,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer""",9b4f77e8b257977fef01387baf76bcd45a32f29d,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
129,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
129,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
130,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm""",4b19644d2fc3138efbdaf7cf5376c61135fdd12f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
130,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm""",4b19644d2fc3138efbdaf7cf5376c61135fdd12f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
131,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
131,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
132,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""trial involving patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor.""",2682199328c3da0ac39fc56e8fe0be6412ea95ef,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
132,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""We conducted a randomized, open-label, noninferiority, postauthorization, safety end-point trial involving patients with active rheumatoid arthritis despite methotrexate treatment""",b5d568091752b3bcdeecd8ff51fb0faf12292c52,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
133,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
133,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
134,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with untreated stage IV or recurrent NSCLC""",33efff137a6cd58155eb0d0d06ddeaa6a6b5bbdc,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
134,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with untreated stage IV or recurrent NSCLC""",33efff137a6cd58155eb0d0d06ddeaa6a6b5bbdc,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
136,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer""",1f3739a104351deb9cde24ec13e40cdeba09639f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
136,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer""",1f3739a104351deb9cde24ec13e40cdeba09639f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
138,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum""",3e7c76a8a46d7d086f63cb923024fab09297eec3,False,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum""",660fbabf16f117bc0651ea2929bfae53d1dce371,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with curable stage T2b, T3, or T4 gastric cancer""",f0b36688c886d85ee84962717b18556b112942e3,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
139,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""523 patients with curable stage T2b, T3, or T4 gastric cancer""",9fe65f075474b6531137c7c7d507c352f5b9a52a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
140,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy""",1105b7cb6258bef7c64f643a10414adc15c1e2c9,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
140,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.""",9f49cb21a38ac744574562f94df408518e7822eb,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
141,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area.",705c3aed868ba525fe510bf294707e35c3b98be4,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
141,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area.",705c3aed868ba525fe510bf294707e35c3b98be4,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
142,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)""",57432a17cb7aa7053bce98336d373103324c88a2,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
142,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)""",57432a17cb7aa7053bce98336d373103324c88a2,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
143,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""Patients with histologically confirmed AIN were randomly assigned to receive either 16 weeks of imiquimod (three times a week), 16 weeks of topical fluorouracil (twice a week), or monthly electrocautery for 4 months.""",3644f7e378d6917fcef3310ada90d9c1e849df3c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
143,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""Patients with histologically confirmed AIN were randomly assigned to receive either 16 weeks of imiquimod (three times a week), 16 weeks of topical fluorouracil (twice a week), or monthly electrocautery for 4 months.""",3644f7e378d6917fcef3310ada90d9c1e849df3c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
144,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we randomly assigned patients with spinal cord compression caused by metastatic cancer""",d933ed9e6709b3f5a2a7a261a9b531930b09239f,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
144,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we randomly assigned patients with spinal cord compression caused by metastatic cancer""",d933ed9e6709b3f5a2a7a261a9b531930b09239f,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
145,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy""",c16f8ca3f52c3e17d98b2dc99ec9c1c0f86d16d7,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
145,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy""",c16f8ca3f52c3e17d98b2dc99ec9c1c0f86d16d7,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
146,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States.""",2de6fa28760472b06638f1df555b31547cda6827,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
146,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States.""",2de6fa28760472b06638f1df555b31547cda6827,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
147,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer""",fa1bb5d29986a28699551aa5d0ae119e6d357b3a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
147,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer""",fa1bb5d29986a28699551aa5d0ae119e6d357b3a,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
148,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.""",c390a3924587575a18fc4500a3e002711ed3b588,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
148,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.""",c390a3924587575a18fc4500a3e002711ed3b588,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
149,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.""",f21d9dcba719e4c7d4b7b11a24127ab157ce6c96,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
149,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.""",f21d9dcba719e4c7d4b7b11a24127ab157ce6c96,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
150,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""we enrolled patients with a histologically proven superficial basal-cell carcinoma""",9751294cd75e0aee278069973f0a2c09bfbe3271,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
151,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.""",517d694e1af036d28860bf23f2b13b022b9d374d,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
151,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.""",517d694e1af036d28860bf23f2b13b022b9d374d,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
152,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We included chemotherapy-naive men (aged ≥18 years) with mCRPC""",6a69fccdc6d285db6f76d7fe85ca6e9ce2a50b95,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
152,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""We included chemotherapy-naive men (aged ≥18 years) with mCRPC""",6a69fccdc6d285db6f76d7fe85ca6e9ce2a50b95,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
153,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment""",8089587e09d6b5b20f8e34a02dc3430bea3ee904,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
153,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment""",8089587e09d6b5b20f8e34a02dc3430bea3ee904,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
154,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""women with HER2-positive breast cancer with progressive brain metastases during or after treatment with trastuzumab, lapatinib, or both, were eligible.""",02a98f806a0f5e1f0f5eaa27d696d2d9b69282fe,False,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
154,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""women with HER2-positive breast cancer with progressive brain metastases""",027def017940daf376745d22ea8451fbe5d502ae,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
155,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer""",e3a7b0ad7b355e68aa420df618198a97d0f53237,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
155,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer""",e3a7b0ad7b355e68aa420df618198a97d0f53237,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
156,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery""",e363714a711912055cf2c55ea3be914025589a34,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
156,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery""",e363714a711912055cf2c55ea3be914025589a34,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
157,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""we enrolled patients with prostate cancer who had high-risk biochemical recurrence""",a4e03d4a21c3558ce3903ac5f4cb5142851e0d70,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
157,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""we enrolled patients with prostate cancer who had high-risk biochemical recurrence""",a4e03d4a21c3558ce3903ac5f4cb5142851e0d70,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
158,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned to TME preceded by 5 × 5 Gy radiotherapy or TME alone (ratio 1:1).,c101f9b89e3da615992555b66701392feaba40da,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
158,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
159,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""radiation therapy to the primary tumour site plus meta-iodobenzylguanidine avid metastases present before myeloablative therapy""",e9855d32d7ae7db785abe78e7ff0610f27348f3b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
159,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""radiation therapy to the primary tumour site plus meta-iodobenzylguanidine avid metastases present before myeloablative therapy""",e9855d32d7ae7db785abe78e7ff0610f27348f3b,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
160,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy""",40c89ddac97d040b0724fb4ed9135a8d69f35e12,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
160,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy""",40c89ddac97d040b0724fb4ed9135a8d69f35e12,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
162,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
162,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer""",6f72cb8719293462c54d0b73e23deb8569b9bd01,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
163,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer""",1c478e87dcc88406a02c20f5e45dd56a4374079e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
163,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer""",1c478e87dcc88406a02c20f5e45dd56a4374079e,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
164,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation""",ddb23a0f0938b5334f19c19f91bf9f16cfc8bde3,False,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
164,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation""",e1bba7b445c37298184b0a7b6cb77e1f1b6c0bf7,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.""",b45beb67bce8ffe76caab8a70e4869bd2232efc9,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
166,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.""",b45beb67bce8ffe76caab8a70e4869bd2232efc9,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
167,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.""",7ff1dd5d0e8a9fbea59316bbf6ed3cfc766892c3,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
167,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.""",7ff1dd5d0e8a9fbea59316bbf6ed3cfc766892c3,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
169,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We enrolled female patients with HER2-overexpressing metastatic breast cancer""",01dba15b0aceb596bda5edaab77444ee0ddca823,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
169,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""We enrolled female patients with HER2-overexpressing metastatic breast cancer""",01dba15b0aceb596bda5edaab77444ee0ddca823,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
170,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""we screened 3100 first-degree relatives of patients with gastric cancer. We randomly assigned 1838 participants with H. pylori infection""",73f79972374e3f2b084c878330b603a157c2eedb,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
170,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""we screened 3100 first-degree relatives of patients with gastric cancer. We randomly assigned 1838 participants with H. pylori infection""",73f79972374e3f2b084c878330b603a157c2eedb,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
171,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""hormone-receptor-positive early breast cancer in premenopausal women""",98a5ba5f17b9110f04a2f069c888555be83e8f36,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
171,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""recurrence of hormone-receptor-positive early breast cancer in premenopausal women""",a6d7365e9384eb318b8b4c200674399212017498,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
173,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""enhances tumor response in patients with metastatic NSCLC.""",bdccdcc2c0c155c20ed9f49856df4e4491d2179d,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
173,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""To assess whether stereotactic body radiotherapy on a single tumor site preceding pembrolizumab treatment enhances tumor response in patients with metastatic NSCLC.""",01b26d2df2e2d57be14b279647c3a1ca8a4eaf62,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
174,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""170 432 eligible men and women, who had indicated on a previous questionnaire that they would probably attend screening if invited""",374c6ed5f286ec093a811d67ccaf373be9e38969,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
174,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""170 432 eligible men and women, who had indicated on a previous questionnaire that they would probably attend screening if invited""",374c6ed5f286ec093a811d67ccaf373be9e38969,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
175,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""patients with locally advanced or metastatic non-small-cell lung cancer""",92c818e306e91a3da2710903d9574f6827920ace,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
175,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer""",1ae19e4849f520394d7ce0e7e5dd86a8ddba608d,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
176,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects).""",58367c66a45cfe1b18d870f213754e26a482f201,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
176,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects)""",770000892fd7ee126223181170b34b8cde3a4396,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
177,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""in patients with stage III or IVA endometrial carcinoma""",25049fc2def443efb17ffe77da755e6e07b1bba7,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
177,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with stage III or IVA endometrial carcinoma""",65d8b67032e4ffdaaeb25be205b7e6e3a085afaa,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
178,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""for patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation""",0caa06b716b45adffc8f3deb9b12b4fe4bda1c67,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
178,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation""",ce20f456354b9a522ddb9e03e0fadb605a61a244,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
181,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""had previously untreated recurrent or metastatic nasopharyngeal carcinoma.""",743d0e341ea28c1d9670362b0c6adecb21c9529c,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""had previously untreated recurrent or metastatic nasopharyngeal carcinoma""",91abde46da8b29dc47ddc94b6d5e595cd01b9f6f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
182,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we randomly assigned patients with stage IV or recurrent NSCLC""",d44806a07a0dda22a5893639e1f7bbc4aade300f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
182,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we randomly assigned patients with stage IV or recurrent NSCLC""",d44806a07a0dda22a5893639e1f7bbc4aade300f,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
183,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with previously untreated stage II or stage III triple-negative breast cancer""",f725748278e482f51738e0b84dbf4f3ca0fb0824,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
183,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with previously untreated stage II or stage III triple-negative breast cancer""",f725748278e482f51738e0b84dbf4f3ca0fb0824,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
184,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""women with HER2-positive locally advanced or inflammatory breast cancer""",9522ac15bc3bf324d82e62b97e23700b8120a2fc,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
184,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""women with HER2-positive locally advanced or inflammatory breast cancer""",9522ac15bc3bf324d82e62b97e23700b8120a2fc,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
186,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""patients with a history of colorectal adenomas""",d88c4488a5a21870904c26faf3c3df13379d9f83,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
186,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""patients with a history of colorectal adenomas""",d88c4488a5a21870904c26faf3c3df13379d9f83,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
187,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""had stage III or stage IV disease and no distant metastases""",bceb191387cd62bde07acd11830c4c6b9464abed,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
187,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""had stage III or stage IV disease and no distant metastases""",bceb191387cd62bde07acd11830c4c6b9464abed,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
188,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""among men with metastatic castration-resistant prostate cancer""",97f90d7254165d3ceb68535581bd315cc294b933,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
188,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes""",1e9e8311585edabe46c172095e5871ea096e3629,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
189,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""exemestane 25 mg a day for the primary prevention of breast cancer""",e0b645dad4ec20095c75603a4b97ee642abbdc99,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
189,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""exemestane 25 mg a day for the primary prevention of breast cancer""",e0b645dad4ec20095c75603a4b97ee642abbdc99,True,NEITHER,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
190,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer""",8334eaeb86074583ffc59ed701e2958df9a8735c,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
190,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""1803 premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer""",4299d90c351f4db3a5af8b3a783ff310c85d911f,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
191,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""documented local recurrence after surgery followed by chemotherapy""",403b61665eeee66ab251ed6a89e9f4f19d469416,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
191,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""documented local recurrence after surgery followed by chemotherapy""",403b61665eeee66ab251ed6a89e9f4f19d469416,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
194,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions""",bd6ba03a86964a041693f9b2f27650ea3710a754,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
194,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions""",bd6ba03a86964a041693f9b2f27650ea3710a754,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
195,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung""",6feeb3bf467f7d4292e3de8de361ec5ed5a73151,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
195,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung""",6feeb3bf467f7d4292e3de8de361ec5ed5a73151,True,BOTH,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
196,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We randomly assigned patients with metastatic breast cancer""",d3b009e709a41c64bb273fe64b92969349640d6b,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
196,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease""",a7272820cc6b86c5419969aa71b77026c850799c,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
197,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Patients aged 18 years and older with metastatic soft-tissue sarcomas""",e17eb61d628f9ff6f98e11266503922cbd02cdbc,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
197,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Patients aged 18 years and older with metastatic soft-tissue sarcomas""",e17eb61d628f9ff6f98e11266503922cbd02cdbc,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
198,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""after resection of localised, primary gastrointestinal stromal tumour""",118164528b0984e5ad7e0a28b4b7cce51855afa8,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
198,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""after resection of localised, primary gastrointestinal stromal tumour""",118164528b0984e5ad7e0a28b4b7cce51855afa8,True,LOCALIZED,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
199,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""men with at least one bone metastasis from castration-resistant prostate cancer""",9ad2ce92b204fec9485ebef3834d8856366cffff,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
199,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment""",2d8dcda2f7c12b6ee1dd9f79923ed5e82e4c5885,True,METASTATIC,anthropic,claude-opus-4-5-20251101,VERDICT: SUPPORTED,SUPPORTED,True,True
0,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual)""",4ff1015be14e55a6dc027019ecdd60952f227167,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
1,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma""",7eb95ff89d5d04f295084806378003c157ff248d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
2,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""advanced or metastatic soft-tissue sarcoma""",1295da81802a04e9192cf06aca1745cbf170765d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
3,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned to receive conventional treatment,a221ae2f909a5817edac074c80bb2975fac17cd6,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
4,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with advanced NSCLC""",92a4edc4f6099300b9741ae88ef7a1c2b68d4c69,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
5,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases""",791525825cbc2e242e5954ea5e81577322076b7b,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
6,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Localised prostate cancer is commonly treated with external beam radiotherapy""",2075df6469616478ab5333572552170c2af23e40,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""we recruited postmenopausal women aged 50-74 years""",825205e9fd92724e1f3afae503bd0345dc57ba91,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""we recruited postmenopausal women aged 40-70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer""",8f5a19f63c284bc566b6b3e23aa0480586670f83,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
9,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma""",bcf0f43a2e7712526ff22f78c8fb384de1bd41c9,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
10,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with HER2-positive early breast cancer""",dff881889bad66db1f693bfe1291b8f93fc1e172,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
11,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"Patients aged at least 18 years with previously untreated locally advanced cervical cancer (adenocarcinoma, squamous, or adenosquamous; International Federation of Gynaecology and Obstetrics [FIGO] 2009 stage IB2-IIB lymph node positive, stage ≥III any lymph node status)",7e0be13bc11e4041ebbd22e9f6a9233c2df3c9aa,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
13,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""5102 patients with HER2-positive early breast cancer.""",6fc60fbc97fb2b7457a5764c0b27d30038e35dd9,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
14,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer""",6e818b07a0449f0743df642ae68dcb5da4241f3a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
15,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer were randomly assigned""",236ca6b96c0ee52756b2e4c598c9b1714840e32c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
16,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.""",42230f67e81e4ec2f07ed82ff6bfb4f61ed2ba5b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
17,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast""",8fc6d07c6cb975cbfd9de12dd6da07ac5b37df01,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
18,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""we randomly assigned healthy women older than 25 years to the HPV 16/18 vaccine or control (1:1)""",caf882292f3c3b0622828cfda4e10574f5663d9e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
19,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer""",3543e5de7079dc26de26adcdc748a01b230c07cb,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
20,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer""",c789aa1f5231e28b683f55b63cc4140b811ab8f8,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations""",503d85a8a9b21b9bc5c1803cd126ceaae88989b1,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
23,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""140 patients with early breast cancer were randomly assigned""",0890677652b8ad2594a3f8720f35149d58544372,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
25,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Barcelona Clinic Liver Cancer stage B or C disease""",ee6acf7308c5058279ee836172140f729acd5690,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
26,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing""",44fac3ea7abefbd5ffca2844d5e92f5c0d6eb117,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
27,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy""",4ff243088b2431b1801bac35f0da031f143cc04e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
30,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""1500 women with axillary node-positive or high-risk node-negative breast cancer""",1ac326d32b2ff256f3ee5a674f7d25f48073a7bb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
31,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""survivors of stages 0 to III breast cancer""",d9e13e8f7c44b394195489cd210728974e1d924e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
33,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""127 patients with dysplastic Barrett's esophagus""",3f420387f846c04acbea6c4fafaf82e586317038,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
35,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy""",9a594005618b79231adb6e89183647cf9b16471f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
36,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1)",87eb828e0f5c5ff35683b3720117d5791cba812b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
38,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma""",1835ed02d5f7f875c5c2c3809f13328736c01a50,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
39,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma""",c83298140f73497cbe3fd0d573745f64b422ce3b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
40,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""615 patients with locoregional, high-risk clear-cell renal-cell carcinoma""",6fb1710a633ca3fa26cb79307bd06252c9850c07,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
42,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b""",a8469e5e1f5c48c19f8ff0ee1de2c99d3557d6ea,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
43,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""men who had newly diagnosed clinically localised prostate cancer""",3b8b754f054461eccf15f981c69dad8883b2ed11,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
44,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""We assessed the effects of combined docetaxel and estramustine on relapse in patients with high-risk localised prostate cancer.""",831b31123235a67340fdb8f3f20f175a66654602,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
45,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma""",a7c93949a9d3fbab608305bfe5f51f22e1412639,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
46,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer""",27b0089ec3d86bbc95e0452d452fbe8401a13826,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
47,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer.""",b68f41ac601a8152689fd5a890798d46b3191ab5,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
48,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we recruited patients aged 18 years or older who had received taxane therapy and undergone two or fewer previous chemotherapy regimens for metastatic breast cancer""",b32da692d78dc577beec180916efb843271fdbc7,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
49,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer""",18ee24010628b521ae0527651fcd2b316c7fb195,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
50,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""we enrolled patients with stage IIIB or IV adenocarcinoma""",85b58150810f2c94fd05d87cf5a0a2db971acf6f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
52,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""The study involved 182,160 men between the ages of 50 and 74 years at entry""",dd7ec2ad87380013f7e156ae4bde2d39ea299042,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
53,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""as adjuvant chemotherapy for operable node-positive breast cancer.""",42578a7a4ea77d80be5d931d0b83628b435dfb14,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
54,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We enrolled patients with stage IV or recurrent NSCLC""",e61aeea04d0bb3f0cbe10067e2e4c6ce9aae2699,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
55,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""finasteride significantly reduced the risk of prostate cancer""",83ff318fc4650375f1b4414008971f066b7db94a,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
57,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"enrolled 160 patients with radiologically confirmed painful bone metastases from September 19, 2014, through June 19, 2018.",e84e0a676af3c6a18e31e7f32ecc7f5faec3063b,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
58,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer""",1d7e7caf17ecbeabbf80e1bd20d1c6066b07cfda,False,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
59,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""trial in patients aged 18 years or older with HER2-positive metastatic gastric or gastro-oesophageal junction cancer.""",f6a8046916bc56ff598ee96fa82e5ff4ef08d99d,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
60,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer""",e0fa8b194e03484d945e29c1e793232b6c72eb22,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
62,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Standard treatment for locally advanced cervical cancer is chemoradiotherapy""",de0ced2cdeae5015e4c49c760fbc5c55b696318c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
63,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC)""",cab9b9359cdd091819a44ebda0376b8b814f4f7b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
65,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease""",05b5f21c2a9a961bc6d7ddd2e808e046a9c662a9,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
66,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment in this phase 3, open-label, randomised controlled trial at 85 centres in Japan.",f11560fc87d66b2648cd745c74c8a4f4b3cd1c5f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
67,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned 1:1 to 28-day cycles of atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) or atezolizumab placebo, vemurafenib, and cobimetinib (control group).",6e694d8175e339756455833fbee51942070e78bc,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
68,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Randomisation was stratified by geographical region, macrovascular portal vein invasion or extrahepatic spread or both""",323ad07c4ab7b5e2a9ed9c6bdf6472037b4c2063,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
70,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Randomization was stratified based on site of metastasis (visceral, bone only, or other)""",9eed8f758a2b678bc01936613f1603a1b183f34b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
71,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
72,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with resected stage III melanoma with BRAF V600E or V600K mutations""",f09bd903e0dfa51bbf2dec8755fa6a0b8e75c47e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
73,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,enrolled patients with T1-T2N0-2 p16-positive OPSCC,64ce7a66da3b9350c6ec61deff324c165f4fd575,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
74,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries.,bb30ac3795423051d209f329381c670f0141d023,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
75,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors""",2f960d29830303309d25eab7b6bd69ffb4550918,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
76,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings.""",f28d16785a4224a97a7d072f680b7ac63dd7f856,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
77,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,25ecd584e5b4a56896c4eee319b874a2c1548069,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
78,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer""",d4f1677604d7c50818a77525aa336404fce8ef1b,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
79,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy""",f907c613faa56569b97218213b1edc9110fc1e17,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
80,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment""",9c1c59183a809bbed82997ce1ee4fc2f5a1a89d8,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
81,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter""",5ce23330d473062f0ce23e20dc7ed49bcc1ded13,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
82,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""we randomly assigned patients 2:1 with untreated locally recurrent inoperable or metastatic triple-negative breast cancer""",530e59e039a361aef6bdecda01be6b4cd7510fc1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
84,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""479 women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized""",52154624a7bf58441edc21d252ab42fd1add94d1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
85,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C""",45347dceca54ce09502c27162d8f9f436b795435,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
86,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy""",43fafd8fd169e7e412bc5896801c0826d5433f6f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
87,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract.",fb9278c2791a54c475e36e439cc3e33ec9537dfc,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
88,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""840 patients with stage IB-IIIA NSCLC""",ce78fa129ae36d8c9267d85106f8126118809625,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
89,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus.""",40f6afe613aca56f68ab3bbb18c3f500a1b69a68,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
90,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""The effect of celecoxib, a COX-2 inhibitor, as treatment for nonmetastatic colon cancer is unknown.""",1b8615d8bdf5c122d0d522339f8a426f5d4b21d8,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
91,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""among patients with melanoma and sentinel-node metastases.""",31976c44d8beb7057dd01cfeda1040912cd5d055,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
93,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence""",54c87f68e178017ae71c2252c76ab5b05323e444,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
94,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""first-line metastatic renal cell carcinoma""",3b52cda5e6eb1229aa3ce0bc75f2c10c70a0e731,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
95,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.""",da26953ee9836d64a30801cbc76a8f15a34ef5cf,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
96,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment""",256301c3da375be8c27f88ea8f0a655c3764e1a5,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
97,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""559 patients with untreated metastatic, squamous NSCLC""",14fc370f6e6034383eb771e6f8ecdccd20262c1e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
98,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation""",b69757cb065eea51fec87605d464eaf5e3f0dc69,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
99,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs)""",47dc5286e6633cb5f65052d2bba85b86d4c9b1c7,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
100,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.""",5732978a51d07233e109bcf444d9665e0f649d1a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
101,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Patients with previously untreated, stage III-IVB (except T3-4N0) nasopharyngeal carcinoma""",27f431a1408d64a891a7d22386bf7834dfe5c42f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
102,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients with previously untreated advanced melanoma""",dcaafc830eeb03c41dba153034529b1ebd830749,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""in patients with localized completely resected high-risk ccRCC.""",230e584283d41f8f6bb09d3f43e5463330fcafaf,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
104,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma""",03f415f9e33719b9adb0cb3c466d86448460cf3f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
106,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
107,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer""",ae793456338175ac0995428dbffbcf6ede75070c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
109,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma""",2e0bcb209b02b1b660c6a753e0515329ed98f44a,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
110,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients with histologically proven, HER2-positive metastatic breast cancer""",7d38d0d335c6d9abf8e7892f675042ba2ad46716,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
111,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,previously untreated unresectable stage IIIc or stage IV melanoma,7af32f2ec7b0ed3174df20894f2640738b8c50ca,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
112,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction.""",b6b33fbea15254056651dbe04f18605c3038f275,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
113,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years""",b71ecc1d16307f4ff61eb107be177c20037a4c25,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
114,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment""",96d6cc4a08801a90159b5e658c102adb5e7835c9,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
115,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with unresectable stage IIIC or IV melanoma""",11e9fadb85f681011f47d41123159358b2f90f2e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
116,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma""",79688df7aa50c025910aa3d2513317840804f731,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
117,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.""",3a8c2754f3b5ccf378f544a227beb00f99c88c68,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
118,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)""",caaf6fda6d566b2b781edeea2c54d96dd2e78659,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
119,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with palpable T1-T2 invasive breast cancer were recruited""",311094d80875682ad3b9a873613b0d56bce94208,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
120,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients aged 18 years or older, with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer""",10a8723a2bc47bb9c825741765682babdd541ce9,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
122,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized 1:1:1 to receive adjuvant RT, CCRT, or SCRT.""",734dfc66f1a369321dfd350d3c09b5795b01455e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
123,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma""",f4800827bd42e0a3e5e59ad63c6149db83c954a0,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
124,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.""",4243d0159b95e7d66eb9410fc86a4c85f5bc2ab0,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
126,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease""",456d88c271f3025523520b59eca94989f3b9a335,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
127,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC""",d330098c362527c8c0fc9f25c22d5618dc2226da,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
128,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer""",9b4f77e8b257977fef01387baf76bcd45a32f29d,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
129,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
130,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm""",4b19644d2fc3138efbdaf7cf5376c61135fdd12f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
131,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligibility criteria included ERBB2-negative metastatic breast cancer""",8e2b228dffb6f528d7174895349654162c1ef4ae,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
132,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""trial involving patients with active rheumatoid arthritis despite methotrexate treatment""",bfeeb4985e01d3761ba4fcbc929bb4e827db9696,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
133,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
134,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients with untreated stage IV or recurrent NSCLC""",33efff137a6cd58155eb0d0d06ddeaa6a6b5bbdc,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
136,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer""",1f3739a104351deb9cde24ec13e40cdeba09639f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
138,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""advanced or metastatic adenocarcinoma of the colon or rectum""",2f19e2fd818508132ff39279f49c89226f4f738e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""523 patients with curable stage T2b, T3, or T4 gastric cancer were randomly assigned during surgery""",969146b64131c36e8a070b398cf99a135c5e63cd,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
140,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.""",9f49cb21a38ac744574562f94df408518e7822eb,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
141,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area.",705c3aed868ba525fe510bf294707e35c3b98be4,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
142,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)""",57432a17cb7aa7053bce98336d373103324c88a2,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
143,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""Patients with histologically confirmed AIN were randomly assigned to receive either 16 weeks of imiquimod (three times a week), 16 weeks of topical fluorouracil (twice a week), or monthly electrocautery for 4 months.""",3644f7e378d6917fcef3310ada90d9c1e849df3c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
144,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we randomly assigned patients with spinal cord compression caused by metastatic cancer""",d933ed9e6709b3f5a2a7a261a9b531930b09239f,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
145,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy""",c16f8ca3f52c3e17d98b2dc99ec9c1c0f86d16d7,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
146,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States.""",2de6fa28760472b06638f1df555b31547cda6827,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
147,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer""",fa1bb5d29986a28699551aa5d0ae119e6d357b3a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
148,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.""",c390a3924587575a18fc4500a3e002711ed3b588,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
149,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors""",1b94424e45a3b69efd550d8b620f81a8d5230a3c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
151,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.""",517d694e1af036d28860bf23f2b13b022b9d374d,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
152,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We included chemotherapy-naive men (aged ≥18 years) with mCRPC""",6a69fccdc6d285db6f76d7fe85ca6e9ce2a50b95,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
153,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment""",8089587e09d6b5b20f8e34a02dc3430bea3ee904,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
154,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""women with HER2-positive breast cancer with progressive brain metastases""",027def017940daf376745d22ea8451fbe5d502ae,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
155,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer""",e3a7b0ad7b355e68aa420df618198a97d0f53237,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
156,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""with clinical stage I endometrial or cervical cancer undergoing curative surgery""",36282199e9cda6ec27e20b233714f9e1b3d6fd8a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
157,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""we enrolled patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less.""",b6a4e63ddc3092b491cbfd3a3aba2357a1961169,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
158,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
159,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""radiation therapy to the primary tumour site plus meta-iodobenzylguanidine avid metastases present before myeloablative therapy""",e9855d32d7ae7db785abe78e7ff0610f27348f3b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
160,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy""",40c89ddac97d040b0724fb4ed9135a8d69f35e12,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
162,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer""",6f72cb8719293462c54d0b73e23deb8569b9bd01,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
163,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer""",1c478e87dcc88406a02c20f5e45dd56a4374079e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
164,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation""",e1bba7b445c37298184b0a7b6cb77e1f1b6c0bf7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane""",fd1996c52fb6536a44bea5442ef04ebdc1934485,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
167,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.""",5a600a145b0b23da959e2f2c6af55a88b1431263,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
169,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We enrolled female patients with HER2-overexpressing metastatic breast cancer who had progressed on or following adjuvant trastuzumab or first-line treatment of metastatic disease with trastuzumab.""",0d325e453020e66c3f8ef2b413d1da33dadf5178,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
170,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""we screened 3100 first-degree relatives of patients with gastric cancer.""",4f257a0c5636f406a7ecea0d4091181f7217f9d6,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
171,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""recurrence of hormone-receptor-positive early breast cancer in premenopausal women""",a6d7365e9384eb318b8b4c200674399212017498,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
173,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""enhances tumor response in patients with metastatic NSCLC.""",bdccdcc2c0c155c20ed9f49856df4e4491d2179d,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
174,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""170 432 eligible men and women, who had indicated on a previous questionnaire that they would probably attend screening if invited, were randomly assigned (1:2) to an intervention group (offered flexible sigmoidoscopy screening) or a control group (not contacted).""",5393df4c4d1977a61d517ef534c97e034eddc3a1,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
175,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with locally advanced or metastatic non-small-cell lung cancer""",92c818e306e91a3da2710903d9574f6827920ace,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
176,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects)""",770000892fd7ee126223181170b34b8cde3a4396,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
177,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with stage III or IVA endometrial carcinoma""",65d8b67032e4ffdaaeb25be205b7e6e3a085afaa,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
178,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation""",ce20f456354b9a522ddb9e03e0fadb605a61a244,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
181,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""had previously untreated recurrent or metastatic nasopharyngeal carcinoma""",91abde46da8b29dc47ddc94b6d5e595cd01b9f6f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
182,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we randomly assigned patients with stage IV or recurrent NSCLC""",d44806a07a0dda22a5893639e1f7bbc4aade300f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
183,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with previously untreated stage II or stage III triple-negative breast cancer""",f725748278e482f51738e0b84dbf4f3ca0fb0824,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
184,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""women with HER2-positive locally advanced or inflammatory breast cancer""",9522ac15bc3bf324d82e62b97e23700b8120a2fc,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
186,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""patients with a history of colorectal adenomas""",d88c4488a5a21870904c26faf3c3df13379d9f83,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
187,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""stage III or stage IV disease and no distant metastases""",dc4e44d8380b38d0f13e206aa4e1af05a0f19370,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
188,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""among men with metastatic castration-resistant prostate cancer""",97f90d7254165d3ceb68535581bd315cc294b933,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
189,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""exemestane 25 mg a day for the primary prevention of breast cancer""",e0b645dad4ec20095c75603a4b97ee642abbdc99,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
190,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""1803 premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer""",4299d90c351f4db3a5af8b3a783ff310c85d911f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
191,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""documented local recurrence after surgery followed by chemotherapy""",403b61665eeee66ab251ed6a89e9f4f19d469416,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
194,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions, Eastern Cooperative Oncology Group score of 0-1, and a life expectancy of at least 6 months were eligible.",a2bb26ee3f4690b802f9ac765f68896bb4dff919,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
195,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung""",6feeb3bf467f7d4292e3de8de361ec5ed5a73151,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
196,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We randomly assigned patients with metastatic breast cancer""",d3b009e709a41c64bb273fe64b92969349640d6b,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
197,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"Patients aged 18 years and older with metastatic soft-tissue sarcomas, an Eastern Cooperative Oncology Group performance status of 0-2, and who had previously received treatment with anthracycline and ifosfamide were randomly assigned (1:1)",702058ff4ccf56d803acf4dc9cf4fd8f894af711,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
198,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""after resection of localised, primary gastrointestinal stromal tumour""",118164528b0984e5ad7e0a28b4b7cce51855afa8,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
199,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment""",2d8dcda2f7c12b6ee1dd9f79923ed5e82e4c5885,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
0,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with resectable NSCLC (stage II to IIIB [N2 node stage]""",bf2ab166578945b59702e53b56dec487b809e250,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
0,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual)""",8652d19d3af47554676d4d308bfa861684af24ea,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
1,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma""",7eb95ff89d5d04f295084806378003c157ff248d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
1,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma""",7eb95ff89d5d04f295084806378003c157ff248d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
2,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""advanced or metastatic soft-tissue sarcoma""",1295da81802a04e9192cf06aca1745cbf170765d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
2,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""advanced or metastatic soft-tissue sarcoma""",1295da81802a04e9192cf06aca1745cbf170765d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
3,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned to receive conventional treatment,a221ae2f909a5817edac074c80bb2975fac17cd6,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
3,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned to receive conventional treatment,a221ae2f909a5817edac074c80bb2975fac17cd6,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
4,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with advanced NSCLC progressing after second-line or further treatment.""",dcae6cbb68d38e056dc1e1ccb363860095c3acf6,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases""",791525825cbc2e242e5954ea5e81577322076b7b,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
5,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases""",1513f8bc2b47bf531ab2184f5d460982913a8172,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
6,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Localised prostate cancer is commonly treated with external beam radiotherapy""",2075df6469616478ab5333572552170c2af23e40,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
6,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Localised prostate cancer is commonly treated with external beam radiotherapy""",2075df6469616478ab5333572552170c2af23e40,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
7,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""we recruited postmenopausal women aged 50-74 years""",825205e9fd92724e1f3afae503bd0345dc57ba91,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""we recruited postmenopausal women aged 50-74 years""",825205e9fd92724e1f3afae503bd0345dc57ba91,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""we recruited postmenopausal women aged 40-70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer""",8f5a19f63c284bc566b6b3e23aa0480586670f83,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
8,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""we recruited postmenopausal women aged 40-70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer""",8f5a19f63c284bc566b6b3e23aa0480586670f83,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
9,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma""",bcf0f43a2e7712526ff22f78c8fb384de1bd41c9,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
9,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma""",bcf0f43a2e7712526ff22f78c8fb384de1bd41c9,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
10,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer""",1cb68dbec11268ea57f620e713080ed3c582315c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
10,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer""",1cb68dbec11268ea57f620e713080ed3c582315c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
11,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"Patients aged at least 18 years with previously untreated locally advanced cervical cancer (adenocarcinoma, squamous, or adenosquamous; International Federation of Gynaecology and Obstetrics [FIGO] 2009 stage IB2-IIB lymph node positive, stage ≥III any lymph node status)",7e0be13bc11e4041ebbd22e9f6a9233c2df3c9aa,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
11,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"Patients aged at least 18 years with previously untreated locally advanced cervical cancer (adenocarcinoma, squamous, or adenosquamous; International Federation of Gynaecology and Obstetrics [FIGO] 2009 stage IB2-IIB lymph node positive, stage ≥III any lymph node status)",7e0be13bc11e4041ebbd22e9f6a9233c2df3c9aa,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
13,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""5102 patients with HER2-positive early breast cancer""",5ef2820aaf9ab4b1d097210517a38aba2c89338e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
13,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""5102 patients with HER2-positive early breast cancer""",5ef2820aaf9ab4b1d097210517a38aba2c89338e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
14,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer""",6e818b07a0449f0743df642ae68dcb5da4241f3a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
14,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer""",6e818b07a0449f0743df642ae68dcb5da4241f3a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
15,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer""",c85bb6f05c217b7b29f7980927c7792a658c531e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
15,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer""",c85bb6f05c217b7b29f7980927c7792a658c531e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
16,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.""",42230f67e81e4ec2f07ed82ff6bfb4f61ed2ba5b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
16,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.""",42230f67e81e4ec2f07ed82ff6bfb4f61ed2ba5b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
17,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast""",8fc6d07c6cb975cbfd9de12dd6da07ac5b37df01,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
17,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast""",8fc6d07c6cb975cbfd9de12dd6da07ac5b37df01,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
18,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""we randomly assigned healthy women older than 25 years to the HPV 16/18 vaccine or control (1:1)""",caf882292f3c3b0622828cfda4e10574f5663d9e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
18,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""we randomly assigned healthy women older than 25 years to the HPV 16/18 vaccine or control (1:1)""",caf882292f3c3b0622828cfda4e10574f5663d9e,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
19,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer""",3543e5de7079dc26de26adcdc748a01b230c07cb,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
19,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer""",3543e5de7079dc26de26adcdc748a01b230c07cb,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
20,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer""",c789aa1f5231e28b683f55b63cc4140b811ab8f8,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
20,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer""",c789aa1f5231e28b683f55b63cc4140b811ab8f8,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
21,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with previously untreated advanced NSCLC with an EGFR mutation""",b904abcb80c192af806439fedd28334b12cb7362,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations""",503d85a8a9b21b9bc5c1803cd126ceaae88989b1,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
22,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations""",503d85a8a9b21b9bc5c1803cd126ceaae88989b1,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
23,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""140 patients with early breast cancer were randomly assigned""",0890677652b8ad2594a3f8720f35149d58544372,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
23,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""140 patients with early breast cancer were randomly assigned""",0890677652b8ad2594a3f8720f35149d58544372,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
25,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Barcelona Clinic Liver Cancer stage B or C disease""",ee6acf7308c5058279ee836172140f729acd5690,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
25,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""Barcelona Clinic Liver Cancer stage B or C disease""",ee6acf7308c5058279ee836172140f729acd5690,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
26,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing""",44fac3ea7abefbd5ffca2844d5e92f5c0d6eb117,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
26,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing""",44fac3ea7abefbd5ffca2844d5e92f5c0d6eb117,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
27,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned (1:1) to receive either open or laparoscopic surgery.""",40a3b1148cd4ea4f88bebde1187024c10a289d06,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
27,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned (1:1) to receive either open or laparoscopic surgery.""",40a3b1148cd4ea4f88bebde1187024c10a289d06,True,LOCALIZED,gemini,gemini-3-flash-preview,"0, which fits the definition of LOCALIZED.",INVALID,False,
30,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""1500 women with axillary node-positive or high-risk node-negative breast cancer""",1ac326d32b2ff256f3ee5a674f7d25f48073a7bb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
30,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""1500 women with axillary node-positive or high-risk node-negative breast cancer""",1ac326d32b2ff256f3ee5a674f7d25f48073a7bb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
31,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""survivors of stages 0 to III breast cancer""",d9e13e8f7c44b394195489cd210728974e1d924e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
31,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously""",bd5381973db04fcb2f620532631dfa8594a97fc8,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
33,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""127 patients with dysplastic Barrett's esophagus""",3f420387f846c04acbea6c4fafaf82e586317038,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
33,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""127 patients with dysplastic Barrett's esophagus""",3f420387f846c04acbea6c4fafaf82e586317038,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
35,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy.""",b49797e3c8aff38eda554e235d45aedee9cda2f7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
35,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy""",9a594005618b79231adb6e89183647cf9b16471f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
36,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1)",87eb828e0f5c5ff35683b3720117d5791cba812b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
36,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations""",f60504f6eb8415503d2a93b7858cf6f864a52a74,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
38,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma""",1835ed02d5f7f875c5c2c3809f13328736c01a50,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
38,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma""",1835ed02d5f7f875c5c2c3809f13328736c01a50,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
39,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma""",c83298140f73497cbe3fd0d573745f64b422ce3b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
39,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""unresectable stage IIIC or stage IV melanoma""",412941f42a2ca5bddcd1f26cf8d863909f8031c5,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
40,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""we assigned 615 patients with locoregional, high-risk clear-cell renal-cell carcinoma""",c0d0b60854063ddcdca9d044704023816c0aaa0b,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
40,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with locoregional, high-risk clear-cell renal-cell carcinoma""",427a61fdf11c46b8799716a9bf8e7bfbc01bbea0,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
42,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627),b1c09b3e60339f032a3371c9409dd5cba859d47c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
42,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627),b1c09b3e60339f032a3371c9409dd5cba859d47c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
43,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""men who had newly diagnosed clinically localised prostate cancer""",3b8b754f054461eccf15f981c69dad8883b2ed11,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
43,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer,59a3763c94c3f0cac7eec1001ce3b4f98d515821,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
44,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""We enrolled patients with treatment-naive prostate cancer and at least one risk factor (ie, stage T3-T4 disease, Gleason score of ≥8, prostate-specific antigen concentration >20 ng/mL, or pathological node-positive).""",d7662cb65997ad633274a61028c2e3b0363bb7b5,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
44,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""We enrolled patients with treatment-naive prostate cancer and at least one risk factor (ie, stage T3-T4 disease, Gleason score of ≥8, prostate-specific antigen concentration >20 ng/mL, or pathological node-positive).""",d7662cb65997ad633274a61028c2e3b0363bb7b5,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
45,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma""",a7c93949a9d3fbab608305bfe5f51f22e1412639,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
45,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma""",a7c93949a9d3fbab608305bfe5f51f22e1412639,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
46,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer""",27b0089ec3d86bbc95e0452d452fbe8401a13826,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
46,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer""",27b0089ec3d86bbc95e0452d452fbe8401a13826,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
47,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""adjuvant therapy in patients with resected pancreatic cancer.""",2d40581a4469011e734edddaf5efc0c7000bf8cb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
47,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with resected pancreatic cancer""",3ef34bfff309c5c5a47a9c2162c50f3840172a20,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
48,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with previously treated metastatic breast cancer""",90363ddf8d53793a44c0f22d3cf63252f7e41c5b,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
48,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we recruited patients aged 18 years or older who had received taxane therapy and undergone two or fewer previous chemotherapy regimens for metastatic breast cancer""",b32da692d78dc577beec180916efb843271fdbc7,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
49,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer""",18ee24010628b521ae0527651fcd2b316c7fb195,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
49,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer""",18ee24010628b521ae0527651fcd2b316c7fb195,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
50,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""we enrolled patients with stage IIIB or IV adenocarcinoma""",85b58150810f2c94fd05d87cf5a0a2db971acf6f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
50,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""we enrolled patients with stage IIIB or IV adenocarcinoma""",85b58150810f2c94fd05d87cf5a0a2db971acf6f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
52,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""The study involved 182,160 men between the ages of 50 and 74 years at entry""",dd7ec2ad87380013f7e156ae4bde2d39ea299042,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
52,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""The study involved 182,160 men between the ages of 50 and 74 years at entry""",dd7ec2ad87380013f7e156ae4bde2d39ea299042,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
53,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""as adjuvant chemotherapy for operable node-positive breast cancer.""",42578a7a4ea77d80be5d931d0b83628b435dfb14,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
53,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""as adjuvant chemotherapy for operable node-positive breast cancer.""",42578a7a4ea77d80be5d931d0b83628b435dfb14,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
54,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We enrolled patients with stage IV or recurrent NSCLC""",e61aeea04d0bb3f0cbe10067e2e4c6ce9aae2699,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
54,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""We enrolled patients with stage IV or recurrent NSCLC""",e61aeea04d0bb3f0cbe10067e2e4c6ce9aae2699,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
55,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""finasteride significantly reduced the risk of prostate cancer""",83ff318fc4650375f1b4414008971f066b7db94a,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
55,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""Finasteride reduced the risk of prostate cancer""",c18e39615052e8159df5e84392902eab4f877f47,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
57,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""enrolled 160 patients with radiologically confirmed painful bone metastases""",66dfe16afde749c512f3a9f75ab7f8a67e75f055,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
57,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""enrolled 160 patients with radiologically confirmed painful bone metastases""",66dfe16afde749c512f3a9f75ab7f8a67e75f055,True,METASTATIC,gemini,gemini-3-flash-preview,"Conclusion: SUPPORTED.

    *Wait",INVALID,False,
58,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer""",1d7e7caf17ecbeabbf80e1bd20d1c6066b07cfda,False,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
58,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer""",6d607229d8c616539211c9914e6f8c6205324446,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
59,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""trial in patients aged 18 years or older with HER2-positive metastatic gastric or gastro-oesophageal junction cancer.""",f6a8046916bc56ff598ee96fa82e5ff4ef08d99d,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
59,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""trial in patients aged 18 years or older with HER2-positive metastatic gastric or gastro-oesophageal junction cancer.""",f6a8046916bc56ff598ee96fa82e5ff4ef08d99d,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
60,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer""",e0fa8b194e03484d945e29c1e793232b6c72eb22,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
60,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer""",e0fa8b194e03484d945e29c1e793232b6c72eb22,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
62,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease)""",0a2d4bf3ff1786514a13b2152a4b67a437955f1d,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
62,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease)""",0a2d4bf3ff1786514a13b2152a4b67a437955f1d,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
63,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC)""",cab9b9359cdd091819a44ebda0376b8b814f4f7b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
63,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) who had disease progression after receiving EGFR tyrosine-kinase inhibitor therapy.""",138a6be02add95b59b03464abbb7f916204520a1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
65,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""these patients included infants (<365 days of age) who had stage 3 or 4 disease""",1925825c4892fc3f99c27c6143b3201d6c3e886c,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
65,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""these patients included infants (<365 days of age) who had stage 3 or 4 disease""",1925825c4892fc3f99c27c6143b3201d6c3e886c,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
66,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment in this phase 3, open-label, randomised controlled trial at 85 centres in Japan.",f11560fc87d66b2648cd745c74c8a4f4b3cd1c5f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
66,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment in this phase 3, open-label, randomised controlled trial at 85 centres in Japan.",f11560fc87d66b2648cd745c74c8a4f4b3cd1c5f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
67,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma""",d560c77a9e6e10afd91ea8edeb1b77e5446919ce,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
67,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned 1:1 to 28-day cycles of atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) or atezolizumab placebo, vemurafenib, and cobimetinib (control group).",6e694d8175e339756455833fbee51942070e78bc,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
68,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Randomisation was stratified by geographical region, macrovascular portal vein invasion or extrahepatic spread or both""",323ad07c4ab7b5e2a9ed9c6bdf6472037b4c2063,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
68,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""macrovascular portal vein invasion or extrahepatic spread or both""",bc50d7f7d96fef6c6a77c7bc83c8c32e96d1415e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
70,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Randomization was stratified based on site of metastasis (visceral, bone only, or other)""",9eed8f758a2b678bc01936613f1603a1b183f34b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
70,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Randomization was stratified based on site of metastasis (visceral, bone only, or other)""",9eed8f758a2b678bc01936613f1603a1b183f34b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
71,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer""",fa5e203b4aad68d3d2f144bfed4da58e9b60ed6c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
71,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
72,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with resected stage III melanoma with BRAF V600E or V600K mutations""",f09bd903e0dfa51bbf2dec8755fa6a0b8e75c47e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
72,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients who had resected stage III melanoma with BRAF V600E or V600K mutations""",2fc9d6cd70ee123c59df87c0bbaa58a1f4743652,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
73,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,enrolled patients with T1-T2N0-2 p16-positive OPSCC,64ce7a66da3b9350c6ec61deff324c165f4fd575,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
73,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,enrolled patients with T1-T2N0-2 p16-positive OPSCC,64ce7a66da3b9350c6ec61deff324c165f4fd575,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
74,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries.,bb30ac3795423051d209f329381c670f0141d023,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
74,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries.,bb30ac3795423051d209f329381c670f0141d023,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
75,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors""",2f960d29830303309d25eab7b6bd69ffb4550918,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
75,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors""",2f960d29830303309d25eab7b6bd69ffb4550918,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
76,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""among 5999 participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings.""",6f0710a8947e4176e0c54f32b4c48a190e1ff1ba,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
76,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings.""",f28d16785a4224a97a7d072f680b7ac63dd7f856,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
77,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,25ecd584e5b4a56896c4eee319b874a2c1548069,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
77,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,25ecd584e5b4a56896c4eee319b874a2c1548069,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
78,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer""",d4f1677604d7c50818a77525aa336404fce8ef1b,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
78,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer""",d4f1677604d7c50818a77525aa336404fce8ef1b,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
79,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy""",f907c613faa56569b97218213b1edc9110fc1e17,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
79,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy""",f907c613faa56569b97218213b1edc9110fc1e17,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
80,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment""",9c1c59183a809bbed82997ce1ee4fc2f5a1a89d8,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
80,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment""",4a8cf56ab851cfbf7e54607b9045867dc1eb2395,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
81,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter""",5ce23330d473062f0ce23e20dc7ed49bcc1ded13,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
81,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter""",5ce23330d473062f0ce23e20dc7ed49bcc1ded13,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
82,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""patients with untreated locally recurrent inoperable or metastatic triple-negative breast cancer""",e023d806bb4b160c343f708723a2cd2e3e257ddb,False,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
82,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""untreated locally recurrent inoperable or metastatic triple-negative breast cancer""",92e265c019e9cb321c2a50d2b720940bf1075e7a,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
84,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""479 women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized""",52154624a7bf58441edc21d252ab42fd1add94d1,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
84,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""479 women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized to 1 of 2 treatment arms""",9c9a7b7a9d505120eaf392a74757c1df810ee5b2,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
85,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C""",45347dceca54ce09502c27162d8f9f436b795435,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
85,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C""",45347dceca54ce09502c27162d8f9f436b795435,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
86,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy""",43fafd8fd169e7e412bc5896801c0826d5433f6f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
86,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""enrolling patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy""",9203da80d71bcd97750ef00459f7237628a25f13,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
87,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract.",fb9278c2791a54c475e36e439cc3e33ec9537dfc,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
87,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract.""",1eeb2256f4273bd4645c2d33b7cc91a36a14ae76,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
88,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""840 patients with stage IB-IIIA NSCLC""",ce78fa129ae36d8c9267d85106f8126118809625,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
88,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""840 patients with stage IB-IIIA NSCLC""",ce78fa129ae36d8c9267d85106f8126118809625,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
89,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus.""",40f6afe613aca56f68ab3bbb18c3f500a1b69a68,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
89,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus.""",40f6afe613aca56f68ab3bbb18c3f500a1b69a68,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
90,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""A total of 2526 patients with stage III colon cancer were enrolled""",ad65bb9951f13ac2dcb8fd34ea1c3097eb6f0223,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
90,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""The effect of celecoxib, a COX-2 inhibitor, as treatment for nonmetastatic colon cancer is unknown.""",1b8615d8bdf5c122d0d522339f8a426f5d4b21d8,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
91,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with node-positive intermediate-thickness melanomas (1.2 to 3.5 mm)""",4b914be7299eb8af652df239e8615613d9f6493e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
91,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""among patients with melanoma and sentinel-node metastases""",df2a91818bb71d7537b5152d1ff46b88d703f914,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
93,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence""",54c87f68e178017ae71c2252c76ab5b05323e444,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
93,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence""",54c87f68e178017ae71c2252c76ab5b05323e444,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
94,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""first-line metastatic renal cell carcinoma""",3b52cda5e6eb1229aa3ce0bc75f2c10c70a0e731,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
94,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""first-line metastatic renal cell carcinoma""",3b52cda5e6eb1229aa3ce0bc75f2c10c70a0e731,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
95,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
95,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.""",da26953ee9836d64a30801cbc76a8f15a34ef5cf,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
96,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment""",256301c3da375be8c27f88ea8f0a655c3764e1a5,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
96,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment""",256301c3da375be8c27f88ea8f0a655c3764e1a5,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
97,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""559 patients with untreated metastatic, squamous NSCLC""",14fc370f6e6034383eb771e6f8ecdccd20262c1e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
97,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""559 patients with untreated metastatic, squamous NSCLC""",14fc370f6e6034383eb771e6f8ecdccd20262c1e,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
98,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation""",b69757cb065eea51fec87605d464eaf5e3f0dc69,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
98,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation""",b69757cb065eea51fec87605d464eaf5e3f0dc69,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
99,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs)""",47dc5286e6633cb5f65052d2bba85b86d4c9b1c7,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
99,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs)""",47dc5286e6633cb5f65052d2bba85b86d4c9b1c7,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
100,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.""",5732978a51d07233e109bcf444d9665e0f649d1a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
100,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.""",5732978a51d07233e109bcf444d9665e0f649d1a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
101,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Patients with previously untreated, stage III-IVB (except T3-4N0) nasopharyngeal carcinoma""",27f431a1408d64a891a7d22386bf7834dfe5c42f,True,LOCALIZED,gemini,gemini-3-flash-preview,: T4 or N3.,INVALID,False,
101,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Patients with previously untreated, stage III-IVB (except T3-4N0) nasopharyngeal carcinoma""",27f431a1408d64a891a7d22386bf7834dfe5c42f,True,LOCALIZED,gemini,gemini-3-flash-preview,"IVB support the ""LOCALIZED"" label (",INVALID,False,
102,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with previously untreated advanced melanoma""",dcaafc830eeb03c41dba153034529b1ebd830749,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
102,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with previously untreated advanced melanoma""",dcaafc830eeb03c41dba153034529b1ebd830749,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.""",ff106cff6f82e4af66967d2e4c4adb0d35c78b76,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
103,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.""",ff106cff6f82e4af66967d2e4c4adb0d35c78b76,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
104,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma""",03f415f9e33719b9adb0cb3c466d86448460cf3f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
104,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma""",03f415f9e33719b9adb0cb3c466d86448460cf3f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
105,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Patients with small-cell lung cancer that responded to first-line treatment but showed evidence of disease relapse or progression at least 90 days after completion of the first-line treatment were eligible to participate.""",5172d251905a57d43546372b9791091e40b8c64c,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
106,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible patients had newly diagnosed metastatic prostate cancer.""",92bf4c8c181840c1e6b85ede53e4e6a7b2565bca,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
106,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
107,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer""",ae793456338175ac0995428dbffbcf6ede75070c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
107,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer""",ae793456338175ac0995428dbffbcf6ede75070c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
109,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma""",2e0bcb209b02b1b660c6a753e0515329ed98f44a,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
109,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma""",2e0bcb209b02b1b660c6a753e0515329ed98f44a,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
110,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with histologically proven, HER2-positive metastatic breast cancer""",7d38d0d335c6d9abf8e7892f675042ba2ad46716,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
110,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""in patients with histologically proven, HER2-positive metastatic breast cancer""",0bda1878459cf8910a5d3f04a849e0ef09fe988d,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
111,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""previously untreated unresectable stage IIIc or stage IV melanoma""",e46dd441c00b51d1b55e22d4973575c6d3d877ae,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
111,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""with previously untreated unresectable stage IIIc or stage IV melanoma""",81d68cc660739cbe06410243d084d719c6b4bc19,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
112,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction""",7dd6043baeec8a77b8812eec4208a6e9bc4b25a4,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
112,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction.""",b6b33fbea15254056651dbe04f18605c3038f275,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
113,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years""",b71ecc1d16307f4ff61eb107be177c20037a4c25,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
113,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years""",b71ecc1d16307f4ff61eb107be177c20037a4c25,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
114,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment""",96d6cc4a08801a90159b5e658c102adb5e7835c9,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
114,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment""",96d6cc4a08801a90159b5e658c102adb5e7835c9,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
115,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""patients with unresectable stage IIIC or IV melanoma""",11e9fadb85f681011f47d41123159358b2f90f2e,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
115,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""we randomly assigned patients with unresectable stage IIIC or IV melanoma""",8ac745e2e3d1ff6895195e2efee2f8b719930830,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
116,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma""",79688df7aa50c025910aa3d2513317840804f731,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
116,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma""",79688df7aa50c025910aa3d2513317840804f731,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
117,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.""",3a8c2754f3b5ccf378f544a227beb00f99c88c68,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
117,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.""",3a8c2754f3b5ccf378f544a227beb00f99c88c68,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
118,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Eligible patients were aged 18-75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)""",57880f1da72449c8aac9386dacfdba30d8619b10,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
118,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)""",caaf6fda6d566b2b781edeea2c54d96dd2e78659,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
119,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with palpable T1-T2 invasive breast cancer were recruited""",311094d80875682ad3b9a873613b0d56bce94208,True,LOCALIZED,gemini,gemini-3-flash-preview,2 indicates the primary tumor size. If the study were for,INVALID,False,
119,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with palpable T1-T2 invasive breast cancer""",798e1eb45dec97bef742ad0128671785a60c2856,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
120,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer""",f90c6498c663cd41f570061741fcfc0aa989693f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
120,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""patients aged 18 years or older, with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer""",10a8723a2bc47bb9c825741765682babdd541ce9,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
122,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized""",b80a615ca2d43e6e4e50908741fd05deb0cb2e8c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
122,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized 1:1:1 to receive adjuvant RT, CCRT, or SCRT.""",734dfc66f1a369321dfd350d3c09b5795b01455e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
123,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma""",f4800827bd42e0a3e5e59ad63c6149db83c954a0,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
123,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma""",f4800827bd42e0a3e5e59ad63c6149db83c954a0,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
124,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall""",af4b8599baca419dc0def290cb5edb0da963922f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
124,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.""",4243d0159b95e7d66eb9410fc86a4c85f5bc2ab0,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
126,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease""",456d88c271f3025523520b59eca94989f3b9a335,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
126,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease""",456d88c271f3025523520b59eca94989f3b9a335,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
127,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC""",d330098c362527c8c0fc9f25c22d5618dc2226da,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
127,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC were enrolled""",d91146e6bb9b20c83651761dc559f57c95629cdb,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
128,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer""",9b4f77e8b257977fef01387baf76bcd45a32f29d,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
128,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer""",9b4f77e8b257977fef01387baf76bcd45a32f29d,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
129,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
129,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
130,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm""",4b19644d2fc3138efbdaf7cf5376c61135fdd12f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
130,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm""",4b19644d2fc3138efbdaf7cf5376c61135fdd12f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
131,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
131,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
132,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""trial involving patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor.""",2682199328c3da0ac39fc56e8fe0be6412ea95ef,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
132,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""We conducted a randomized, open-label, noninferiority, postauthorization, safety end-point trial involving patients with active rheumatoid arthritis despite methotrexate treatment""",b5d568091752b3bcdeecd8ff51fb0faf12292c52,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
133,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
133,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
134,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with untreated stage IV or recurrent NSCLC""",33efff137a6cd58155eb0d0d06ddeaa6a6b5bbdc,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
134,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with untreated stage IV or recurrent NSCLC""",33efff137a6cd58155eb0d0d06ddeaa6a6b5bbdc,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
136,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer""",1f3739a104351deb9cde24ec13e40cdeba09639f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
136,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer""",1f3739a104351deb9cde24ec13e40cdeba09639f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
138,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum""",3e7c76a8a46d7d086f63cb923024fab09297eec3,False,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum""",660fbabf16f117bc0651ea2929bfae53d1dce371,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with curable stage T2b, T3, or T4 gastric cancer""",f0b36688c886d85ee84962717b18556b112942e3,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
139,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""523 patients with curable stage T2b, T3, or T4 gastric cancer""",9fe65f075474b6531137c7c7d507c352f5b9a52a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
140,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy""",1105b7cb6258bef7c64f643a10414adc15c1e2c9,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
140,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.""",9f49cb21a38ac744574562f94df408518e7822eb,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
141,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area.",705c3aed868ba525fe510bf294707e35c3b98be4,True,METASTATIC,gemini,gemini-3-flash-preview,"thought
*   Label: METASTATIC (Only patients with distant metastatic disease are eligible).
    *   Quote: ""Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area.""
    *   Analysis: The quote explicitly states ""Eligible patients... had metastatic cancer"". It does not mention patients with localized disease being eligible.
    *   Conclusion: The quote supports the label METASTATIC.

    VERDICT: SUPPORTEDVERDICT: SUPPORTED",INVALID,False,
141,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area.",705c3aed868ba525fe510bf294707e35c3b98be4,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
142,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)""",57432a17cb7aa7053bce98336d373103324c88a2,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
142,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)""",57432a17cb7aa7053bce98336d373103324c88a2,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
143,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""Patients with histologically confirmed AIN were randomly assigned to receive either 16 weeks of imiquimod (three times a week), 16 weeks of topical fluorouracil (twice a week), or monthly electrocautery for 4 months.""",3644f7e378d6917fcef3310ada90d9c1e849df3c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
143,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""Patients with histologically confirmed AIN were randomly assigned to receive either 16 weeks of imiquimod (three times a week), 16 weeks of topical fluorouracil (twice a week), or monthly electrocautery for 4 months.""",3644f7e378d6917fcef3310ada90d9c1e849df3c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
144,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we randomly assigned patients with spinal cord compression caused by metastatic cancer""",d933ed9e6709b3f5a2a7a261a9b531930b09239f,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
144,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we randomly assigned patients with spinal cord compression caused by metastatic cancer""",d933ed9e6709b3f5a2a7a261a9b531930b09239f,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
145,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy""",c16f8ca3f52c3e17d98b2dc99ec9c1c0f86d16d7,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
145,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy""",c16f8ca3f52c3e17d98b2dc99ec9c1c0f86d16d7,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
146,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States.""",2de6fa28760472b06638f1df555b31547cda6827,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
146,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States.""",2de6fa28760472b06638f1df555b31547cda6827,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
147,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer""",fa1bb5d29986a28699551aa5d0ae119e6d357b3a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
147,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer""",fa1bb5d29986a28699551aa5d0ae119e6d357b3a,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
148,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.""",c390a3924587575a18fc4500a3e002711ed3b588,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
148,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.""",c390a3924587575a18fc4500a3e002711ed3b588,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
149,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.""",f21d9dcba719e4c7d4b7b11a24127ab157ce6c96,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
149,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.""",f21d9dcba719e4c7d4b7b11a24127ab157ce6c96,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
150,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""we enrolled patients with a histologically proven superficial basal-cell carcinoma""",9751294cd75e0aee278069973f0a2c09bfbe3271,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
151,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.""",517d694e1af036d28860bf23f2b13b022b9d374d,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
151,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.""",517d694e1af036d28860bf23f2b13b022b9d374d,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
152,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We included chemotherapy-naive men (aged ≥18 years) with mCRPC""",6a69fccdc6d285db6f76d7fe85ca6e9ce2a50b95,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
152,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""We included chemotherapy-naive men (aged ≥18 years) with mCRPC""",6a69fccdc6d285db6f76d7fe85ca6e9ce2a50b95,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
153,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment""",8089587e09d6b5b20f8e34a02dc3430bea3ee904,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
153,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment""",8089587e09d6b5b20f8e34a02dc3430bea3ee904,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
154,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""women with HER2-positive breast cancer with progressive brain metastases during or after treatment with trastuzumab, lapatinib, or both, were eligible.""",02a98f806a0f5e1f0f5eaa27d696d2d9b69282fe,False,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
154,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""women with HER2-positive breast cancer with progressive brain metastases""",027def017940daf376745d22ea8451fbe5d502ae,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
155,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer""",e3a7b0ad7b355e68aa420df618198a97d0f53237,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
155,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer""",e3a7b0ad7b355e68aa420df618198a97d0f53237,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
156,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery""",e363714a711912055cf2c55ea3be914025589a34,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
156,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery""",e363714a711912055cf2c55ea3be914025589a34,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
157,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""we enrolled patients with prostate cancer who had high-risk biochemical recurrence""",a4e03d4a21c3558ce3903ac5f4cb5142851e0d70,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
157,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""we enrolled patients with prostate cancer who had high-risk biochemical recurrence""",a4e03d4a21c3558ce3903ac5f4cb5142851e0d70,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
158,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned to TME preceded by 5 × 5 Gy radiotherapy or TME alone (ratio 1:1).,c101f9b89e3da615992555b66701392feaba40da,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
158,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
159,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""radiation therapy to the primary tumour site plus meta-iodobenzylguanidine avid metastases present before myeloablative therapy""",e9855d32d7ae7db785abe78e7ff0610f27348f3b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
159,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""radiation therapy to the primary tumour site plus meta-iodobenzylguanidine avid metastases present before myeloablative therapy""",e9855d32d7ae7db785abe78e7ff0610f27348f3b,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
160,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy""",40c89ddac97d040b0724fb4ed9135a8d69f35e12,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
160,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy""",40c89ddac97d040b0724fb4ed9135a8d69f35e12,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
162,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
162,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer""",6f72cb8719293462c54d0b73e23deb8569b9bd01,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
163,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer""",1c478e87dcc88406a02c20f5e45dd56a4374079e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
163,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer""",1c478e87dcc88406a02c20f5e45dd56a4374079e,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
164,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation""",ddb23a0f0938b5334f19c19f91bf9f16cfc8bde3,False,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
164,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation""",e1bba7b445c37298184b0a7b6cb77e1f1b6c0bf7,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.""",b45beb67bce8ffe76caab8a70e4869bd2232efc9,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
166,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.""",b45beb67bce8ffe76caab8a70e4869bd2232efc9,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
167,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.""",7ff1dd5d0e8a9fbea59316bbf6ed3cfc766892c3,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
167,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.""",7ff1dd5d0e8a9fbea59316bbf6ed3cfc766892c3,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
169,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We enrolled female patients with HER2-overexpressing metastatic breast cancer""",01dba15b0aceb596bda5edaab77444ee0ddca823,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
169,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""We enrolled female patients with HER2-overexpressing metastatic breast cancer""",01dba15b0aceb596bda5edaab77444ee0ddca823,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
170,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""we screened 3100 first-degree relatives of patients with gastric cancer. We randomly assigned 1838 participants with H. pylori infection""",73f79972374e3f2b084c878330b603a157c2eedb,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
170,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""we screened 3100 first-degree relatives of patients with gastric cancer. We randomly assigned 1838 participants with H. pylori infection""",73f79972374e3f2b084c878330b603a157c2eedb,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
171,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""hormone-receptor-positive early breast cancer in premenopausal women""",98a5ba5f17b9110f04a2f069c888555be83e8f36,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
171,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""recurrence of hormone-receptor-positive early breast cancer in premenopausal women""",a6d7365e9384eb318b8b4c200674399212017498,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
173,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""enhances tumor response in patients with metastatic NSCLC.""",bdccdcc2c0c155c20ed9f49856df4e4491d2179d,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
173,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""To assess whether stereotactic body radiotherapy on a single tumor site preceding pembrolizumab treatment enhances tumor response in patients with metastatic NSCLC.""",01b26d2df2e2d57be14b279647c3a1ca8a4eaf62,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
174,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""170 432 eligible men and women, who had indicated on a previous questionnaire that they would probably attend screening if invited""",374c6ed5f286ec093a811d67ccaf373be9e38969,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
174,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""170 432 eligible men and women, who had indicated on a previous questionnaire that they would probably attend screening if invited""",374c6ed5f286ec093a811d67ccaf373be9e38969,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
175,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""patients with locally advanced or metastatic non-small-cell lung cancer""",92c818e306e91a3da2710903d9574f6827920ace,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
175,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer""",1ae19e4849f520394d7ce0e7e5dd86a8ddba608d,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
176,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects).""",58367c66a45cfe1b18d870f213754e26a482f201,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
176,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects)""",770000892fd7ee126223181170b34b8cde3a4396,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
177,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""in patients with stage III or IVA endometrial carcinoma""",25049fc2def443efb17ffe77da755e6e07b1bba7,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
177,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with stage III or IVA endometrial carcinoma""",65d8b67032e4ffdaaeb25be205b7e6e3a085afaa,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
178,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""for patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation""",0caa06b716b45adffc8f3deb9b12b4fe4bda1c67,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
178,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation""",ce20f456354b9a522ddb9e03e0fadb605a61a244,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
181,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""had previously untreated recurrent or metastatic nasopharyngeal carcinoma.""",743d0e341ea28c1d9670362b0c6adecb21c9529c,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
181,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""had previously untreated recurrent or metastatic nasopharyngeal carcinoma""",91abde46da8b29dc47ddc94b6d5e595cd01b9f6f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
182,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we randomly assigned patients with stage IV or recurrent NSCLC""",d44806a07a0dda22a5893639e1f7bbc4aade300f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
182,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we randomly assigned patients with stage IV or recurrent NSCLC""",d44806a07a0dda22a5893639e1f7bbc4aade300f,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
183,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with previously untreated stage II or stage III triple-negative breast cancer""",f725748278e482f51738e0b84dbf4f3ca0fb0824,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
183,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with previously untreated stage II or stage III triple-negative breast cancer""",f725748278e482f51738e0b84dbf4f3ca0fb0824,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
184,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""women with HER2-positive locally advanced or inflammatory breast cancer""",9522ac15bc3bf324d82e62b97e23700b8120a2fc,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
184,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""women with HER2-positive locally advanced or inflammatory breast cancer""",9522ac15bc3bf324d82e62b97e23700b8120a2fc,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
186,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""patients with a history of colorectal adenomas""",d88c4488a5a21870904c26faf3c3df13379d9f83,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
186,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""patients with a history of colorectal adenomas""",d88c4488a5a21870904c26faf3c3df13379d9f83,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
187,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""had stage III or stage IV disease and no distant metastases""",bceb191387cd62bde07acd11830c4c6b9464abed,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
187,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""had stage III or stage IV disease and no distant metastases""",bceb191387cd62bde07acd11830c4c6b9464abed,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
188,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""among men with metastatic castration-resistant prostate cancer""",97f90d7254165d3ceb68535581bd315cc294b933,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
188,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes""",1e9e8311585edabe46c172095e5871ea096e3629,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
189,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""exemestane 25 mg a day for the primary prevention of breast cancer""",e0b645dad4ec20095c75603a4b97ee642abbdc99,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
189,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""exemestane 25 mg a day for the primary prevention of breast cancer""",e0b645dad4ec20095c75603a4b97ee642abbdc99,True,NEITHER,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
190,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer""",8334eaeb86074583ffc59ed701e2958df9a8735c,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
190,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""1803 premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer""",4299d90c351f4db3a5af8b3a783ff310c85d911f,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
191,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""documented local recurrence after surgery followed by chemotherapy""",403b61665eeee66ab251ed6a89e9f4f19d469416,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
191,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""documented local recurrence after surgery followed by chemotherapy""",403b61665eeee66ab251ed6a89e9f4f19d469416,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
194,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions""",bd6ba03a86964a041693f9b2f27650ea3710a754,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
194,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions""",bd6ba03a86964a041693f9b2f27650ea3710a754,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
195,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung""",6feeb3bf467f7d4292e3de8de361ec5ed5a73151,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
195,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung""",6feeb3bf467f7d4292e3de8de361ec5ed5a73151,True,BOTH,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
196,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We randomly assigned patients with metastatic breast cancer""",d3b009e709a41c64bb273fe64b92969349640d6b,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
196,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease""",a7272820cc6b86c5419969aa71b77026c850799c,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
197,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Patients aged 18 years and older with metastatic soft-tissue sarcomas""",e17eb61d628f9ff6f98e11266503922cbd02cdbc,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
197,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Patients aged 18 years and older with metastatic soft-tissue sarcomas""",e17eb61d628f9ff6f98e11266503922cbd02cdbc,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
198,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""after resection of localised, primary gastrointestinal stromal tumour""",118164528b0984e5ad7e0a28b4b7cce51855afa8,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
198,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""after resection of localised, primary gastrointestinal stromal tumour""",118164528b0984e5ad7e0a28b4b7cce51855afa8,True,LOCALIZED,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
199,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""men with at least one bone metastasis from castration-resistant prostate cancer""",9ad2ce92b204fec9485ebef3834d8856366cffff,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
199,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment""",2d8dcda2f7c12b6ee1dd9f79923ed5e82e4c5885,True,METASTATIC,gemini,gemini-3-flash-preview,VERDICT: SUPPORTED,SUPPORTED,True,True
0,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual)""",4ff1015be14e55a6dc027019ecdd60952f227167,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
1,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma""",7eb95ff89d5d04f295084806378003c157ff248d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
2,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""advanced or metastatic soft-tissue sarcoma""",1295da81802a04e9192cf06aca1745cbf170765d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned to receive conventional treatment,a221ae2f909a5817edac074c80bb2975fac17cd6,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
4,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with advanced NSCLC""",92a4edc4f6099300b9741ae88ef7a1c2b68d4c69,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases""",791525825cbc2e242e5954ea5e81577322076b7b,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
6,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Localised prostate cancer is commonly treated with external beam radiotherapy""",2075df6469616478ab5333572552170c2af23e40,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
7,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""we recruited postmenopausal women aged 50-74 years""",825205e9fd92724e1f3afae503bd0345dc57ba91,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
8,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""we recruited postmenopausal women aged 40-70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer""",8f5a19f63c284bc566b6b3e23aa0480586670f83,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
9,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma""",bcf0f43a2e7712526ff22f78c8fb384de1bd41c9,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
10,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with HER2-positive early breast cancer""",dff881889bad66db1f693bfe1291b8f93fc1e172,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
11,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"Patients aged at least 18 years with previously untreated locally advanced cervical cancer (adenocarcinoma, squamous, or adenosquamous; International Federation of Gynaecology and Obstetrics [FIGO] 2009 stage IB2-IIB lymph node positive, stage ≥III any lymph node status)",7e0be13bc11e4041ebbd22e9f6a9233c2df3c9aa,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
13,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""5102 patients with HER2-positive early breast cancer.""",6fc60fbc97fb2b7457a5764c0b27d30038e35dd9,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
14,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer""",6e818b07a0449f0743df642ae68dcb5da4241f3a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
15,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer were randomly assigned""",236ca6b96c0ee52756b2e4c598c9b1714840e32c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
16,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.""",42230f67e81e4ec2f07ed82ff6bfb4f61ed2ba5b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
17,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast""",8fc6d07c6cb975cbfd9de12dd6da07ac5b37df01,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
18,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""we randomly assigned healthy women older than 25 years to the HPV 16/18 vaccine or control (1:1)""",caf882292f3c3b0622828cfda4e10574f5663d9e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
19,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer""",3543e5de7079dc26de26adcdc748a01b230c07cb,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
20,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer""",c789aa1f5231e28b683f55b63cc4140b811ab8f8,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations""",503d85a8a9b21b9bc5c1803cd126ceaae88989b1,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
23,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""140 patients with early breast cancer were randomly assigned""",0890677652b8ad2594a3f8720f35149d58544372,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
25,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Barcelona Clinic Liver Cancer stage B or C disease""",ee6acf7308c5058279ee836172140f729acd5690,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
26,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing""",44fac3ea7abefbd5ffca2844d5e92f5c0d6eb117,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
27,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy""",4ff243088b2431b1801bac35f0da031f143cc04e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
30,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""1500 women with axillary node-positive or high-risk node-negative breast cancer""",1ac326d32b2ff256f3ee5a674f7d25f48073a7bb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
31,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""survivors of stages 0 to III breast cancer""",d9e13e8f7c44b394195489cd210728974e1d924e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
33,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""127 patients with dysplastic Barrett's esophagus""",3f420387f846c04acbea6c4fafaf82e586317038,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
35,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy""",9a594005618b79231adb6e89183647cf9b16471f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
36,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1)",87eb828e0f5c5ff35683b3720117d5791cba812b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
38,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma""",1835ed02d5f7f875c5c2c3809f13328736c01a50,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
39,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma""",c83298140f73497cbe3fd0d573745f64b422ce3b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
40,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""615 patients with locoregional, high-risk clear-cell renal-cell carcinoma""",6fb1710a633ca3fa26cb79307bd06252c9850c07,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
42,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b""",a8469e5e1f5c48c19f8ff0ee1de2c99d3557d6ea,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
43,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""men who had newly diagnosed clinically localised prostate cancer""",3b8b754f054461eccf15f981c69dad8883b2ed11,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
44,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""We assessed the effects of combined docetaxel and estramustine on relapse in patients with high-risk localised prostate cancer.""",831b31123235a67340fdb8f3f20f175a66654602,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
45,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma""",a7c93949a9d3fbab608305bfe5f51f22e1412639,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
46,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer""",27b0089ec3d86bbc95e0452d452fbe8401a13826,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
47,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer.""",b68f41ac601a8152689fd5a890798d46b3191ab5,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
48,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we recruited patients aged 18 years or older who had received taxane therapy and undergone two or fewer previous chemotherapy regimens for metastatic breast cancer""",b32da692d78dc577beec180916efb843271fdbc7,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
49,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer""",18ee24010628b521ae0527651fcd2b316c7fb195,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
50,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""we enrolled patients with stage IIIB or IV adenocarcinoma""",85b58150810f2c94fd05d87cf5a0a2db971acf6f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
52,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""The study involved 182,160 men between the ages of 50 and 74 years at entry""",dd7ec2ad87380013f7e156ae4bde2d39ea299042,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
53,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""as adjuvant chemotherapy for operable node-positive breast cancer.""",42578a7a4ea77d80be5d931d0b83628b435dfb14,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
54,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We enrolled patients with stage IV or recurrent NSCLC""",e61aeea04d0bb3f0cbe10067e2e4c6ce9aae2699,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
55,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""finasteride significantly reduced the risk of prostate cancer""",83ff318fc4650375f1b4414008971f066b7db94a,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
57,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"enrolled 160 patients with radiologically confirmed painful bone metastases from September 19, 2014, through June 19, 2018.",e84e0a676af3c6a18e31e7f32ecc7f5faec3063b,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
58,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer""",1d7e7caf17ecbeabbf80e1bd20d1c6066b07cfda,False,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
59,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""trial in patients aged 18 years or older with HER2-positive metastatic gastric or gastro-oesophageal junction cancer.""",f6a8046916bc56ff598ee96fa82e5ff4ef08d99d,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
60,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer""",e0fa8b194e03484d945e29c1e793232b6c72eb22,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
62,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Standard treatment for locally advanced cervical cancer is chemoradiotherapy""",de0ced2cdeae5015e4c49c760fbc5c55b696318c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
63,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC)""",cab9b9359cdd091819a44ebda0376b8b814f4f7b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
65,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease""",05b5f21c2a9a961bc6d7ddd2e808e046a9c662a9,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
66,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment in this phase 3, open-label, randomised controlled trial at 85 centres in Japan.",f11560fc87d66b2648cd745c74c8a4f4b3cd1c5f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
67,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned 1:1 to 28-day cycles of atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) or atezolizumab placebo, vemurafenib, and cobimetinib (control group).",6e694d8175e339756455833fbee51942070e78bc,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
68,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Randomisation was stratified by geographical region, macrovascular portal vein invasion or extrahepatic spread or both""",323ad07c4ab7b5e2a9ed9c6bdf6472037b4c2063,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
70,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Randomization was stratified based on site of metastasis (visceral, bone only, or other)""",9eed8f758a2b678bc01936613f1603a1b183f34b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
71,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
72,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with resected stage III melanoma with BRAF V600E or V600K mutations""",f09bd903e0dfa51bbf2dec8755fa6a0b8e75c47e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
73,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,enrolled patients with T1-T2N0-2 p16-positive OPSCC,64ce7a66da3b9350c6ec61deff324c165f4fd575,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
74,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries.,bb30ac3795423051d209f329381c670f0141d023,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
75,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors""",2f960d29830303309d25eab7b6bd69ffb4550918,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
76,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings.""",f28d16785a4224a97a7d072f680b7ac63dd7f856,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
77,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,25ecd584e5b4a56896c4eee319b874a2c1548069,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
78,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer""",d4f1677604d7c50818a77525aa336404fce8ef1b,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
79,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy""",f907c613faa56569b97218213b1edc9110fc1e17,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
80,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment""",9c1c59183a809bbed82997ce1ee4fc2f5a1a89d8,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
81,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter""",5ce23330d473062f0ce23e20dc7ed49bcc1ded13,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
82,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""we randomly assigned patients 2:1 with untreated locally recurrent inoperable or metastatic triple-negative breast cancer""",530e59e039a361aef6bdecda01be6b4cd7510fc1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
84,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""479 women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized""",52154624a7bf58441edc21d252ab42fd1add94d1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
85,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C""",45347dceca54ce09502c27162d8f9f436b795435,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
86,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy""",43fafd8fd169e7e412bc5896801c0826d5433f6f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
87,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract.",fb9278c2791a54c475e36e439cc3e33ec9537dfc,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
88,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""840 patients with stage IB-IIIA NSCLC""",ce78fa129ae36d8c9267d85106f8126118809625,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
89,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus.""",40f6afe613aca56f68ab3bbb18c3f500a1b69a68,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
90,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""The effect of celecoxib, a COX-2 inhibitor, as treatment for nonmetastatic colon cancer is unknown.""",1b8615d8bdf5c122d0d522339f8a426f5d4b21d8,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
91,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""among patients with melanoma and sentinel-node metastases.""",31976c44d8beb7057dd01cfeda1040912cd5d055,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
93,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence""",54c87f68e178017ae71c2252c76ab5b05323e444,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
94,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""first-line metastatic renal cell carcinoma""",3b52cda5e6eb1229aa3ce0bc75f2c10c70a0e731,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
95,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.""",da26953ee9836d64a30801cbc76a8f15a34ef5cf,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
96,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment""",256301c3da375be8c27f88ea8f0a655c3764e1a5,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
97,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""559 patients with untreated metastatic, squamous NSCLC""",14fc370f6e6034383eb771e6f8ecdccd20262c1e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
98,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation""",b69757cb065eea51fec87605d464eaf5e3f0dc69,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
99,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs)""",47dc5286e6633cb5f65052d2bba85b86d4c9b1c7,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
100,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.""",5732978a51d07233e109bcf444d9665e0f649d1a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
101,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Patients with previously untreated, stage III-IVB (except T3-4N0) nasopharyngeal carcinoma""",27f431a1408d64a891a7d22386bf7834dfe5c42f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
102,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients with previously untreated advanced melanoma""",dcaafc830eeb03c41dba153034529b1ebd830749,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""in patients with localized completely resected high-risk ccRCC.""",230e584283d41f8f6bb09d3f43e5463330fcafaf,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
104,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma""",03f415f9e33719b9adb0cb3c466d86448460cf3f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
106,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
107,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer""",ae793456338175ac0995428dbffbcf6ede75070c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
109,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma""",2e0bcb209b02b1b660c6a753e0515329ed98f44a,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
110,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients with histologically proven, HER2-positive metastatic breast cancer""",7d38d0d335c6d9abf8e7892f675042ba2ad46716,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
111,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,previously untreated unresectable stage IIIc or stage IV melanoma,7af32f2ec7b0ed3174df20894f2640738b8c50ca,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
112,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction.""",b6b33fbea15254056651dbe04f18605c3038f275,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
113,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years""",b71ecc1d16307f4ff61eb107be177c20037a4c25,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
114,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment""",96d6cc4a08801a90159b5e658c102adb5e7835c9,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
115,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with unresectable stage IIIC or IV melanoma""",11e9fadb85f681011f47d41123159358b2f90f2e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
116,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma""",79688df7aa50c025910aa3d2513317840804f731,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
117,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.""",3a8c2754f3b5ccf378f544a227beb00f99c88c68,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
118,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)""",caaf6fda6d566b2b781edeea2c54d96dd2e78659,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
119,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with palpable T1-T2 invasive breast cancer were recruited""",311094d80875682ad3b9a873613b0d56bce94208,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
120,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients aged 18 years or older, with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer""",10a8723a2bc47bb9c825741765682babdd541ce9,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
122,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized 1:1:1 to receive adjuvant RT, CCRT, or SCRT.""",734dfc66f1a369321dfd350d3c09b5795b01455e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
123,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma""",f4800827bd42e0a3e5e59ad63c6149db83c954a0,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
124,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.""",4243d0159b95e7d66eb9410fc86a4c85f5bc2ab0,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
126,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease""",456d88c271f3025523520b59eca94989f3b9a335,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
127,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC""",d330098c362527c8c0fc9f25c22d5618dc2226da,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
128,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer""",9b4f77e8b257977fef01387baf76bcd45a32f29d,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
129,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
130,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm""",4b19644d2fc3138efbdaf7cf5376c61135fdd12f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
131,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligibility criteria included ERBB2-negative metastatic breast cancer""",8e2b228dffb6f528d7174895349654162c1ef4ae,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
132,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""trial involving patients with active rheumatoid arthritis despite methotrexate treatment""",bfeeb4985e01d3761ba4fcbc929bb4e827db9696,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
133,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
134,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients with untreated stage IV or recurrent NSCLC""",33efff137a6cd58155eb0d0d06ddeaa6a6b5bbdc,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
136,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer""",1f3739a104351deb9cde24ec13e40cdeba09639f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
138,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""advanced or metastatic adenocarcinoma of the colon or rectum""",2f19e2fd818508132ff39279f49c89226f4f738e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
139,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""523 patients with curable stage T2b, T3, or T4 gastric cancer were randomly assigned during surgery""",969146b64131c36e8a070b398cf99a135c5e63cd,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
140,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.""",9f49cb21a38ac744574562f94df408518e7822eb,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
141,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area.",705c3aed868ba525fe510bf294707e35c3b98be4,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
142,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)""",57432a17cb7aa7053bce98336d373103324c88a2,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
143,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""Patients with histologically confirmed AIN were randomly assigned to receive either 16 weeks of imiquimod (three times a week), 16 weeks of topical fluorouracil (twice a week), or monthly electrocautery for 4 months.""",3644f7e378d6917fcef3310ada90d9c1e849df3c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
144,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we randomly assigned patients with spinal cord compression caused by metastatic cancer""",d933ed9e6709b3f5a2a7a261a9b531930b09239f,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
145,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy""",c16f8ca3f52c3e17d98b2dc99ec9c1c0f86d16d7,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
146,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States.""",2de6fa28760472b06638f1df555b31547cda6827,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
147,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer""",fa1bb5d29986a28699551aa5d0ae119e6d357b3a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
148,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.""",c390a3924587575a18fc4500a3e002711ed3b588,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
149,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors""",1b94424e45a3b69efd550d8b620f81a8d5230a3c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
151,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.""",517d694e1af036d28860bf23f2b13b022b9d374d,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
152,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We included chemotherapy-naive men (aged ≥18 years) with mCRPC""",6a69fccdc6d285db6f76d7fe85ca6e9ce2a50b95,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
153,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment""",8089587e09d6b5b20f8e34a02dc3430bea3ee904,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
154,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""women with HER2-positive breast cancer with progressive brain metastases""",027def017940daf376745d22ea8451fbe5d502ae,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
155,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer""",e3a7b0ad7b355e68aa420df618198a97d0f53237,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
156,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""with clinical stage I endometrial or cervical cancer undergoing curative surgery""",36282199e9cda6ec27e20b233714f9e1b3d6fd8a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
157,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""we enrolled patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less.""",b6a4e63ddc3092b491cbfd3a3aba2357a1961169,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
158,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
159,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""radiation therapy to the primary tumour site plus meta-iodobenzylguanidine avid metastases present before myeloablative therapy""",e9855d32d7ae7db785abe78e7ff0610f27348f3b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
160,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy""",40c89ddac97d040b0724fb4ed9135a8d69f35e12,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
162,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer""",6f72cb8719293462c54d0b73e23deb8569b9bd01,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
163,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer""",1c478e87dcc88406a02c20f5e45dd56a4374079e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
164,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation""",e1bba7b445c37298184b0a7b6cb77e1f1b6c0bf7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane""",fd1996c52fb6536a44bea5442ef04ebdc1934485,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
167,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.""",5a600a145b0b23da959e2f2c6af55a88b1431263,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
169,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We enrolled female patients with HER2-overexpressing metastatic breast cancer who had progressed on or following adjuvant trastuzumab or first-line treatment of metastatic disease with trastuzumab.""",0d325e453020e66c3f8ef2b413d1da33dadf5178,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
170,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""we screened 3100 first-degree relatives of patients with gastric cancer.""",4f257a0c5636f406a7ecea0d4091181f7217f9d6,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
171,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""recurrence of hormone-receptor-positive early breast cancer in premenopausal women""",a6d7365e9384eb318b8b4c200674399212017498,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
173,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""enhances tumor response in patients with metastatic NSCLC.""",bdccdcc2c0c155c20ed9f49856df4e4491d2179d,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
174,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""170 432 eligible men and women, who had indicated on a previous questionnaire that they would probably attend screening if invited, were randomly assigned (1:2) to an intervention group (offered flexible sigmoidoscopy screening) or a control group (not contacted).""",5393df4c4d1977a61d517ef534c97e034eddc3a1,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
175,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with locally advanced or metastatic non-small-cell lung cancer""",92c818e306e91a3da2710903d9574f6827920ace,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
176,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects)""",770000892fd7ee126223181170b34b8cde3a4396,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
177,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with stage III or IVA endometrial carcinoma""",65d8b67032e4ffdaaeb25be205b7e6e3a085afaa,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
178,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation""",ce20f456354b9a522ddb9e03e0fadb605a61a244,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""had previously untreated recurrent or metastatic nasopharyngeal carcinoma""",91abde46da8b29dc47ddc94b6d5e595cd01b9f6f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
182,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""we randomly assigned patients with stage IV or recurrent NSCLC""",d44806a07a0dda22a5893639e1f7bbc4aade300f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
183,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""patients with previously untreated stage II or stage III triple-negative breast cancer""",f725748278e482f51738e0b84dbf4f3ca0fb0824,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
184,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""women with HER2-positive locally advanced or inflammatory breast cancer""",9522ac15bc3bf324d82e62b97e23700b8120a2fc,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
186,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""patients with a history of colorectal adenomas""",d88c4488a5a21870904c26faf3c3df13379d9f83,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
187,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""stage III or stage IV disease and no distant metastases""",dc4e44d8380b38d0f13e206aa4e1af05a0f19370,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
188,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""among men with metastatic castration-resistant prostate cancer""",97f90d7254165d3ceb68535581bd315cc294b933,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
189,openai,gpt-5.2-2025-12-11,evidence_required,1,NEITHER,"""exemestane 25 mg a day for the primary prevention of breast cancer""",e0b645dad4ec20095c75603a4b97ee642abbdc99,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
190,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""1803 premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer""",4299d90c351f4db3a5af8b3a783ff310c85d911f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
191,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""documented local recurrence after surgery followed by chemotherapy""",403b61665eeee66ab251ed6a89e9f4f19d469416,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
194,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions, Eastern Cooperative Oncology Group score of 0-1, and a life expectancy of at least 6 months were eligible.",a2bb26ee3f4690b802f9ac765f68896bb4dff919,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
195,openai,gpt-5.2-2025-12-11,evidence_required,1,BOTH,"""We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung""",6feeb3bf467f7d4292e3de8de361ec5ed5a73151,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
196,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""We randomly assigned patients with metastatic breast cancer""",d3b009e709a41c64bb273fe64b92969349640d6b,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
197,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"Patients aged 18 years and older with metastatic soft-tissue sarcomas, an Eastern Cooperative Oncology Group performance status of 0-2, and who had previously received treatment with anthracycline and ifosfamide were randomly assigned (1:1)",702058ff4ccf56d803acf4dc9cf4fd8f894af711,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
198,openai,gpt-5.2-2025-12-11,evidence_required,1,LOCALIZED,"""after resection of localised, primary gastrointestinal stromal tumour""",118164528b0984e5ad7e0a28b4b7cce51855afa8,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
199,openai,gpt-5.2-2025-12-11,evidence_required,1,METASTATIC,"""men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment""",2d8dcda2f7c12b6ee1dd9f79923ed5e82e4c5885,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
0,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with resectable NSCLC (stage II to IIIB [N2 node stage]""",bf2ab166578945b59702e53b56dec487b809e250,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
0,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the AJCC Cancer Staging Manual)""",8652d19d3af47554676d4d308bfa861684af24ea,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
1,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma""",7eb95ff89d5d04f295084806378003c157ff248d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
1,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma""",7eb95ff89d5d04f295084806378003c157ff248d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
2,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""advanced or metastatic soft-tissue sarcoma""",1295da81802a04e9192cf06aca1745cbf170765d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
2,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""advanced or metastatic soft-tissue sarcoma""",1295da81802a04e9192cf06aca1745cbf170765d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
3,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned to receive conventional treatment,a221ae2f909a5817edac074c80bb2975fac17cd6,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
3,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,Patients with stage II-IV ovarian cancer were randomly assigned to receive conventional treatment,a221ae2f909a5817edac074c80bb2975fac17cd6,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
4,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with advanced NSCLC progressing after second-line or further treatment.""",dcae6cbb68d38e056dc1e1ccb363860095c3acf6,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
5,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases""",791525825cbc2e242e5954ea5e81577322076b7b,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
5,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases""",1513f8bc2b47bf531ab2184f5d460982913a8172,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
6,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Localised prostate cancer is commonly treated with external beam radiotherapy""",2075df6469616478ab5333572552170c2af23e40,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
6,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Localised prostate cancer is commonly treated with external beam radiotherapy""",2075df6469616478ab5333572552170c2af23e40,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
7,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""we recruited postmenopausal women aged 50-74 years""",825205e9fd92724e1f3afae503bd0345dc57ba91,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
7,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""we recruited postmenopausal women aged 50-74 years""",825205e9fd92724e1f3afae503bd0345dc57ba91,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
8,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""we recruited postmenopausal women aged 40-70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer""",8f5a19f63c284bc566b6b3e23aa0480586670f83,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
8,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""we recruited postmenopausal women aged 40-70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer""",8f5a19f63c284bc566b6b3e23aa0480586670f83,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
9,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma""",bcf0f43a2e7712526ff22f78c8fb384de1bd41c9,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
9,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma""",bcf0f43a2e7712526ff22f78c8fb384de1bd41c9,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
10,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer""",1cb68dbec11268ea57f620e713080ed3c582315c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
10,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer""",1cb68dbec11268ea57f620e713080ed3c582315c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
11,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"Patients aged at least 18 years with previously untreated locally advanced cervical cancer (adenocarcinoma, squamous, or adenosquamous; International Federation of Gynaecology and Obstetrics [FIGO] 2009 stage IB2-IIB lymph node positive, stage ≥III any lymph node status)",7e0be13bc11e4041ebbd22e9f6a9233c2df3c9aa,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
11,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"Patients aged at least 18 years with previously untreated locally advanced cervical cancer (adenocarcinoma, squamous, or adenosquamous; International Federation of Gynaecology and Obstetrics [FIGO] 2009 stage IB2-IIB lymph node positive, stage ≥III any lymph node status)",7e0be13bc11e4041ebbd22e9f6a9233c2df3c9aa,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
13,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""5102 patients with HER2-positive early breast cancer""",5ef2820aaf9ab4b1d097210517a38aba2c89338e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
13,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""5102 patients with HER2-positive early breast cancer""",5ef2820aaf9ab4b1d097210517a38aba2c89338e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
14,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer""",6e818b07a0449f0743df642ae68dcb5da4241f3a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
14,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""had stage I-III histologically proven and operable invasive hormone receptor-positive breast cancer""",6e818b07a0449f0743df642ae68dcb5da4241f3a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
15,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer""",c85bb6f05c217b7b29f7980927c7792a658c531e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
15,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer""",c85bb6f05c217b7b29f7980927c7792a658c531e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
16,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.""",42230f67e81e4ec2f07ed82ff6bfb4f61ed2ba5b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
16,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins.""",42230f67e81e4ec2f07ed82ff6bfb4f61ed2ba5b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
17,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast""",8fc6d07c6cb975cbfd9de12dd6da07ac5b37df01,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
17,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast""",8fc6d07c6cb975cbfd9de12dd6da07ac5b37df01,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
18,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""we randomly assigned healthy women older than 25 years to the HPV 16/18 vaccine or control (1:1)""",caf882292f3c3b0622828cfda4e10574f5663d9e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
18,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""we randomly assigned healthy women older than 25 years to the HPV 16/18 vaccine or control (1:1)""",caf882292f3c3b0622828cfda4e10574f5663d9e,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
19,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer""",3543e5de7079dc26de26adcdc748a01b230c07cb,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
19,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer""",3543e5de7079dc26de26adcdc748a01b230c07cb,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
20,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer""",c789aa1f5231e28b683f55b63cc4140b811ab8f8,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
20,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer""",c789aa1f5231e28b683f55b63cc4140b811ab8f8,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
21,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with previously untreated advanced NSCLC with an EGFR mutation""",b904abcb80c192af806439fedd28334b12cb7362,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
22,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations""",503d85a8a9b21b9bc5c1803cd126ceaae88989b1,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
22,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations""",503d85a8a9b21b9bc5c1803cd126ceaae88989b1,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
23,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""140 patients with early breast cancer were randomly assigned""",0890677652b8ad2594a3f8720f35149d58544372,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
23,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""140 patients with early breast cancer were randomly assigned""",0890677652b8ad2594a3f8720f35149d58544372,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
25,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Barcelona Clinic Liver Cancer stage B or C disease""",ee6acf7308c5058279ee836172140f729acd5690,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
25,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""Barcelona Clinic Liver Cancer stage B or C disease""",ee6acf7308c5058279ee836172140f729acd5690,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
26,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing""",44fac3ea7abefbd5ffca2844d5e92f5c0d6eb117,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
26,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing""",44fac3ea7abefbd5ffca2844d5e92f5c0d6eb117,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
27,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned (1:1) to receive either open or laparoscopic surgery.""",40a3b1148cd4ea4f88bebde1187024c10a289d06,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
27,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Patients (aged 18-80 years) with cT3N0-2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned (1:1) to receive either open or laparoscopic surgery.""",40a3b1148cd4ea4f88bebde1187024c10a289d06,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
30,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""1500 women with axillary node-positive or high-risk node-negative breast cancer""",1ac326d32b2ff256f3ee5a674f7d25f48073a7bb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
30,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""1500 women with axillary node-positive or high-risk node-negative breast cancer""",1ac326d32b2ff256f3ee5a674f7d25f48073a7bb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
31,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""survivors of stages 0 to III breast cancer""",d9e13e8f7c44b394195489cd210728974e1d924e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
31,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""survivors of stages 0 to III breast cancer who had completed cancer treatments at least 12 months previously""",bd5381973db04fcb2f620532631dfa8594a97fc8,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
33,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""127 patients with dysplastic Barrett's esophagus""",3f420387f846c04acbea6c4fafaf82e586317038,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
33,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""127 patients with dysplastic Barrett's esophagus""",3f420387f846c04acbea6c4fafaf82e586317038,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
35,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy.""",b49797e3c8aff38eda554e235d45aedee9cda2f7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
35,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy""",9a594005618b79231adb6e89183647cf9b16471f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
36,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1)",87eb828e0f5c5ff35683b3720117d5791cba812b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
36,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations""",f60504f6eb8415503d2a93b7858cf6f864a52a74,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
38,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma""",1835ed02d5f7f875c5c2c3809f13328736c01a50,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
38,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma""",1835ed02d5f7f875c5c2c3809f13328736c01a50,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
39,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma""",c83298140f73497cbe3fd0d573745f64b422ce3b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
39,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""unresectable stage IIIC or stage IV melanoma""",412941f42a2ca5bddcd1f26cf8d863909f8031c5,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
40,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""we assigned 615 patients with locoregional, high-risk clear-cell renal-cell carcinoma""",c0d0b60854063ddcdca9d044704023816c0aaa0b,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
40,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with locoregional, high-risk clear-cell renal-cell carcinoma""",427a61fdf11c46b8799716a9bf8e7bfbc01bbea0,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
42,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627),b1c09b3e60339f032a3371c9409dd5cba859d47c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
42,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627),b1c09b3e60339f032a3371c9409dd5cba859d47c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
43,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""men who had newly diagnosed clinically localised prostate cancer""",3b8b754f054461eccf15f981c69dad8883b2ed11,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
43,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,men who had newly diagnosed clinically localised prostate cancer,59a3763c94c3f0cac7eec1001ce3b4f98d515821,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
44,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""We enrolled patients with treatment-naive prostate cancer and at least one risk factor (ie, stage T3-T4 disease, Gleason score of ≥8, prostate-specific antigen concentration >20 ng/mL, or pathological node-positive).""",d7662cb65997ad633274a61028c2e3b0363bb7b5,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
44,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""We enrolled patients with treatment-naive prostate cancer and at least one risk factor (ie, stage T3-T4 disease, Gleason score of ≥8, prostate-specific antigen concentration >20 ng/mL, or pathological node-positive).""",d7662cb65997ad633274a61028c2e3b0363bb7b5,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
45,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma""",a7c93949a9d3fbab608305bfe5f51f22e1412639,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
45,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma""",a7c93949a9d3fbab608305bfe5f51f22e1412639,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
46,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer""",27b0089ec3d86bbc95e0452d452fbe8401a13826,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
46,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer""",27b0089ec3d86bbc95e0452d452fbe8401a13826,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
47,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""adjuvant therapy in patients with resected pancreatic cancer.""",2d40581a4469011e734edddaf5efc0c7000bf8cb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
47,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with resected pancreatic cancer""",3ef34bfff309c5c5a47a9c2162c50f3840172a20,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
48,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with previously treated metastatic breast cancer""",90363ddf8d53793a44c0f22d3cf63252f7e41c5b,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
48,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we recruited patients aged 18 years or older who had received taxane therapy and undergone two or fewer previous chemotherapy regimens for metastatic breast cancer""",b32da692d78dc577beec180916efb843271fdbc7,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
49,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer""",18ee24010628b521ae0527651fcd2b316c7fb195,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
49,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer""",18ee24010628b521ae0527651fcd2b316c7fb195,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
50,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""we enrolled patients with stage IIIB or IV adenocarcinoma""",85b58150810f2c94fd05d87cf5a0a2db971acf6f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
50,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""we enrolled patients with stage IIIB or IV adenocarcinoma""",85b58150810f2c94fd05d87cf5a0a2db971acf6f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
52,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""The study involved 182,160 men between the ages of 50 and 74 years at entry""",dd7ec2ad87380013f7e156ae4bde2d39ea299042,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
52,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""The study involved 182,160 men between the ages of 50 and 74 years at entry""",dd7ec2ad87380013f7e156ae4bde2d39ea299042,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
53,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""as adjuvant chemotherapy for operable node-positive breast cancer.""",42578a7a4ea77d80be5d931d0b83628b435dfb14,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
53,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""as adjuvant chemotherapy for operable node-positive breast cancer.""",42578a7a4ea77d80be5d931d0b83628b435dfb14,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
54,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We enrolled patients with stage IV or recurrent NSCLC""",e61aeea04d0bb3f0cbe10067e2e4c6ce9aae2699,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
54,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""We enrolled patients with stage IV or recurrent NSCLC""",e61aeea04d0bb3f0cbe10067e2e4c6ce9aae2699,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
55,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""finasteride significantly reduced the risk of prostate cancer""",83ff318fc4650375f1b4414008971f066b7db94a,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
55,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""Finasteride reduced the risk of prostate cancer""",c18e39615052e8159df5e84392902eab4f877f47,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
57,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""enrolled 160 patients with radiologically confirmed painful bone metastases""",66dfe16afde749c512f3a9f75ab7f8a67e75f055,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
57,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""enrolled 160 patients with radiologically confirmed painful bone metastases""",66dfe16afde749c512f3a9f75ab7f8a67e75f055,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
58,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer""",1d7e7caf17ecbeabbf80e1bd20d1c6066b07cfda,False,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
58,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer""",6d607229d8c616539211c9914e6f8c6205324446,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
59,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""trial in patients aged 18 years or older with HER2-positive metastatic gastric or gastro-oesophageal junction cancer.""",f6a8046916bc56ff598ee96fa82e5ff4ef08d99d,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
59,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""trial in patients aged 18 years or older with HER2-positive metastatic gastric or gastro-oesophageal junction cancer.""",f6a8046916bc56ff598ee96fa82e5ff4ef08d99d,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
60,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer""",e0fa8b194e03484d945e29c1e793232b6c72eb22,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
60,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""premenopausal and postmenopausal women 35-70 years of age deemed to be at an increased risk of developing breast cancer""",e0fa8b194e03484d945e29c1e793232b6c72eb22,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
62,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease)""",0a2d4bf3ff1786514a13b2152a4b67a437955f1d,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
62,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease)""",0a2d4bf3ff1786514a13b2152a4b67a437955f1d,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
63,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC)""",cab9b9359cdd091819a44ebda0376b8b814f4f7b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
63,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) who had disease progression after receiving EGFR tyrosine-kinase inhibitor therapy.""",138a6be02add95b59b03464abbb7f916204520a1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
65,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""these patients included infants (<365 days of age) who had stage 3 or 4 disease""",1925825c4892fc3f99c27c6143b3201d6c3e886c,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
65,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""these patients included infants (<365 days of age) who had stage 3 or 4 disease""",1925825c4892fc3f99c27c6143b3201d6c3e886c,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
66,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment in this phase 3, open-label, randomised controlled trial at 85 centres in Japan.",f11560fc87d66b2648cd745c74c8a4f4b3cd1c5f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
66,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment in this phase 3, open-label, randomised controlled trial at 85 centres in Japan.",f11560fc87d66b2648cd745c74c8a4f4b3cd1c5f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
67,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma""",d560c77a9e6e10afd91ea8edeb1b77e5446919ce,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
67,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned 1:1 to 28-day cycles of atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) or atezolizumab placebo, vemurafenib, and cobimetinib (control group).",6e694d8175e339756455833fbee51942070e78bc,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
68,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Randomisation was stratified by geographical region, macrovascular portal vein invasion or extrahepatic spread or both""",323ad07c4ab7b5e2a9ed9c6bdf6472037b4c2063,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
68,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""macrovascular portal vein invasion or extrahepatic spread or both""",bc50d7f7d96fef6c6a77c7bc83c8c32e96d1415e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
70,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Randomization was stratified based on site of metastasis (visceral, bone only, or other)""",9eed8f758a2b678bc01936613f1603a1b183f34b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
70,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Randomization was stratified based on site of metastasis (visceral, bone only, or other)""",9eed8f758a2b678bc01936613f1603a1b183f34b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
71,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer""",fa5e203b4aad68d3d2f144bfed4da58e9b60ed6c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
71,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy.",f14077a2fa45544a20572bd783f5cc71712c274f,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
72,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with resected stage III melanoma with BRAF V600E or V600K mutations""",f09bd903e0dfa51bbf2dec8755fa6a0b8e75c47e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
72,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients who had resected stage III melanoma with BRAF V600E or V600K mutations""",2fc9d6cd70ee123c59df87c0bbaa58a1f4743652,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
73,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,enrolled patients with T1-T2N0-2 p16-positive OPSCC,64ce7a66da3b9350c6ec61deff324c165f4fd575,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
73,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,enrolled patients with T1-T2N0-2 p16-positive OPSCC,64ce7a66da3b9350c6ec61deff324c165f4fd575,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
74,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries.,bb30ac3795423051d209f329381c670f0141d023,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
74,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries.,bb30ac3795423051d209f329381c670f0141d023,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
75,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors""",2f960d29830303309d25eab7b6bd69ffb4550918,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
75,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors""",2f960d29830303309d25eab7b6bd69ffb4550918,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
76,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""among 5999 participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings.""",6f0710a8947e4176e0c54f32b4c48a190e1ff1ba,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
76,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings.""",f28d16785a4224a97a7d072f680b7ac63dd7f856,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
77,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,25ecd584e5b4a56896c4eee319b874a2c1548069,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
77,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,Participants (N = 516) were low-level community or household ambulators with stage IIIC or IV solid or hematologic cancer.,25ecd584e5b4a56896c4eee319b874a2c1548069,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
78,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer""",d4f1677604d7c50818a77525aa336404fce8ef1b,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
78,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer""",d4f1677604d7c50818a77525aa336404fce8ef1b,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
79,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy""",f907c613faa56569b97218213b1edc9110fc1e17,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
79,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""patients with clear-cell renal-cell carcinoma who were at high risk for recurrence after nephrectomy, with or without metastasectomy""",f907c613faa56569b97218213b1edc9110fc1e17,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
80,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment""",9c1c59183a809bbed82997ce1ee4fc2f5a1a89d8,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
80,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment""",4a8cf56ab851cfbf7e54607b9045867dc1eb2395,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
81,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter""",5ce23330d473062f0ce23e20dc7ed49bcc1ded13,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
81,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter""",5ce23330d473062f0ce23e20dc7ed49bcc1ded13,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
82,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""patients with untreated locally recurrent inoperable or metastatic triple-negative breast cancer""",e023d806bb4b160c343f708723a2cd2e3e257ddb,False,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
82,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""untreated locally recurrent inoperable or metastatic triple-negative breast cancer""",92e265c019e9cb321c2a50d2b720940bf1075e7a,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
84,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""479 women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized""",52154624a7bf58441edc21d252ab42fd1add94d1,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
84,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""479 women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized to 1 of 2 treatment arms""",9c9a7b7a9d505120eaf392a74757c1df810ee5b2,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
85,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C""",45347dceca54ce09502c27162d8f9f436b795435,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
85,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C""",45347dceca54ce09502c27162d8f9f436b795435,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
86,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy""",43fafd8fd169e7e412bc5896801c0826d5433f6f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
86,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""enrolling patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy""",9203da80d71bcd97750ef00459f7237628a25f13,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
87,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract.",fb9278c2791a54c475e36e439cc3e33ec9537dfc,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
87,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""eligible patients had histologically confirmed, radiologically evident mUC of the urinary tract.""",1eeb2256f4273bd4645c2d33b7cc91a36a14ae76,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
88,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""840 patients with stage IB-IIIA NSCLC""",ce78fa129ae36d8c9267d85106f8126118809625,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
88,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""840 patients with stage IB-IIIA NSCLC""",ce78fa129ae36d8c9267d85106f8126118809625,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
89,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus.""",40f6afe613aca56f68ab3bbb18c3f500a1b69a68,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
89,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus.""",40f6afe613aca56f68ab3bbb18c3f500a1b69a68,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
90,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""A total of 2526 patients with stage III colon cancer were enrolled""",ad65bb9951f13ac2dcb8fd34ea1c3097eb6f0223,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
90,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""The effect of celecoxib, a COX-2 inhibitor, as treatment for nonmetastatic colon cancer is unknown.""",1b8615d8bdf5c122d0d522339f8a426f5d4b21d8,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
91,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with node-positive intermediate-thickness melanomas (1.2 to 3.5 mm)""",4b914be7299eb8af652df239e8615613d9f6493e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
91,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""among patients with melanoma and sentinel-node metastases""",df2a91818bb71d7537b5152d1ff46b88d703f914,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
93,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence""",54c87f68e178017ae71c2252c76ab5b05323e444,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
93,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence""",54c87f68e178017ae71c2252c76ab5b05323e444,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
94,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""first-line metastatic renal cell carcinoma""",3b52cda5e6eb1229aa3ce0bc75f2c10c70a0e731,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
94,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""first-line metastatic renal cell carcinoma""",3b52cda5e6eb1229aa3ce0bc75f2c10c70a0e731,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
95,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.,bb6dc179cfb7920a2b89f8bbae2243766fd6d536,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
95,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligibility criteria included at least one radiologically confirmed bone metastasis from a histologically confirmed breast cancer.""",da26953ee9836d64a30801cbc76a8f15a34ef5cf,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
96,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment""",256301c3da375be8c27f88ea8f0a655c3764e1a5,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
96,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""men with radiographically documented metastatic castration-resistant prostate cancer that had progressed after docetaxel treatment""",256301c3da375be8c27f88ea8f0a655c3764e1a5,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
97,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""559 patients with untreated metastatic, squamous NSCLC""",14fc370f6e6034383eb771e6f8ecdccd20262c1e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
97,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""559 patients with untreated metastatic, squamous NSCLC""",14fc370f6e6034383eb771e6f8ecdccd20262c1e,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
98,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation""",b69757cb065eea51fec87605d464eaf5e3f0dc69,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
98,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation""",b69757cb065eea51fec87605d464eaf5e3f0dc69,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
99,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs)""",47dc5286e6633cb5f65052d2bba85b86d4c9b1c7,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
99,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs)""",47dc5286e6633cb5f65052d2bba85b86d4c9b1c7,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
100,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.""",5732978a51d07233e109bcf444d9665e0f649d1a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
100,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate.""",5732978a51d07233e109bcf444d9665e0f649d1a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
101,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Patients with previously untreated, stage III-IVB (except T3-4N0) nasopharyngeal carcinoma""",27f431a1408d64a891a7d22386bf7834dfe5c42f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
101,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Patients with previously untreated, stage III-IVB (except T3-4N0) nasopharyngeal carcinoma""",27f431a1408d64a891a7d22386bf7834dfe5c42f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
102,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with previously untreated advanced melanoma""",dcaafc830eeb03c41dba153034529b1ebd830749,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
102,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with previously untreated advanced melanoma""",dcaafc830eeb03c41dba153034529b1ebd830749,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
103,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.""",ff106cff6f82e4af66967d2e4c4adb0d35c78b76,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
103,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""To evaluate the safety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in patients with localized completely resected high-risk ccRCC.""",ff106cff6f82e4af66967d2e4c4adb0d35c78b76,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
104,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma""",03f415f9e33719b9adb0cb3c466d86448460cf3f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
104,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Eligible patients had pathological stage high-grade T1b or greater with completely resected non-metastatic renal-cell carcinoma""",03f415f9e33719b9adb0cb3c466d86448460cf3f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
105,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Patients with small-cell lung cancer that responded to first-line treatment but showed evidence of disease relapse or progression at least 90 days after completion of the first-line treatment were eligible to participate.""",5172d251905a57d43546372b9791091e40b8c64c,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
106,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible patients had newly diagnosed metastatic prostate cancer.""",92bf4c8c181840c1e6b85ede53e4e6a7b2565bca,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
106,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,Eligible patients had newly diagnosed metastatic prostate cancer.,cdfbb7de98552d07161d0a6e5601da1211c79bc4,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
107,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer""",ae793456338175ac0995428dbffbcf6ede75070c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
107,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer""",ae793456338175ac0995428dbffbcf6ede75070c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
109,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma""",2e0bcb209b02b1b660c6a753e0515329ed98f44a,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
109,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma""",2e0bcb209b02b1b660c6a753e0515329ed98f44a,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
110,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with histologically proven, HER2-positive metastatic breast cancer""",7d38d0d335c6d9abf8e7892f675042ba2ad46716,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
110,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""in patients with histologically proven, HER2-positive metastatic breast cancer""",0bda1878459cf8910a5d3f04a849e0ef09fe988d,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
111,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""previously untreated unresectable stage IIIc or stage IV melanoma""",e46dd441c00b51d1b55e22d4973575c6d3d877ae,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
111,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""with previously untreated unresectable stage IIIc or stage IV melanoma""",81d68cc660739cbe06410243d084d719c6b4bc19,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
112,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction""",7dd6043baeec8a77b8812eec4208a6e9bc4b25a4,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
112,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction.""",b6b33fbea15254056651dbe04f18605c3038f275,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
113,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years""",b71ecc1d16307f4ff61eb107be177c20037a4c25,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
113,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years""",b71ecc1d16307f4ff61eb107be177c20037a4c25,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
114,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment""",96d6cc4a08801a90159b5e658c102adb5e7835c9,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
114,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment""",96d6cc4a08801a90159b5e658c102adb5e7835c9,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
115,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""patients with unresectable stage IIIC or IV melanoma""",11e9fadb85f681011f47d41123159358b2f90f2e,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
115,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""we randomly assigned patients with unresectable stage IIIC or IV melanoma""",8ac745e2e3d1ff6895195e2efee2f8b719930830,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
116,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma""",79688df7aa50c025910aa3d2513317840804f731,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
116,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma""",79688df7aa50c025910aa3d2513317840804f731,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
117,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.""",3a8c2754f3b5ccf378f544a227beb00f99c88c68,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
117,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women.""",3a8c2754f3b5ccf378f544a227beb00f99c88c68,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
118,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Eligible patients were aged 18-75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)""",57880f1da72449c8aac9386dacfdba30d8619b10,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
118,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease)""",caaf6fda6d566b2b781edeea2c54d96dd2e78659,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
119,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with palpable T1-T2 invasive breast cancer were recruited""",311094d80875682ad3b9a873613b0d56bce94208,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
119,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with palpable T1-T2 invasive breast cancer""",798e1eb45dec97bef742ad0128671785a60c2856,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
120,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer""",f90c6498c663cd41f570061741fcfc0aa989693f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
120,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""patients aged 18 years or older, with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer""",10a8723a2bc47bb9c825741765682babdd541ce9,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
122,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized""",b80a615ca2d43e6e4e50908741fd05deb0cb2e8c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
122,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized 1:1:1 to receive adjuvant RT, CCRT, or SCRT.""",734dfc66f1a369321dfd350d3c09b5795b01455e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
123,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma""",f4800827bd42e0a3e5e59ad63c6149db83c954a0,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
123,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma""",f4800827bd42e0a3e5e59ad63c6149db83c954a0,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
124,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall""",af4b8599baca419dc0def290cb5edb0da963922f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
124,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included.""",4243d0159b95e7d66eb9410fc86a4c85f5bc2ab0,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
126,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease""",456d88c271f3025523520b59eca94989f3b9a335,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
126,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease""",456d88c271f3025523520b59eca94989f3b9a335,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
127,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC""",d330098c362527c8c0fc9f25c22d5618dc2226da,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
127,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC were enrolled""",d91146e6bb9b20c83651761dc559f57c95629cdb,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
128,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer""",9b4f77e8b257977fef01387baf76bcd45a32f29d,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
128,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer""",9b4f77e8b257977fef01387baf76bcd45a32f29d,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
129,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
129,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
130,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm""",4b19644d2fc3138efbdaf7cf5376c61135fdd12f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
130,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm""",4b19644d2fc3138efbdaf7cf5376c61135fdd12f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
131,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
131,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,Eligibility criteria included ERBB2-negative metastatic breast cancer,b7095452191b73c0bf384af62dfbd1c39d7a3c31,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
132,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""trial involving patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor.""",2682199328c3da0ac39fc56e8fe0be6412ea95ef,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
132,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""We conducted a randomized, open-label, noninferiority, postauthorization, safety end-point trial involving patients with active rheumatoid arthritis despite methotrexate treatment""",b5d568091752b3bcdeecd8ff51fb0faf12292c52,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
133,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
133,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.""",3b71a1b34b555bf7d4db68e8efd75bd37b77fb24,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
134,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with untreated stage IV or recurrent NSCLC""",33efff137a6cd58155eb0d0d06ddeaa6a6b5bbdc,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
134,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients with untreated stage IV or recurrent NSCLC""",33efff137a6cd58155eb0d0d06ddeaa6a6b5bbdc,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
136,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer""",1f3739a104351deb9cde24ec13e40cdeba09639f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
136,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer""",1f3739a104351deb9cde24ec13e40cdeba09639f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
138,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum""",3e7c76a8a46d7d086f63cb923024fab09297eec3,False,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
138,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum""",660fbabf16f117bc0651ea2929bfae53d1dce371,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
139,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with curable stage T2b, T3, or T4 gastric cancer""",f0b36688c886d85ee84962717b18556b112942e3,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
139,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""523 patients with curable stage T2b, T3, or T4 gastric cancer""",9fe65f075474b6531137c7c7d507c352f5b9a52a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
140,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy""",1105b7cb6258bef7c64f643a10414adc15c1e2c9,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
140,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.""",9f49cb21a38ac744574562f94df408518e7822eb,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
141,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area.",705c3aed868ba525fe510bf294707e35c3b98be4,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
141,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area.",705c3aed868ba525fe510bf294707e35c3b98be4,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
142,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)""",57432a17cb7aa7053bce98336d373103324c88a2,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
142,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0)""",57432a17cb7aa7053bce98336d373103324c88a2,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
143,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""Patients with histologically confirmed AIN were randomly assigned to receive either 16 weeks of imiquimod (three times a week), 16 weeks of topical fluorouracil (twice a week), or monthly electrocautery for 4 months.""",3644f7e378d6917fcef3310ada90d9c1e849df3c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
143,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""Patients with histologically confirmed AIN were randomly assigned to receive either 16 weeks of imiquimod (three times a week), 16 weeks of topical fluorouracil (twice a week), or monthly electrocautery for 4 months.""",3644f7e378d6917fcef3310ada90d9c1e849df3c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
144,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we randomly assigned patients with spinal cord compression caused by metastatic cancer""",d933ed9e6709b3f5a2a7a261a9b531930b09239f,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
144,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we randomly assigned patients with spinal cord compression caused by metastatic cancer""",d933ed9e6709b3f5a2a7a261a9b531930b09239f,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
145,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy""",c16f8ca3f52c3e17d98b2dc99ec9c1c0f86d16d7,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
145,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy""",c16f8ca3f52c3e17d98b2dc99ec9c1c0f86d16d7,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
146,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States.""",2de6fa28760472b06638f1df555b31547cda6827,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
146,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States.""",2de6fa28760472b06638f1df555b31547cda6827,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
147,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer""",fa1bb5d29986a28699551aa5d0ae119e6d357b3a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
147,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer""",fa1bb5d29986a28699551aa5d0ae119e6d357b3a,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
148,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.""",c390a3924587575a18fc4500a3e002711ed3b588,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
148,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer.""",c390a3924587575a18fc4500a3e002711ed3b588,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
149,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.""",f21d9dcba719e4c7d4b7b11a24127ab157ce6c96,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
149,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.""",f21d9dcba719e4c7d4b7b11a24127ab157ce6c96,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
150,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""we enrolled patients with a histologically proven superficial basal-cell carcinoma""",9751294cd75e0aee278069973f0a2c09bfbe3271,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
151,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.""",517d694e1af036d28860bf23f2b13b022b9d374d,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
151,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate.""",517d694e1af036d28860bf23f2b13b022b9d374d,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
152,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We included chemotherapy-naive men (aged ≥18 years) with mCRPC""",6a69fccdc6d285db6f76d7fe85ca6e9ce2a50b95,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
152,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""We included chemotherapy-naive men (aged ≥18 years) with mCRPC""",6a69fccdc6d285db6f76d7fe85ca6e9ce2a50b95,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
153,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment""",8089587e09d6b5b20f8e34a02dc3430bea3ee904,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
153,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment""",8089587e09d6b5b20f8e34a02dc3430bea3ee904,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
154,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""women with HER2-positive breast cancer with progressive brain metastases during or after treatment with trastuzumab, lapatinib, or both, were eligible.""",02a98f806a0f5e1f0f5eaa27d696d2d9b69282fe,False,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
154,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""women with HER2-positive breast cancer with progressive brain metastases""",027def017940daf376745d22ea8451fbe5d502ae,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
155,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer""",e3a7b0ad7b355e68aa420df618198a97d0f53237,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
155,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer""",e3a7b0ad7b355e68aa420df618198a97d0f53237,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
156,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery""",e363714a711912055cf2c55ea3be914025589a34,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
156,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients aged 18 years or older with clinical stage I endometrial or cervical cancer undergoing curative surgery""",e363714a711912055cf2c55ea3be914025589a34,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
157,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""we enrolled patients with prostate cancer who had high-risk biochemical recurrence""",a4e03d4a21c3558ce3903ac5f4cb5142851e0d70,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
157,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""we enrolled patients with prostate cancer who had high-risk biochemical recurrence""",a4e03d4a21c3558ce3903ac5f4cb5142851e0d70,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
158,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned to TME preceded by 5 × 5 Gy radiotherapy or TME alone (ratio 1:1).,c101f9b89e3da615992555b66701392feaba40da,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
158,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned,b1e8cfa2035861a4dc733a3dad9c409685d90f37,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
159,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""radiation therapy to the primary tumour site plus meta-iodobenzylguanidine avid metastases present before myeloablative therapy""",e9855d32d7ae7db785abe78e7ff0610f27348f3b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
159,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""radiation therapy to the primary tumour site plus meta-iodobenzylguanidine avid metastases present before myeloablative therapy""",e9855d32d7ae7db785abe78e7ff0610f27348f3b,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
160,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy""",40c89ddac97d040b0724fb4ed9135a8d69f35e12,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
160,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy""",40c89ddac97d040b0724fb4ed9135a8d69f35e12,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
162,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer",802a79a2fe1cc83cabf70393b3d06da18117ee17,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
162,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer""",6f72cb8719293462c54d0b73e23deb8569b9bd01,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
163,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer""",1c478e87dcc88406a02c20f5e45dd56a4374079e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
163,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""we enrolled patients aged 18-70 years with operable, node positive, early-stage breast cancer""",1c478e87dcc88406a02c20f5e45dd56a4374079e,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
164,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation""",ddb23a0f0938b5334f19c19f91bf9f16cfc8bde3,False,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
164,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation""",e1bba7b445c37298184b0a7b6cb77e1f1b6c0bf7,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
166,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.""",b45beb67bce8ffe76caab8a70e4869bd2232efc9,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
166,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.""",b45beb67bce8ffe76caab8a70e4869bd2232efc9,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
167,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.""",7ff1dd5d0e8a9fbea59316bbf6ed3cfc766892c3,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
167,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.""",7ff1dd5d0e8a9fbea59316bbf6ed3cfc766892c3,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
169,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We enrolled female patients with HER2-overexpressing metastatic breast cancer""",01dba15b0aceb596bda5edaab77444ee0ddca823,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
169,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""We enrolled female patients with HER2-overexpressing metastatic breast cancer""",01dba15b0aceb596bda5edaab77444ee0ddca823,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
170,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""we screened 3100 first-degree relatives of patients with gastric cancer. We randomly assigned 1838 participants with H. pylori infection""",73f79972374e3f2b084c878330b603a157c2eedb,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
170,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""we screened 3100 first-degree relatives of patients with gastric cancer. We randomly assigned 1838 participants with H. pylori infection""",73f79972374e3f2b084c878330b603a157c2eedb,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
171,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""hormone-receptor-positive early breast cancer in premenopausal women""",98a5ba5f17b9110f04a2f069c888555be83e8f36,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
171,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""recurrence of hormone-receptor-positive early breast cancer in premenopausal women""",a6d7365e9384eb318b8b4c200674399212017498,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
173,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""enhances tumor response in patients with metastatic NSCLC.""",bdccdcc2c0c155c20ed9f49856df4e4491d2179d,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
173,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""To assess whether stereotactic body radiotherapy on a single tumor site preceding pembrolizumab treatment enhances tumor response in patients with metastatic NSCLC.""",01b26d2df2e2d57be14b279647c3a1ca8a4eaf62,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
174,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""170 432 eligible men and women, who had indicated on a previous questionnaire that they would probably attend screening if invited""",374c6ed5f286ec093a811d67ccaf373be9e38969,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
174,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""170 432 eligible men and women, who had indicated on a previous questionnaire that they would probably attend screening if invited""",374c6ed5f286ec093a811d67ccaf373be9e38969,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
175,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""patients with locally advanced or metastatic non-small-cell lung cancer""",92c818e306e91a3da2710903d9574f6827920ace,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
175,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer""",1ae19e4849f520394d7ce0e7e5dd86a8ddba608d,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
176,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects).""",58367c66a45cfe1b18d870f213754e26a482f201,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
176,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects)""",770000892fd7ee126223181170b34b8cde3a4396,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
177,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""in patients with stage III or IVA endometrial carcinoma""",25049fc2def443efb17ffe77da755e6e07b1bba7,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
177,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with stage III or IVA endometrial carcinoma""",65d8b67032e4ffdaaeb25be205b7e6e3a085afaa,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
178,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""for patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation""",0caa06b716b45adffc8f3deb9b12b4fe4bda1c67,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
178,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""patients with unresectable or metastatic cholangiocarcinoma with IDH1 mutation""",ce20f456354b9a522ddb9e03e0fadb605a61a244,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: NOT_SUPPORTED,NOT_SUPPORTED,True,False
181,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""had previously untreated recurrent or metastatic nasopharyngeal carcinoma.""",743d0e341ea28c1d9670362b0c6adecb21c9529c,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
181,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""had previously untreated recurrent or metastatic nasopharyngeal carcinoma""",91abde46da8b29dc47ddc94b6d5e595cd01b9f6f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
182,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""we randomly assigned patients with stage IV or recurrent NSCLC""",d44806a07a0dda22a5893639e1f7bbc4aade300f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
182,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""we randomly assigned patients with stage IV or recurrent NSCLC""",d44806a07a0dda22a5893639e1f7bbc4aade300f,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
183,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""patients with previously untreated stage II or stage III triple-negative breast cancer""",f725748278e482f51738e0b84dbf4f3ca0fb0824,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
183,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""patients with previously untreated stage II or stage III triple-negative breast cancer""",f725748278e482f51738e0b84dbf4f3ca0fb0824,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
184,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""women with HER2-positive locally advanced or inflammatory breast cancer""",9522ac15bc3bf324d82e62b97e23700b8120a2fc,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
184,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""women with HER2-positive locally advanced or inflammatory breast cancer""",9522ac15bc3bf324d82e62b97e23700b8120a2fc,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
186,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""patients with a history of colorectal adenomas""",d88c4488a5a21870904c26faf3c3df13379d9f83,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
186,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""patients with a history of colorectal adenomas""",d88c4488a5a21870904c26faf3c3df13379d9f83,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
187,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""had stage III or stage IV disease and no distant metastases""",bceb191387cd62bde07acd11830c4c6b9464abed,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
187,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""had stage III or stage IV disease and no distant metastases""",bceb191387cd62bde07acd11830c4c6b9464abed,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
188,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""among men with metastatic castration-resistant prostate cancer""",97f90d7254165d3ceb68535581bd315cc294b933,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
188,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes""",1e9e8311585edabe46c172095e5871ea096e3629,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
189,openai,gpt-5.2-2025-12-11,evidence_required,2,NEITHER,"""exemestane 25 mg a day for the primary prevention of breast cancer""",e0b645dad4ec20095c75603a4b97ee642abbdc99,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
189,openai,gpt-5.2-2025-12-11,evidence_required,3,NEITHER,"""exemestane 25 mg a day for the primary prevention of breast cancer""",e0b645dad4ec20095c75603a4b97ee642abbdc99,True,NEITHER,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
190,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer""",8334eaeb86074583ffc59ed701e2958df9a8735c,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
190,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""1803 premenopausal women with endocrine-receptor-positive early-stage (stage I-II) breast cancer""",4299d90c351f4db3a5af8b3a783ff310c85d911f,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
191,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""documented local recurrence after surgery followed by chemotherapy""",403b61665eeee66ab251ed6a89e9f4f19d469416,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
191,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""documented local recurrence after surgery followed by chemotherapy""",403b61665eeee66ab251ed6a89e9f4f19d469416,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
194,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions""",bd6ba03a86964a041693f9b2f27650ea3710a754,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
194,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions""",bd6ba03a86964a041693f9b2f27650ea3710a754,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
195,openai,gpt-5.2-2025-12-11,evidence_required,2,BOTH,"""We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung""",6feeb3bf467f7d4292e3de8de361ec5ed5a73151,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
195,openai,gpt-5.2-2025-12-11,evidence_required,3,BOTH,"""We enrolled adults with stage IIIB or IV squamous cell carcinoma of the lung""",6feeb3bf467f7d4292e3de8de361ec5ed5a73151,True,BOTH,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
196,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""We randomly assigned patients with metastatic breast cancer""",d3b009e709a41c64bb273fe64b92969349640d6b,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
196,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease""",a7272820cc6b86c5419969aa71b77026c850799c,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
197,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""Patients aged 18 years and older with metastatic soft-tissue sarcomas""",e17eb61d628f9ff6f98e11266503922cbd02cdbc,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
197,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""Patients aged 18 years and older with metastatic soft-tissue sarcomas""",e17eb61d628f9ff6f98e11266503922cbd02cdbc,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
198,openai,gpt-5.2-2025-12-11,evidence_required,2,LOCALIZED,"""after resection of localised, primary gastrointestinal stromal tumour""",118164528b0984e5ad7e0a28b4b7cce51855afa8,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
198,openai,gpt-5.2-2025-12-11,evidence_required,3,LOCALIZED,"""after resection of localised, primary gastrointestinal stromal tumour""",118164528b0984e5ad7e0a28b4b7cce51855afa8,True,LOCALIZED,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
199,openai,gpt-5.2-2025-12-11,evidence_required,2,METASTATIC,"""men with at least one bone metastasis from castration-resistant prostate cancer""",9ad2ce92b204fec9485ebef3834d8856366cffff,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
199,openai,gpt-5.2-2025-12-11,evidence_required,3,METASTATIC,"""men with at least one bone metastasis from castration-resistant prostate cancer that had progressed after docetaxel treatment""",2d8dcda2f7c12b6ee1dd9f79923ed5e82e4c5885,True,METASTATIC,openai,gpt-5.2-2025-12-11,VERDICT: SUPPORTED,SUPPORTED,True,True
